[go: up one dir, main page]

WO2013106643A2 - Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase - Google Patents

Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase Download PDF

Info

Publication number
WO2013106643A2
WO2013106643A2 PCT/US2013/021136 US2013021136W WO2013106643A2 WO 2013106643 A2 WO2013106643 A2 WO 2013106643A2 US 2013021136 W US2013021136 W US 2013021136W WO 2013106643 A2 WO2013106643 A2 WO 2013106643A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
optionally substituted
syndrome
disease
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/021136
Other languages
French (fr)
Other versions
WO2013106643A3 (en
Inventor
Craig M. Crews
Dennis BUCKLEY
Alessio CIULLI
William Jorgensen
Peter C. Gareiss
Inge Van MOLLE
Jeffrey GUSTAFSON
Hyun-Seop Tae
Julien MICHEL
Dentin Wade HOYER
Anke G. ROTH
John David Harling
Ian Edward David Smith
Afjal Hussain MIAH
Sebastien Andre Campos
Joelle Le
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
GlaxoSmithKline Intellectual Property Development Ltd
Yale University
Original Assignee
Cambridge Enterprise Ltd
GlaxoSmithKline Intellectual Property Development Ltd
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR112014017095-9A priority Critical patent/BR112014017095A2/en
Priority to CN201380013806.8A priority patent/CN104736569A/en
Priority to KR1020207005900A priority patent/KR102438072B1/en
Priority to MX2014008520A priority patent/MX358660B/en
Application filed by Cambridge Enterprise Ltd, GlaxoSmithKline Intellectual Property Development Ltd, Yale University filed Critical Cambridge Enterprise Ltd
Priority to EP19181352.6A priority patent/EP3608317A1/en
Priority to CA2861066A priority patent/CA2861066C/en
Priority to KR1020227029492A priority patent/KR102668696B1/en
Priority to MX2018010430A priority patent/MX394449B/en
Priority to JP2014552319A priority patent/JP2015508414A/en
Priority to US14/371,956 priority patent/US10730862B2/en
Priority to KR1020147022606A priority patent/KR102204989B1/en
Priority to AU2013207900A priority patent/AU2013207900B2/en
Priority to EP13736209.1A priority patent/EP2802608A4/en
Priority to HK15109544.5A priority patent/HK1208875A1/en
Priority to CN202311258079.3A priority patent/CN117736134A/en
Priority to RU2014133019A priority patent/RU2666530C2/en
Priority to KR1020247016674A priority patent/KR20240096553A/en
Publication of WO2013106643A2 publication Critical patent/WO2013106643A2/en
Publication of WO2013106643A3 publication Critical patent/WO2013106643A3/en
Anticipated expiration legal-status Critical
Priority to AU2018201554A priority patent/AU2018201554B2/en
Priority to US16/224,088 priority patent/US20190127359A1/en
Priority to AU2020239664A priority patent/AU2020239664B2/en
Priority to AU2022205187A priority patent/AU2022205187B2/en
Priority to AU2024201732A priority patent/AU2024201732A1/en
Priority to US18/667,078 priority patent/US20240317729A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Definitions

  • the present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins, which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention.
  • the present invention is directed to compounds, which contain on one end a VHL ligand, which binds to the VHL E3 ubiquitin
  • ligase (defined as a ubiquitin ligand binding moiety or group) and on the other end a moiety, which binds a target protein (defined as a protein/polypeptide targeting moiety or
  • the present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.
  • E3 ubiquitin ligases (of which over 600 are known in humans) 1 confer substrate specificity for ubiquitination and are more attractive therapeutic targets than general proteasome inhibitors 3 ' 4 due to their specificity for certain protein substrates.
  • ligands of E3 ligase have proven challenging, in part due to the fact that they must disrupt protein-protein interactions 5 recent developments have provided specific ligands which bind to these ligases. Protein-protein interaction interactions are notoriously difficult to target using small molecules due to their large contact surfaces and the shallow grooves or flat interfaces involved. Conversely, most small molecule drugs bind enzymes or receptors in tight and well-defined pockets. 6 Since the discovery of nutlins, the first small molecule E3 ligase inhibitors, 7 additional compounds have been reported that target Inhibitors of
  • IAPs Apoptosis Proteins (IAPs), 8>9 sCF Met30 , 10 and SCF cdc4 ; n however, the field remains underdeveloped.
  • VHL von Hippel-Lindau
  • VCB the substrate recognition subunit of the E3 ligase complex
  • Hypoxia Inducible Factor la a transcription factor that upregulates genes such as the pro-angiogenic growth factor VEGF and the red blood cell inducing cytokine
  • HIF- la is constitutively expressed, its intracellular levels are kept very low under normoxic conditions via its hydroxylation by prolyl hydroxylase domain (PHD) proteins and subsequent VHL-mediated ubiquitination (Figure 1).
  • PLD prolyl hydroxylase domain
  • VHL Von Hippel Lindau
  • HIF- la the major substrate of VHL.
  • a principal rationale for the present invention is the need for a small molecule E3 ligase ligand for our PROTAC (Proteolysis Targeting Chimera) technology. This technology brings targeted proteins/polypeptides to E3 ligases for ubiquitination and subsequent proteasomal degradation. In several proof-of-concept experiments, the present inventors demonstrated the utility of this approach using the short peptide sequence from HIF that binds VHL.
  • the inventors have replaced the HIF peptide with a 'small molecule' VHL ligand, thus providing a means to recruit proteins to E3 ligases for ubiquitination and degradation, to the endpoint of providing therapies based upon this protein degradation.
  • Figure 1 shows (A) HIF-l accumulation leads to the transcriptional upregulation of genes involved in the hypoxic response, such as erythropoietin and VEGF. (B) Under normoxic conditions, HIF-la is hydroxylated, recognized by VHL, ubiquitinated and degraded by the proteasome, preventing transcriptional upregulation.
  • Figure 3 shows a pictorial representation shows the key interactions between 15 and
  • Figure 4 shows the 2.9 A co-crystal structure of 15 (lightest gray carbons) bound to VHL indicates that its binding mimics that of the HIF-la peptide (light gray carbons, pdb 1LM8 17 )
  • Figure 5 shows the crystal structures of V 54 BC apo (A) and in complex with 15 (B). Electron density (2F 0 -F C ) superimposed around Hyp binding site residues (sticks, yellow carbons) and conserved water molecules (red dots), and 15 (sticks, cyan carbons) are shown in blue and are contoured at 1.2 ⁇ . The protein surface is shown in green at 50% transparency.
  • Figures 6-12A and B show the activity of individual compounds according to the present invention in the described VHL polarization/displacement assay. Compounds according to the present invention are indicated with numerals at the top of each graph.
  • Control compound is presented in figure 15 B and served as minimum polarization
  • Figure 13 (along with Table 2- Affinity Table) shows numerous exemplary
  • Figure 14 shows numerous preferred compounds from Table 2 according to the present invention.
  • Figure 15 shows a further number of compounds according to the present invention and their activity. Most compounds are active below concentrations of 100 ⁇ .
  • Figure 16 shows numerous preferred compounds from Figure 15 according to the present invention.
  • Figure 17 shows eight particularly preferred compounds from Figure 15 according to the present invention.
  • Figure 18 shows six preferred compounds according to the present invention which contain estrogen binding protein targeting moieties linked to preferred ubiquitin ligand binding moieties.
  • Figure 19 shows a genus of preferred compounds according to the present invention. Brief Description of the Invention
  • the present invention is based on the discovery that an ubiquitin pathway protein ubiquitinates any target protein once the ubiquitin pathway protein and the target protein are placed in proximity by a chimeric construct that binds the ubiquitin pathway protein and the target protein. Accordingly the present invention provides a composition that results in the ubiquitination of a chosen target protein. The present invention also provides a library of compositions and the use thereof.
  • the present invention provides a composition useful for regulating protein activity.
  • the composition comprises a ubiquitin pathway protein binding moiety (preferably for an E3 ubiquitin ligase, alone or in complex with an E2 ubiquitin conjugating enzyme which is responsible for the transfer of ubiquitin to targeted proteins) according to a defined chemical structure and a protein targeting moiety which are linked together, preferably through a linker, wherein the ubiquitin pathway protein binding moiety recognizes an ubiquitin pathway protein and the targeting moiety recognizes a target protein and wherein the ubiquitin pathway protein binding moiety is coupled to the targeting moiety.
  • a ubiquitin pathway protein binding moiety preferably for an E3 ubiquitin ligase, alone or in complex with an E2 ubiquitin conjugating enzyme which is responsible for the transfer of ubiquitin to targeted proteins
  • a protein targeting moiety which are linked together, preferably through a linker
  • the present invention provides a library of compounds.
  • the library comprises more than one compound wherein each composition has a formula of A-B, wherein A is a ubiquitin pathway protein binding moiety (preferably, an E3 ubiquitin ligase moiety as otherwise disclosed herein) and B is a protein binding member of a molecular library, wherein A is coupled (preferably, through a linker moiety) to B, and wherein the ubiquitin pathway protein binding moiety recognizes an ubiquitin pathway protein, in particular, an E3 ubiquitin ligase.
  • A is a ubiquitin pathway protein binding moiety (preferably, an E3 ubiquitin ligase moiety as otherwise disclosed herein)
  • B is a protein binding member of a molecular library, wherein A is coupled (preferably, through a linker moiety) to B, and wherein the ubiquitin pathway protein binding moiety recognizes an ubiquitin pathway protein, in particular, an E3 ubiquitin ligase.
  • the library contains a specific ubiquitination recognition peptide of VHL for an E3 ubiquitin ligase (ubiquitin pathway protein binding moiety as otherwise disclosed herein) with random target protein binding elements (e.g., a chemical compound library).
  • E3 ubiquitin ligase ubiquitin pathway protein binding moiety as otherwise disclosed herein
  • target protein binding elements e.g., a chemical compound library.
  • the target protein is not determined in advance and the method can be used to determine the activity of a putative protein binding element and its pharmacological value as a target upon degradation by ubiquitin ligase.
  • the present invention provides a method of screening a library of the present invention to identify a compound containing a targeting moiety, which recognizes a target protein associated with a predetermined function of a cell.
  • the method comprises incubating a cell with a pool of entities from the library; monitoring the predetermined function of the cell; identifying a pool of entities that change the
  • predetermined function of the cell incubating the cell with a composition from the identified pool of entities; monitoring the predetermined function of the cell; and identifying a composition that changes the predetermined function of the cell, wherein the identified composition contains a targeting moiety which recognizes a target protein associated with the predetermined function.
  • the present invention provides a method of screening a library of the present invention to identify a composition containing a targeting moiety, which recognizes a target protein associated with a predetermined function of a cell.
  • the method comprises incubating a cell with each composition from the library; monitoring the predetermined function of the cell; identifying a composition that changes the predetermined function of the cell; wherein the identified composition contains a targeting moiety, which recognizes a target protein associated with the predetermined function.
  • the present invention provides a method of identifying a target protein associated with a predetermined function of a cell.
  • the method comprises incubating a cell with a composition from the library of the present invention; monitoring the predetermined function of the cell; identifying a composition that changes the predetermined function of the cell; identifying a target protein that binds to the identified composition, wherein the target protein is associated with the predetermined function of the cell.
  • the present invention provides a method of identifying a target protein associated with a predetermined function of a cell.
  • the method comprises incubating a cell with a pool of entities from the library of the present invention; monitoring the predetermined function of the cell; identifying a pool of entities that change the predetermined function of the cell; incubating the cell with a composition from the identified pool of entities; monitoring the predetermined function of the cell; identifying a composition that changes the predetermined function of the cell; and identifying a target protein that binds to the identified composition, wherein the target protein is associated with the predetermined function of the cell.
  • the present invention provides a method of ubiquitinating/degrading a target protein in a cell.
  • the method comprises administering a bifunctional composition comprising an ubiquitin pathway protein binding moiety and a targeting moiety, preferably linked through a linker moiety, as otherwise described herein, wherein the ubiquitin pathway protein binding moiety is coupled to the targeting moiety and wherein the ubiquitin pathway protein binding moiety recognizes a ubiquitin pathway protein (e.g., an ubiquitin ligase, preferably an E3 ubiquitin ligase) and the targeting moiety recognizes the target protein such that degradation of the target protein will occur when the target protein is placed in proximity to the ubiquitin ligase, thus resulting in
  • a ubiquitin pathway protein e.g., an ubiquitin ligase, preferably an E3 ubiquitin ligase
  • the control of protein levels afforded by the present invention provides treatment of a disease state or condition, which is modulated through the target protein by lowering the level of that protein in the cells of a patient.
  • the present invention is directed to a method of treating a patient in need for a disease state or condition modulated through a protein where the degradation of that protein will produce a therapeutic effect in that patient, the method comprising administering to a patient in need an effective amount of a compound according to the present invention, optionally in combination with another bioactive agent.
  • the disease state or condition may be a disease caused by a microbial agent or other exogenous agent such as a virus, bacteria, fungus, protozoa or other microbe or may be a disease state, which is caused by overexpression of a protein, which leads to a disease state and/or condition.
  • the present invention is directed to a compound according to the structure:
  • linker group is a linker group and is a ubiquitin ligase binding moiety, wherein said linker group is optionally further
  • the present invention is directed to a compound which
  • an ubiquitin ligase binding moiety preferably a ligand, which binds an ubiquitin ligase, preferably an E3 ubiquitin ligase;
  • protein targeting moiety is a chemical moiety (protein targeting moiety), which binds to a target protein or polypeptide, which is ubiquitinated by an ubiquitin ligase and is chemically linked directly to
  • L is a linker moiety which may be present or absent and which chemically (covalently) links
  • the compound resembles a dimeric compound where both ends of the compound comprise an ubiquitin ligase binding moiety as otherwise described herein.
  • R 1 is an optionally substituted Ci-C alkyl group, an optionally substituted
  • Ri and R 2 are each independently H or a Ci-C ⁇ alkyl group which may be optionally substituted with one or two hydroxyl groups or up to three halogen groups (preferably fluorine);
  • Rs is a C C 6 alkyl group, an optionally substituted aryl, heteroaryl or heterocycle group or a -(CH 2 ) m NR!R 2 group,
  • R is an optionally substituted alkyl, an optionally substituted
  • RIN and R 2 are each independently H, Ci-C 6 alkyl which is optionally substituted with one or two hydroxyl groups and up to three halogen groups or an optionally substituted
  • V is O, S or NRi
  • R 1 and Rp are each independently H or a Cj-C 3 alkyl group
  • X ⁇ ' and X* 3' are each independently an optionally substituted -CH 2 ) n -, -CH 2 ) n -
  • CH(X V ) CH(X V )- (cis or trans), -CH 2 ) n -CH ⁇ CH- , -(CH 2 CH 2 0) n - or a C 3 -C 6 cycloalkyl group, where X v is H, a halo or a Cj-C 3 alkyl group which is optionally substituted;
  • Each m is independently 0, 1, 2, 3, 4, 5, 6;
  • Each m' is independently 0 or 1 ;
  • n is independently 0, 1, 2, 3, 4, 5, 6;
  • n' is independently 0 or 1 ;
  • Each u is independently 0 or 1 ;
  • Each v is independently 0 or 1 ;
  • Each w is independently 0 or 1 ;
  • any one or more ofR ⁇ R and R J are modified to bind a linker group to which is further covalently bonded to the , or when , any one or more ofR ⁇ R ⁇ R ⁇ ofeach of are modified to be covalently bonded to each other directly or through a linker group, or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof.
  • any one or more ofR ⁇ R and R J are modified to bind a linker group to which is further covalently bonded to the , or when , any one or more ofR' , R , R J of each of are modified to be covalently bonded to each other directly or through a linker group, or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof.
  • R 1 is preferably a hydroxyl group or a group which may be metabolized to a hydroxyl or carboxylic group, such that the compound represents a prodrug form of an active compound.
  • exemplary preferred R groups include, for example, -(CH 2 ) n OH, (CH 2 ) n -0-(Ci-C 6 )alkyl group, -(CH 2 ) n COOH, -(CH 2 0) n H, an optionally substituted -(CH 2 ) n OC(0)-(C 1 -C 6 alkyl), or an optionally substituted -(CH 2 ) n C(O)- 0-(C!-C 6 alkyl), wherein n is 0 or 1.
  • R 1 is or contains a carboxylic acid group, a hydroxyl group or an amine group, the hydroxyl group, carboxylic acid group or amine (each of which may be optionally substituted), may be further chemically modified to
  • T may also be a -(CH 2 0) n - group, a -(OCH 2 ) lake- group, a -(CH 2 CH 2 0) n - group, a -(OCH 2 CH 2 ) n - group, all of which groups are optionally substituted.
  • Preferred Aryl groups for R 2 include optionally substituted phenyl or naphthyl groups, preferably phenyl groups, wherein the phenyl group is optionally substituted with a
  • linker group to which is attached a group (including a group), a halogen
  • substituted isothiazole an optionally substituted pyrrole including a methylsubstituted pyrrole, an optionally substituted imidazole including a methylimidazole, an optionally substituted benzimidazole or methoxybenzylimidazole, an optionally substituted oximidazole or methyloximidazole, an optionally substituted diazole group, including a methyldiazole group, an optionally substituted triazole group, including a methylsubstituted triazole group, an optionally substituted pyridine group, including a halo- (preferably, F) or
  • methylsubstitutedpyridine group or an oxapyridine group (where the pyridine group is linked to the phenyl group by an oxygen), an optionally substituted furan, an optionally substituted benzofuran, an optionally substituted dihydrobenzofuran, an optionally substituted indole, indolizine or azaindolizine (2, 3, or 4-azaindolizine), an optionally substituted quinoline, an optionally substituted group according to the chemical structure:
  • S c is CHR , NR , or O;
  • R HET is H, CN, N0 2 , halo (preferably CI or F), optionally substituted C C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF 3 ), optionally substituted 0(C ⁇ -C alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C ⁇ C-R a where R a is H or a Ci-C 6 alkyl group (preferably Cj-C 3 alkyl);
  • R ss is H, CN, N0 2 , halo (preferably F or CI), optionally substituted CrC 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(Cj-C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(C ! -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
  • R URE is H, a C]-C 6 alkyl (preferably H or Q-C 3 alkyl) or a -C(OXd-C 6 alkyl) each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted phenyl group, an optionally substituted heteroaryl, or an optionally substituted heterocycle, preferably for example piperidine, morpholine, pyrrolidine, tetrahydrofuran); R is H, optionally substituted Cj-C 6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene
  • R PR01 and R PR02 are each independently H, an optionally subsituted C)-C 3 alkyl group or together form a keto group;
  • each n is independently 0, 1, 2, 3, 4, 5, or 6 (preferably 0 or 1), or
  • an optionally substituted heterocycle preferably tetrahydrofuran, tetrahydrothiene, piperidine, piperazine or morpholine (each of which groups when substituted, are preferably substituted with a methyl or halo (F, Br, CI),
  • each of which groups may be optionally substituted with a linker group to which is attached a
  • R and n are the same as above.
  • Preferred heteroaryl groups for R include an optionally substituted quinoline (which may be attached to the pharmacophore or substituted on any carbon atom within the quinoline ring), an optionally substituted indole, an optionally substituted indolizine, an optionally substituted azaindolizine, an optionally substituted benzofuran, including an optionally substituted benzofuran, an optionally substituted isoxazole, an optionally substituted thiazole, an optionally substituted isothiazole, an optionally substituted thiophene, an optionally substituted pyridine (2-, 3, or 4-pyridine), an optionally substituted imidazole, an optionally substituted pyrrole, an optionally substituted diazole, an optionally substituted triazole, a tetrazole, an optionally substituted oximidazole, or a group according to the chemical structure:
  • S c is CHR SS , NR URE , or O;
  • R HET is H, CN, N0 2 , halo (preferably CI or F), optionally substituted d-C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF 3 ), optionally substituted 0(Ci-C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C ⁇ C-R a where R a is H or a Ci-C alkyl group (preferably Cj-C 3 alkyl);
  • R ss is H, CN, N0 2 , halo (preferably F or CI), optionally substituted C C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally
  • substituted 0-(C)-C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(C ! -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
  • R URE is H, a d-C 6 alkyl (preferably H or C C 3 alkyl) or a -C(0)(d-C 6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and
  • Y c is N or C-R YC , where R YC is H, OH, CN, N0 2 , halo (preferably CI or F), optionally substituted Ci-C alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF 3 ), optionally substituted 0(C ! -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C ⁇ C-R a where R a is H or a Ci-C 6 alkyl group (preferably Cj-C 3 alkyl),
  • each of which groups may be optionally substituted with a linker group to which is attached a
  • Preferred heterocycle groups for R include tetrahydrofuran, tetrahydrothiene, tetrahydroquinoline, piperidine, piperazine, pyrrollidine, morpholine, oxane or thiane, each of which groups may be optionally substituted, or a group according to the chemical structure:
  • R is H, optionally substituted Q-C 6 alkyl or an optionally substituted
  • R and R are each independently H, an optionally subsituted Ci-C 3 alkyl group or together form a keto group and
  • n is independently 0, 1, 2, 3, 4, 5, or 6 (often 0 or 1), each of which groups may be
  • linker group to which is attached a group (including a
  • R 2 substituents for use in the present invention also include specifically (and without limitation to the specific compound disclosed) the R 2 substituents which are found in the identified compounds disclosed herein (which includes the specific compounds which are disclosed in the present specification, and the figures which are attached hereto). Each of these R substituents may be used in conjunction with any number of R
  • R 3 is preferably an optionally substituted -T-Aryl, an optionally substituted
  • R 1 is H or a C C 3 alkyl group, preferably H or CH 3
  • T is an optionally substituted -(CH 2 ) n - group, wherein each one of the methylene groups may be optionally substituted with one or two substituents, preferably selected from halogen, a C1-C3 alkyl group or the sidechain of an amino acid as otherwise described herein, preferably methyl, which may be optionally substituted; and n is 0 to 6, often 0, 1, 2, or 3 preferably 0 or 1.
  • T may also be a -(CH 2 0) n - group, a -(OCH 2 ) n - group, a -(CH 2 CH 2 0) n - group, a -(OCH 2 CH 2 ) n - group, each of which groups is optionally substituted.
  • Preferred aryl groups for R include optionally substituted phenyl or naphthyl groups, preferably phenyl groups, wherein the phenyl or naphthyl group is optionally substituted with
  • linker group to which is attached a 1 J group (including a group) and/or a halogen (preferably F or CI), an amine, monoalkyl- or dialkyl amine (preferably,
  • Rs is a a Cj-C 6 alkyl group, an optionally substituted aryl, heteroaryl or heterocycle group or a -(CH 2 ) m NR 1 R 2 group), each of which may be substituted in ortho-, meta- and/or para- positions of the phenyl ring, preferably para-), or an Aryl (preferably phenyl), Heteroaryl or Heterocycle.
  • said substituent phenyl group is an optionally substituted phenyl group (i.e., the substituent phenyl group itself is preferably substituted with at least one of F, CI, OH, SH, COOH, CH 3 , CF 3 , OMe, OCF 3 , N0 2 , CN or a linker
  • a naphthyl group which may be optionally substituted including as described above, an optionally substituted heteroaryl (preferably an optionally substituted isoxazole including a methylsubstituted isoxazole, an optionally substituted oxazole including a methylsubstituted oxazole, an optionally substituted thiazole including a methyl substituted thiazole, an optionally substituted pyrrole including a methylsubstituted pyrrole, an optionally substituted imidazole including a methylimidazole, a benzylimidazole or methoxybenzylimidazole, an oximidazole or methyloximidazole, an optionally substituted diazole group, including a methyldiazole group, an optionally substituted
  • methylsubstitutedpyridine group or an oxapyridine group (where the pyridine group is linked to the phenyl group by an oxygen) or an optionally substituted heterocycle (tetrahydrofuran, tetrahydrothiophene, pyrrolidine, piperidine, morpholine, piperazine, tetrahydroquinoline, oxane or thiane.
  • an optionally substituted heterocycle tetrahydrofuran, tetrahydrothiophene, pyrrolidine, piperidine, morpholine, piperazine, tetrahydroquinoline, oxane or thiane.
  • Each of the aryl, heteroaryl or heterocyclic groups may be optionally
  • PTM ULM' substituted with a linker group to which is attached a group (including a
  • Preferred Heteroaryl groups for R include an optionally substituted quinoline (which may be attached to the pharmacophore or substituted on any carbon atom within the quinoline ring), an optionally substituted indole (including dihydroindole), an optionally substituted indolizine, an optionally substituted azaindolizine (2, 3 or 4-azaindolizine) an optionally substituted benzimidazole, benzodiazole, benzoxofuran, an optionally substituted imidazole, an optionally substituted isoxazole, an optionally substituted oxazole (preferably methyl substituted), an optionally substituted diazole, an optionally substituted triazole, a tetrazole, an optionally substituted benzofuran, an optionally substituted thiophene, an optionally substituted thiazole (preferably methyl and/or thiol substituted), an optionally substituted isothiazole, an optionally substituted triazole
  • S c is CHR , NR URt , or O;
  • R HET is H, CN, N0 2 , halo (preferably CI or F), optionally substituted d-C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF 3 ), optionally substituted 0(d-C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C ⁇ C-R a where R a is H or a Cj-C 6 alkyl group (preferably d-C 3 alkyl);
  • R ss is H, CN, N0 2 , halo (preferably F or CI), optionally substituted d-C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(d-C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(d-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
  • R URE is H, a d-C 6 alkyl (preferably H or C1-C3 alkyl) or a -C(0)(d-C 6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and
  • Y c is N or C-R YC , where R YC is H, OH, CN, N0 2 , halo (preferably CI or F), optionally substituted Ci-C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF 3 ), optionally substituted 0(C ! -C alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C ⁇ C-R a where R a is H or a Q-Q alkyl group (preferably Ci-C 3 alkyl).
  • Each of said heteroaryl groups may be optionally substituted with a linker group to which is attached a
  • Preferred heterocycle groups for R 3 include tetrahydroquinoline, piperidine, piperazine, pyrrollidine, morpholine, tetrahydrofuran, tetrahydrothiophene, oxane and thiane, each of which groups may be optionally substituted or a group according to the chemical structure:
  • R is H, optionally substituted Cj-C 6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a C !
  • R and R are each independently H, an optionally subsituted C!-C 3 alkyl group or together form a keto group, and
  • n 0, 1 , 2, 3, 4, 5, or 6 (preferably 0 or 1), wherein each of said Heteocycle groups may
  • R substituents for use in the present invention also include specifically (and without limitation to the specific compound disclosed) the R 3 substituents which are found in the identified compounds disclosed herein (which includes the specific compounds which are disclosed in the present specification, and the figures which are attached hereto). Each of these R substituents may be used in conjunction with any number of R
  • R 2 is an optionally substituted -NRi- X ⁇ ' -alkyl group, -NRi-X ⁇ ' -Aryl group; an optionally substituted -NRj- X ⁇ ' -HET, an optionally substituted -NR ⁇ X ⁇ -Aryl-HET or an optionally substituted -NRj- X ⁇ ' -HET- Aryl ,
  • R] is H or a C]-C 3 alkyl group (preferably H);
  • X v is H, a halo or a Q-C3 alkyl group which is optionally substituted with one or two hydroxyl groups or up to three halogen groups;
  • Alkyl is an optionally substituted Cl -C 10 alkyl (preferably a Q-Q alkyl) group (in certain preferred embodiments, the alkyl group is end-capped with a halo group, often a CI or Br);
  • Aryl is an optionally substituted phenyl or naphthyl group (preferably, a phenyl group);
  • HET is an optionally substituted oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofiiran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, benzofuran, indole, indolizine, azaindolizine, quinoline (when substituted, each preferably substituted with a alkyl group, preferably
  • S° is CHR , NR , or O
  • R HET is H, CN, N0 2 , halo (preferably CI or F), optionally substituted d-C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF 3 ), optionally substituted 0(Ci-C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C ⁇ C-R a where R a is H or a d-C 6 alkyl group (preferably Ci-C 3 alkyl);
  • R ss is H, CN, N0 2 , halo (preferably F or CI), optionally substituted d-C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(C ! -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(C 1 -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
  • R URE is H, a d-C 6 alkyl (preferably H or d-C 3 alkyl) or a -C(0)(C r C 6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and
  • Y c is N or C-R YC , where R YC is H, OH, CN, N0 2 , halo (preferably CI or F), optionally substituted CrQ alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF 3 ), optionally substituted 0(C ! -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C ⁇ C-R a where R a is H or a Cj-C 6 alkyl group (preferably C[-C 3 alkyl);
  • R PR0 is H, optionally substituted Ci-C 6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a Cj-C 3 alkyl group, preferably methyl or a halo group, preferably F or CI), benzofuran, indole, indolizine, azaindolizine;
  • R PR01 and R PR02 are each independently H, an optionally subsituted C C 3 alkyl group or together form a keto group, and
  • n is independently 0, 1, 2, 3, 4, 5, or 6 (preferably 0 or 1).
  • Each of said groups may be
  • linker group to which is attached a group (including a
  • R 3 is an optionally substituted -(CH 2 ) n -(V) n '-(CH 2 ) n -(V) n '-R group, an optionally substituted
  • R is an optionally substituted alkyl group (Ci-C) 0 , preferably Q-C 6 alkyl), an optionally substituted Aryl group or a HET group;
  • Rj- is H or a C ! -C 3 alkyl group (preferably H);
  • V is O, S or NR r ;
  • X v is H, a halo or a Q-C3 alkyl group which is optionally substituted with one or two hydroxyl groups or up to three halogen groups;
  • Alkyl is an optionally substituted Q-Qo alkyl (preferably a Cj-C 6 alkyl) group (in certain preferred embodiments, the alkyl group is end-capped with a halo group, often a CI or Br);
  • Aryl is an optionally substituted phenyl or napthyl group (preferably, a phenyl group); and
  • HET is an optionally substituted oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydroiuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, benzofuran, indole, indolizine, azaindolizine, quinoline (when substituted, each preferably substituted with a Q-C3 alky
  • S c is CHR SS , NR. , or O;
  • R HET is H, CN, N0 2 , halo (preferably CI or F), optionally substituted d-C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF 3 ), optionally substituted 0(Ci-C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C ⁇ C-R a where R a is H or a Ci-C 6 alkyl group (preferably C C 3 alkyl);
  • R is H, CN, N0 2 , halo (preferably F or CI), optionally substituted Ci-C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(C!-C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(Ci-C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
  • halo preferably F or CI
  • Ci-C 6 alkyl preferably substituted with one or two hydroxyl groups or up to three halo groups
  • 0-(C!-C 6 alkyl) preferably substituted with one or two hydroxyl groups or up to three halo groups
  • -C(0)(Ci-C 6 alkyl) preferably substituted with one or two hydroxyl groups or up to three halo groups
  • R URE is H, a Ci-C 6 alkyl (preferably H or C C 3 alkyl) or a -C(O)(C 0 -C 6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and
  • Y c is N or C-R YC , where R YC is H, OH, CN, N0 2 , halo (preferably CI or F), optionally substituted C ⁇ -Ce alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF 3 ), optionally substituted 0(Ci-C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C ⁇ C-R a where R a is H or a Cj-C 6 alkyl group (preferably Cj-C 3 alkyl);
  • R PR0 is H, optionally substituted Cj-C 6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a C C 3 alkyl group, preferably methyl or a halo group, preferably F or CI), benzofuran, indole, indolizine, azaindolizine;
  • R PR0] and R PR02 are each independently H, an optionally subsituted Cj-C 3 alkyl group or together form a keto group, and
  • n is independently 0, 1, 2, 3, 4, 5, or 6 (preferably 0 or 1);
  • Each m' is 0 or 1 ;
  • n' is 0 or 1
  • each of said compounds preferably on the alkyl, Aryl or Het groups, is substituted
  • linker group to which is attached a group (including a group).
  • R 3 ' is -(CH 2 ) relieve-Aryl, -(CH 2 CH 2 0) n -Aryl, -(CH 2 ) n -HET or -(CH 2 CH 2 0) n -HET;
  • Aryl is phenyl which is optionally substituted with one or two substitutents, wherein said substituent(s) is preferably selected from -(CH 2 ) n OH, Cj-C 6 alkyl which itself is further optionally substituted with CN, halo (up to three halo groups), OH, -(CH2) n O(C 1 -C 6 )alkyl, amine, mono- or di-(Q-C 6 alkyl) amine wherein the alkyl group on the amine is optionally substituted with 1 or 2 hydroxyl groups or up to three halo (preferably F, CI) groups, or said Aryl group is substituted with -(CH 2 ) deliberatelyOH, -(CH 2 ) n -0-(C 1 -C 6 )alkyl, -(CH 2 ) n -0-(CH 2 ) n - (Ci-C 6 )alkyl, -(CH 2 ) favour-C(O)(C
  • S c is CHR 1 ⁇ 2 , NR URE , or O;
  • R HET is H, CN, N0 2 , halo (preferably CI or F), optionally substituted C,-C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF 3 ), optionally substituted 0(Ci-C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C ⁇ C-R a where R a is H or a C]-C 6 alkyl group (preferably C1-C3 alkyl);
  • R ss is H, CN, N0 2 , halo (preferably F or CI), optionally substituted C C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(Ci-C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(C ! -C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
  • R URE is H, a d-C 6 alkyl (preferably H or C C 3 alkyl) or a -C(O)(C 0 -C 6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and
  • Y c is N or C-R YC , where R YC is H, OH, CN, N0 2 , halo (preferably CI or F), optionally substituted C C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF 3 ), optionally substituted 0(Cj-C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C ⁇ C-R a where R a is H or a Cj-C 6 alkyl group (preferably Q-C 3 alkyl);
  • R PR0 is H, optionally substituted C C 6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a C C 3 alkyl group, preferably methyl or a halo group, preferably F or CI), benzofuran, indole, indolizine, azaindolizine;
  • R PR01 and R PR02 are each independently H, an optionally subsituted C ! -C 3 alkyl group or together form a keto group;
  • HET is preferably oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene,
  • S c is CHR SS , NR URE , or O;
  • R HET is H, CN, N0 , halo (preferably CI or F), optionally substituted d-C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF 3 ), optionally substituted 0(Ci-C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C ⁇ C-R a where R a is H or a CrC 6 alkyl group (preferably C1-C3 alkyl);
  • R ss is H, CN, N0 2 , halo (preferably F or CI), optionally substituted d-C 6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(Cj-C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(Cj-C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
  • R URE is H, a d-C 6 alkyl (preferably H or C r C 3 alkyl) or a -C(O)(C 0 -C 6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and
  • Y c is N or C-R YC , where R YC is H, OH, CN, N0 2 , halo (preferably CI or F), optionally substituted Ci-C alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF 3 ), optionally substituted 0(C!-C 6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C ⁇ C-R a where R a is H or a C C 6 alkyl group (preferably Q-C3 alkyl);
  • R PR0 is H, optionally substituted Q-C 6 alkyl or an optionally substituted aryl, heteroaryl or heterocyclic group;
  • R PR01 and R PR02 are each independently H, an optionally subsituted Cj-Q alkyl group or together form a keto group,
  • Each m' is independently 0 or 1
  • n is independently 0, 1, 2, 3, 4, 5, or 6 (preferably 0 or 1),
  • a linker group to which is attached a group (including a group).
  • preferred compounds include those according to the chemical structure:
  • R 1 ' is OH or a group which is metabolized in a patient or subject to OH;
  • R is a -NH-CH 2 -Aryl-HET (preferably, a phenyl linked directly to a methyl substituted thiazole);
  • R 3' is a -CHR CR3' -NH-C(0)-R 3P1 group or a -CHR CR3' -R 3P2 group;
  • R is a Q-Q alkyl group, preferably methyl, isopropyl or tert-butyl;
  • R is Q-C3 alkyl (preferably methyl), an optionally substituted oxetane group (preferably methyl substituted, a -(CH 2 ) n OCH3 group where n is 1 or 2 (preferably 2), or a
  • the ethyl ether group is preferably meta- substituted on the phenyl moiety
  • a morpholino grop (linked to the carbonyl at the 2- or 3- position;
  • R 3P2 is a group
  • Aryl is phenyl
  • HET is an optionally substituted thiazole or isothiazole
  • R HET is H or a halo group (preferably H),
  • each of said compounds is substituted with a linker group to which is attached a
  • groups for inclusion in compounds according to the present invention include:
  • X is CI, F, Cj-C 3 alkyl (preferably methyl) or heterocycle (preferably an optionally substituted heterocycle, including as defined above for R ;
  • R 1 and R 2 are each independently H, Q-C 3 alkyl (preferably methyl), or phenyl and each of said compounds is substituted with a linker group or a linker group to which is attached a
  • n 0 or 1 ;
  • R is a linker or a linker attached to a group
  • X is H, F, CI, C 1 -C 3 alkyl (preferably methyl) or heterocycle (preferably an optionally substituted heterocycle, especially including a water soluble heterocycle such as a morpholino group, including as defined above for R 3 ), or
  • Additional preferred groups for inclusion in compounds according to the present invention include for example:
  • n 0 or 1 ;
  • R is a linker or a linker attached to a group a linker or a linker attached to a
  • R 1 is Cj-C 3 alkyl (optionally substituted with one or two hydroxyl groups) or -C(0)NR 3 R 4 where R 3 and R 4 are each independently H, Cj-C 3 alkyl (preferably methyl), phenyl or heterocycle (including a heterocycle such as a morpholino, piperazine or other group which increases water solubility),
  • X is H, F, CI, C[-C 3 alkyl (preferably methyl) or heterocycle (preferably an optionally substituted heterocycle, including a water soluble heterocycle, including as defined above for R 3 ), or a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
  • Still further preferred groups for inclusion in compounds according to the present invention include for example
  • n 0 or 1 ;
  • R is a linker or a linker attached to a group linked to the group through an amide, ester, ether, carbamate or heterocyclic group (preferably an optionally substituted heterocycle, including as defined above for R 3 );
  • R is H, F, CI, Ci-C 3 alkyl (optionally substituted with one or two hydroxyl groups, preferably methyl), -0-C(0)NR 3 R 4 or -C(0)NR 3 R 4 wherein each of R 3 and R 4 is independently H, Q- C 3 alkyl (preferably methyl), phenyl or heterocycle, including a water soluble heterocycle, or A pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
  • n 0 or 1
  • R is a linker or a linker attached to a group linked to the group through an amide, ester, ether, carbamate or heterocyclic group;
  • Each X is independently is H, F, CI, Q-C 3 alkyl (optionally substituted with one or two hydroxyl groups, preferably methyl), heterocyle (preferably an optionally substituted heterocycle, including a water soluble heterocycle, and/or as defined above for R 3 ), -O- C(0)NR 3 R 4 or -C(0)NR 3 R 4 wherein each of R 3 and R 4 is independently H, C C 3 alkyl (preferably methyl), or phenyl, or
  • n 0 or 1 ;
  • R is a linker or a linker attached to a group linked to the group through an amide, ester, ether, carbamate or heterocyclic group;
  • R 1 is C1-C3 alkyl, which is optionally substituted with one or two hydroxyl groups,
  • R 3 and R 4 are independently H, d-C 3 alkyl (preferably methyl), or phenyl;
  • X is independently is H, F, CI, C1-C3 alkyl (optionally substituted with one or two hydroxyl groups, preferably methyl) or heterocycle (preferably an optionally substituted heterocycle, including a water soluble heterocycle, and/or as defined above for R ), or a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
  • n 0 or 1 ;
  • R is a linker or a linker attached to a group linked to the group through an amide, ester, ether, carbamate or heterocyclic group;
  • R is H, Ci-C 3 alkyl, which is optionally substituted with one or two hydroxyl groups, -0-C(0)NR 3 R 4 or -C(0)NR 3 R 4 wherein each of R 3 and R 4 is independently H, d-C 3 alkyl (preferably methyl), or phenyl; and
  • Each X is independently is H, F, CI, C!-C 3 alkyl (optionally substituted with one or two hydroxyl groups, preferably methyl) or heterocycle (preferably an optionally substituted heterocycle, including a water soluble heterocycle and/or including as defined above for R 3 ), or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof.
  • particularly preferred compounds according to the present invention may be identified according to any one or more of the chemical structures as set forth in figure 19 hereof:
  • Ri PC Ri PC
  • R 2 pc R3P0 R4P0 R 5 pc, epc, R-7PC, R-SPC, R9P& Riopc, Rnpc , R12PC , Rnpc and Ri 4P c is a group
  • L is a linker group and is a protein targeting moiety
  • a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thererof is a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thererof.
  • R 7 pc, R 8 pc> R9PC5 RIOPC, Rnpc > RI2PC , Ri3PC and R 14P c is group and the other of groups R 1PC , R 2 pc, R3PC, ipe, R 5 pc, Repc, R7PC, RSPC, R9PC, RIOPC, Rnpc ,
  • R12PC Rope and Ri 4P care independently H or a CH 3 group, often H.
  • R 7 pc and Riopc are each independently a L- PTM
  • R 7 pc or RIOPC is a L- PTM
  • the compound has the chemical structure:
  • R 7 PC is a group, or
  • a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof is a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • the compound has the chemical structure:
  • R 7 pc, Rnpc, RI2PC, RI3PC andR 1 PC is a L- PTM
  • a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof is a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • the compound has the chemical structure:
  • RI3PC and R 14 pc are each independently a
  • R 4 pc, R 7 pc or one of Rj ⁇ PC, Ri 2 pc, ROPC and R 14 pc is a L- PTM
  • a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof is a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • RI IPC RI2PC, RI3PC and R 14 pc are each independently a group or H, or
  • a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof is preferably,
  • R.3PC, R 7 pc, Ri IPC, Ri2pc, Rope group and the other groups are H, or
  • a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof is a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • the compound has the chemical structure:
  • R 7 PC and Riopc are each independently a L- PTM
  • R 7 pc and Riopc is a L- PTM
  • a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof is a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • the compound has the chemical structure:
  • R 7 pc andRi 0 pc are each independently a group or H and R 8 PC is H or CH 3 , or
  • a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof is preferably,
  • R 7 PC and RIOPC are a group and the other group is H and R 8 pc is H, or
  • a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof is a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • the compound has the chemical structure:
  • R 7 pc andRiopc are each independently a group or H and
  • a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof is preferably,
  • R 7 pc and 10 pc is a group and the other group is H and R 8PC is H, or
  • a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof is a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • the compound has the chemical structure:
  • R 7 PC andRnopc is group and the other group is H and RSPC is H, or
  • a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof is a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • the compound has the chemical structure:
  • R 7 PC and Riopc are group and the other group is H, or
  • a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof is a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • the compound has the chemical structure:
  • R 7 pc and R 9 pc are each independently a L- PTM
  • R 7 pc and R pc are L- PTM
  • a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof is a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • the compound has the chemical structure:
  • n R 7 pc group or H and each of R 12 PC and R 13 PC is H or CH 3 , or
  • a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof is preferably,
  • R 7 PC and R 14 PC is a L- M
  • R 7 pc and R 14 pc group is H and each of R 12 pc and RI 3 PC is H,
  • a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof is a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • the compound has the chemical structure:
  • R PC and R 9 PC are each independently a group or H, or
  • R 7 PC and R 9 group and the other group is H, or
  • a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof is a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • the compound has the chemical structure:
  • R PC and R 9 pc are each independently a group or H, or
  • a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof is preferably,
  • R 7 pc and R 9 PC is a group and the other group is H, or
  • a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof is a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • the compound has the chemical structure:
  • R 7 PC andR 10 pc are each independently a L- PTM group or H and Rgpc is H or CH 3 , or
  • a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof is H and R 9 pc is H, or
  • a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof is a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
  • the linker group may be any linker group as described hereinabove, below is preferably a polyethylene glycol group ranging in size from about 1 to about 12 ethylene glycol units, between 1 and about 10 ethylene glycol units, about 2 about 6 ethylene glycol units, between about 2 and 5 ethylene glycol units, between about 2 and 4 ethylene glycole units.
  • the linker group L is a group:
  • Z is a group which links to X; and X is a group linking Z to group group).
  • Z is absent (a bond), -(CH 2 )j-0, -(CH 2 )j-S, -(CH 2 )j-N-R, a group wherein Xi Yj forms an amide group, or a urethane group, ester or thioester group, or a
  • Each R is H, or a d-C 3 alkyl, an alkanol group or a heterocycle (including a water soluble heterocycle, preferably, a morpholino , piperidine or piperazine group to promote water solubility of the linker group);
  • Each Y is independently a bond, O, S or N-R; and each i is independently 0 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5;
  • X is a
  • j is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5;
  • k is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5; preferably k is 1, 2, 3, 4, or 5;
  • m' is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5;
  • n is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, l to 8, 1 to 6, 1 , 2, 3, 4 or 5;
  • X 1 is O, S or N-R, preferably O;
  • a connector group (which may be a bond) which connects Z to X, when present in the linker group.
  • I 1 is a bond (absent), a heterocycle including a water soluble heterocycle such as a piperazinyl or other group or a group,
  • X 2 is O, S, NR 4 , S(O), S(0) 2 , -S(0) 2 0, -OS(0) 2 , or OS(0) 2 0;
  • X 3 is O, S, CHR 4 , NR 4 ;
  • R is H or a C ! -C 3 alkyl group optionally substituted with one or two hydroxyl groups, or a pharmaceutically acceptable salt, enantiomer or stereoisomer thereof.
  • the linker group is a (poly)ethyleneglycol having between 1 and about 100 ethylene glycol units, between about 1 and about 50 ethylene glycol units, between 1 and about 25 ethylene glycol units, between about 1 and 10 ethylene glycol units, between 1 and about 8 ethylene glycol units and 1 and 6 ethylene glycol units, between 2 and 4 ethylene glycol units.
  • the linker is nded to the group (including a ) f bl through an amide, ester, thioester, keto group, carbamate
  • the linker may be linked to an optionally substituted alkyl, alkylene, alkene or alkyne group, an aryl group or a heterocyclic group on the groups.
  • the group is a group, which binds to
  • Targets of the group are numerous in kind and are selected from proteins that are expressed in a cell such that at least a portion of the sequences is found in
  • protein includes oligopeptides and
  • polypeptide sequences of sufficient length that they can bind to a group according to the present invention Any protein in a eukaryotic system or a microbial system, including a virus, bacteria or fungus, as otherwise described herein, are targets for ubiquitination mediated by the compounds according to the present invention.
  • the target protein is a eukaryotic protein.
  • the protein binding moiety is a haloalkane
  • a halo group at the distil end of the alkyl group i.e., away from the linker or group
  • a dehalogenase enzyme in a patient or subject or in a diagnostic assay.
  • groups according to the present invention include, for example, include any moiety which binds to a protein specifically (binds to a target protein) and includes the following non-limiting examples of small molecule target protein moieties: Hsp90 inhibitors, kinase inhibitors, MDM2 inhibitors, compounds targeting Human BET Bromodomain- containing proteins, HDAC inhibitors, human lysine methyltransferase inhibitors,
  • angiogenesis inhibitors immunosuppressive compounds, and compounds targeting the aryl hydrocarbon receptor (AHR), among numerous others.
  • the compositions described below exemplify some of the members of these nine types of small molecule target protein binding moieties.
  • Such small molecule target protein binding moieties also include pharmaceutically acceptable salts, enantiomers, solvates and polymorphs of these compositions, as well as other small molecules that may target a protein of interest.
  • These binding moieties are linked to the ubiquitin ligase binding moiety preferably through a linker in order to present a target protein (to which the protein target moiety is bound) in proximity to the ubiquitin ligase for ubiquitination and degradation.
  • target proteins may include, for example, structural proteins, receptors, enzymes, cell surface proteins, proteins pertinent to the integrated function of a cell, including proteins involved in catalytic activity, aromatase activity, motor activity, helicase activity, metabolic processes (anabolism and catrabolism), antioxidant activity, proteolysis, biosynthesis, proteins with kinase activity, oxidoreductase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, ligase activity, enzyme regulator activity, signal transducer activity, structural molecule activity, binding activity (protein, lipid carbohydrate), receptor activity, cell motility, membrane fusion, cell communication, regulation of biological processes, development, cell differentiation, response to stimulus, behavioral proteins, cell adhesion proteins, proteins involved in cell death, proteins involved in transport (including protein transporter activity,
  • Proteins of interest can include proteins from eurkaryotes and prokaryotes including humans as targets for drug therapy, other animals, including domesticated animals, microbials for the determination of targets for antibiotics and other antimicrobials and plants, and even viruses, among numerous others.
  • the group is a haloalkyl group, wherein said alkyl group generally ranges in size from about 1 or 2 carbons to about 12 carbons in length, often about 2 to 10 carbons in length, often about 3 carbons to about 8 carbons in length, more often about 4 carbons to about 6 carbons in length.
  • the haloalkyl groups are generally linear alkyl groups (although branched-chain alkyl groups may also be used) and are end-capped with at least one halogen group, preferably a single halogen group, often a single chloride
  • Haloalkyl ' 1 groups for use in the present invention are preferably represented by the chemical structure -(CH 2 ) v -Halo where v is any integer from 2 to about 12, often about 3 to about 8, more often about 4 to about 6.
  • Halo may be any halogen, but is preferably CI or Br, more often CI.
  • the group is a
  • g roU p 5 where w is 0 to 3, preferably 1 or 2.
  • This group binds selectively to estrogen receptors and is useful for treating diseases which are modulated through estrogen receptors, and in particular cancers, such as breast cancer, endometrial cancer, ovarian cancer and uterine cancer, among others.
  • the present invention may be used to treat a number of disease states and/or conditions, including any disease state and/or condition in which proteins are dysregulated and where a patient would benefit from the degradation of proteins.
  • the present invention relates to pharmaceutical compositions comprising an effective amount of a compound as set forth hereinabove, in combination with a pharmaceutically acceptable carrier, additive or excipient, and optionally an additional bioactive agent.
  • the present invention relates to a method for treating a disease state by degrading a protein or polypeptide through which a disease state or condition is modulated comprising administering to said patient or subject an effective amount of at least one compound as described hereinabove, optionally in combination with an additional bioactive agent.
  • the method according to the present invention may be used to treat a large number of disease states or conditions including cancer, by virtue of the administration of effective amounts of at least one compound described herein.
  • compound refers to any specific chemical compound disclosed herein and includes tautomers, regioisomers, geometric isomers, and where applicable, stereoisomers, including optical isomers
  • the term compound generally refers to a single compound, but also may include other compounds such as stereoisomers, regioisomers and/or optical isomers (including racemic mixtures) as well as specific enantiomers or enantiomerically enriched mixtures of disclosed compounds.
  • the term also refers, in context to prodrug forms of compounds which have been modified to facilitate the administration and delivery of compounds to a site of activity. It is noted that in describing the present compounds, numerous substituents and variables associated with same, among others, are described. It is understood by those of ordinary skill that molecules which are described herein are stable compounds as generally described hereunder. When the bond is shown, both a double bond and single bond are represented within the context of the compound shown.
  • patient or “subject” is used throughout the specification to describe an animal, preferably a human or a domesticated animal, to whom treatment, including prophylactic treatment, with the compositions according to the present invention is provided.
  • patient refers to that specific animal, including a domesticated animal such as a dog or cat or a farm animal such as a horse, cow, sheep, etc.
  • patient refers to a human patient unless otherwise stated or implied from the context of the use of the term.
  • VCB E3 Ubiquitin Ligase "Hippel-Lindau E3 Ubiquitin Ligase” or "Ubiquitin Ligase” is used to describe a target enzyme(s) binding site of ubiquitin ligase moieties in the bifunctional (chimeric) compounds according to the present invention.
  • VCB E3 is a protein that in combination with an E2 ubiquitin-conjugating enzyme causes the attachment of ubiquitin to a lysine on a target protein; the E3 ubiquitin ligase targets specific protein substrates for degradation by the proteasome.
  • E3 ubiquitin ligase alone or in complex with an E2 ubiquitin conjugating enzyme is responsible for the transfer of ubiquitin to targeted proteins.
  • the ubiquitin ligase is involved in polyubiquitination such that a second ubiquitin is attached to the first, a third is attached to the second, and so forth.
  • Polyubiquitination marks proteins for degradation by the proteasome.
  • Mono-ubiquitinated proteins are not targeted to the proteasome for degradation, but may instead be altered in their cellular location or function, for example, via binding other proteins that have domains capable of binding ubiquitin. Further complicating matters, different lysines on ubiquitin can be targeted by an E3 to make chains. The most common lysine is Lys48 on the ubiquitin chain. This is the lysine used to make polyubiquitin, which is recognized by the proteasome.
  • protein target moiety or PTM is used to describe a small molecule which binds to a target protein or other protein or polypeptide of interest and places/presents that protein or polypeptide in proximity to an ubiquitin ligase such that degradation of the protein or polypeptide by ubiquitin ligase may occur.
  • small molecule target protein binding moieties include Hsp90 inhibitors, kinase inhibitors, MDM2 inhibitors, compounds targeting Human BET Bromodomain-containing proteins, HDAC inhibitors, human lysine methyltransferase inhibitors, angiogenesis inhibitors, immunosuppressive compounds, and compounds targeting the aryl hydrocarbon receptor (AHR), among numerous others.
  • AHR aryl hydrocarbon receptor
  • Protein target moieties according to the present invention include, for example, Haloalkane halogenase inhibitors, Hsp90 inhibitors, kinase inhibitors, MDM2 inhibitors, compounds targeting Human BET Bromodomain-containing proteins, HDAC inhibitors, human lysine methyltransferase inhibitors, angiogenesis inhibitors, immunosuppressive compounds, and compounds targeting the aryl hydrocarbon receptor (AHR).
  • Haloalkane halogenase inhibitors include, for example, Haloalkane halogenase inhibitors, Hsp90 inhibitors, kinase inhibitors, MDM2 inhibitors, compounds targeting Human BET Bromodomain-containing proteins, HDAC inhibitors, human lysine methyltransferase inhibitors, angiogenesis inhibitors, immunosuppressive compounds, and compounds targeting the aryl hydrocarbon receptor (AHR).
  • AHR aryl hydrocarbon receptor
  • compositions described below exemplify some of the members of these types of small molecule target protein binding moieties.
  • Such small molecule target protein binding moieties also include pharmaceutically acceptable salts, enantiomers, solvates and polymorphs of these compositions, as well as other small molecules that may target a protein of interest. References which are cited hereinbelow are incorporated by reference herein in their entirety.
  • HSP90 Heat Shock Protein 90
  • HSP90 inhibitors as used herein include, but are not limited to:
  • HSP90 inhibitors identified in Vallee, et al., "Tricyclic Series of Heat Shock Protein 90 (HSP90) Inhibitors Part I: Discovery of Tricyclic Imidazo[4,5-C]Pyridines as Potent Inhibitors of the HSP90 Molecular Chaperone (2011) J.Med.Chem. 54: 7206, including YKB
  • a linker group L group is attached via the terminal acetylene group
  • HSP90 inhibitors modified
  • J.MED.CHEM. vol: 51, pag:196 (2008) including the compound 2GJ (5- DIHYDROXY-5-( 1 -METHYLETHYL)PHENYL]-N-ETHYL-4-[4-(MORPHOLIN-4- LE-3 -C ARBOXAMIDE) having the structure:
  • HSP90 inhibitors modified (modified) identified in Wright, et ah, Structure-Activity Relationships in Purine-Based Inhibitor Binding to HSP90 Isoforms, Chem Biol. 2004 Jun;l l(6):775-85, including the HSP90 inhibitor PU3 having the structure:
  • Kinase inhibitors as used herein include, but are not limited to:
  • R is a linker group L or group attached via the ether group
  • R is a linker group L or a group attached to the pyrrole moiety
  • kinase inhibitors identified in Lountos, et ai "Structural Characterization of Inhibitor Complexes with Checkpoint Kinase 2 (Chk2), a Drug Target for Cancer Therapy", J.STRUCT.BIOL. vol:176, pag:292 (2011), including the kinase inhibitors XK9 and NXP (derivatized) having the structures:
  • butenamide (Derivatized where a linker group L or a group is attached preferably via the aliphatic amine group); 13.
  • the kinase inhibitor Fostamatinib (derivatized) ([6-( ⁇ 5-fluoro-2-[(3,4,5- trimethoxyphenyl)amino]pyrimidin-4-yl ⁇ amino)-2,2-dimethyl-3- oxo-2,3-dihydro-4H- pyrido[3,2-b]- -oxazin-4-yl]methyl disodium phosphate hexahydrate) (Derivatized where a
  • linker group L group is attached preferably via a methoxy group
  • group L or a group is attached preferably via a methoxy or ether group
  • Vandetanib (derivatized) ( V-(4-bromo-2-fluorophenyl)-6- methoxy-7-[(l -methylpiperidin-4-yl)methoxy]quinazolin-4-amine) (derivatized where a
  • linker group L or group is attached preferably via the methoxy or hydroxyl group); and 17.
  • the kinase inhibitor Vemurafenib (derivatized) (propane-l-sulfonic acid ⁇ 3-[5-(4- chlorophenyl)-lH-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl ⁇ -amide3
  • VEGFR3 inhibitor The kinase inhibitor Pazopanib (derivatized) (VEGFR3 inhibitor):
  • R is a linker group L or a — group preferably attached to the phenyl moiety or via the aniline amine group
  • R is a linker gro up L or a group attached preferably to the phenyl moiety
  • R is a linker group L or a attached preferably to the phenyl moiety
  • the kinase inhibitor Nilotanib (derivatized) Abl inhibitor Nilotanib (derivatized) Abl inhibitor:
  • R is a linker group L or a group attached to the phenyl moiety or the diazole group
  • R is a linker group L or a group attached preferably to the phenyl moiety
  • R is a linker group L or a attached to the phenyl moiety or a hydroxyl or ether group on the quinoline moiety
  • the inhibitor (derivatized) of BRAF (BRAF V600E )/MEK is attached preferably at R. 33.
  • MDM2 inhibitors as used herein include, but are not limited to:
  • Compounds targeting Human BET Bromodomain-containing proteins include, but are not limited to the compounds assoc below, where "R"
  • HDAC Inhibitors include, but are not limited to
  • Human Lysine Methyltransferase inhibitors include, but are not limited to:
  • Angiogenesis inhibitors include, but are not limited to:
  • GA-1 derivatized and derivatives and analogs thereof, having the structure(s) and binding to linkers as described in Sakamoto, et ah, Development of Protacs to target cancer- promoting proteins for ubiquitination and degradation, Mol Cell Proteomics 2003 Dec;2(12):1350-8;
  • Estradiol which may be bound to a linker group L or a
  • Estradiol, testosterone (derivatized) and related derivatives including but not limited to DHT and derivatives and analogs thereof, having the structure(s) and binding to a linker
  • Immunosuppressive compounds include, but are not limited to:
  • Glucocorticoids e.g., hydrocortisone, prednisone, prednisolone, and
  • Ciclosporin (Derivatized where a linker group or a
  • rapamycin Derivatized where a linker group L or a group can be bound, e.g. at one of the methoxy groups
  • AHR aryl hydrocarbon receptor
  • Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells, Science 10 September 2010: Vol. 329 no. 5997 pp. 1345-1348.
  • Thyroid Hormone Receptor Ligand (derivatized)
  • MOMO indicates a methoxymethoxy group
  • L is a linker group as otherwise described herein and said — ' rou is as otherwise
  • target protein is used to describe a protein or polypeptide, which is a target for binding to a compound according to the present invention and degradation by ubiquitin ligase hereunder.
  • target protein binding moieties also include pharmaceutically acceptable salts, enantiomers, solvates and polymorphs of these
  • compositions as well as other small molecules that may target a protein of interest.
  • binding moieties are linked to through linker groups L.
  • Target proteins which may be bound to the protein target moiety and degraded by the ligase to which the ubiquitin ligase binding moiety is bound include structural proteins, receptors, enzymes, cell surface proteins, proteins pertinent to the integrated function of a cell, including proteins involved in catalytic activity, aromatase activity, motor activity, helicase activity, metabolic processes (anabolism and catrabolism), antioxidant activity, proteolysis, biosynthesis, proteins with kinase activity, oxidoreductase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, ligase activity, enzyme regulator activity, signal transducer activity, structural molecule activity, binding activity (protein, lipid carbohydrate), receptor activity, cell motility, membrane fusion, cell communication, regulation of biological processes, development, cell differentiation, response to stimulus, behavioral proteins, cell adhesion proteins, proteins involved in cell death, proteins involved in transport (including protein transporter activity, nuclear transport, ion transporter activity, channel transporter activity, carrier activity,
  • Proteins of interest can include proteins from eurkaryotes and prokaryotes, including microbes, viruses, fungi and parasites, including humans, microbes, viruses, fungi and parasites, among numerous others, as targets for drug therapy, other animals, including domesticated animals, microbials for the determination of targets for antibiotics and other antimicrobials and plants, and even viruses, among numerous others
  • a number of drug targets for human therapeutics represent protein targets to which protein target moiety may be bound and incorporated into compounds according to the present invention.
  • proteins which may be used to restore function in numerous polygenic diseases including for example B7.1 and B7, TINFRlm, TNFR2, NADPH oxidase, BclIBax and other partners in the apotosis pathway, C5a receptor, HMG-CoA reductase, PDE V phosphodiesterase type, PDE IV phosphodiesterase type 4, PDE I, PDEII, PDEIII, squalene cyclase inhibitor, CXCR1, CXCR2, nitric oxide (NO) synthase, cyclo-oxygenase 1 , cyclo-oxygenase 2, 5HT receptors, dopamine receptors, G Proteins, i.e., Gq, histamine receptors, 5 -lipoxygenase, tryptase serine protease
  • Additional protein targets include, for example, ecdysone 20-monooxygenase, ion channel of the GABA gated chloride channel, acetylcholinesterase, voltage-sensitive sodium channel protein, calcium release channel, and chloride channels. Still further target proteins include Acetyl-CoA carboxylase,
  • adenylosuccinate synthetase adenylosuccinate synthetase, protoporphyrinogen oxidase, and enolpyruvylshikimate- phosphate synthase.
  • Haloalkane dehalogenase enzymes are another target of specific compounds according to the present invention.
  • Compounds according to the present invention which contain chloroalkane peptide binding moieties may be used to inhibit and/or degrade haloalkane dehalogenase enzymes which are used in fusion proteins or related dioagnostic proteins as described in PCT/US 2012/063401 filed December 6, 2011 and published as WO 2012/078559 on June 14, 2012, the contents of which is incorporated by reference herein.
  • disease state or condition is used to describe any disease state or condition wherein protein dysregulation (i.e., the amount of protein expressed in a patient is elevated) occurs and where degradation of one or more proteins in a patient may provide beneficial therapy or relief of symptoms to a patient in need thereof. In certain instances, the disease state or condition may be cured.
  • Disease states of conditions which may be treated using compounds according to the present invention include, for example, asthma, autoimmune diseases such as multiple sclerosis, various cancers, ciliopathies, cleft palate, diabetes, heart disease, hypertension, inflammatory bowel disease, mental retardation, mood disorder, obesity, refractive error, infertility, Angelman syndrome, Canavan disease, Coeliac disease, Charcot-Marie-Tooth disease, Cystic fibrosis, Duchenne muscular dystrophy, Haemochromatosis, Haemophilia, Klinefelter's syndrome, Neurofibromatosis, Phenylketonuria, Polycystic kidney disease, (PKDl) or 4 (PKD2) Prader-Willi syndrome, Sickle-cell disease, Tay-Sachs disease, Turner syndrome.
  • autoimmune diseases such as multiple sclerosis, various cancers, ciliopathies, cleft palate, diabetes, heart disease, hypertension, inflammatory bowel disease, mental retardation, mood disorder, obesity, refractive
  • Further disease states or conditions which may be treated by compounds according to the present invention include Alzheimer's disease, Amyotrophic lateral sclerosis (Lou Gehrig's disease), Anorexia nervosa, Anxiety disorder, Atherosclerosis, Attention deficit hyperactivity disorder, Autism, Bipolar disorder, Chronic fatigue syndrome, Chronic obstructive pulmonary disease, Crohn's disease, Coronary heart disease, Dementia,
  • Diabetes mellitus type 1 Diabetes mellitus type 2
  • Epilepsy Guillain-Barre syndrome, Irritable bowel syndrome, Lupus, Metabolic syndrome, Multiple sclerosis, Myocardial infarction, Obesity, Obsessive-compulsive disorder, Panic disorder, Parkinson's disease, Psoriasis, Rheumatoid arthritis, Sarcoidosis, Schizophrenia, Stroke, Thromboangiitis obliterans, Tourette syndrome, Vasculitis.
  • Still additional disease states or conditions which can be treated by compounds according to the present invention include aceruloplasminemia, Achondrogenesis type II, achondroplasia, Acrocephaly, Gaucher disease type 2, acute intermittent porphyria, Canavan disease, Adenomatous Polyposis Coli, ALA dehydratase deficiency, adenylosuccinate lyase deficiency, Adrenogenital syndrome, Adrenoleukodystrophy, ALA-D porphyria, ALA dehydratase deficiency, Alkaptonuria, Alexander disease, Alkaptonuric ochronosis, alpha 1- antitrypsin deficiency, alpha- 1 proteinase inhibitor, emphysema, amyotrophic lateral sclerosis Alstrom syndrome, Alexander disease, Amelogenesis imperfecta, ALA dehydratase deficiency, Anderson-Fabry disease, androgen insensitivity syndrome, Anemia
  • Arthrochalasis multiplex congenital (Ehlers-Danlos syndrome#arthrochalasia type) ataxia telangiectasia, Rett syndrome, primary pulmonary hypertension,
  • Sandhoff disease neurofibromatosis type II, Beare-Stevenson cutis gyrata syndrome, Mediterranean fever, familial, Benjamin syndrome, beta-thalassemia
  • thrombophilia Bloch- Sulzberger syndrome (incontinentia pigmenti), Bloom syndrome, X- linked sideroblastic anemia, Bonnevie-Ullrich syndrome (Turner syndrome), Bourneville disease (tuberous sclerosis), prion disease, Birt-Hogg-Dube syndrome, Brittle bone disease (osteogenesis imperfecta), Broad Thumb-Hallux syndrome (Rubinstein-Taybi syndrome), Bronze Diabetes/Bronzed Cirrhosis (hemochromatosis), Bulbospinal muscular atrophy (Kennedy's disease), Burger-Grutz syndrome (lipoprotein lipase deficiency), CGD Chronic granulomatous disorder, Campomelic dysplasia, biotinidase deficiency, Cardiomyopathy (Noonan syndrome), Cri du chat, CAVD (congenital absence of the vas deferens), Caylor cardiofacial syndrome (CBAVD), CEP (congenital erythropoietic porphyri
  • otospondylomegaepiphyseal dysplasia Lesch-Nyhan syndrome, galactosemia, Ehlers-Danlos syndrome, Thanatophoric dysplasia, Coffin-Lowry syndrome, Cockayne syndrome, (familial adenomatous polyposis), Congenital erythropoietic porphyria, Congenital heart disease, Methemoglobinemia/Congenital methaemoglobinaemia, achondroplasia, X-linked
  • Craniofacial dysarthrosis Crouzon syndrome
  • Creutzfeldt- Jakob disease prion disease
  • Cockayne syndrome Cowden syndrome
  • Curschmann-Batten-Steinert syndrome myotonic dystrophy
  • Beare-Stevenson cutis gyrata syndrome primary hyperoxaluria
  • spondyloepimetaphyseal dysplasia Strudwick type
  • muscular dystrophy Duchenne and Becker types (DBMD)
  • Usher syndrome Degenerative nerve diseases including de Grouchy syndrome and Dejerine-Sottas syndrome, developmental disabilities, distal spinal muscular atrophy, type V, androgen insensitivity syndrome, Diffuse Globoid Body Sclerosis (Krabbe disease), Di George's syndrome, Dihydrotestosterone receptor deficiency, androgen insensitivity syndrome, Down syndrome, Dwarfism, erythropoietic protoporphyria
  • PPH primary pulmonary hypertension
  • Fibrocystic disease of the pancreas Fibrocystic disease of the pancreas
  • fragile X syndrome fragile X syndrome
  • galactosemia galactosemia
  • genetic brain disorders Giant cell hepatitis (Neonatal)
  • hemochromatosis hematomosis
  • Gronblad-Strandberg syndrome pseudoxanthoma elasticum
  • Gunther disease congenital erythropoietic porphyria
  • haemochromatosis Hallgren syndrome
  • sickle cell anemia hemophilia
  • hepatoerythropoietic porphyria HEP
  • Hippel-Lindau disease von Hippel-Lindau disease
  • Huntington's disease Hutchinson-Gilford progeria syndrome (progeria), Hyperandrogenism
  • Hypochondroplasia Hypochromic anemia
  • Immune system disorders including X-linked severe combined immunodeficiency, Insley-Astley syndrome, Jackson- Weiss syndrome, Joubert syndrome, Lesch-Nyhan syndrome, Jackson- Weiss syndrome, Kidney diseases, including hyperoxaluria, Klinefelter's syndrome, Kniest dysplasia, Lacunar dementia,Langer-Saldino achondrogenesis, ataxi
  • SED Strudwick spondyloepimetaphyseal dysplasia, Strudwick type
  • SEDc pondyloepiphyseal dysplasia congenita
  • SEMD Strudwick type (spondyloepimetaphyseal dysplasia, Strudwick type), Shprintzen syndrome, Skin pigmentation disorders, Smith-Lemli-Opitz syndrome, South- African genetic porphyria (variegate porphyria), infantile-onset ascending hereditary spastic paralysis, Speech and communication disorders, sphingolipidosis, Tay-Sachs disease,
  • Xeroderma pigmentosum among others.
  • neoplasia or “cancer” is used throughout the specification to refer to the pathological process that results in the formation and growth of a cancerous or malignant neoplasm, i.e., abnormal tissue that grows by cellular proliferation, often more rapidly than normal and continues to grow after the stimuli that initiated the new growth cease.
  • malignant neoplasms show partial or complete lack of structural organization and functional
  • neoplasia is used to describe all cancerous disease states and embraces or encompasses the pathological process associated with malignant hematogenous, ascitic and solid tumors.
  • Exemplary cancers which may be treated by the present compounds either alone or in combination with at least one additional anti-cancer agent include squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, and renal cell carcinomas, cancer of the bladder, bowel, breast, cervix, colon, esophagus, head, kidney, liver, lung, neck, ovary, pancreas, prostate, and stomach; leukemias; benign and malignant lymphomas, particularly Burkitt's lymphoma and Non-Hodgkin's lymphoma; benign and malignant melanomas; myeloproliferative diseases; sarcomas, including Ewing's sarcoma, hemangiosarcoma, Kaposi's sarcoma, liposarcoma, myosarcomas, peripheral neuroepithelioma, synovial sarcoma, gliomas, astrocytomas, oligodendro
  • Additional cancers which may be treated using compounds according to the present invention include, for example, T-lineage Acute lymphoblastic Leukemia (T-ALL), T-lineage lymphoblastic Lymphoma (T-LL), Peripheral T-cell lymphoma, Adult T-cell Leukemia, Pre- B ALL, Pre-B Lymphomas, Large B-cell Lymphoma, Burkitts Lymphoma, B-cell ALL, Philadelphia chromosome positive ALL and Philadelphia chromosome positive CML,
  • T-ALL T-lineage Acute lymphoblastic Leukemia
  • T-LL T-lineage lymphoblastic Lymphoma
  • Peripheral T-cell lymphoma Peripheral T-cell lymphoma
  • Adult T-cell Leukemia Pre- B ALL, Pre-B Lymphomas, Large B-cell Lymphoma
  • Burkitts Lymphoma B-cell ALL, Philadelphia chromosome positive ALL and Philadelphia chromosome positive CML
  • bioactive agent is used to describe an agent, other than a compound according to the present invention, which is used in combination with the present compounds as an agent with biological activity to assist in effecting an intended therapy, inhibition and/or prevention/prophylaxis for which the present compounds are used.
  • Preferred bioactive agents for use herein include those agents which have pharmacological activity similar to that for which the present compounds are used or administered and include for example, anti-cancer agents, antiviral agents, especially including anti-HIV agents and anti-HCV agents, antimicrobial agents, antifungal agents, etc.
  • additional anti-cancer agent is used to describe an anti-cancer agent, which may be combined with compounds according to the present invention to treat cancer.
  • agents include, for example, everolimus, trabectedin, abraxane, TLK 286, AV-299, DN-101, pazopanib, GSK690693, RTA 744, ON 0910.Na, AZD 6244 (ARRY- 142886), AMN-107, TKI-258, GSK461364, AZD 1152, enzastaurin, vandetanib, ARQ-197, MK-0457, MLN8054, PHA-739358, R-763, AT-9263, a FLT-3 inhibitor, a VEGFR inhibitor, an EGFR TK inhibitor, an aurora kinase inhibitor, a PIK-1 modulator, a Bel -2 inhibitor, an HDAC inhbitor, a c-MET inhibitor, a PARP inhibitor, a Cdk inhibitor,
  • KRN951 aminoglutethimide, arnsacrine, anagrelide, L-asparaginase, Bacillus Calmette- Guerin (BCG) vaccine, adriamycin, bleomycin, buserelin, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, diethylstilbestrol, epirubicin, fludarabine, fludrocortisone, fluoxymesterone, flutamide, gleevec, gemcitabine, hydroxyurea, idarubicin, ifosfamide, imatinib, leuprolide, levamisole, lomustine, mechlorethamine, melphalan, 6-mercaptopurine, mesna, methotrexate, mit
  • LY293646 wortmannin, ZM336372, L-779,450, PEG-filgrastim, darbepoetin, erythropoietin, granulocyte colony-stimulating factor, zolendronate, prednisone, cetuximab, granulocyte macrophage colony-stimulating factor, histrelin, pegylated interferon alfa-2a, interferon alfa- 2a, pegylated interferon alfa-2b, interferon alfa-2b, azacitidine, PEG-L-asparaginase, lenalidomide, gemtuzumab, hydrocortisone, interleukin-11, dexrazoxane, alemtuzumab, all- transretinoic acid, ketoconazole, interleukin-2, megestrol, immune globulin, nitrogen mustard, methylprednisolone, ibritgumom
  • metoclopramide metoclopramide, lorazepam, alprazolam, haloperidol, droperidol, dronabinol, dexamethasone, methylprednisolone, prochlorperazine, granisetron, ondansetron, dolasetron, tropisetron, pegfilgrastim, erythropoietin, epoetin alfa, darbepoetin alfa and mixtures thereof.
  • anti-HIV agent or “additional anti-HIV agent” includes, for example, nucleoside reverse transcriptase inhibitors (NRTI), other non-nucloeoside reverse transcriptase inhibitors (NRTI), other non-nucloeoside reverse transcriptase inhibitors (NRTI), other non-nucloeoside reverse transcriptase inhibitors (NRTI), other non-nucloeoside reverse transcriptase inhibitors (NRTI), other non-nucloeoside reverse transcriptase inhibitors (NRTI), other non-nucloeoside reverse
  • transcriptase inhibitors i.e., those which are not representative of the present invention
  • protease inhibitors fusion inhibitors, among others, exemplary compounds of which may include, for example, 3TC (Lamivudine), AZT (Zidovudine), (-)-FTC, ddl (Didanosine), ddC (zalcitabine), abacavir (ABC), tenofovir (PMPA), D-D4FC (Reverset), D4T (Stavudine), Racivir, L-FddC, L-FD4C, NVP (Nevirapine), DLV (Delavirdine), EFV (Efavirenz), SQVM (Saquinavir mesylate), RTV (Ritonavir), IDV (Indinavir), SQV (Saquinavir), NFV
  • fusion inhibitors such as T20, among others, fuseon and mixtures thereof, including anti-HIV compounds presently in clinical trials or in development.
  • TMC125 Trovirdine
  • Ly300046.HCl MKC-442 (emivirine, coactinon), HI-236, HI-240, HI-280, HI-281, rilpivirine (TMC-278), MSC-127, HBY 097, DMP266, Baicalin (TJN-151)
  • ADAM-II Metal-II (Methyl 3',3'-dichloro-4',4"-dimethoxy-5',5"-bis(methoxycarbonyl)-6,6- diphenylhexenoate), Methyl 3-Bromo-5-(l-5-bromo-4-methoxy-3- (methoxycarbonyl)phenyl)hept- 1 -enyl)-2-methoxybenzoate (Alkenyl diary lmethane analog, Adam analog), 5C13PhS-2IndolCONH2 (5-chloro-3-(phenylsulfmyl)-2
  • pharmaceutically acceptable salt is used throughout the specification to describe, where applicable, a salt form of one or more of the compounds described herein which are presented to increase the solubility of the compound in the gastic juices of the patient's gastrointestinal tract in order to promote dissolution and the bioavailability of the compounds.
  • Pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic bases and acids, where applicable. Suitable salts include those derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium, magnesium and ammonium salts, among numerous other acids and bases well known in the pharmaceutical art. Sodium and potassium salts are particularly preferred as neutralization salts of the phosphates according to the present invention.
  • any pharmaceutically acceptable prodrug form such as an ester, amide other prodrug group
  • any pharmaceutically acceptable prodrug form such as an ester, amide other prodrug group
  • hydrocarbyl shall mean a compound which contains carbon and hydrogen and which may be fully saturated, partially unsaturated or aromatic and includes aryl groups, alkyl groups, alkenyl groups and alkynyl groups.
  • alkyl shall mean within its context a linear, branch-chained or cyclic fully saturated hydrocarbon radical or alkyl group, preferably a Cj-Cio, more preferably a Cj-C6, alternatively a Cj-C? alkyl group, which may be optionally substituted.
  • alkyl groups are methyl, ethyl, n-butyl, sec-butyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, isopropyl, 2-methylpropyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclopentylethyl, cyclohexylethyl and cyclohexyl, among others.
  • compounds according to the present invention which may be used to covalently bind to dehalogenase enzymes.
  • These compounds generally contain a side chain (often linked through a polyethylene glycol group) which terminates in an alkyl group which has a halogen substituent (often chlorine or bromine) on its distil end which results in covalent binding of the compound containing such a moiety to the protein.
  • a side chain often linked through a polyethylene glycol group
  • a halogen substituent often chlorine or bromine
  • Alkynyl refers to linear, branch- chained or cyclic C 2 -C 10 (preferably C 2 -C 6 ) hydrocarbon radicals containing at least one C ⁇ C bond.
  • alkylene when used, refers to a -(CH 2 ) n - group (n is an integer generally from 0-6), which may be optionally substituted.
  • the alkylene group preferably is substituted on one or more of the methylene groups with a Ci-C 6 alkyl group (including a cyclopropyl group or a t-butyl group), more preferably a methyl group, but may also be substituted with one or more halo groups, preferably from 1 to 3 halo groups or one or two hydroxyl groups, 0-(C ! -C 6 alkyl) groups or amino acid sidechains as otherwise disclosed herein.
  • a Ci-C 6 alkyl group including a cyclopropyl group or a t-butyl group
  • halo groups preferably from 1 to 3 halo groups or one or two hydroxyl groups, 0-(C ! -C 6 alkyl) groups or amino acid sidechains as otherwise disclosed herein.
  • an alkylene group may be substituted with a urethane or alkoxy group (or other group) which is further substituted with a polyethylene glycol chain (of from 1 to 10, preferably 1 to 6, often 1 to 4 ethylene glycol units) to which is substituted (preferably, but not exclusively on the distal end of the polyethylene glycol chain) an alkyl chain substituted with a single halogen group, preferably a chlorine group.
  • a polyethylene glycol chain of from 1 to 10, preferably 1 to 6, often 1 to 4 ethylene glycol units
  • the alkylene (often, a methylene) group may be substituted with an amino acid sidechain group such as a sidechain group of a natural or unnatural amino acid, for example, alanine, ⁇ -alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamic acid, glutamine, glycine, phenylalanine, histidine, isoleucine, lysine, leucine, methionine, proline, serine, threonine, valine, tryptophan or tyrosine.
  • an amino acid sidechain group such as a sidechain group of a natural or unnatural amino acid, for example, alanine, ⁇ -alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamic acid, glutamine, glycine, phenylalanine, histidine, isoleucine, lysine, leucine, methion
  • unsubstituted shall mean substituted only with hydrogen atoms.
  • a range of carbon atoms which includes C 0 means that carbon is absent and is replaced with H.
  • a range of carbon atoms which is C 0 -C 6 includes carbons atoms of 1, 2, 3, 4, 5 and 6 and for Co, H stands in place of carbon.
  • substituted or “optionally substituted” shall mean independently (i.e., where more than substituent occurs, each substituent is independent of another substituent) one or more substituents (independently up to five substitutents, preferably up to three substituents, often 1 or 2 substituents on a moiety in a compound according to the present invention and may include substituents which themselves may be further substituted) at a carbon (or nitrogen) position anywhere on a molecule within context, and includes as substituents hydroxyl, thiol, carboxyl, cyano (C ⁇ N), nitro (N0 2 ), halogen (preferably, 1 , 2 or 3 halogens, especially on an alkyl, especially a methyl group such as a trifluoromethyl), an alkyl group (preferably, C 1 -C 10 ; more preferably, Q-C 6 ), aryl (especially phenyl and substituted phenyl for example benzyl or benzoyl), alkoxy group
  • Substituents according to the present invention may include, for example -SiRiR 2 R 3 groups where each of Ri and R 2 is as otherwise described herein and R 3 is H or a Ci-C 6 alkyl group, preferably R 1 ? R 2 , R 3 in this context is a C!-C 3 alkyl group (including an isopropyl or t-butyl group).
  • Each of the above-described groups may be linked directly to the substituted moiety or alternatively, the substituent may be linked to the substituted moiety (preferably in the case of an aryl or heteraryl moiety) through an optionally substituted -(CH 2 ) m - or alternatively an optionally substituted -(OCH 2 ) m -, -(OCH 2 CH 2 ) m - or - (CH 2 CH 2 0) m - group, which may be substituted with any one or more of the above-described substituents.
  • Alkylene groups -(CH 2 ) m - or -(CH 2 ) n - groups or other chains such as ethylene glycol chains, as identified above, may be substituted anywhere on the chain.
  • Preferred substitutents on alkylene groups include halogen or C C 6 (preferably C!-C 3 ) alkyl groups, which may be optionally substituted with one or two hydroxyl groups, one or two ether groups (0-Ci-C 6 groups), up to three halo groups (preferably F), or a sideshain of an amino acid as otherwise described herein and optionally substituted amide (preferably carboxamide substituted as described above) or urethane groups (often with one or two C 0 -C 6 alkyl substitutents, which group(s) may be further substituted).
  • the alkylene group (often a single methylene group) is substituted with one or two optionally substituted Ci-Ce alkyl groups, preferably C]-C 4 alkyl group, most often methyl or O-methyl groups or a sidechain of an amino acid as otherwise described herein.
  • a moiety in a molecule may be optionally substituted with up to five substituents, preferably up to three substituents. Most often, in the present invention moieties which are substituted are substituted with one or two substituents.
  • substituted (each substituent being independent of any other substituent) shall also mean within its context of use C!-C 6 alkyl, C!-C alkoxy, halogen, amido, carboxamido, sulfone, including sulfonamide, keto, carboxy, Q-Q ester (oxyester or carbonylester), C Q keto, urethane -0-C(0)-NR 1 R 2 or -N(R 1 )-C(0)-0-R 1 , nitro, cyano and amine (especially including a Q-Q alkylene-NRiR 2 , a mono- or di- Ci-C 6 alkyl substituted amines which may be optionally substituted with one or two hydroxyl groups).
  • Ri and R 2 are each, within context, H or a Ci-C 6 alkyl group (which may be optionally substituted with one or two hydroxyl groups or up to three halogen groups, preferably fluorine).
  • substituted shall also mean, within the chemical context of the compound defined and substituent used, an optionally substituted aryl or heteroaryl group or an optionally substituted heterocyclic group as otherwise described herein.
  • Alkylene groups may also be substituted as otherwise disclosed herein, preferably with optionally substituted C ! -C 6 alkyl groups (methyl, ethyl or hydroxymethyl or
  • hydroxyethyl is preferred, thus providing a chiral center), a sidechain of an amino acid group as otherwise described herein, an amido group as described hereinabove, or a urethane group 0-C(0)-NR!R 2 group where Rj and R 2 are as otherwise described herein, although numerous other groups may also be used as substituents.
  • Various optionally substituted moieties may be substituted with 3 or more substituents, preferably no more than 3 substituents and preferably with 1 or 2 substituents.
  • aryl or "aromatic”, in context, refers to a substituted (as otherwise described herein) or unsubstituted monovalent aromatic radical having a single ring (e.g. , benzene, phenyl, benzyl) or condensed rings (e.g., naphthyl, anthracenyl, phenanthrenyl, etc.) and can be bound to the compound according to the present invention at any available stable position on the ring(s) or as otherwise indicated in the chemical structure presented.
  • aryl groups in context, may include heterocyclic aromatic ring systems
  • heteroaryl groups having one or more nitrogen, oxygen, or sulfur atoms in the ring
  • heteroaryl groups which may be mentioned include nitrogen- containing heteroaryl groups such as pyrrole, pyridine, pyridone, pyridazine, pyrimidine, pyrazine, pyrazole, imidazole, triazole, triazine, tetrazole, indole, isoindole, indolizine, azaindolizine, purine, indazole, quinoline, dihydroquinoline, tetrahydroquinoline,
  • heterocycle refers to a cyclic group which contains at least one
  • heteroatom i.e., 0, N or S
  • heteroaryl may be aromatic (heteroaryl) or non-aromatic.
  • heteroaryl moieties are subsumed under the definition of heterocycle, depending on the context of its use.
  • Exemplary heteroaryl groups are described hereinabove.
  • Exemplary non- aromatic heterocyclic groups for use in the present invention include, for example,
  • pyrrolidinyl pyrrolinyl, piperidinyl, piperazinyl, N-methylpiperazinyl, pyrazolidinyl, imidazolidinyl, morpholinyl, tetrahydropyranyl, azetidinyl, oxetanyl, oxathiolanyl, pyridone, 2-pyrrolidone, ethyleneurea, 1,3-dioxolane, 1,3-dioxane, 1,4-dioxane, phthalimide and succinimide, among others, as described herein.
  • treat refers to any action providing a benefit to a patient for which the present compounds may be administered, including the treatment of any disease state or condition which is modulated through the protein to which the present compounds bind.
  • Disease states or conditions, including cancer, which may be treated using compounds according to the present invention are set forth hereinabove.
  • co-administration shall mean that at least two compounds or compositions are administered to the patient at the same time, such that effective amounts or concentrations of each of the two or more compounds may be found in the patient at a given point in time.
  • compounds according to the present invention may be co-administered to a patient at the same time, the term embraces both administration of two or more agents at the same time or at different times, provided that effective concentrations of all coadministered compounds or compositions are found in the subject at a given time.
  • one or more of the present compounds described above are coadministered in combination with at least one additional bioactive agent, especially including an anticancer agent.
  • the co-administration of compounds results in synergistic therapeutic, including anticancer therapy.
  • compositions comprising combinations of an effective amount of at least one bifunctional compound according to the present invention, and one or more of the compounds otherwise described herein, all in effective amounts, in combination with a pharmaceutically effective amount of a carrier, additive or excipient, represents a further aspect of the present invention.
  • the present invention includes, where applicable, the compositions comprising the pharmaceutically acceptable salts, in particular, acid or base addition salts of compounds of the present invention.
  • the acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds useful in this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., l, -methylene-bis-(2-hydroxy-3 naphtho
  • Pharmaceutically acceptable base addition salts may also be used to produce pharmaceutically acceptable salt forms of the compounds or derivatives according to the present invention.
  • pharmaceutically acceptable base salts of the present compounds that are acidic in nature are those that form non-toxic base salts with such compounds.
  • non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (eg., potassium and sodium) and alkaline earth metal cations (eg, calcium, zinc and magnesium), ammonium or water-soluble amine addition salts such as N- methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines, among others.
  • the compounds of the present invention may, in accordance with the invention, be administered in single or divided doses by the oral, parenteral or topical routes.
  • Administration of the active compound may range from continuous (intravenous drip) to several oral administrations per day (for example, Q.I.D.) and may include oral, topical, parenteral, intramuscular, intravenous, sub-cutaneous, transdermal (which may include a penetration enhancement agent), buccal, sublingual and suppository administration, among other routes of administration.
  • Enteric coated oral tablets may also be used to enhance bioavailability of the compounds from an oral route of administration. The most effective dosage form will depend upon the pharmacokinetics of the particular agent chosen as well as the severity of disease in the patient.
  • Administration of compounds according to the present invention as sprays, mists, or aerosols for intra-nasal, intra-tracheal or pulmonary
  • compositions comprising an effective amount of compound according to the present invention, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.
  • Compounds according to the present invention may be administered in immediate release, intermediate release or sustained or controlled release forms. Sustained or controlled release forms are preferably administered orally, but also in suppository and transdermal or other topical forms. Intramuscular injections in liposomal form may also be used to control or sustain the release of compound at an injection site.
  • the compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers and may also be administered in controlled-release formulations.
  • Pharmaceutically acceptable carriers that may be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as prolamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene- polyoxypropylene-block polymers, polyethylene glycol and wool fat.
  • ion exchangers alumina, aluminum stearate, lecithin
  • serum proteins such as human serum albumin
  • buffer substances such as phosphates, glycine, sorbic
  • compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic,
  • compositions are administered orally, intraperitoneally or intravenously.
  • Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1, 3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are examples of acceptable vehicles and solvents that may be employed.
  • any bland fixed oil may be employed including synthetic mono- or di-glycerides.
  • Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as Ph. Helv or similar alcohol.
  • the pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
  • carriers which are commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried corn starch.
  • aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
  • compositions of this invention may be administered in the form of suppositories for rectal administration.
  • suppositories for rectal administration.
  • a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
  • suitable non-irritating excipient include cocoa butter, beeswax and polyethylene glycols.
  • compositions of this invention may also be administered topically. Suitable topical formulations are readily prepared for each of these areas or organs. Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-acceptable transdermal patches may also be used.
  • the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers.
  • Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
  • the compounds may be coated onto a stent which is to be surgically implanted into a patient in order to inhibit or reduce the likelihood of occlusion occurring in the stent in the patient.
  • compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2- octyldodecanol, benzyl alcohol and water.
  • the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with our without a preservative such as
  • compositions may be formulated in an ointment such as petrolatum.
  • compositions of this invention may also be administered by nasal aerosol or inhalation.
  • Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance
  • bioavailability fluorocarbons, and/or other conventional solubilizing or dispersing agents.
  • the amount of compound in a pharmaceutical composition of the instant invention that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host and disease treated, the particular mode of administration.
  • compositions should be formulated to contain between about 0.05 milligram to about 750 milligrams or more, more preferably about 1 milligram to about 600 milligrams, and even more preferably about 10 milligrams to about 500 milligrams of active ingredient, alone or in combination with at least one other compound according to the present invention.
  • a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease or condition being treated.
  • a patient or subject in need of therapy using compounds according to the present invention can be treated by administering to the patient (subject) an effective amount of the compound according to the present invention including pharmaceutically acceptable salts, solvates or polymorphs, thereof optionally in a pharmaceutically acceptable carrier or diluent, either alone, or in combination with other known erythopoiesis stimulating agents as otherwise identified herein.
  • These compounds can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, including
  • transdermally in liquid, cream, gel, or solid form, or by aerosol form.
  • the active compound is included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient a therapeutically effective amount for the desired indication, without causing serious toxic effects in the patient treated.
  • a preferred dose of the active compound for all of the herein-mentioned conditions is in the range from about 10 ng/kg to 300 mg/kg, preferably 0.1 to 100 mg/kg per day, more generally 0.5 to about 25 mg per kilogram body weight of the recipient/patient per day.
  • a typical topical dosage will range from 0.01 -5% wt/wt in a suitable carrier.
  • the compound is conveniently administered in any suitable unit dosage form, including but not limited to one containing less than lmg, 1 mg to 3000 mg, preferably 5 to 500 mg of active ingredient per unit dosage form.
  • An oral dosage of about 25-250 mg is often convenient.
  • the active ingredient is preferably administered to achieve peak plasma
  • concentrations of the active compound of about 0.00001-30 mM, preferably about 0.1-30 ⁇ . This may be achieved, for example, by the intravenous injection of a solution or formulation of the active ingredient, optionally in saline, or an aqueous medium or administered as a bolus of the active ingredient. Oral administration is also appropriate to generate effective plasma concentrations of active agent.
  • the concentration of active compound in the drug composition will depend on absorption, distribution, inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the
  • compositions and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.
  • the active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
  • Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound or its prodrug derivative can be incorporated with excipients and used in the form of tablets, troches, or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a dispersing agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a dispersing agent such as alginic acid, Primogel, or corn starch
  • a lubricant such as magnesium stearate or Sterotes
  • a glidant such as colloidal silicon dioxide
  • the active compound or pharmaceutically acceptable salt thereof can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like.
  • a syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
  • the active compound or pharmaceutically acceptable salts thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as erythropoietin stimulating agents, including EPO and darbapoietin alfa, among others.
  • erythropoietin stimulating agents including EPO and darbapoietin alfa
  • one or more compounds according to the present invention are coadministered with another bioactive agent, such as an erythropoietin stimulating agent or a would healing agent, including an antibiotic, as otherwise described herein.
  • Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • the parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • preferred carriers are physiological saline or phosphate buffered saline (PBS).
  • the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
  • Liposomal suspensions may also be pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811 (which is incorporated herein by reference in its entirety).
  • liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container.
  • An aqueous solution of the active such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol
  • the container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
  • the pyrrolidine amine may be protected and the carboxylic acid moiety may be condensed with a nucleophilic group on a right hand fragment to provide an amide on the right hand portion of the pyrrolidine moiety.
  • the left and right hand fragments to be condensed onto, respectively, the amine and carboxylic acid group of the pyrrolidine moiety are preferably prepared prior to condensing onto the pyrrolidine group, but other approaches may be taken to introduce groups onto the pyrrolidine group.
  • the individual components which are combined to produce a ULM group can be prepared using blocking groups at preferred functional groups on the ULM group which can be removed so as to react with and covalently link a linker group which is prepared to accommodate a PTM moiety to which is already bound a protein binding moiety, or PTM group or may be further reacted to form a covalent bound with a PTM group, which may also may comprise a ULM' group as otherwise described herein.
  • a carboxylic acid containing left hand fragment may be condensed onto the amine group of the pyrroline, thus forming an amide group with an R 1 left hand fragment as depicted below.
  • any number of nucleophilic (preferably, amine containing) right hand fragments may be condensed onto the carboxyl group to provide an amide group with an R 2 right fragment as depicted below.
  • Formation of the pre-synthesized groups to condense onto the amine and/or the carboxyl moiety of the pyrrolidine proceeds in a facile manner.
  • Virtually any compound can be synthesized readily using this approach.
  • the solid phase synthetic method can also be used and employs similar methods used in the solution phase synthesis, the major difference being that the hydroxyl group may be bound to a solid support as the other steps of the synthesis occur.
  • Solid-phase synthesis makes it easier to conduct multistep reactions and to drive reactions to completion, because excess reagents can be added and then easily washed away after each reaction step.
  • Another key factor in favor of solid-phase synthesis is that it makes it possible to use split synthesis, a technique developed in 1982.
  • Split synthesis produces large support-bound libraries in which each solid-phase particle holds a single compound, or soluble libraries produced by cleavage of compounds from the solid support. For example in a split synthesis method if you have 3 compound addition steps with 10 compounds used at each step i.e. 10 containers for those compounds. This will generate 10 3 compounds.
  • Solution phase chemistry is favored by many for library construction due to the wider range of organic reactions available for solution-phase synthesis, the technology used traditionally by most synthetic organic chemists, and products in solution can be more easily identified in standard drug target assays and characterized.
  • a problem for solution-phase synthesis of one molecule at a time is the final purification that can be both expensive and slow. Chromatography is commonly a first resort since it usually works.
  • the problems associated with solution chemistry are compounded when attempting to make tens of thousands of compounds to generate a library or a "book' for a library.
  • the present invention provides a mechanism to overcome these problems in drug and small molecule discovery.
  • the target protein-binding element of the compounds of the invention has been identified. These optimal binding molecules are then subjected to further chemistry to add the ubiquitin ligase binding moiety (ULM), pursuant to the disclosure of the present application.
  • ULM ubiquitin ligase binding moiety
  • An alternative approach to the discovery of the target protein-binding moiety is based on solution phase screening. In such an example compounds (available either via synthesis, natural products or from companies such as ArQule (www.arqule.com), Pharmacopeia (www.pharmacopiea), and Cerep (www.cerep.com) are obtained and added to the target protein of interest and then subjected to size exclusion to remove the unbound compounds.
  • the protein bound fraction is then subjected to GC/MS to identify the molecules. In this way the solution phase screening is made rapid and facile for compounds in solution..
  • ligand binding including, for example, detecting changes in the Tm of the protein upon the ligand binding, among others.
  • Target protein is selected, for example, an enzyme or protein involved in a particular biological process.
  • Target protein for the subject invention come from numerous fields where small molecules are used to achieve modulation of a biological system in eukaryotic organisms. Examples of such fields are antivirals, antimicrobials, anti-parasitics, or other drug targets in a human patient, which may be rather diverse, etc.
  • the target protein is then either purified from a natural source in order to provide sufficient material for the screen or expressed via recombinant methods to provide sufficient material for the screens.
  • the target protein is then either labeled directly with a detectable species such as a radioactive, electrochemiluminescent, and chemiluminescent or fluorescent label or with an indirectly detectable species such as an enzyme, or particle.
  • a detectable species such as a radioactive, electrochemiluminescent, and chemiluminescent or fluorescent label or with an indirectly detectable species such as an enzyme, or particle.
  • an antibody or equivalent with binding activity to the target protein is labeled.
  • the next step is to provide a library of compounds for screening.
  • a library of from 1,000 to 1,000,000 is typical of the size that is screened. These are available from a series of companies, which are well known in the art. These libraries of compounds are used to screen for the binding of the target protein. Ideally compounds are bought still bound to the solid phase or are screened for binding directly to immobilized target protein using methods as described below for screening. It is also possible to generate a chemical library of various potential binding molecules bound to a solid phase following conventional methods to give rise to differing potential compounds. The optimal methods for the construction of the chemical library is to employ the methods of split synthesis coupled to the solid phase (as outlined above).
  • the library is generated using a series of solid phase chemistries such as to give rise to various compilations that form the basis of a library.
  • the library is screened in the form of a library or in the form of the compilations. Typically one would take the products from the split synthesis and pool the solid phase and use this as the basis for the screen.
  • a mixture of buffer, detergents, salts and blocking agents such as serum albumin or other proteins are added.
  • This buffer addition step is used to block the beads or solid phase in such a way that any significant non-specific binding of the selected target protein does not occur.
  • the beads are washed and followed by the addition of the target protein either labeled or not.
  • the beads or solid phase are then incubated to allow the binding of the target protein binding elements to the target protein.
  • the beads are washed and then the binding of the labeled target protein detected directly.
  • the beads are then placed in to a substrate reaction solution to detect the presence of the enzyme label.
  • an enzyme label substrates for these detection methods are based on insoluble chromogenic products.
  • the beads are subjected to another binding reaction where the antibody or equivalent, is labeled either directly or indirectly as suggested for the labeling of the target protein. It is also possible at this step to not use a labeled antibody or equivalent and to add a further step where the labeled antibody or equivalent is used. These additional steps can be detected using the same standard methods known in the art as suggested for the directly labeled target protein.
  • a series of beads are identified and these beads are selected from the bead population and subject to analysis to determine the structure of the binding molecule that is able to bind the target protein as in this example. This is achieved by the use of GC/MS or via molecular tags used during the construction of the library as described earlier. Alternatively, a pool which was positive is re-made generating a series of sub pools for screening and further re-synthesis and dividing out of the various pooled compounds until a single compound is presented in a single well for analysis allowing the determination of the active compound.
  • This method can be repeated and/or adapted for identifying peptide target binding moieties (PTM) for virtually any target protein.
  • the step of screening for specific molecules is made easy in the invention as only binding activity is desired and not specific modulation of the target protein as is required in traditional drug discovery.
  • a library of compounds for screening One can buy a library of compounds for screening.
  • the library may be constructed using a series of chemical methods resulting in pools of the solid phase used during synthesis, which form the basis of the entries which make up the library.
  • the solid phase pools are stored in sub-pools in the libraries. These so called entries and sub-pools form the basis for screening as they contain not only pools of compounds but also a known chemical-coupling step used in synthesis.
  • the library can then be screened using two approaches.
  • the solid phase from the chemical library to be screened is subjected incubation with assay buffers with blocking agents such as for example; proteins (i.e. BSA, gelatin), polyvinylpyrrolidone, ficoll, heparin, detergents (i.e. SDS, Tween, NP40, Triton X-100).
  • This incubation step is to block the non-specific binding sites on the solid phase used in the generation of the library and allow the determination of specific binding events.
  • This initial incubation is an art recognized step in various binding assays such as ELISA, southerns, westerns etc.
  • the protein of interest is then added to a buffer which typically has the same composition as that during the blocking step but can also be modified using lower or no additional blocking agents with the exception of the detergents which are typically always present during a binding reaction.
  • the entries following the blocking step are then subjected to binding with the purified target protein.
  • the solid phase from this incubation is then washed and subjected to a second binding step with a labeled reagent which binds to the tag sequence added to the receptor sub-unit during the recombinant engineering for the expression of the receptor sub-unit.
  • a labeled reagent which binds to the tag sequence added to the receptor sub-unit during the recombinant engineering for the expression of the receptor sub-unit.
  • an antibody to this tag recognizes the tag sequence; examples that are in common use are the myc, flag, arid his epitopes.
  • the presence of the labeled binding species is detected by the presence of the label that is typically an enzyme such as alkaline phosphatase or peroxidase.
  • the detection step typically makes use of an insoluble chromogenic substrate that is readily detected by eye or by image analysis systems.
  • soluble substrates can also be used and screened using ELISA plate readers, eye or other spectrophotometric methods.
  • the various entries from the library are screened by eye to look for beads that have developed a color due to the enzymatic action on the chromogenic substrate. These colored beads indicate that the receptor subunit is binding to one of the compounds within the group of entries the next step is to determine if these so called positive group of entries contain specific binding or if binding is just to the tag binding reagent or some non-specific activation of the chromogenic substrate. To achieve this, the positive entries are screened with out the specific binding step to the receptor sub-unit.
  • This resynthesis results in the formation of a new series of solid phase compound pools which have the last two chemical coupling steps known.
  • This new series of solid phase compound pools are screened as in the initial screen and positive pools are checked as previously for the binding specificity to identify positive pools.
  • the positive pool(s) now allow the re-synthesis of the pool(s) with the last two steps for the generation of the compound, which specifically binds to the receptor subunit.
  • the positive pools are then subjected to the same cycle of re-synthesis and screening as just described but with the last two chemical coupling steps know the pools are maintained individually prior to the last know step. In this way the synthesis of the specific compound able to bind to the receptor sub-unit is deconvoluted from the chemical library and identified.
  • the positive solid phase is removed from the screen and collected. These are then subjected to the cleavage reaction, which removed the specific chemistry from the solid phase followed by the analysis of the various chemical species using GC to separate the individual compounds followed by MS to determine the molecular weight. This information coupled with the synthesis methods used is used to determine the compound identity. After the determination of these various candidate specific binding molecules they are then re-synthesized and subjected to the binding assay to check if these are the specific compounds that resulted in the positive solid phases.
  • the compounds of the invention are then subject to analysis to determine which of the compounds from the chemical library screen with which of the individual ubiquitin ligase binding moiety element is able to function most effectively in the targeted ubiquitination and/or degradation of the target protein.
  • the ubiquitin ligase binding moiety may be determined by the methods as otherwise described in the examples section hereinbelow.
  • the compounds of the invention can be tested in a mammalian tissue culture system where the target protein either intact or as an engineered fragment is expressed.
  • the compounds effect on the target protein's level is determined by making use of the tag sequence which can be engineered into the recombinant expression of the target protein during the construction of the mammalian tissue culture test system.
  • the tag sequence is used to determine the levels of the target protein during the incubation with the potential compounds screened and synthesized as described above.
  • This assay for the tag sequence can take the form of a western blot or via an ELISA, for example.
  • Other tags, which are valuable to use are those based on the green fluorescent protein, which allows the analysis of protein levels in living cells and/or organisms.
  • the compounds that show the optimal activity in the test systems will then form the basis for the next stage of drug development. In this next stage these selected compounds are subjected to the recognized drug development path.
  • the drug development path determines the potential value of the compounds by evaluating a series of factors including
  • This invention also relates to a method for the control of protein levels with a cell. This is based on the use of compounds of the invention, which are known to interact with a specific target protein such that degradation of a target protein in vivo will result in the control of the amount of protein in a biological system, prerferably to a particular therapeutic benefit.
  • compounds of the invention which are known to interact with a specific target protein such that degradation of a target protein in vivo will result in the control of the amount of protein in a biological system, prerferably to a particular therapeutic benefit.
  • the following examples are used to assist in describing the present invention, but should not be seen as limiting the present invention in any way.
  • 16 1 and 2 were synthesized to test a promising design featuring an isoxazole moiety positioned to interact with a crystallographic water observed in the structure of VHL bound to the HIF peptide (549-582) 14 and a benzyl group stacked along the side chain of Tyr98.
  • aAverage IC50 values were determined from three independent trials, each in triplicate.
  • VHL ligands ability of VHL ligands to compete for the HIF la binding site on VCB was determined through a fluorescence polarization competition assay as described in the literature (Buckley et al. J ACS, 2012, 134, 4465 ⁇ 1468).
  • HPLC was performed using a Dynamax SD200 solvent delivery system connected to a Dynamax UV-1 Absorbance Detector with a YMC-Pack ODS-AM preparative column (250 x 20 mm, 5 ⁇ particle size, 12 nm pore size).
  • a linear gradient of MeCN in H 2 0 from 20% to 100% MeCN, with constant 0.1% TFA was run over 40 minutes.
  • Method F subsumes methods C, D and E and is a general method which proceeds through commercially available amines.
  • Fmoc-Hyp(OtBu)OH (24.9 g, 60.8 mmol, 1 eq) was dissolved in DMF (300 mL) at room temperature.
  • Sodium bicarbonate (12.8 g, 152 mmol, 2.5 eq) was added, followed by allyl bromide (25.3 mL, 300 mmol, 4.9 eq).
  • the solution was fitted with an air condenser and heated to 50 °C for 20 hours. It was then cooled to room temperature, diluted with EtOAc, washed with aqueous 1 M HC1, saturated sodium bicarbonate, water and brine. The organic layer was dried with sodium sulfate, filtered and condensed.
  • Fmoc-Hyp(OtBu)-OAllyl (23.42 g, 52.1 mmol) was dissolved in DCM (306 mL) at room temperature. TFA (54 mL, 15% vol/vol) was added and the solution was stirred for 13 hours. The solution was poured into water, neutralized by slow addition of saturated aqueous sodium bicarbonate and extracted twice with DCM and once with EtOAc. The combined organic layers were dried with sodium sulfate, filtered and condensed. Purification by column chromatography (30 to 80% EtOAc/hexanes) gave Fmoc-Hyp(OH)-OAllyl as a yellowish oil (16.7 g, 42.4 mmol, 81%). ! H and 13 C NMR spectra matched those reported in the
  • Fmoc-Hyp(OWang)-OAllyl resin (1 eq) was swelled DMF, then reacted with 20% piperidine in DMF for 30 minutes. The resin was then washed once with piperidine, and reacted again with 20% piperidine for 30 minutes to ensure complete deprotection. The resin was then washed twice with DMF and once with MeOH followed by DCM. The resulting free amine was then coupled with 3-methyl-5-isoxazoleacetic acid (4 eq), PyBOP (4 eq) HOBt (4 eq) and DIPEA (7 eq) in DMF for 4 hours. The resin was then washed thrice with DMF and twice with MeOH followed by DCM.
  • the resin was then swelled with freshly distilled DCM, and reacted with Pd(PPh 3 ) 4 (0.1 eq) and PhSiH 3 (10 eq) for 30 minutes.
  • the resin was then washed once with DCM, and reacted again with Pd(PPh 3 ) 4 (0.1 eq) and PhSiH 3 (10 eq) in distilled DCM for 30 minutes, after which the resin was washed twice with DMF and once with MeOH followed by DCM.
  • the resulting carboxylic acid was then coupled with the appropriate amine (or a salt of the appropriate amine), RN3 ⁇ 4 (4 eq) with PyBOP (4 eq), HOBt (4 eq) and DIPEA (7 eq for free amines, 8 eq for amine salts) in DMF for 4 hours.
  • the resin was then washed 5 times with DMF, thrice with MeOH and 5 times with DCM.
  • the resin was then reacted with 20% TFA in DCM for 2 hours.
  • the reaction mixture was then drained and the resin was washed with DCM. Condensation under reduced pressure, and purification by column chromatography (1% to 10% 0.5M NH 3 in MeOH/DCM desired VHL ligand.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)

Description

Compounds and Methods for the Enhanced Degradation of Targeted Proteins and
Other Polypeptides by an E3 Ubiquitin Ligase
Field of the Invention
The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins, which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand, which binds to the VHL E3 ubiquitin
ULM
ligase (defined as a ubiquitin ligand binding moiety or group) and on the other end a moiety, which binds a target protein (defined as a protein/polypeptide targeting moiety or
PTM
group) such that the target protein/polypeptide is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.
Related Applications and Grant Support
This application claims the benefit of priority of provisional application
US61/585,769, of identical title, filed January 12, 2011, the entire contents of which are incorporated by reference herein.
This invention was made with government support under grant no. AI084140 of the National Institutes of Health. The government has certain rights in the invention.
Background of the Invention
E3 ubiquitin ligases (of which over 600 are known in humans)1 confer substrate specificity for ubiquitination and are more attractive therapeutic targets than general proteasome inhibitors3'4 due to their specificity for certain protein substrates. Although the development of ligands of E3 ligase has proven challenging, in part due to the fact that they must disrupt protein-protein interactions5 recent developments have provided specific ligands which bind to these ligases. Protein-protein interaction interactions are notoriously difficult to target using small molecules due to their large contact surfaces and the shallow grooves or flat interfaces involved. Conversely, most small molecule drugs bind enzymes or receptors in tight and well-defined pockets.6 Since the discovery of nutlins, the first small molecule E3 ligase inhibitors,7 additional compounds have been reported that target Inhibitors of
Apoptosis Proteins (IAPs),8>9 sCFMet30,10 and SCFcdc4;n however, the field remains underdeveloped.
One E3 ligase with exciting therapeutic potential is the von Hippel-Lindau (VHL) tumor suppressor, the substrate recognition subunit of the E3 ligase complex VCB, which also consists of elongins B and C, Cul2 and Rbxl. The primary substrate of VHL is
Hypoxia Inducible Factor la (HIF- la), a transcription factor that upregulates genes such as the pro-angiogenic growth factor VEGF and the red blood cell inducing cytokine
erythropoietin in response to low oxygen levels. While HIF- la is constitutively expressed, its intracellular levels are kept very low under normoxic conditions via its hydroxylation by prolyl hydroxylase domain (PHD) proteins and subsequent VHL-mediated ubiquitination (Figure 1).
Using rational design, we have generated the first small molecule ligands of Von Hippel Lindau (VHL), the substrate recognition subunit of the E3 ligase VCB, an important target in cancer, chronic anemia and ischemia.2 We have also obtained crystal structures of VHL with our most potent ligand, 15, confirming that the compound mimics the binding mode of the transcription factor HIF- la, the major substrate of VHL.
From earlier biochemical and structural studies of a hydroxylated HIF peptide bound to VHL, it became clear that hydroxyproline played an important role in mediating this protein:protein interaction. As a consequence of that work, the present inventors developed a hydroxylated HIF peptide:VHL fluorescence polarization (FP) binding assay with which they assayed >120 compounds possessing the central hydroxyproline residue flanked by non- peptidic moieties. Further to that research, the inventors now have developed co-crystal structures of VHL complexed with seven of the top compounds. Analysis of these ligand bound structures is driving the design/synthesis of the next generation of VHL ligands, which are linked with protein binding moieties to produce bifunctional compounds according to the present invention. . A principal rationale for the present invention is the need for a small molecule E3 ligase ligand for our PROTAC (Proteolysis Targeting Chimera) technology. This technology brings targeted proteins/polypeptides to E3 ligases for ubiquitination and subsequent proteasomal degradation. In several proof-of-concept experiments, the present inventors demonstrated the utility of this approach using the short peptide sequence from HIF that binds VHL. In order to make a more 'drug-like' PROTAC, the inventors have replaced the HIF peptide with a 'small molecule' VHL ligand, thus providing a means to recruit proteins to E3 ligases for ubiquitination and degradation, to the endpoint of providing therapies based upon this protein degradation.
Objects of the Invention
It is an object of the invention to provide compounds which function to recruit endogenous proteins to E3 Ubiquitin Ligase for degradation.
It is an additional object of the invention to provide compounds which modulate protein degradation in a patient or subject and can be used for treating disease states or conditions which are modulated through the degraded protein.
It is another object of the invention to provide pharmaceutical compositions based upon the above-described modulators, especially including inhibitors for therapeutic treatment of a patient or subject, preferably including a human patient or subject.
It is also an object of the invention to provide methods for determining protein binding moieties which bind to proteins of interest.
It is yet another object of the invention to provide methods for identifying endogenous proteins in a biological system, especially including a human system, which bind to protein binding moieties in compounds according to the present invention.
It is still another object of the invention to provide methods for identifying the effects of the degradation of proteins of interest in a biological system using compounds according to the present invention. It is still another aspect of the invention to provide methods for treating patients where the degradation of a targeted protein will produce an intended therapeutic effect.
It is another object of the invention to provide compounds and compositions which may be used in a first medical application.
It is yet another aspect of the invention to provide compounds and/or compositons which are used for treating patients where the degradation of a targeted protein will produce an intended therapeutic effect.
Any one or more of these and/or other objects of the invention may be readily gleaned from a routine scrutiny of the description of the invention which follows.
Brief Description of the Figures
Figure 1 shows (A) HIF-l accumulation leads to the transcriptional upregulation of genes involved in the hypoxic response, such as erythropoietin and VEGF. (B) Under normoxic conditions, HIF-la is hydroxylated, recognized by VHL, ubiquitinated and degraded by the proteasome, preventing transcriptional upregulation.
Figure 2. WaterLOGS Y NMR spectroscopy shows binding of 3, but not L-Hyp or NAc-Hyp-NMe to VHL.
Figure 3 shows a pictorial representation shows the key interactions between 15 and
VHL.
Figure 4 shows the 2.9 A co-crystal structure of 15 (lightest gray carbons) bound to VHL indicates that its binding mimics that of the HIF-la peptide (light gray carbons, pdb 1LM817)
Figure 5 shows the crystal structures of V54BC apo (A) and in complex with 15 (B). Electron density (2F0-FC) superimposed around Hyp binding site residues (sticks, yellow carbons) and conserved water molecules (red dots), and 15 (sticks, cyan carbons) are shown in blue and are contoured at 1.2σ. The protein surface is shown in green at 50% transparency.
Figures 6-12A and B show the activity of individual compounds according to the present invention in the described VHL polarization/displacement assay. Compounds according to the present invention are indicated with numerals at the top of each graph.
Control compound is presented in figure 15 B and served as minimum polarization
(maximum displacement) for comparison purposes. The percent inhibition as presented was determined by normalizing to maximum and minimum polarization, and graphed against the log [VL]. ICso values were determined using Prism 5 for each replicate (n=9), where were then averaged to determine the average IC50 and the standard of error of the mean (SEM).
Figure 13 (along with Table 2- Affinity Table) shows numerous exemplary
compounds according to the present invention.
Figure 14 shows numerous preferred compounds from Table 2 according to the present invention.
Figure 15 shows a further number of compounds according to the present invention and their activity. Most compounds are active below concentrations of 100 μΜ.
Figure 16 shows numerous preferred compounds from Figure 15 according to the present invention.
Figure 17 shows eight particularly preferred compounds from Figure 15 according to the present invention.
Figure 18 shows six preferred compounds according to the present invention which contain estrogen binding protein targeting moieties linked to preferred ubiquitin ligand binding moieties.
Figure 19 shows a genus of preferred compounds according to the present invention. Brief Description of the Invention
The present invention is based on the discovery that an ubiquitin pathway protein ubiquitinates any target protein once the ubiquitin pathway protein and the target protein are placed in proximity by a chimeric construct that binds the ubiquitin pathway protein and the target protein. Accordingly the present invention provides a composition that results in the ubiquitination of a chosen target protein. The present invention also provides a library of compositions and the use thereof.
In one embodiment, the present invention provides a composition useful for regulating protein activity. The composition comprises a ubiquitin pathway protein binding moiety (preferably for an E3 ubiquitin ligase, alone or in complex with an E2 ubiquitin conjugating enzyme which is responsible for the transfer of ubiquitin to targeted proteins) according to a defined chemical structure and a protein targeting moiety which are linked together, preferably through a linker, wherein the ubiquitin pathway protein binding moiety recognizes an ubiquitin pathway protein and the targeting moiety recognizes a target protein and wherein the ubiquitin pathway protein binding moiety is coupled to the targeting moiety.
In another embodiment, the present invention provides a library of compounds. The library comprises more than one compound wherein each composition has a formula of A-B, wherein A is a ubiquitin pathway protein binding moiety (preferably, an E3 ubiquitin ligase moiety as otherwise disclosed herein) and B is a protein binding member of a molecular library, wherein A is coupled (preferably, through a linker moiety) to B, and wherein the ubiquitin pathway protein binding moiety recognizes an ubiquitin pathway protein, in particular, an E3 ubiquitin ligase. In a particular embodiment, the library contains a specific ubiquitination recognition peptide of VHL for an E3 ubiquitin ligase (ubiquitin pathway protein binding moiety as otherwise disclosed herein) with random target protein binding elements (e.g., a chemical compound library). As such, the target protein is not determined in advance and the method can be used to determine the activity of a putative protein binding element and its pharmacological value as a target upon degradation by ubiquitin ligase.
In still another embodiment, the present invention provides a method of screening a library of the present invention to identify a compound containing a targeting moiety, which recognizes a target protein associated with a predetermined function of a cell. The method comprises incubating a cell with a pool of entities from the library; monitoring the predetermined function of the cell; identifying a pool of entities that change the
predetermined function of the cell; incubating the cell with a composition from the identified pool of entities; monitoring the predetermined function of the cell; and identifying a composition that changes the predetermined function of the cell, wherein the identified composition contains a targeting moiety which recognizes a target protein associated with the predetermined function.
In another embodiment, the present invention provides a method of screening a library of the present invention to identify a composition containing a targeting moiety, which recognizes a target protein associated with a predetermined function of a cell. The method comprises incubating a cell with each composition from the library; monitoring the predetermined function of the cell; identifying a composition that changes the predetermined function of the cell; wherein the identified composition contains a targeting moiety, which recognizes a target protein associated with the predetermined function.
In still another embodiment, the present invention provides a method of identifying a target protein associated with a predetermined function of a cell. The method comprises incubating a cell with a composition from the library of the present invention; monitoring the predetermined function of the cell; identifying a composition that changes the predetermined function of the cell; identifying a target protein that binds to the identified composition, wherein the target protein is associated with the predetermined function of the cell.
In yet another embodiment, the present invention provides a method of identifying a target protein associated with a predetermined function of a cell. The method comprises incubating a cell with a pool of entities from the library of the present invention; monitoring the predetermined function of the cell; identifying a pool of entities that change the predetermined function of the cell; incubating the cell with a composition from the identified pool of entities; monitoring the predetermined function of the cell; identifying a composition that changes the predetermined function of the cell; and identifying a target protein that binds to the identified composition, wherein the target protein is associated with the predetermined function of the cell.
In yet another embodiment, the present invention provides a method of ubiquitinating/degrading a target protein in a cell. The method comprises administering a bifunctional composition comprising an ubiquitin pathway protein binding moiety and a targeting moiety, preferably linked through a linker moiety, as otherwise described herein, wherein the ubiquitin pathway protein binding moiety is coupled to the targeting moiety and wherein the ubiquitin pathway protein binding moiety recognizes a ubiquitin pathway protein (e.g., an ubiquitin ligase, preferably an E3 ubiquitin ligase) and the targeting moiety recognizes the target protein such that degradation of the target protein will occur when the target protein is placed in proximity to the ubiquitin ligase, thus resulting in
degradation/inhibition of the effects of the target protein and the control of protein levels. The control of protein levels afforded by the present invention provides treatment of a disease state or condition, which is modulated through the target protein by lowering the level of that protein in the cells of a patient.
In another embodiment, the present invention is directed to a method of treating a patient in need for a disease state or condition modulated through a protein where the degradation of that protein will produce a therapeutic effect in that patient, the method comprising administering to a patient in need an effective amount of a compound according to the present invention, optionally in combination with another bioactive agent. The disease state or condition may be a disease caused by a microbial agent or other exogenous agent such as a virus, bacteria, fungus, protozoa or other microbe or may be a disease state, which is caused by overexpression of a protein, which leads to a disease state and/or condition.
In one embodiment, the present invention is directed to a compound according to the structure:
ULM
is a linker group and
Figure imgf000009_0001
is a ubiquitin ligase binding moiety, wherein said linker group is optionally further
PTM
linked to a group. In another embodiment, the present invention is directed to a compound which
PTM
comprises a group according to the general structure:
Figure imgf000010_0001
ULM
Where is an ubiquitin ligase binding moiety, preferably a ligand, which binds an ubiquitin ligase, preferably an E3 ubiquitin ligase;
PTM
is a chemical moiety (protein targeting moiety), which binds to a target protein or polypeptide, which is ubiquitinated by an ubiquitin ligase and is chemically linked directly to
ULM PTM ULM
the group or through a linker moiety L, or is alternatively a
group which also an ubiquitin ligase binding moiety, which may be the same or different than
ULM ULM
the group and is linked directly to the group directly or through the linker moiety; and
L is a linker moiety which may be present or absent and which chemically (covalently) links
Figure imgf000010_0002
Or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate or polymorph thereof.
In certain aspects of the invention, where
Figure imgf000010_0003
group, the compound resembles a dimeric compound where both ends of the compound comprise an ubiquitin ligase binding moiety as otherwise described herein.
ULM ULM
In preferred aspects of the invention, and where present, , are each independently a group according to the chemical structure:
Figure imgf000011_0001
Where R1 is an optionally substituted Ci-C alkyl group, an optionally substituted
-(CH2)nOH, an optionally substituted -(CH2)nSH, an optionally substituted (CH2)n-0-(Cr C6)alkyl group, an optionally substituted (CH2)n-WCOCW-(Co-C6)alkyl group containing an epoxide moiety WCOCW where each W is independently H or a Q-C3 alkyl group, an optionally substituted -(CH2)„COOH, an optionally substituted -(CH2)nC(0)-(Ci-C6 alkyl), an optionally substituted -(CH2)nNHC(0)-R1, an optionally substituted -(CH2)nC(0)-NRjR2, an optionally substituted -(CH2)nOC(0)-NRiR2, -(CH20)nH, an optionally substituted - (CH2)nOC(0)-(Ci-C6 alkyl), an optionally substituted -(CH2)nC(0)-0-(C1-C6 alkyl), an optionally substituted
-(CH20)nCOOH, an optionally substituted -(OCH2)nO-(d-C6 alkyl), an optionally substituted -(CH20)nC(0)-(Cj-C6 alkyl), an optionally substituted -(OCH2)nNHC(0)-Ri, an optionally substituted -(CH20)nC(0)-NR1R2, -(CH2CH20)nH, an optionally substituted
-(CH2CH20)nCOOH, an optionally substituted -(OCH2CH2)nO-(C1-C6 alkyl), an optionally substituted -(CH2CH20)nC(0)-(C C6 alkyl), an optionally substituted
-(OCH2CH2)nNHC(0)-Ri, an optionally substituted -(CH2CH20)nC(0)-NR1R2,an optionally substituted -S02Rs, an optionally substituted S(0)Rs, N02, CN or halogen (F, CI, Br, I, preferably F or CI);
Ri and R2 are each independently H or a Ci-C^ alkyl group which may be optionally substituted with one or two hydroxyl groups or up to three halogen groups (preferably fluorine);
Rs is a C C6 alkyl group, an optionally substituted aryl, heteroaryl or heterocycle group or a -(CH2)mNR!R2 group,
X and X' are each independently C=0, C=S, -S(O), S(0)2 , (preferably X and X' are both C=0); 2'
R is an optionally substituted -(CH2)n-(C=0)u(NRi)v(S02)walkyl group, an optionally substituted -(CH2)n-(C=0)u(NR1)v(S02)wNR1NR2N group, an optionally substituted -(CH2)n- (C=0)u(NR1)v(S02)w-Aryl, an optionally substituted
-(CH2)n-(C=O)u(NR1)v(S02)w-Heteroaryl, an optionally substituted
-(CH2)n-(C=O)vNR1(S02)w-Heterocycle, an optionally substituted
-NR1-(CH2)n-C(0)u(NRi)v(S02)w-alkyl, an optionally substituted
-NR1-(CH2)n-C(0)u(NR1)v(S02)w- NR1NR2N, an optionally substituted
-NR1-(CH2)„-C(0)u(NRi)v(S02)w-NR1C(0)R1N, an optionally substituted
-NR1-(CH2)n-(C=0)u(NR1)v(S02)w-Aryl, an optionally substituted
-NR1-(CH2)n-(C=0)u(NR1)v(S02)w-Heteroaryl or an optionally substituted
-NR1-(CH2)n-(C=0)vNRi(S02)w-Heterocycle, an optionally substituted
-X -alkyl group; an optionally substituted
-X - Aryl group; an optionally substituted
-Xm - Heteroaryl group; an optionally substituted
-X - Heterocycle group; an optionally substituted;
R is an optionally substituted alkyl, an optionally substituted
-(CH2)n-C(0)u(NR1)v(S02)w-alkyl, an optionally substituted
-(CH2)„-C(0)u(NR1)v(S02)w-NR1NR2N, an optionally substituted
-(CH2)n-C(0)u(NRi)v(S02)w-NR1C(0)R1N, an optionally substituted
-(CH2)n-C(0)u(NR1)v(S02)w-C(0)NR1R2, an optionally substituted
-(CH2)n-C(0)u(NRi)v(S02)w-Aryl, an optionally substituted
-(CH2)n-C(0)u(NR1)v(S02)w-Heteroaryl, an optionally substituted
-(CH2)n-C(0)u(NR1)v(S02)w-Heterocycle, an optionally substituted
-NR1-(CH2)„-C(0)u(NR1)v(SO2)w-alkyl, an optionally substituted
-NR1-(CH2)n-C(0)u(NR1)v(S02)w- NR1NR2N, an optionally substituted
-NR1-(CH2)n-C(0)u(NR1)v(SO2)w- NRiC(0)RiN, an optionally substituted
-NR1-(CH2)n-C(0)u(NR1)v(S02)w-Aryl, an optionally substituted
-NR1-(CH2)n-C(0)u(NRi)v(SO2)w-Heteroaryl, an optionally substituted
-NR1-(CH2)n-C(0)u(NR1)v(S02)w-Heterocycle, an optionally substituted
-O-(CH2)n-(C=O)u(NR v(SO2)w-alkyl, an optionally substituted
-0-(CH2)n-(C=0)u(NR1)v(S02)w-NRiNR2N, an optionally substituted
-0-(CH2)n-(C=0)u(NRi)v(S02)w-NR1C(0)R1N, an optionally substituted
-O-(CH2)n-(C=O)u(NR v(SO2)w-Aryl, an optionally substituted -0-(CH2)n-(C=0)u(NRi)v(S02)w-Heteroaryl or an optionally substituted
-0-(CH2)n- (C=0)u(NR1)v(S02)w-Heterocycle;
-(CH2)n-(V)n'-(CH2)n-(V)n'-alkyl group, an optionally substituted
-(CH2)n-(V)n'-(CH2)n-(V)n-Aryl group, an optionally substituted
-(CH2)n-(V)n'-(CH2)n-(V)n'-Heteroaryl group, an optionally substituted
-(CH2)n-(V)n'-(CH2)n-(V)n'-Heterocycle group, an optionally substituted
-(CH2)n-N(R1-)(C=0)m'-(V)n'-alkyl group, an optionally substituted
-(CH2)n-N(R1')(C=0)m'-(V)n'-Aryl group, an optionally substituted
-(CH2)„-N(R1
Figure imgf000013_0001
group, an optionally substituted
-(CH2)n-N(R1')(C=0)m'-(V)n'-Heterocycle group, an optionally substituted
-XR3 - alkyl group; an optionally substituted
-X - Aryl group; an optionally substituted
-XR3 - Heteroaryl group; an optionally substituted
-X - Heterocycle group; an optionally substituted;
Where RIN and R2 are each independently H, Ci-C6 alkyl which is optionally substituted with one or two hydroxyl groups and up to three halogen groups or an optionally substituted
-(CH2)n-Aryl, -(CH2)n-Heteroaryl or -(CH2)n-Heterocycle group;
V is O, S or NRi;
Ri is the same as above;
R1 and Rp are each independently H or a Cj-C3 alkyl group;
X^' and X*3' are each independently an optionally substituted -CH2)n-, -CH2)n-
CH(XV)=CH(XV)- (cis or trans), -CH2)n-CH≡CH- , -(CH2CH20)n- or a C3-C6 cycloalkyl group, where Xv is H, a halo or a Cj-C3 alkyl group which is optionally substituted;
Each m is independently 0, 1, 2, 3, 4, 5, 6;
Each m' is independently 0 or 1 ;
Each n is independently 0, 1, 2, 3, 4, 5, 6;
Each n' is independently 0 or 1 ;
Each u is independently 0 or 1 ;
Each v is independently 0 or 1 ;
Each w is independently 0 or 1 ; and
ULM
wherein any one or more of Rr, R2', R3,, X and X' of is modified to be covalently
PTM
bonded to the group through a linker group when
Figure imgf000013_0002
, or when PTM ULM' ULM
, any one or more of R1', R2', R3', X and X' of each of and
Figure imgf000014_0001
are modified to be covalently bonded to each other directly or through a group, or
a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
ULM ULM'
In alternative aspects of the present invention and when present, are each independently a group according to the chemical structure
R1'
Figure imgf000014_0002
Wherein each of R r1 , R 2' and RJ 3' are the same as above and X is C=0, C=S, -S(O) group or a S(0)2 group, more preferably a C=0 group, and
wherein any one or more ofR\ R and RJ are modified to bind a linker group to which is further covalently bonded to the
Figure imgf000014_0003
, or when
Figure imgf000014_0004
, any one or more ofR^ R^ R^ ofeach of
Figure imgf000014_0005
are modified to be covalently bonded to each other directly or through a linker group, or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof.
ULM
In still further preferred aspects of the invention, and when
ULM
present, are each independently according to the chemical structure:
Figure imgf000015_0001
wherein any one or more ofR\ R and RJ are modified to bind a linker group to which is further covalently bonded to the
Figure imgf000015_0002
, or when
Figure imgf000015_0003
, any one or more ofR' , R , RJ of each of
Figure imgf000015_0004
are modified to be covalently bonded to each other directly or through a linker group, or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof.
In further preferred aspects of the invention, R1 is preferably a hydroxyl group or a group which may be metabolized to a hydroxyl or carboxylic group, such that the compound represents a prodrug form of an active compound. Exemplary preferred R groups include, for example, -(CH2)nOH, (CH2)n-0-(Ci-C6)alkyl group, -(CH2)nCOOH, -(CH20)nH, an optionally substituted -(CH2)nOC(0)-(C1-C6 alkyl), or an optionally substituted -(CH2)nC(O)- 0-(C!-C6 alkyl), wherein n is 0 or 1. Where R1 is or contains a carboxylic acid group, a hydroxyl group or an amine group, the hydroxyl group, carboxylic acid group or amine (each of which may be optionally substituted), may be further chemically modified to provide a
PTM ULM
covalent link to a linker group to which the group (including a group) is bonded.
X and X', where present, are preferably a C=0, C=S, -S(O) group or a S(0)2 group, more preferably a C=0 group. preferably an optionally substituted -NR -T-Aryl, an optionally substituted -NR^T-Heteroaryl group or an optionally substituted -NR'-T-Heterocycle, where R1 is H or CH3, preferably H and T is an optionally substituted -(CH2)n- group, wherein each one of the methylene groups may be optionally substituted with one or two substituents, preferably selected from halogen, an amino acid sidechain as otherwise described herein or a Cj-Ca alkyl group, preferably one or two methyl groups, which may be optionally substituted; and n is 0 to 6, often 0, 1, 2 or 3, preferably 0 or 1. Alternatively, T may also be a -(CH20)n- group, a -(OCH2)„- group, a -(CH2CH20)n- group, a -(OCH2CH2)n- group, all of which groups are optionally substituted.
Preferred Aryl groups for R2 include optionally substituted phenyl or naphthyl groups, preferably phenyl groups, wherein the phenyl group is optionally substituted with a
PTM ULM
linker group to which is attached a group (including a group), a halogen
(preferably F or CI), an amine, monoalkyl- or dialkyl amine (preferably, dimethylamine), F, CI, OH, COOH, Ci-C6 alkyl, preferably CH3, CF3, OMe, OCF3, N02, or CN group (each of which may be substituted in ortho-, meta- and/or para- positions of the phenyl ring,
preferably para-), an optionally substituted phenyl group (the phenyl group itself is preferably
PTM ULM'
substituted with a linker group attached to a group, including a group), and/or at least one of F, CI, OH, COOH, CH3, CF3, OMe, OCF3, N02, or CN group (in ortho-, meta- and/or para- positions of the phenyl ring, preferably para-), a naphthyl group, which may be optionally substituted, an optionally substituted heteroaryl, preferably an optionally substituted isoxazole including a methylsubstituted isoxazole, an optionally substituted oxazole including a methylsubstituted oxazole, an optionally substituted thiazole including a methyl substituted thiazole, an optionally substituted isothiazole including a methyl
substituted isothiazole, an optionally substituted pyrrole including a methylsubstituted pyrrole, an optionally substituted imidazole including a methylimidazole, an optionally substituted benzimidazole or methoxybenzylimidazole, an optionally substituted oximidazole or methyloximidazole, an optionally substituted diazole group, including a methyldiazole group, an optionally substituted triazole group, including a methylsubstituted triazole group, an optionally substituted pyridine group, including a halo- (preferably, F) or
methylsubstitutedpyridine group or an oxapyridine group (where the pyridine group is linked to the phenyl group by an oxygen), an optionally substituted furan, an optionally substituted benzofuran, an optionally substituted dihydrobenzofuran, an optionally substituted indole, indolizine or azaindolizine (2, 3, or 4-azaindolizine), an optionally substituted quinoline, an optionally substituted group according to the chemical structure:
Figure imgf000017_0001
Where Sc is CHR , NR , or O;
RHET is H, CN, N02, halo (preferably CI or F), optionally substituted C C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(C\-C alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C≡C-Ra where Ra is H or a Ci-C6 alkyl group (preferably Cj-C3 alkyl);
Rss is H, CN, N02, halo (preferably F or CI), optionally substituted CrC6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(Cj-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(C!-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
RURE is H, a C]-C6 alkyl (preferably H or Q-C3 alkyl) or a -C(OXd-C6 alkyl) each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted phenyl group, an optionally substituted heteroaryl, or an optionally substituted heterocycle, preferably for example piperidine, morpholine, pyrrolidine, tetrahydrofuran); R is H, optionally substituted Cj-C6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a Cj-C3 alkyl group, preferably methyl or a halo group, preferably F or CI), benzofuran, indole, indolizine, azaindolizine;
RPR01 and RPR02 are each independently H, an optionally subsituted C)-C3 alkyl group or together form a keto group; and
each n is independently 0, 1, 2, 3, 4, 5, or 6 (preferably 0 or 1), or
an optionally substituted heterocycle, preferably tetrahydrofuran, tetrahydrothiene, piperidine, piperazine or morpholine (each of which groups when substituted, are preferably substituted with a methyl or halo (F, Br, CI),
each of which groups may be optionally substituted with a linker group to which is attached a
Figure imgf000018_0001
In certain preferred aspects,
Figure imgf000018_0002
a
Figure imgf000018_0003
group,
Where R and n are the same as above. Preferred heteroaryl groups for R include an optionally substituted quinoline (which may be attached to the pharmacophore or substituted on any carbon atom within the quinoline ring), an optionally substituted indole, an optionally substituted indolizine, an optionally substituted azaindolizine, an optionally substituted benzofuran, including an optionally substituted benzofuran, an optionally substituted isoxazole, an optionally substituted thiazole, an optionally substituted isothiazole, an optionally substituted thiophene, an optionally substituted pyridine (2-, 3, or 4-pyridine), an optionally substituted imidazole, an optionally substituted pyrrole, an optionally substituted diazole, an optionally substituted triazole, a tetrazole, an optionally substituted oximidazole, or a group according to the chemical structure:
Figure imgf000019_0001
Where Sc is CHRSS, NRURE, or O;
RHET is H, CN, N02, halo (preferably CI or F), optionally substituted d-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(Ci-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C≡C-Ra where Ra is H or a Ci-C alkyl group (preferably Cj-C3 alkyl);
Rss is H, CN, N02, halo (preferably F or CI), optionally substituted C C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally
substituted 0-(C)-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(C!-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
RURE is H, a d-C6 alkyl (preferably H or C C3 alkyl) or a -C(0)(d-C6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and
Yc is N or C-RYC, where RYC is H, OH, CN, N02, halo (preferably CI or F), optionally substituted Ci-C alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(C!-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C≡C-Ra where Ra is H or a Ci-C6 alkyl group (preferably Cj-C3 alkyl),
each of which groups may be optionally substituted with a linker group to which is attached a
Figure imgf000020_0001
2'
Preferred heterocycle groups for R include tetrahydrofuran, tetrahydrothiene, tetrahydroquinoline, piperidine, piperazine, pyrrollidine, morpholine, oxane or thiane, each of which groups may be optionally substituted, or a group according to the chemical structure:
Figure imgf000020_0002
group,
Where R is H, optionally substituted Q-C6 alkyl or an optionally substituted
heteroaryl or heterocyclic group; R and R are each independently H, an optionally subsituted Ci-C3 alkyl group or together form a keto group and
Each n is independently 0, 1, 2, 3, 4, 5, or 6 (often 0 or 1), each of which groups may be
PTM
optionally substituted with a linker group to which is attached a group (including a
ULM
group).
Preferred R2 substituents for use in the present invention also include specifically (and without limitation to the specific compound disclosed) the R2 substituents which are found in the identified compounds disclosed herein (which includes the specific compounds which are disclosed in the present specification, and the figures which are attached hereto). Each of these R substituents may be used in conjunction with any number of R
substituents which are also disclosed herein.
R3 is preferably an optionally substituted -T-Aryl, an optionally substituted
-T-Heteroaryl, an optionally substituted -T-Heterocycle, an optionally substituted
-NR1 -T-Aryl, an optionally substituted -NR1 -T-Heteroaryl or an optionally substituted -NR1 -T-Heterocycle, where R1 is H or a C C3 alkyl group, preferably H or CH3, T is an optionally substituted -(CH2)n- group, wherein each one of the methylene groups may be optionally substituted with one or two substituents, preferably selected from halogen, a C1-C3 alkyl group or the sidechain of an amino acid as otherwise described herein, preferably methyl, which may be optionally substituted; and n is 0 to 6, often 0, 1, 2, or 3 preferably 0 or 1. Alternatively, T may also be a -(CH20)n- group, a -(OCH2)n- group, a -(CH2CH20)n- group, a -(OCH2CH2)n- group, each of which groups is optionally substituted.
Preferred aryl groups for R include optionally substituted phenyl or naphthyl groups, preferably phenyl groups, wherein the phenyl or naphthyl group is optionally substituted with
PTM ULM'
a linker group to which is attached a 1 J group (including a group) and/or a halogen (preferably F or CI), an amine, monoalkyl- or dialkyl amine (preferably,
dimethylamine), an amido group (preferably a -(CH2)m-NR1C(0)R2 group where m, Rj and R2 are the same as above), a halo (often F or CI), OH, CH3, CF3, OMe, OCF3, N02, ,CN or a S(0)2Rs group (Rs is a a Cj-C6 alkyl group, an optionally substituted aryl, heteroaryl or heterocycle group or a -(CH2)mNR1R2 group), each of which may be substituted in ortho-, meta- and/or para- positions of the phenyl ring, preferably para-), or an Aryl (preferably phenyl), Heteroaryl or Heterocycle. Preferably said substituent phenyl group is an optionally substituted phenyl group (i.e., the substituent phenyl group itself is preferably substituted with at least one of F, CI, OH, SH, COOH, CH3, CF3, OMe, OCF3, N02, CN or a linker
PTM ULM
group to which is attached a group (including a group), wherein the substitution occurs in ortho-, meta- and/or para- positions of the phenyl ring, preferably para- ), a naphthyl group, which may be optionally substituted including as described above, an optionally substituted heteroaryl (preferably an optionally substituted isoxazole including a methylsubstituted isoxazole, an optionally substituted oxazole including a methylsubstituted oxazole, an optionally substituted thiazole including a methyl substituted thiazole, an optionally substituted pyrrole including a methylsubstituted pyrrole, an optionally substituted imidazole including a methylimidazole, a benzylimidazole or methoxybenzylimidazole, an oximidazole or methyloximidazole, an optionally substituted diazole group, including a methyldiazole group, an optionally substituted triazole group, including a methylsubstituted triazole group, a pyridine group, including a halo- (preferably, F) or
methylsubstitutedpyridine group or an oxapyridine group (where the pyridine group is linked to the phenyl group by an oxygen) or an optionally substituted heterocycle (tetrahydrofuran, tetrahydrothiophene, pyrrolidine, piperidine, morpholine, piperazine, tetrahydroquinoline, oxane or thiane. Each of the aryl, heteroaryl or heterocyclic groups may be optionally
PTM ULM' substituted with a linker group to which is attached a group (including a
group).
Preferred Heteroaryl groups for R include an optionally substituted quinoline (which may be attached to the pharmacophore or substituted on any carbon atom within the quinoline ring), an optionally substituted indole (including dihydroindole), an optionally substituted indolizine, an optionally substituted azaindolizine (2, 3 or 4-azaindolizine) an optionally substituted benzimidazole, benzodiazole, benzoxofuran, an optionally substituted imidazole, an optionally substituted isoxazole, an optionally substituted oxazole (preferably methyl substituted), an optionally substituted diazole, an optionally substituted triazole, a tetrazole, an optionally substituted benzofuran, an optionally substituted thiophene, an optionally substituted thiazole (preferably methyl and/or thiol substituted), an optionally substituted isothiazole, an optionally substituted triazole (preferably a 1,2,3-triazole substituted with a methyl group, a triisopropylsilyl group, an optionally substituted -(CH2)m-0-d-C6 alkyl group or an optionally substituted -(CH2)m-C(0)-0-C1-C6 alkyl group), an optionally substituted pyridine (2-, 3, or 4-pyridine) or a group according to the chemical structure:
Figure imgf000023_0001
Where Sc is CHR , NRURt, or O;
RHET is H, CN, N02, halo (preferably CI or F), optionally substituted d-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(d-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C≡C-Ra where Ra is H or a Cj-C6 alkyl group (preferably d-C3 alkyl);
Rss is H, CN, N02, halo (preferably F or CI), optionally substituted d-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(d-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(d-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
RURE is H, a d-C6 alkyl (preferably H or C1-C3 alkyl) or a -C(0)(d-C6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and
Yc is N or C-RYC, where RYC is H, OH, CN, N02, halo (preferably CI or F), optionally substituted Ci-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(C!-C alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C≡C-Ra where Ra is H or a Q-Q alkyl group (preferably Ci-C3 alkyl). Each of said heteroaryl groups may be optionally substituted with a linker group to which is attached a
PTM ULM
group (including a group).
Preferred heterocycle groups for R3 include tetrahydroquinoline, piperidine, piperazine, pyrrollidine, morpholine, tetrahydrofuran, tetrahydrothiophene, oxane and thiane, each of which groups may be optionally substituted or a group according to the chemical structure:
Figure imgf000024_0001
Preferably, a
Figure imgf000024_0002
group,
Where R is H, optionally substituted Cj-C6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a C!-C3 alkyl group, preferably methyl or a halo group, preferably F or CI), benzofuran, indole, indolizine, azaindolizine; R and R are each independently H, an optionally subsituted C!-C3 alkyl group or together form a keto group, and
Each n is 0, 1 , 2, 3, 4, 5, or 6 (preferably 0 or 1), wherein each of said Heteocycle groups may
PTM
be optionally substituted with a linker group to which is attached a group (including
ULM
group).
Preferred R substituents for use in the present invention also include specifically (and without limitation to the specific compound disclosed) the R3 substituents which are found in the identified compounds disclosed herein (which includes the specific compounds which are disclosed in the present specification, and the figures which are attached hereto). Each of these R substituents may be used in conjunction with any number of R
substituents which are also disclosed herein.
In certain alternative preferred embodiments, R2 is an optionally substituted -NRi- X^'-alkyl group, -NRi-X^'-Aryl group; an optionally substituted -NRj- X^'-HET, an optionally substituted -NR^X^ -Aryl-HET or an optionally substituted -NRj- X^'-HET- Aryl ,
Where R] is H or a C]-C3 alkyl group (preferably H);
X 2' is an optionally substituted -CH2)n- , -CH2)n-CH(Xv)=CH(Xv)- (cis or trans),
-CH2)n-CH≡CH- , -(CH2CH20)n- or a C3-C6 cycloalkyl group;
where Xv is H, a halo or a Q-C3 alkyl group which is optionally substituted with one or two hydroxyl groups or up to three halogen groups;
Alkyl is an optionally substituted Cl -C10 alkyl (preferably a Q-Q alkyl) group (in certain preferred embodiments, the alkyl group is end-capped with a halo group, often a CI or Br); Aryl is an optionally substituted phenyl or naphthyl group (preferably, a phenyl group); and HET is an optionally substituted oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofiiran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, benzofuran, indole, indolizine, azaindolizine, quinoline (when substituted, each preferably substituted with a
Figure imgf000025_0001
alkyl group, preferably methyl or a halo group, preferably F or CI) or a group according to the chemical structure:
Figure imgf000026_0001
Where S° is CHR , NR , or O;
RHET is H, CN, N02, halo (preferably CI or F), optionally substituted d-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(Ci-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C≡C-Ra where Ra is H or a d-C6 alkyl group (preferably Ci-C3 alkyl);
Rss is H, CN, N02, halo (preferably F or CI), optionally substituted d-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(C!-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(C1-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
RURE is H, a d-C6 alkyl (preferably H or d-C3 alkyl) or a -C(0)(CrC6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and
Yc is N or C-RYC, where RYC is H, OH, CN, N02, halo (preferably CI or F), optionally substituted CrQ alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(C!-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C≡C-Ra where Ra is H or a Cj-C6 alkyl group (preferably C[-C3 alkyl);
RPR0 is H, optionally substituted Ci-C6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a Cj-C3 alkyl group, preferably methyl or a halo group, preferably F or CI), benzofuran, indole, indolizine, azaindolizine;
RPR01 and RPR02 are each independently H, an optionally subsituted C C3 alkyl group or together form a keto group, and
Each n is independently 0, 1, 2, 3, 4, 5, or 6 (preferably 0 or 1). Each of said groups may be
PTM
optionally substituted with a linker group to which is attached a group (including a
ULM'
group).
In certain alternative preferred embodiments of the present invention, R3 is an optionally substituted -(CH2)n-(V)n'-(CH2)n-(V)n'-R group, an optionally substituted
-(CH2)n-N(Rr)(C:=0)m-(V)n'-RS3' group, an optionally substituted -XR3'-alkyl group, an optionally substituted -XR3 -Aryl group; an optionally substituted -X3 -HET group, an optionally substituted -X -Aryl-HET group or an optionally substituted -X -HET- Aryl group,
Where R is an optionally substituted alkyl group (Ci-C)0, preferably Q-C6 alkyl), an optionally substituted Aryl group or a HET group;
Rj- is H or a C!-C3 alkyl group (preferably H);
V is O, S or NRr; XR3' is -(CH2)n- , -(CH2CH20)n-, -CH2)n-CH(Xv)=CH(Xv)- (cis or trans), -CH2)n-CH≡CH- , or a C3-C6 cycloalkyl group, all optionally substituted;
where Xv is H, a halo or a Q-C3 alkyl group which is optionally substituted with one or two hydroxyl groups or up to three halogen groups;
Alkyl is an optionally substituted Q-Qo alkyl (preferably a Cj-C6 alkyl) group (in certain preferred embodiments, the alkyl group is end-capped with a halo group, often a CI or Br); Aryl is an optionally substituted phenyl or napthyl group (preferably, a phenyl group); and HET is an optionally substituted oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydroiuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, benzofuran, indole, indolizine, azaindolizine, quinoline (when substituted, each preferably substituted with a Q-C3 alkyl group, preferably methyl or a halo group, preferably F or CI), or a group according to the chemical structure:
Figure imgf000028_0001
Where Sc is CHRSS, NR. , or O;
RHET is H, CN, N02, halo (preferably CI or F), optionally substituted d-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(Ci-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C≡C-Ra where Ra is H or a Ci-C6 alkyl group (preferably C C3 alkyl);
R is H, CN, N02, halo (preferably F or CI), optionally substituted Ci-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(C!-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(Ci-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
RURE is H, a Ci-C6 alkyl (preferably H or C C3 alkyl) or a -C(O)(C0-C6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and
Yc is N or C-RYC, where RYC is H, OH, CN, N02, halo (preferably CI or F), optionally substituted C\-Ce alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(Ci-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C≡C-Ra where Ra is H or a Cj-C6 alkyl group (preferably Cj-C3 alkyl);
RPR0 is H, optionally substituted Cj-C6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a C C3 alkyl group, preferably methyl or a halo group, preferably F or CI), benzofuran, indole, indolizine, azaindolizine;
RPR0] and RPR02 are each independently H, an optionally subsituted Cj-C3 alkyl group or together form a keto group, and
Each n is independently 0, 1, 2, 3, 4, 5, or 6 (preferably 0 or 1);
Each m' is 0 or 1 ; and
Each n' is 0 or 1, Wherein each of said compounds, preferably on the alkyl, Aryl or Het groups, is substituted
PTM ULM
with a linker group to which is attached a group (including a group).
In alternative embodiments, R3' is -(CH2)„-Aryl, -(CH2CH20)n-Aryl, -(CH2)n-HET or -(CH2CH20)n-HET;
Where Aryl is phenyl which is optionally substituted with one or two substitutents, wherein said substituent(s) is preferably selected from -(CH2)nOH, Cj-C6 alkyl which itself is further optionally substituted with CN, halo (up to three halo groups), OH, -(CH2)nO(C1-C6)alkyl, amine, mono- or di-(Q-C6 alkyl) amine wherein the alkyl group on the amine is optionally substituted with 1 or 2 hydroxyl groups or up to three halo (preferably F, CI) groups, or said Aryl group is substituted with -(CH2)„OH, -(CH2)n-0-(C1-C6)alkyl, -(CH2)n-0-(CH2)n- (Ci-C6)alkyl, -(CH2)„-C(O)(C0-C6) alkyl, -(CH2)„-C(O)O(C0-C6)alkyl, -(CH2)n-OC(O)(C0- C6)alkyl, amine, mono- or di-(Ci-C6 alkyl) amine wherein the alkyl group on the amine is optionally substituted with 1 or 2 hydroxyl groups or up to three halo (preferably F, CI) groups, CN, N02, an optionally substituted -(CH2)n-(V)m'-CH2)n-(V)m'-(C1-C6)alkyl group, a -(V)m-(CH2CH20)„-RPEG group where V is O, S or NRr, Rr is H or a d-C3 alkyl group (preferably H) and RPEG is H or a C C6 alkyl group which is optionally substituted (including being optionally substituted with a carboxyl group), or said Aryl group is optionally substituted with a heterocycle, including a heteroaryl, selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, benzofuran, indole, indolizine, azaindolizine, (when substituted each preferably substituted with a C1-C3 alkyl group, preferably methyl or a halo group, preferably F or CI), or a group according to the chemical structure:
Figure imgf000031_0001
Where Sc is CHR½, NRURE, or O;
RHET is H, CN, N02, halo (preferably CI or F), optionally substituted C,-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(Ci-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C≡C-Ra where Ra is H or a C]-C6 alkyl group (preferably C1-C3 alkyl);
Rss is H, CN, N02, halo (preferably F or CI), optionally substituted C C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(Ci-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(C!-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
RURE is H, a d-C6 alkyl (preferably H or C C3 alkyl) or a -C(O)(C0-C6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and
Yc is N or C-RYC, where RYC is H, OH, CN, N02, halo (preferably CI or F), optionally substituted C C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(Cj-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C≡C-Ra where Ra is H or a Cj-C6 alkyl group (preferably Q-C3 alkyl);
RPR0 is H, optionally substituted C C6 alkyl or an optionally substituted aryl (phenyl or napthyl), heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a C C3 alkyl group, preferably methyl or a halo group, preferably F or CI), benzofuran, indole, indolizine, azaindolizine;
RPR01 and RPR02 are each independently H, an optionally subsituted C!-C3 alkyl group or together form a keto group;
HET is preferably oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene,
tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, (each preferably substituted with a C!-C3 alkyl group, preferably methyl or a halo group, preferably F or CI), benzofuran, indole, indolizine, azaindolizine, or a group according to the chemical structure:
Figure imgf000033_0001
Where Sc is CHRSS, NRURE, or O;
RHET is H, CN, N0 , halo (preferably CI or F), optionally substituted d-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(Ci-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C≡C-Ra where Ra is H or a CrC6 alkyl group (preferably C1-C3 alkyl);
Rss is H, CN, N02, halo (preferably F or CI), optionally substituted d-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally substituted 0-(Cj-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(Cj-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
RURE is H, a d-C6 alkyl (preferably H or CrC3 alkyl) or a -C(O)(C0-C6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted heterocycle, for example piperidine, morpholine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, each of which is optionally substituted, and
Yc is N or C-RYC, where RYC is H, OH, CN, N02, halo (preferably CI or F), optionally substituted Ci-C alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(C!-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C≡C-Ra where Ra is H or a C C6 alkyl group (preferably Q-C3 alkyl);
RPR0 is H, optionally substituted Q-C6 alkyl or an optionally substituted aryl, heteroaryl or heterocyclic group;
RPR01 and RPR02 are each independently H, an optionally subsituted Cj-Q alkyl group or together form a keto group,
Each m' is independently 0 or 1, and
Each n is independently 0, 1, 2, 3, 4, 5, or 6 (preferably 0 or 1),
Wherein each of said compounds, preferably on said Aryl or HET groups, is substituted with
PTM ULM'
a linker group to which is attached a group (including a group).
In still additional embodiments, preferred compounds include those according to the chemical structure:
R 1
Figure imgf000034_0001
Where R1 ' is OH or a group which is metabolized in a patient or subject to OH;
R is a -NH-CH2-Aryl-HET (preferably, a phenyl linked directly to a methyl substituted thiazole);
R3' is a -CHRCR3'-NH-C(0)-R3P1 group or a -CHRCR3'-R3P2 group;
Where R is a Q-Q alkyl group, preferably methyl, isopropyl or tert-butyl; R is Q-C3 alkyl (preferably methyl), an optionally substituted oxetane group (preferably methyl substituted, a -(CH2)nOCH3 group where n is 1 or 2 (preferably 2), or a
Figure imgf000035_0001
(the ethyl ether group is preferably meta- substituted on the phenyl moiety), a morpholino grop (linked to the carbonyl at the 2- or 3- position;
R3P2 is a
Figure imgf000035_0002
group,
Where Aryl is phenyl;
HET is an optionally substituted thiazole or isothiazole; and
RHET is H or a halo group (preferably H),
Or a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof, wherein
PTM
each of said compounds is substituted with a linker group to which is attached a
ULM'
group (including a ' ' group)
ULM
In an alternative embodiment, groups for inclusion in compounds according to the present invention include:
Figure imgf000035_0003
Where X is CI, F, Cj-C3 alkyl (preferably methyl) or heterocycle (preferably an optionally substituted heterocycle, including as defined above for R ;
R1 and R2 are each independently H, Q-C3 alkyl (preferably methyl), or phenyl and each of said compounds is substituted with a linker group or a linker group to which is attached a
PTM
group, or
a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
ULM
Additional preferred groups for inclusion in compounds according to the present invention i
Figure imgf000036_0001
Where n is 0 or 1 ;
PTM
R is a linker or a linker attached to a group
X is H, F, CI, C1-C3 alkyl (preferably methyl) or heterocycle (preferably an optionally substituted heterocycle, especially including a water soluble heterocycle such as a morpholino group, including as defined above for R3 ), or
a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
ULM
Additional preferred groups for inclusion in compounds according to the present invention include for example:
Figure imgf000037_0001
Where n is 0 or 1 ;
PTM PTM
R is a linker or a linker attached to a group a linker or a linker attached to a
ULM
group linked to the 1 1 group through an amide, ester, ether or carbamate group;
R1 is Cj-C3 alkyl (optionally substituted with one or two hydroxyl groups) or -C(0)NR3R4 where R3 and R4 are each independently H, Cj-C3 alkyl (preferably methyl), phenyl or heterocycle (including a heterocycle such as a morpholino, piperazine or other group which increases water solubility),
X is H, F, CI, C[-C3 alkyl (preferably methyl) or heterocycle (preferably an optionally substituted heterocycle, including a water soluble heterocycle, including as defined above for R3 ), or a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
. ULM
Still further preferred groups for inclusion in compounds according to the present invention include for example
Figure imgf000037_0002
Where n is 0 or 1 ; PTM ULM
R is a linker or a linker attached to a group linked to the group through an amide, ester, ether, carbamate or heterocyclic group (preferably an optionally substituted heterocycle, including as defined above for R3 );
R is H, F, CI, Ci-C3 alkyl (optionally substituted with one or two hydroxyl groups, preferably methyl), -0-C(0)NR3R4 or -C(0)NR3R4 wherein each of R3 and R4 is independently H, Q- C3 alkyl (preferably methyl), phenyl or heterocycle, including a water soluble heterocycle, or A pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
. ULM
Yet still further preferred groups for inclusion in compounds according to the present invention include for example:
Figure imgf000038_0001
Where n is 0 or 1;
PTM ULM
R is a linker or a linker attached to a group linked to the group through an amide, ester, ether, carbamate or heterocyclic group; and
Each X is independently is H, F, CI, Q-C3 alkyl (optionally substituted with one or two hydroxyl groups, preferably methyl), heterocyle (preferably an optionally substituted heterocycle, including a water soluble heterocycle, and/or as defined above for R3 ), -O- C(0)NR3R4 or -C(0)NR3R4 wherein each of R3 and R4 is independently H, C C3 alkyl (preferably methyl), or phenyl, or
a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
ULM
Yet additional further preferred groups for inclusion in compounds according to the present invention include for example:
Figure imgf000039_0001
Where n is 0 or 1 ;
PTM ULM
R is a linker or a linker attached to a group linked to the group through an amide, ester, ether, carbamate or heterocyclic group;
R1 is C1-C3 alkyl, which is optionally substituted with one or two hydroxyl groups,
-0-C(0)NR3R4 or -C(0)NR3R4 wherein each of R3 and R4 is independently H, d-C3 alkyl (preferably methyl), or phenyl; and
X is independently is H, F, CI, C1-C3 alkyl (optionally substituted with one or two hydroxyl groups, preferably methyl) or heterocycle (preferably an optionally substituted heterocycle, including a water soluble heterocycle, and/or as defined above for R ), or a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
ULM
Yet additional further preferred groups for inclusion in compounds according to the present invention include for example:
Figure imgf000039_0002
Where n is 0 or 1 ;
PTM ULM
R is a linker or a linker attached to a group linked to the group through an amide, ester, ether, carbamate or heterocyclic group;
R is H, Ci-C3 alkyl, which is optionally substituted with one or two hydroxyl groups, -0-C(0)NR3R4 or -C(0)NR3R4 wherein each of R3 and R4 is independently H, d-C3 alkyl (preferably methyl), or phenyl; and
Each X is independently is H, F, CI, C!-C3 alkyl (optionally substituted with one or two hydroxyl groups, preferably methyl) or heterocycle (preferably an optionally substituted heterocycle, including a water soluble heterocycle and/or including as defined above for R3 ), or a pharmaceutically acceptable salt, enantiomer, diastereomer, solvate or polymorph thereof.
In an additional embodiment, particularly preferred compounds according to the present invention may be identified according to any one or more of the chemical structures as set forth in figure 19 hereof:
Wherein any one or more of RiPC, R2pc, R3P0 R4P0 R5pc, epc, R-7PC, R-SPC, R9P& Riopc, Rnpc , R12PC , Rnpc and Ri4Pc is a
Figure imgf000040_0001
group,
PTM
Where L is a linker group and is a protein targeting moiety, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thererof.
In preferred embodiments, no more than two of Ripe, R2P0 R3pc? R4P0 R5pc, R6PC,
R7pc, R8pc> R9PC5 RIOPC, Rnpc > RI2PC , Ri3PC and R14Pc is
Figure imgf000040_0002
group and the other of groups R1PC, R2pc, R3PC, ipe, R5pc, Repc, R7PC, RSPC, R9PC, RIOPC, Rnpc ,
R12PC Rope and Ri4Pcare independently H or a CH3 group, often H.
Certain preferred embodiments are directed to compounds according to the chemical structure:
Figure imgf000040_0003
Wherein R7pc and Riopc are each independently a
Figure imgf000041_0001
L- PTM
group or H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably, either of R7pc or RIOPC is a L- PTM
group and the other R7PC or R10PC
In other preferred embodiments, the compound has the chemical structure:
Wherein
Figure imgf000041_0002
R7PC is a group, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
In still other preferred embodiments, the compound has the chemical structure:
Figure imgf000041_0003
group or H, or A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably, one of R7pc, Rnpc, RI2PC, RI3PC andR1 PC is a L- PTM
group and the other groups are H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
In still other preferred embodiments, the compound has the chemical structure:
Figure imgf000042_0001
RI3PC and R14pc are each independently a
Figure imgf000042_0002
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably, either of R4pc, R7pc or one of Rj \PC, Ri2pc, ROPC and R14pc is a L- PTM
group and the other groups are H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
RI IPC RI2PC, RI3PC and R14pc are each independently a
Figure imgf000043_0001
group or H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably,
Figure imgf000043_0002
one of R.3PC, R7pc, Ri IPC, Ri2pc, Rope group and the other groups are H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
In still other preferred embodiments, the compound has the chemical structure:
Figure imgf000043_0003
Wherein R7PC and Riopc are each independently a L- PTM
group or H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably, one of R7pc and Riopc is a L- PTM
group and the other group is H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
In still other preferred embodiments, the compound has the chemical structure:
Figure imgf000043_0004
Wherein R7pc andRi0pc are each independently a
Figure imgf000044_0001
group or H and R8PC is H or CH3, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably,
Figure imgf000044_0002
one of R7PC and RIOPC is a group and the other group is H and R8pc is H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
In still other preferred embodiments, the compound has the chemical structure:
Figure imgf000044_0003
PTM
Wherein R7pc andRiopc are each independently a group or H and
Figure imgf000044_0004
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably,
Figure imgf000044_0005
one of R7pc and 10pc is a group and the other group is H and R8PC is H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
In still other preferred embodiments, the compound has the chemical structure:
Figure imgf000044_0006
group or H and
Figure imgf000045_0001
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably, one of R7PC andRnopc is
Figure imgf000045_0002
group and the other group is H and RSPC is H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
In still other preferred embodiments, the compound has the chemical structure:
Figure imgf000045_0003
group or H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably, one of R7PC and Riopc is
Figure imgf000045_0004
group and the other group is H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
In still other preferred embodiments, the compound has the chemical structure:
Figure imgf000045_0005
Wherein R7pc and R9pc are each independently a
Figure imgf000046_0001
L- PTM
group or H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably, one of R7pc and R pc is a L- PTM
group and the other group is H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
In still other preferred embodiments, the compound has the chemical structure:
Wherei
Figure imgf000046_0002
n R7pc group or H and each of R12PC and R13PC is H or CH3, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably,
PT
one of R7PC and R14PC is a L- M
group and the other of R7pc and R14pc group is H and each of R12pc and RI3PC is H,
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
In still other preferred embodiments, the compound has the chemical structure:
Figure imgf000046_0003
Wherein R PC and R9PC are each independently a
Figure imgf000047_0001
group or H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably, one of R7PC and R9
Figure imgf000047_0002
group and the other group is H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
In still other preferred embodiments, the compound has the chemical structure:
Wherein R PC and R9pc
Figure imgf000047_0003
are each independently a group or H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably,
Figure imgf000047_0004
one of R7pc and R9PC is a group and the other group is H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
In still other preferred embodiments, the compound has the chemical structure:
Figure imgf000047_0005
Wherein R7PC andR10pc are each independently a
Figure imgf000048_0001
L- PTM group or H and Rgpc is H or CH3, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. Preferably, one of R7PC and R1
Figure imgf000048_0002
and the other group is H and R9pc is H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
In the above embodiments, the linker group may be any linker group as described hereinabove, below is preferably a polyethylene glycol group ranging in size from about 1 to about 12 ethylene glycol units, between 1 and about 10 ethylene glycol units, about 2 about 6 ethylene glycol units, between about 2 and 5 ethylene glycol units, between about 2 and 4 ethylene glycole units.
In preferred embodiments, the linker group L is a group:
Figure imgf000048_0003
ULM
Where Z is a group which links to X; and X is a group linking Z to group
Figure imgf000048_0005
group). rred aspects, Z is absent (a bond), -(CH2)j-0, -(CH2)j-S, -(CH2)j-N-R, a
Figure imgf000048_0004
group wherein Xi Yj forms an amide group, or a urethane group, ester or thioester group, or a
O
-<σ¾)Γ— or -Y-c-Y- group
Each R is H, or a d-C3 alkyl, an alkanol group or a heterocycle (including a water soluble heterocycle, preferably, a morpholino , piperidine or piperazine group to promote water solubility of the linker group);
Each Y is independently a bond, O, S or N-R; and each i is independently 0 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5;
In preferred aspects X is a
Figure imgf000049_0001
Where each D is independently a bond (absent),
O
— (CH2) -Y-C-Y (CH2) -.
"(CH2)m-
Figure imgf000049_0002
j is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5;
k is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5; preferably k is 1, 2, 3, 4, or 5;
m' is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, 1 to 8, 1 to 6, 1, 2, 3, 4 or 5;
n is 1 to 100, 1 to 75, 1 to 60, 1 to 55, 1 to 50, 1 to 45, 1 to 40, 2 to 35, 3 to 30, 1 to 15, 1 to 10, l to 8, 1 to 6, 1 , 2, 3, 4 or 5;
X1 is O, S or N-R, preferably O;
Y is the same as above; and
CON
is a connector group (which may be a bond) which connects Z to X, when present in the linker group.
CON
In preferred aspects, I 1 is a bond (absent), a heterocycle including a water soluble heterocycle such as a piperazinyl or other group or a
Figure imgf000050_0001
group,
Where X2 is O, S, NR4, S(O), S(0)2, -S(0)20, -OS(0)2, or OS(0)20;
X3 is O, S, CHR4, NR4; and
R is H or a C!-C3 alkyl group optionally substituted with one or two hydroxyl groups, or a pharmaceutically acceptable salt, enantiomer or stereoisomer thereof.
In alternative preferred aspects, the linker group is a (poly)ethyleneglycol having between 1 and about 100 ethylene glycol units, between about 1 and about 50 ethylene glycol units, between 1 and about 25 ethylene glycol units, between about 1 and 10 ethylene glycol units, between 1 and about 8 ethylene glycol units and 1 and 6 ethylene glycol units, between 2 and 4 ethylene glycol units.
In alternative preferred aspects,
Figure imgf000050_0002
or an amide group.
ULM
Although the
Figure imgf000050_0004
group (including a group) may be covalently linked to the linker group through any group which is appropriate and stable to the chemistry of the linker, in preferred aspects of the present invention, the linker is nded to the
Figure imgf000050_0005
group (including a
Figure imgf000050_0003
) f bl through an amide, ester, thioester, keto group, carbamate
ULM
(urethane) or ether, each of which groups may be inserted anywhere on the group
PTM ULM'
and group (including a group) to provide maximum binding of the ULM PTM
group on the ubiquitin ligase and the group on the target protein to be degraded. (It is noted that in certain aspects where the
Figure imgf000051_0001
group, the target protein for degradation may be the ubiquitin ligase itself). In certain preferred aspects, the linker may be linked to an optionally substituted alkyl, alkylene, alkene or alkyne group, an aryl group or a heterocyclic group on the
Figure imgf000051_0002
groups.
PTM
In preferred aspects of the invention, the group is a group, which binds to
PTM
target proteins. Targets of the group are numerous in kind and are selected from proteins that are expressed in a cell such that at least a portion of the sequences is found in
PTM
the cell and may bind to a group. The term "protein" includes oligopeptides and
PTM
polypeptide sequences of sufficient length that they can bind to a group according to the present invention. Any protein in a eukaryotic system or a microbial system, including a virus, bacteria or fungus, as otherwise described herein, are targets for ubiquitination mediated by the compounds according to the present invention. Preferably, the target protein is a eukaryotic protein. In certain aspects, the protein binding moiety is a haloalkane
(preferably a CI -CIO alkyl group which is substituted with at least one halo group, preferably
ULM
a halo group at the distil end of the alkyl group (i.e., away from the linker or group), which may covalently bind to a dehalogenase enzyme in a patient or subject or in a diagnostic assay.
PTM
groups according to the present invention include, for example, include any moiety which binds to a protein specifically (binds to a target protein) and includes the following non-limiting examples of small molecule target protein moieties: Hsp90 inhibitors, kinase inhibitors, MDM2 inhibitors, compounds targeting Human BET Bromodomain- containing proteins, HDAC inhibitors, human lysine methyltransferase inhibitors,
angiogenesis inhibitors, immunosuppressive compounds, and compounds targeting the aryl hydrocarbon receptor (AHR), among numerous others. The compositions described below exemplify some of the members of these nine types of small molecule target protein binding moieties. Such small molecule target protein binding moieties also include pharmaceutically acceptable salts, enantiomers, solvates and polymorphs of these compositions, as well as other small molecules that may target a protein of interest. These binding moieties are linked to the ubiquitin ligase binding moiety preferably through a linker in order to present a target protein (to which the protein target moiety is bound) in proximity to the ubiquitin ligase for ubiquitination and degradation.
PTM
Any protein, which can bind to a protein target moiety or 1 1 group and acted on or degraded by an ubiquitin ligase is a target protein according to the present invention. In general, target proteins may include, for example, structural proteins, receptors, enzymes, cell surface proteins, proteins pertinent to the integrated function of a cell, including proteins involved in catalytic activity, aromatase activity, motor activity, helicase activity, metabolic processes (anabolism and catrabolism), antioxidant activity, proteolysis, biosynthesis, proteins with kinase activity, oxidoreductase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, ligase activity, enzyme regulator activity, signal transducer activity, structural molecule activity, binding activity (protein, lipid carbohydrate), receptor activity, cell motility, membrane fusion, cell communication, regulation of biological processes, development, cell differentiation, response to stimulus, behavioral proteins, cell adhesion proteins, proteins involved in cell death, proteins involved in transport (including protein transporter activity, nuclear transport, ion transporter activity, channel transporter activity, carrier activity, permease activity, secretion activity, electron transporter activity, pathogenesis, chaperone regulator activity, nucleic acid binding activity, transcription regulator activity, extracellular organization and biogenesis activity, translation regulator activity. Proteins of interest can include proteins from eurkaryotes and prokaryotes including humans as targets for drug therapy, other animals, including domesticated animals, microbials for the determination of targets for antibiotics and other antimicrobials and plants, and even viruses, among numerous others.
PTM
In still other embodiments, the group is a haloalkyl group, wherein said alkyl group generally ranges in size from about 1 or 2 carbons to about 12 carbons in length, often about 2 to 10 carbons in length, often about 3 carbons to about 8 carbons in length, more often about 4 carbons to about 6 carbons in length. The haloalkyl groups are generally linear alkyl groups (although branched-chain alkyl groups may also be used) and are end-capped with at least one halogen group, preferably a single halogen group, often a single chloride
PTM
group. Haloalkyl ' 1 groups for use in the present invention are preferably represented by the chemical structure -(CH2)v-Halo where v is any integer from 2 to about 12, often about 3 to about 8, more often about 4 to about 6. Halo may be any halogen, but is preferably CI or Br, more often CI.
PTM
In still other embodiments, the group is a
Figure imgf000053_0001
groUp5 where w is 0 to 3, preferably 1 or 2. This group binds selectively to estrogen receptors and is useful for treating diseases which are modulated through estrogen receptors, and in particular cancers, such as breast cancer, endometrial cancer, ovarian cancer and uterine cancer, among others.
The present invention may be used to treat a number of disease states and/or conditions, including any disease state and/or condition in which proteins are dysregulated and where a patient would benefit from the degradation of proteins.
In another aspect, the present invention relates to pharmaceutical compositions comprising an effective amount of a compound as set forth hereinabove, in combination with a pharmaceutically acceptable carrier, additive or excipient, and optionally an additional bioactive agent.
In alternative aspects, the present invention relates to a method for treating a disease state by degrading a protein or polypeptide through which a disease state or condition is modulated comprising administering to said patient or subject an effective amount of at least one compound as described hereinabove, optionally in combination with an additional bioactive agent. The method according to the present invention may be used to treat a large number of disease states or conditions including cancer, by virtue of the administration of effective amounts of at least one compound described herein.
Detailed Description of the Invention
The following terms are used to describe the present invention. In instances where a term is not specifically defined herein, that term is given an art-recognized meaning by those of ordinary skill applying that term in context to its use in describing the present invention.
Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise (such as in the case of a group containing a number of carbon atoms in which case each carbon atom number falling within the range is provided), between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either both of those included limits are also included in the invention.
The term "compound", as used herein, unless otherwise indicated, refers to any specific chemical compound disclosed herein and includes tautomers, regioisomers, geometric isomers, and where applicable, stereoisomers, including optical isomers
(enantiomers) and other stereoisomers (diastereomers) thereof, as well as pharmaceutically acceptable salts and derivatives (including prodrug forms) thereof where applicable, in context. Within its use in context, the term compound generally refers to a single compound, but also may include other compounds such as stereoisomers, regioisomers and/or optical isomers (including racemic mixtures) as well as specific enantiomers or enantiomerically enriched mixtures of disclosed compounds. The term also refers, in context to prodrug forms of compounds which have been modified to facilitate the administration and delivery of compounds to a site of activity. It is noted that in describing the present compounds, numerous substituents and variables associated with same, among others, are described. It is understood by those of ordinary skill that molecules which are described herein are stable compounds as generally described hereunder. When the bond is shown, both a double bond and single bond are represented within the context of the compound shown.
The term "patient" or "subject" is used throughout the specification to describe an animal, preferably a human or a domesticated animal, to whom treatment, including prophylactic treatment, with the compositions according to the present invention is provided. For treatment of those infections, conditions or disease states which are specific for a specific animal such as a human patient, the term patient refers to that specific animal, including a domesticated animal such as a dog or cat or a farm animal such as a horse, cow, sheep, etc. In general, in the present invention, the term patient refers to a human patient unless otherwise stated or implied from the context of the use of the term.
The term "effective" is used to describe an amount of a compound, composition or component which, when used within the context of its intended use, effects an intended result. The term effective subsumes all other effective amount or effective concentration terms, which are otherwise described or used in the present application.
The term "VCB E3 Ubiquitin Ligase", "Hippel-Lindau E3 Ubiquitin Ligase" or "Ubiquitin Ligase" is used to describe a target enzyme(s) binding site of ubiquitin ligase moieties in the bifunctional (chimeric) compounds according to the present invention. VCB E3 is a protein that in combination with an E2 ubiquitin-conjugating enzyme causes the attachment of ubiquitin to a lysine on a target protein; the E3 ubiquitin ligase targets specific protein substrates for degradation by the proteasome. Thus, E3 ubiquitin ligase alone or in complex with an E2 ubiquitin conjugating enzyme is responsible for the transfer of ubiquitin to targeted proteins. In general, the ubiquitin ligase is involved in polyubiquitination such that a second ubiquitin is attached to the first, a third is attached to the second, and so forth. Polyubiquitination marks proteins for degradation by the proteasome. However, there are some ubiquitination events that are limited to mono-ubiquitination, in which only a single ubiquitin is added by the ubiquitin ligase to a substrate molecule. Mono-ubiquitinated proteins are not targeted to the proteasome for degradation, but may instead be altered in their cellular location or function, for example, via binding other proteins that have domains capable of binding ubiquitin. Further complicating matters, different lysines on ubiquitin can be targeted by an E3 to make chains. The most common lysine is Lys48 on the ubiquitin chain. This is the lysine used to make polyubiquitin, which is recognized by the proteasome.
The term "protein target moiety" or PTM is used to describe a small molecule which binds to a target protein or other protein or polypeptide of interest and places/presents that protein or polypeptide in proximity to an ubiquitin ligase such that degradation of the protein or polypeptide by ubiquitin ligase may occur. Non-limiting examples of small molecule target protein binding moieties include Hsp90 inhibitors, kinase inhibitors, MDM2 inhibitors, compounds targeting Human BET Bromodomain-containing proteins, HDAC inhibitors, human lysine methyltransferase inhibitors, angiogenesis inhibitors, immunosuppressive compounds, and compounds targeting the aryl hydrocarbon receptor (AHR), among numerous others. The compositions described below exemplify some of the members of these nine types of small molecule target protein.
Protein target moieties according to the present invention include, for example, Haloalkane halogenase inhibitors, Hsp90 inhibitors, kinase inhibitors, MDM2 inhibitors, compounds targeting Human BET Bromodomain-containing proteins, HDAC inhibitors, human lysine methyltransferase inhibitors, angiogenesis inhibitors, immunosuppressive compounds, and compounds targeting the aryl hydrocarbon receptor (AHR). The
compositions described below exemplify some of the members of these types of small molecule target protein binding moieties. Such small molecule target protein binding moieties also include pharmaceutically acceptable salts, enantiomers, solvates and polymorphs of these compositions, as well as other small molecules that may target a protein of interest. References which are cited hereinbelow are incorporated by reference herein in their entirety.
I. Heat Shock Protein 90 (HSP90) Inhibitors:
HSP90 inhibitors as used herein include, but are not limited to:
1. The HSP90 inhibitors identified in Vallee, et al., "Tricyclic Series of Heat Shock Protein 90 (HSP90) Inhibitors Part I: Discovery of Tricyclic Imidazo[4,5-C]Pyridines as Potent Inhibitors of the HSP90 Molecular Chaperone (2011) J.Med.Chem. 54: 7206, including YKB
-[4-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-9H-FLUOREN-9-YL]-SUCCINAMIDE
Figure imgf000057_0001
Derivatized where a linker group L or a
Figure imgf000057_0002
group is attached via the terminal amide group;
2. The HSP90 inhibitor p54 (modified): p54
8-[(2,4-dimethylphenyl)sulfanyl]-3-pent-4-yn-1 -yl-3H-purin-6-amine
Figure imgf000057_0003
a linker group L group is attached via the terminal acetylene group;
3. The HSP90 inhibitors (modified) identified in Brough, et ai, "4,5-Diarylisoxazole HSP90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer", J.MED.CHEM. vol: 51, pag:196 (2008), including the compound 2GJ (5- DIHYDROXY-5-( 1 -METHYLETHYL)PHENYL]-N-ETHYL-4-[4-(MORPHOLIN-4- LE-3 -C ARBOXAMIDE) having the structure:
D
Figure imgf000058_0001
erivatized, where a linker group L or a is attached via the amide group (at the amine or at the alkyl group on the amine;
4. The HSP90 inhibitors (modified) identified in Wright, et ah, Structure-Activity Relationships in Purine-Based Inhibitor Binding to HSP90 Isoforms, Chem Biol. 2004 Jun;l l(6):775-85, including the HSP90 inhibitor PU3 having the structure:
Figure imgf000058_0002
5. The HSP90 inhibitor Geldanamycin ((4E,6Z,8S,9S,10E,12S,13i?,14S,16R)-13- hydroxy-8, 14, 19-trimethoxy-4, 10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[l 6.3.1 ] (derivatized) or any of its derivatives (e.g. 17-alkylamino-17-desmethoxygeldanamycin ("17- AAG") or 17-(2-dimethylaminoethyl)amino-17-desmethoxy eldanamycin ("17-DMAG"))
Figure imgf000059_0001
(derivatized, where a linker group L group is attached via the amide group).
II. Kinase and Phosphatase Inhibitors:
Kinase inhibitors as used herein include, but are not limited to:
1. Erlotinib Derivative Tyrosine Kinase Inhibitor
Figure imgf000059_0002
Where R is a linker group L or
Figure imgf000059_0003
group attached via the ether group;
2. The kinase inhibitor Sunitanib (derivatized):
Figure imgf000059_0004
(Derivatized where R is a linker group L or a
Figure imgf000060_0001
group attached to the pyrrole moiety);
1
3. Kinase Inhibitor Sorafenib (derivatized)
(Derivat
Figure imgf000060_0002
ized where R is a linker group L or a group attached to the phenyl moiety);
4. The kinase inhibitor Desatinib (derivatized)
(Derivatized w
Figure imgf000060_0003
here R is a linker group Lor attached to the pyrimidine);
5. The kinase inhibitor Lapatinib (derivatized)
Figure imgf000061_0001
terminal methyl of the sulfonyl methyl group;
The kinase inhibitor U09-CX-5279 (Derivatized)
Figure imgf000061_0002
CX-5279
3-(cyclopropylamino)-5-{[3-(trifluoromethyl)phenyl]amino}pyrimido[4,5-c]quinoline-8-^ acid
Derivatized where a linker group L or a
Figure imgf000061_0003
group is attached via the amine (aniline), carboxylic acid or amine alpha to cyclopropyl group, or cyclopropyl group; 7. The kinase inhibitors identified in Millan, et ah, Design and Synthesis of Inhaled P38 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease, J. MED. CHEM. vol:54, pag:7797 (2011), including the kinase inhibitors Yl W and YIX (Derivatized) having the structures:
Figure imgf000062_0001
YIX
1 -ethyl-3-(2-{[3-(1 -methylethyl)[1 ^.^triazolo^.S-alpyridin-e-y^sulfanylJbenzy urea
Derivatized where a linker group L
Figure imgf000062_0002
group is attached preferably via the propyl group;
Figure imgf000062_0003
1 -(3-tert-butyl-1 -phenyl-1 H-pyrazol-5-yl)-3-(2-{[3-(1 -methylethyl)[1 ,2,4]triazolo[4,3-a]pyridin-6-yl]sulfanyl}benzyl)i
Derivatized where a linker group L or a
Figure imgf000062_0004
group is attached preferably via either the propyl group or the butyl group; 8. The kinase inhibitors identified in Schenkel, et al., Discovery of Potent and Highly Selective Thienopyridine Janus Kinase 2 Inhibitors J. Med. Chem., 2011, 54 (24), pp -8450, including the compounds 6TP and OTP (Derivatized) having the structures:
Figure imgf000063_0001
6TP
4-amino-2-[4-(tert-butylsulfamoyl)phenyl]-N^
Thienopyridine 19
Derivatized where a linker group L or a
Figure imgf000063_0002
group is attached preferably via the terminal methyl group bound to amide moiety;
Figure imgf000063_0003
OTP
4-amino-N-methyl-2-[4-(morpholin-4^
Thienopyridine 8
Derivatized where a linker group L or a
Figure imgf000063_0004
group is attached preferably via the terminal methyl group bound to the amide moiety;
9. The kinase inhibitors identified in Van Eis, et al., "2,6-Naphthyridines as potent and selective inhibitors of the novel protein kinase C isozymes", Biorg. Med. Chem. Lett.20\ l Dec 15;21(24):7367-72, including the kinase inhibitor 07U having the structure:
Figure imgf000064_0001
07U
2-methyl-N~1~-[3-(pyridin-4-yl)-2,6-naphth iamine
Derivatized where a linker group L or a
Figure imgf000064_0002
group is attached preferably via the secondary amine or terminal amino g
10. The kinase inhibitors identified in Lountos, et ah, "Structural Characterization of Inhibitor Complexes with Checkpoint Kinase 2 (Chk2), a Drug Target for Cancer Therapy", J.STRUCT.BIOL. vol: 176, pag:292 (2011), including the kinase inhibitor YCF having the
Figure imgf000064_0003
Derivatized where a linker group L or a
Figure imgf000064_0004
group is attached preferably via either of the terminal hydroxyl groups;
11. The kinase inhibitors identified in Lountos, et ai, "Structural Characterization of Inhibitor Complexes with Checkpoint Kinase 2 (Chk2), a Drug Target for Cancer Therapy", J.STRUCT.BIOL. vol:176, pag:292 (2011), including the kinase inhibitors XK9 and NXP (derivatized) having the structures:
Figure imgf000065_0001
XK9
N-{4-[(1 E)-N-(N-hydroxycarbamimidoyl)ethanehydrazonoyl]phenyl}-7-nitro-1 H-indole-2-carbo
Figure imgf000065_0002
XP
N-{4-[(1 E)-N-CARBAMIMIDOYLETHANEHYDRAZONOYL]PHENYL}-1 H-INDOLE-3-CARBOXAMIDE
Derivatized where a linker group L or a
Figure imgf000065_0003
group is attached preferably via the terminal hydroxyl group (XK9) or the hydrazone group (NXP);
12. The kinase inhibitor Afatinib (derivatized) fN-[4-[(3-Chloro-4-fluorophenyl)amino]- 7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4(dimethylarnino)-2-
Figure imgf000065_0004
butenamide)(Derivatized where a linker group L or a group is attached preferably via the aliphatic amine group); 13. The kinase inhibitor Fostamatinib (derivatized) ([6-({5-fluoro-2-[(3,4,5- trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-3- oxo-2,3-dihydro-4H- pyrido[3,2-b]- -oxazin-4-yl]methyl disodium phosphate hexahydrate) (Derivatized where a
linker group L
Figure imgf000066_0001
group is attached preferably via a methoxy group);
14. The kinase inhibitor Gefitinib (derivatized) (N-(3-chloro-4-fluoro-phenyl)-7- methoxy-6-( -morpholin-4-ylpropoxy)quinazolin-4-amine) (Derivatized where a linker
group L or a
Figure imgf000066_0002
group is attached preferably via a methoxy or ether group);
Figure imgf000066_0003
15. The kinase inhibitor Lenvatinib (derivatized) (4-[3-chloro-4- (cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide) (Derivatized
where a linker group L
Figure imgf000066_0004
s attached preferably via the cyclopropyl group);
16. The kinase inhibitor Vandetanib (derivatized) ( V-(4-bromo-2-fluorophenyl)-6- methoxy-7-[(l -methylpiperidin-4-yl)methoxy]quinazolin-4-amine) (derivatized where a
Figure imgf000066_0005
linker group L or group is attached preferably via the methoxy or hydroxyl group); and 17. The kinase inhibitor Vemurafenib (derivatized) (propane-l-sulfonic acid {3-[5-(4- chlorophenyl)-lH-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide3
(Derivatized where a linker group L
Figure imgf000067_0001
group is attached preferably via the sulfonyl propyl group)
The kinase inhibitor Gleevec (derivatized):
(Deriva
Figure imgf000067_0002
tized where R as a linker group L is attached preferably via the amide group or via the aniline amine group);
19. The kinase inhibitor Pazopanib (derivatized) (VEGFR3 inhibitor):
Figure imgf000067_0003
(Derivatized where R is a linker group L or a — group preferably attached to the phenyl moiety or via the aniline amine group);
The kinase inhibitor AT-9283 (Derivatized) Aurora Kinase Inhibitor
(where R is a linker gro
Figure imgf000068_0001
up L or a group attached preferably to the phenyl moiety);
The kinase inhibitor TAE684 (derivatized) ALK inhibitor
Figure imgf000068_0002
(where R is a linker group L or a
Figure imgf000068_0003
attached preferably to the phenyl moiety);
The kinase inhibitor Nilotanib (derivatized) Abl inhibitor:
Figure imgf000069_0001
group attached preferably to the phenyl moiety or the aniline amine group);
Kinase Inhibitor NVP-BSK805 (derivatized) JAK2 Inhibitor
Figure imgf000069_0002
(Derivatized where R is a linker group L or a group attached to the phenyl moiety or the diazole group);
28. Kinase Inhibitor Crizotinib Derivatized Alk Inhibitor
(Derivatized wh
Figure imgf000070_0001
ere R is a linker group L or a group attached to the phenyl moiety or the diazole group);
29. Kinase Inhibitor JNJ FMS (derivatized) Inhibitor
(Derivatized w
Figure imgf000070_0002
here R is a linker group L or a group attached preferably to the phenyl moiety);
The kinase inhibitor Foretinib (derivatized) Met Inhibitor
Figure imgf000070_0003
(Derivatized where R is a linker group L or a
Figure imgf000071_0001
attached to the phenyl moiety or a hydroxyl or ether group on the quinoline moiety);
The allosteric Protein Tyrosine Phosphatase Inhibitor PTPIB (derivatized):
Figure imgf000071_0002
attached at R, as indicated.
The inhibitor of SHP-2 Domain of Tyrosine Phosphatase (derivatized):
Figure imgf000071_0003
group is attached preferably at R. 33. The inhibitor (derivatized) of BRAF (BRAFV600E)/MEK:
Derivat
Figure imgf000072_0001
ized where a linker group L or a group is attached preferably at R.
Inhibitor (derivatized) of Tyrosine Kinase ABL
Figure imgf000072_0002
(Derivatized where "R" designates a site for attachment of a linker group L or a
Figure imgf000072_0003
group on the piperazine moiety
III. MDM2 Inhibitors:
MDM2 inhibitors as used herein include, but are not limited to:
1. The MDM2 inhibitors identified in Vassilev, et al, In vivo activation of the p53 pathway by small-molecule antagonists of MDM2, SCIENCE vol:303, pag:844-848 (2004), and Schneekloth, et al., Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics, Bioorg. Med. Chem. Lett. 18 (2008) 5904-5908, including (or additionally) the compounds nutlin-3, nutlin-2, and nutlin-1 (derivatized) as described below, as well as all derivatives and analogs thereof:
Nutlin-3
Figure imgf000073_0001
(Derivatized where a linker group L or a
Figure imgf000073_0002
group is attached
(
Figure imgf000073_0003
Derivatized where a linker group L or a group is attached preferably at the methoxy group or hydroxyl group);
Figure imgf000074_0001
(Derivatized where a linker group L or a group is attached via the methoxy group or as a hydroxyl group); and
2. Trans-4-Iodo-4'-Boranyl-Chalcone
(Deri
Figure imgf000074_0002
vatized where a linker group L or a a linker group L or
Figure imgf000074_0003
group is attached a linker group L or a — group is attached group is attached via a hydroxy group);
IV. Compounds Targeting Human BET Bromodomain-containing proteins:
Compounds targeting Human BET Bromodomain-containing proteins include, but are not limited to the compounds assoc below, where "R"
designates a site for linker group L
Figure imgf000074_0004
attachment:
1. Protein targets: Brd2, Brd3, Brd4
Figure imgf000075_0001
JQl, Filippakopoulos et al. Selective inhibition of BET.bromodomains. Nature (2010)
2.
Figure imgf000075_0002
I-BET, Nicodeme et al. Suppression of inflammation by a synthetic histone mimic. Nature (2010) Chung et al. Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains. Journal of medicinal chemistry (2011)
3.
4d, Hewings et al. 3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands. J. Med. Chem. (2011) vol. 54 (19) pp. 6761-70
4.
Figure imgf000076_0001
I-BET151, Dawson et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature (2011) a site for attachment of a linker group L or a
Figure imgf000076_0002
group .
V. HDAC Inhibitors;
HDAC Inhibitors (derivatized) include, but are not limited to
1.
Figure imgf000076_0003
Finnin, M.S. et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401 , 188-193 (1999).
(Derivatized where "R" designates a site for attachment of a linker group L or a
Figure imgf000076_0004
2. Compounds as defined by formula (I) of PC "DEACETYLASE
INHIBITORS") (Derivatized where a linker group L or a
Figure imgf000076_0005
is attached via the hydroxyl group); VI. Human Lysine Methyltransferase Inhibitors:
Human Lysine Methyltransferase inhibitors include, but are not limited to:
Figure imgf000077_0001
BIX-01294
Chang et al. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX- 01294. Nat Struct Mol Biol (2009) vol. 16 (3) pp. 312-7
(Derivatized where "R" designates a site for attachment of a linker group L or a
Figure imgf000077_0002
2.
Figure imgf000077_0003
UNC0224
Liu F, Chen X, Allali-Hassani A, et al. Discovery of a 2,4-diamino-7- aminoalkoxyquinazoline as a potent and selective inhibitor of histone Iysine methyltransferase G9a. J Med Chem
2009;52(24):7950-3
(Derivatized where "R" designates a potential site for attachment of a linker group L or a
Figure imgf000077_0004
3. Azacitidine (derivatized) (4-amino-l- -D-ribofuranos l-l 3 5-triazin-2(l )-one)
Figure imgf000078_0001
(Derivatized where a linker group L or a attached via the hydroxy or amino groups); and
4. Decitabine (derivatized) (4-amino-l-(2-deoxy-b-D-erythro-pentofuranosyl)-l, 3, 5-
Figure imgf000078_0002
triazin-2(lH)-one) (Derivatized where a linker group L or a
is attached via either of the hydroxy groups or at the amino group).
VII. Angiogenesis Inhibitors:
Angiogenesis inhibitors include, but are not limited to:
1. GA-1 (derivatized) and derivatives and analogs thereof, having the structure(s) and binding to linkers as described in Sakamoto, et ah, Development of Protacs to target cancer- promoting proteins for ubiquitination and degradation, Mol Cell Proteomics 2003 Dec;2(12):1350-8;
' 2. Estradiol (derivatized), which may be bound to a linker group L or a
Figure imgf000078_0003
as is generally described in Rodriguez-Gonzalez, et ah,
Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer, Oncogene (2008) 27, 7201-7211 ;
3. Estradiol, testosterone (derivatized) and related derivatives, including but not limited to DHT and derivatives and analogs thereof, having the structure(s) and binding to a linker
Figure imgf000078_0004
group L or a as generally described in Sakamoto, et ah,
Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation, Mol Cell Proteomics 2003 Dec; 2(12):1350-8; and 4. Ovalicin, fumagillin (derivatized), and derivatives and analogs thereof, having the
structure(s) and binding to a linker group L
Figure imgf000079_0001
generally described in Sakamoto, et al., Protacs: chimeric molecules that target proteins to the Skpl-Cullin-F box complex for ubiquitination and degradation Proc Natl Acad Sci USA. 2001 Jul 17;98(15):8554-9 and United States Patent No. 7,208,157.
VIII. Immunosuppressive Compounds:
Immunosuppressive compounds include, but are not limited to:
ed), having the structure(s) and binding to a linker group L or a
Figure imgf000079_0002
group as is generally described in Schneekloth, et al., Chemical Genetic Control of Protein Levels: Selective in Vivo Targeted Degradation, J. AM. CHEM. SOC. 2004, 126, 3748-3754;
2. Glucocorticoids (e.g., hydrocortisone, prednisone, prednisolone, and
methylprednisolone) (Derivatized where a linker group L or a
Figure imgf000079_0003
dipropionate (Derivatized where a linker group or a
to a proprionate);
3. Methotrexate (Derivatized where a linker group or a
Figure imgf000079_0004
group can be bound, e.g. to either of the terminal hydroxyls); 4. Ciclosporin (Derivatized where a linker group or a
Figure imgf000080_0001
can be bound, e.g. at any of the butyl groups); -506) and rapamycin (Derivatized where a linker group L or a
Figure imgf000080_0002
group can be bound, e.g. at one of the methoxy groups); and
6. Actinomycins (Derivatized where a linker group L or a
Figure imgf000080_0003
group can be bound, e.g. at one of the isopropyl groups).
IX. Compounds targeting the aryl hydrocarbon receptor (AHR):
Compounds targeting the aryl hydrocarbon receptor (AHR) include, but are not limited to:
1. Apigenin (Derivatized in a way which binds to a linker group L or a
Figure imgf000080_0004
is generally illustrated in Lee, et al, , Targeted
Degradation of the Aryl Hydrocarbon Receptor by the PROTAC Approach: A Useful
Chemical Genetic Tool, ChemBioChem Volume 8, Issue 17, pages 2058-2062, November 23, 2007); and such that a linker group L or a
Figure imgf000080_0005
described in Boitano, et al., Aryl Hydrocarbon
Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells, Science 10 September 2010: Vol. 329 no. 5997 pp. 1345-1348.
X. Compounds targeting RAF Receptor (Kinase) :
Figure imgf000081_0001
group attachment).
XI. Compounds Targeting FKBP
Figure imgf000081_0002
group attachment).
XII. Compounds Targeting Androgen Receptor (AR)
1. RU59063 Ligand (derivatized) of Androgen Rceptor
Figure imgf000081_0003
Figure imgf000082_0001
(Der vat ze w ere "R" esignates a site for a linker group L or a group attachment).
2. SARM Ligand (derivatized) of Androgen Receptor
Figure imgf000082_0002
(Derivatized where "R" designates a site for a linker group L
Figure imgf000082_0003
group attachment).
3. Androgen Receptor Ligand DHT (derivatized)
Figure imgf000082_0004
(Derivatized where "R" designates a site for a linker group L or
Figure imgf000082_0005
group attachment).
XIII. Compounds Targeting Estrogen Receptor (ER) ICI-182780
1. Estrogen Receptor Ligand
Figure imgf000082_0006
(Derivatized where "R" designates a site for linker group L or
Figure imgf000083_0001
group attachment).
XIV. Compounds Targeting Thyroid Hormone Receptor (TR)
1. Thyroid Hormone Receptor Ligand (derivatized)
Figure imgf000083_0002
group attachment and MOMO indicates a methoxymethoxy group).
XV. Compounds targeting HIV Protease
1. Inhibitor of HIV Protease (derivatized)
Figure imgf000083_0003
group attachment). See, J. Med. Chem. 2010, 53, 521-538. Inhibitor of HIV Protease
Figure imgf000084_0001
(Derivatized where "R" designates a potential site for linker group L or
Figure imgf000084_0002
group attachment). See, J Med. Chem. 2010, 53, 521-538.
XVI. Compounds targeting HIV Integrase
1. Inhibitor of HIV Integrase (derivatized)
Figure imgf000084_0003
(Derivatized where "R" designates a site for linker group L or
Figure imgf000084_0004
group attachment). See, J. Med. Chem. 2010, 53, 6466.
2. Inhibitor of HIV Integrase (derivatized)
Figure imgf000085_0001
group attachment). See, J. Med. Chem. 2010, 53, 6466.
XVII. Compounds targeting HCV Protease
1. Inhibitors of HCV Protease (derivatized)
Figure imgf000085_0002
group attachment).
XVIII. Compounds targeting Acyl-protein Thioesterase-1 and -2 (APTl and APT2)
1. Inhibitor of APTl and APT2 (derivatized)
Figure imgf000086_0001
(Derivatized where "R" designates a site for linker group L
Figure imgf000086_0002
group attachment). See, Angew. Chem. Int. Ed. 2011, 50, 9838 -9842, where
L is a linker group as otherwise described herein and said — ' rou is as otherwise
Figure imgf000086_0003
described herein such that group to a
Figure imgf000086_0004
otherwise described herein.
The term "target protein" is used to describe a protein or polypeptide, which is a target for binding to a compound according to the present invention and degradation by ubiquitin ligase hereunder. Such small molecule target protein binding moieties also include pharmaceutically acceptable salts, enantiomers, solvates and polymorphs of these
compositions, as well as other small molecules that may target a protein of interest. These
binding moieties are linked to
Figure imgf000086_0005
through linker groups L.
Target proteins which may be bound to the protein target moiety and degraded by the ligase to which the ubiquitin ligase binding moiety is bound include structural proteins, receptors, enzymes, cell surface proteins, proteins pertinent to the integrated function of a cell, including proteins involved in catalytic activity, aromatase activity, motor activity, helicase activity, metabolic processes (anabolism and catrabolism), antioxidant activity, proteolysis, biosynthesis, proteins with kinase activity, oxidoreductase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, ligase activity, enzyme regulator activity, signal transducer activity, structural molecule activity, binding activity (protein, lipid carbohydrate), receptor activity, cell motility, membrane fusion, cell communication, regulation of biological processes, development, cell differentiation, response to stimulus, behavioral proteins, cell adhesion proteins, proteins involved in cell death, proteins involved in transport (including protein transporter activity, nuclear transport, ion transporter activity, channel transporter activity, carrier activity, permease activity, secretion activity, electron transporter activity, pathogenesis, chaperone regulator activity, nucleic acid binding activity, transcription regulator activity, extracellular organization and biogenesis activity, translation regulator activity. Proteins of interest can include proteins from eurkaryotes and prokaryotes, including microbes, viruses, fungi and parasites, including humans, microbes, viruses, fungi and parasites, among numerous others, as targets for drug therapy, other animals, including domesticated animals, microbials for the determination of targets for antibiotics and other antimicrobials and plants, and even viruses, among numerous others
More specifically, a number of drug targets for human therapeutics represent protein targets to which protein target moiety may be bound and incorporated into compounds according to the present invention. These include proteins which may be used to restore function in numerous polygenic diseases, including for example B7.1 and B7, TINFRlm, TNFR2, NADPH oxidase, BclIBax and other partners in the apotosis pathway, C5a receptor, HMG-CoA reductase, PDE V phosphodiesterase type, PDE IV phosphodiesterase type 4, PDE I, PDEII, PDEIII, squalene cyclase inhibitor, CXCR1, CXCR2, nitric oxide (NO) synthase, cyclo-oxygenase 1 , cyclo-oxygenase 2, 5HT receptors, dopamine receptors, G Proteins, i.e., Gq, histamine receptors, 5 -lipoxygenase, tryptase serine protease, thymidylate synthase, purine nucleoside phosphorylase, GAPDH trypanosomal, glycogen phosphorylase, Carbonic anhydrase, chemokine receptors, JAW STAT, RXR and similar, HIV 1 protease, HIV 1 integrase, influenza, neuramimidase, hepatitis B reverse transcriptase, sodium channel, multi drug resistance (MDR), protein P-glycoprotein (and MRP), tyrosine kinases, CD23, CD124, tyrosine kinase p56 lck, CD4, CD5, IL-2 receptor, IL-1 receptor, TNF-alphaR, ICAM1, Cat+ channels, VCAM, VLA-4 integrin, selectins, CD40/CD40L, newokinins and receptors, inosine monophosphate dehydrogenase, p38 MAP Kinase, RaslRaflMEWERK pathway, interleukin-1 converting enzyme, caspase, HCV, NS3 protease, HCV NS3 RNA helicase, glycinamide ribonucleotide formyl transferase, rhino virus 3C protease, herpes simplex virus- 1 (HSV-I), protease, cytomegalovirus (CMV) protease, poly (ADP-ribose) polymerase, cyclin dependent kinases, vascular endothelial growth factor, oxytocin receptor, microsomal transfer protein inhibitor, bile acid transport inhibitor, 5 alpha reductase inhibitors, angiotensin 11, glycine receptor, noradrenaline reuptake receptor, endothelin receptors, neuropeptide Y and receptor, estrogen receptors, androgen receptors, adenosine receptors, adenosine kinase and AMP deaminase, purinergic receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2X1-7), farnesyltransferases, geranylgeranyl transferase, TrkA a receptor for NGF, beta-amyloid, tyrosine kinase Flk-IIKDR, vitronectin receptor, integrin receptor, Her-21 neu, telomerase inhibition, cytosolic phospholipaseA2 and EGF receptor tyrosine kinase.
Additional protein targets include, for example, ecdysone 20-monooxygenase, ion channel of the GABA gated chloride channel, acetylcholinesterase, voltage-sensitive sodium channel protein, calcium release channel, and chloride channels. Still further target proteins include Acetyl-CoA carboxylase,
adenylosuccinate synthetase, protoporphyrinogen oxidase, and enolpyruvylshikimate- phosphate synthase.
Haloalkane dehalogenase enzymes are another target of specific compounds according to the present invention. Compounds according to the present invention which contain chloroalkane peptide binding moieties (Cj-Cn often about C -Cj0 alkyl halo groups) may be used to inhibit and/or degrade haloalkane dehalogenase enzymes which are used in fusion proteins or related dioagnostic proteins as described in PCT/US 2012/063401 filed December 6, 2011 and published as WO 2012/078559 on June 14, 2012, the contents of which is incorporated by reference herein.
These various protein targets may be used in screens that identify compound moieties which bind to the protein and by incorporation of the moiety into compounds according to the present invention, the level of activity of the protein may be altered for therapeutic end result.
The term "disease state or condition" is used to describe any disease state or condition wherein protein dysregulation (i.e., the amount of protein expressed in a patient is elevated) occurs and where degradation of one or more proteins in a patient may provide beneficial therapy or relief of symptoms to a patient in need thereof. In certain instances, the disease state or condition may be cured.
Disease states of conditions which may be treated using compounds according to the present invention include, for example, asthma, autoimmune diseases such as multiple sclerosis, various cancers, ciliopathies, cleft palate, diabetes, heart disease, hypertension, inflammatory bowel disease, mental retardation, mood disorder, obesity, refractive error, infertility, Angelman syndrome, Canavan disease, Coeliac disease, Charcot-Marie-Tooth disease, Cystic fibrosis, Duchenne muscular dystrophy, Haemochromatosis, Haemophilia, Klinefelter's syndrome, Neurofibromatosis, Phenylketonuria, Polycystic kidney disease, (PKDl) or 4 (PKD2) Prader-Willi syndrome, Sickle-cell disease, Tay-Sachs disease, Turner syndrome.
Further disease states or conditions which may be treated by compounds according to the present invention include Alzheimer's disease, Amyotrophic lateral sclerosis (Lou Gehrig's disease), Anorexia nervosa, Anxiety disorder, Atherosclerosis, Attention deficit hyperactivity disorder, Autism, Bipolar disorder, Chronic fatigue syndrome, Chronic obstructive pulmonary disease, Crohn's disease, Coronary heart disease, Dementia,
Depression, Diabetes mellitus type 1 , Diabetes mellitus type 2, Epilepsy, Guillain-Barre syndrome, Irritable bowel syndrome, Lupus, Metabolic syndrome, Multiple sclerosis, Myocardial infarction, Obesity, Obsessive-compulsive disorder, Panic disorder, Parkinson's disease, Psoriasis, Rheumatoid arthritis, Sarcoidosis, Schizophrenia, Stroke, Thromboangiitis obliterans, Tourette syndrome, Vasculitis.
Still additional disease states or conditions which can be treated by compounds according to the present invention include aceruloplasminemia, Achondrogenesis type II, achondroplasia, Acrocephaly, Gaucher disease type 2, acute intermittent porphyria, Canavan disease, Adenomatous Polyposis Coli, ALA dehydratase deficiency, adenylosuccinate lyase deficiency, Adrenogenital syndrome, Adrenoleukodystrophy, ALA-D porphyria, ALA dehydratase deficiency, Alkaptonuria, Alexander disease, Alkaptonuric ochronosis, alpha 1- antitrypsin deficiency, alpha- 1 proteinase inhibitor, emphysema, amyotrophic lateral sclerosis Alstrom syndrome, Alexander disease, Amelogenesis imperfecta, ALA dehydratase deficiency, Anderson-Fabry disease, androgen insensitivity syndrome, Anemia
Angiokeratoma Corporis Diffusum, Angiomatosis retinae (von Hippel-Lindau disease) Apert syndrome, Arachnodactyly (Marfan syndrome), Stickler syndrome,
Arthrochalasis multiplex congenital (Ehlers-Danlos syndrome#arthrochalasia type) ataxia telangiectasia, Rett syndrome, primary pulmonary hypertension,
Sandhoff disease, neurofibromatosis type II, Beare-Stevenson cutis gyrata syndrome, Mediterranean fever, familial, Benjamin syndrome, beta-thalassemia
Bilateral Acoustic Neurofibromatosis (neurofibromatosis type II), factor V Leiden
thrombophilia, Bloch- Sulzberger syndrome (incontinentia pigmenti), Bloom syndrome, X- linked sideroblastic anemia, Bonnevie-Ullrich syndrome (Turner syndrome), Bourneville disease (tuberous sclerosis), prion disease, Birt-Hogg-Dube syndrome, Brittle bone disease (osteogenesis imperfecta), Broad Thumb-Hallux syndrome (Rubinstein-Taybi syndrome), Bronze Diabetes/Bronzed Cirrhosis (hemochromatosis), Bulbospinal muscular atrophy (Kennedy's disease), Burger-Grutz syndrome (lipoprotein lipase deficiency), CGD Chronic granulomatous disorder, Campomelic dysplasia, biotinidase deficiency, Cardiomyopathy (Noonan syndrome), Cri du chat, CAVD (congenital absence of the vas deferens), Caylor cardiofacial syndrome (CBAVD), CEP (congenital erythropoietic porphyria), cystic fibrosis, congenital hypothyroidism, Chondrodystrophy syndrome (achondroplasia),
otospondylomegaepiphyseal dysplasia, Lesch-Nyhan syndrome, galactosemia, Ehlers-Danlos syndrome, Thanatophoric dysplasia, Coffin-Lowry syndrome, Cockayne syndrome, (familial adenomatous polyposis), Congenital erythropoietic porphyria, Congenital heart disease, Methemoglobinemia/Congenital methaemoglobinaemia, achondroplasia, X-linked
sideroblastic anemia, Connective tissue disease, Conotruncal anomaly face syndrome, Cooley's Anemia (beta-thalassemia), Copper storage disease (Wilson's disease), Copper transport disease (Menkes disease), hereditary coproporphyria, Cowden syndrome,
Craniofacial dysarthrosis (Crouzon syndrome), Creutzfeldt- Jakob disease (prion disease), Cockayne syndrome, Cowden syndrome, Curschmann-Batten-Steinert syndrome (myotonic dystrophy), Beare-Stevenson cutis gyrata syndrome, primary hyperoxaluria,
spondyloepimetaphyseal dysplasia (Strudwick type), muscular dystrophy, Duchenne and Becker types (DBMD), Usher syndrome, Degenerative nerve diseases including de Grouchy syndrome and Dejerine-Sottas syndrome, developmental disabilities, distal spinal muscular atrophy, type V, androgen insensitivity syndrome, Diffuse Globoid Body Sclerosis (Krabbe disease), Di George's syndrome, Dihydrotestosterone receptor deficiency, androgen insensitivity syndrome, Down syndrome, Dwarfism, erythropoietic protoporphyria
Erythroid 5-aminolevulinate synthetase deficiency, Erythropoietic porphyria, erythropoietic protoporphyria, erythropoietic uroporphyria, Friedreich's ataxia,, familial paroxysmal polyserositis, porphyria cutanea tarda, familial pressure sensitive neuropathy,
primary pulmonary hypertension (PPH), Fibrocystic disease of the pancreas, fragile X syndrome, galactosemia, genetic brain disorders, Giant cell hepatitis (Neonatal
hemochromatosis), Gronblad-Strandberg syndrome ( pseudoxanthoma elasticum), Gunther disease (congenital erythropoietic porphyria), haemochromatosis, Hallgren syndrome, sickle cell anemia, hemophilia, hepatoerythropoietic porphyria (HEP), Hippel-Lindau disease (von Hippel-Lindau disease), Huntington's disease, Hutchinson-Gilford progeria syndrome (progeria), Hyperandrogenism, Hypochondroplasia, Hypochromic anemia, Immune system disorders, including X-linked severe combined immunodeficiency, Insley-Astley syndrome, Jackson- Weiss syndrome, Joubert syndrome, Lesch-Nyhan syndrome, Jackson- Weiss syndrome, Kidney diseases, including hyperoxaluria, Klinefelter's syndrome, Kniest dysplasia, Lacunar dementia,Langer-Saldino achondrogenesis, ataxia telangiectasia, Lynch syndrome, Lysyl-hydroxylase deficiency, Machado- Joseph disease, Metabolic disorders, including Kniest dysplasia, Marfan syndrome, Movement disorders, Mowat- Wilson syndrome, cystic fibrosis, Muenke syndrome, Multiple neurofibromatosis, Nance-Insley syndrome, Nance- Sweeney chondrodysplasia, Niemann-Pick disease, Noack syndrome (Pfeiffer syndrome), Osier- Weber-Rendu disease, Peutz-Jeghers syndrome, Polycystic kidney disease, polyostotic fibrous dysplasia (McCune-Albright syndrome), Peutz-Jeghers syndrome, Prader-Labhart- Willi syndrome, hemochromatosis, primary hyperuricemia syndrome (Lesch- Nyhan syndrome), primary pulmonary hypertension, primary senile degenerative dementia, prion disease, progeria (Hutchinson Gilford Progeria Syndrome), progressive chorea, chronic hereditary (Huntington) (Huntington's disease), progressive muscular atrophy, spinal muscular atrophy, propionic acidemia, protoporphyria, proximal myotonic dystrophy, pulmonary arterial hypertension, PXE (pseudoxanthoma elasticum), Rb (retinoblastoma), Recklinghausen disease (neurofibromatosis type I), Recurrent polyserositis, Retinal disorders, Retinoblastoma, Rett syndrome, RFALS type 3, Ricker syndrome, Riley-Day syndrome, Roussy-Levy syndrome, severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), Li-Fraumeni syndrome, sarcoma, breast, leukemia, and adrenal gland (SBLA) syndrome, sclerosis tuberose (tuberous sclerosis), SDAT, SED congenital
(spondyloepiphyseal dysplasia congenita), SED Strudwick (spondyloepimetaphyseal dysplasia, Strudwick type), SEDc (spondyloepiphyseal dysplasia congenita)
SEMD, Strudwick type (spondyloepimetaphyseal dysplasia, Strudwick type), Shprintzen syndrome, Skin pigmentation disorders, Smith-Lemli-Opitz syndrome, South- African genetic porphyria (variegate porphyria), infantile-onset ascending hereditary spastic paralysis, Speech and communication disorders, sphingolipidosis, Tay-Sachs disease,
spinocerebellar ataxia, Stickler syndrome, stroke, androgen insensitivity syndrome, tetrahydrobiopterin deficiency, beta-thalassemia, Thyroid disease
Tomaculous neuropathy (hereditary neuropathy with liability to pressure palsies)
Treacher Collins syndrome, Triplo X syndrome ( triple X syndrome), Trisomy 21
(Down syndrome), Trisomy X, VHL syndrome (von Hippel-Lindau disease), Vision impairment and blindness (Alstrom syndrome), Vrolik disease, Waardenburg syndrome, Warburg Sjo Fledelius Syndrome, Weissenbacher-Zweymuller syndrome, Wolf-Hirschhorn syndrome, Wolff Periodic disease, Weissenbacher-Zweymuller syndrome and
Xeroderma pigmentosum, among others.
The term "neoplasia" or "cancer" is used throughout the specification to refer to the pathological process that results in the formation and growth of a cancerous or malignant neoplasm, i.e., abnormal tissue that grows by cellular proliferation, often more rapidly than normal and continues to grow after the stimuli that initiated the new growth cease. Malignant neoplasms show partial or complete lack of structural organization and functional
coordination with the normal tissue and most invade surrounding tissues, metastasize to several sites, and are likely to recur after attempted removal and to cause the death of the patient unless adequately treated. As used herein, the term neoplasia is used to describe all cancerous disease states and embraces or encompasses the pathological process associated with malignant hematogenous, ascitic and solid tumors. Exemplary cancers which may be treated by the present compounds either alone or in combination with at least one additional anti-cancer agent include squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, and renal cell carcinomas, cancer of the bladder, bowel, breast, cervix, colon, esophagus, head, kidney, liver, lung, neck, ovary, pancreas, prostate, and stomach; leukemias; benign and malignant lymphomas, particularly Burkitt's lymphoma and Non-Hodgkin's lymphoma; benign and malignant melanomas; myeloproliferative diseases; sarcomas, including Ewing's sarcoma, hemangiosarcoma, Kaposi's sarcoma, liposarcoma, myosarcomas, peripheral neuroepithelioma, synovial sarcoma, gliomas, astrocytomas, oligodendrogliomas, ependymomas, gliobastomas, neuroblastomas, ganglioneuromas, gangliogliomas, medulloblastomas, pineal cell tumors, meningiomas, meningeal sarcomas, neurofibromas, and Schwannomas; bowel cancer, breast cancer, prostate cancer, cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, esophageal cancer, pancreatic cancer, stomach cancer, liver cancer, colon cancer, melanoma; carcinosarcoma, Hodgkin's disease, Wilms' tumor and teratocarcinomas.
Additional cancers which may be treated using compounds according to the present invention include, for example, T-lineage Acute lymphoblastic Leukemia (T-ALL), T-lineage lymphoblastic Lymphoma (T-LL), Peripheral T-cell lymphoma, Adult T-cell Leukemia, Pre- B ALL, Pre-B Lymphomas, Large B-cell Lymphoma, Burkitts Lymphoma, B-cell ALL, Philadelphia chromosome positive ALL and Philadelphia chromosome positive CML,
The term "bioactive agent" is used to describe an agent, other than a compound according to the present invention, which is used in combination with the present compounds as an agent with biological activity to assist in effecting an intended therapy, inhibition and/or prevention/prophylaxis for which the present compounds are used. Preferred bioactive agents for use herein include those agents which have pharmacological activity similar to that for which the present compounds are used or administered and include for example, anti-cancer agents, antiviral agents, especially including anti-HIV agents and anti-HCV agents, antimicrobial agents, antifungal agents, etc.
The term "additional anti-cancer agent" is used to describe an anti-cancer agent, which may be combined with compounds according to the present invention to treat cancer. These agents include, for example, everolimus, trabectedin, abraxane, TLK 286, AV-299, DN-101, pazopanib, GSK690693, RTA 744, ON 0910.Na, AZD 6244 (ARRY- 142886), AMN-107, TKI-258, GSK461364, AZD 1152, enzastaurin, vandetanib, ARQ-197, MK-0457, MLN8054, PHA-739358, R-763, AT-9263, a FLT-3 inhibitor, a VEGFR inhibitor, an EGFR TK inhibitor, an aurora kinase inhibitor, a PIK-1 modulator, a Bel -2 inhibitor, an HDAC inhbitor, a c-MET inhibitor, a PARP inhibitor, a Cdk inhibitor, an EGFR TK inhibitor, an IGFR-TK inhibitor, an anti-HGF antibody, a PI3 kinase inhibitors, an AKT inhibitor, a JAK/STAT inhibitor, a checkpoint- 1 or 2 inhibitor, a focal adhesion kinase inhibitor, a Map kinase kinase (mek) inhibitor, a VEGF trap antibody, pemetrexed, erlotinib, dasatanib, nilotinib, decatanib, panitumumab, amrubicin, oregovomab, Lep-etu, nolatrexed, azd2171 , batabulin, ofatumumab, zanolimumab, edotecarin, tetrandrine, rubitecan, tesmilifene, oblimersen, ticilimumab, ipilimumab, gossypol, Bio 111, 131-I-TM-601, ALT- 110, BIO 140, CC 8490, cilengitide, gimatecan, IL13-PE38QQR, INO 1001, IPdRj KRX-0402, lucanthone, LY317615, neuradiab, vitespan, Rta 744, Sdx 102, talampanel, atrasentan, Xr 311,
romidepsin, ADS-100380, sunitinib, 5-fluorouracil, vorinostat, etoposide, gemcitabine, doxorubicin, liposomal doxorubicin, 5'-deoxy-5-fluorouridine, vincristine, temozolomide, ZK-304709, seliciclib; PD0325901, AZD-6244, capecitabine, L-Glutamic acid, N-[4-[2-(2- amino-4,7-dihydro-4-oxo-l H - pyrrolo[2,3- d]pyrimidin-5-yl)ethyl]benzoyl]-, disodium salt, heptahydrate, camptothecin, PEG-labeled irinotecan, tamoxifen, toremifene citrate, anastrazole, exemestane, letrozole, DES(diethylstilbestrol), estradiol, estrogen, conjugated estrogen, bevacizumab, IMC-1C11, CHIR-258); 3-[5-(methylsulfonylpiperadinemethyl)- indolylj-quinolone, vatalanib, AG-013736, AVE-0005, the acetate salt of [D- Ser(Bu t ) 6 ,Azgly 10 ] (pyro-Glu-His-Trp-Ser-Tyr-D-Ser(Bu t )-Leu-Arg-Pro- Azgly-NH 2 acetate [C59H84 18Oi4 -(C2H402)x where x = 1 to 2.4], goserelin acetate, leuprolide acetate, triptorelin pamoate, medroxyprogesterone acetate, hydroxyprogesterone caproate, megestrol acetate, raloxifene, bicalutamide, flutamide, nilutamide, megestrol acetate, CP-724714; TAK-
165, HKI-272, erlotinib, lapatanib, canertinib, ABX-EGF antibody, erbitux, EKB-569, PKI-
166, GW-572016, Ionafarnib, BMS-214662, tipifarnib; amifostine, NVP-LAQ824, suberoyl analide hydroxamic acid, valproic acid, trichostatin A, FK-228, SU11248, sorafenib,
KRN951 , aminoglutethimide, arnsacrine, anagrelide, L-asparaginase, Bacillus Calmette- Guerin (BCG) vaccine, adriamycin, bleomycin, buserelin, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, diethylstilbestrol, epirubicin, fludarabine, fludrocortisone, fluoxymesterone, flutamide, gleevec, gemcitabine, hydroxyurea, idarubicin, ifosfamide, imatinib, leuprolide, levamisole, lomustine, mechlorethamine, melphalan, 6-mercaptopurine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, octreotide, oxaliplatin, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozocin, teniposide, testosterone, thalidomide, thioguanine, thiotepa, tretinoin, vindesine, 13-cis-retinoic acid, phenylalanine mustard, uracil mustard, estramustine, altretamine, floxuridine, 5-deooxyuridine, cytosine arabinoside, 6-mecaptopurine, deoxycoformycin, calcitriol, valrubicin, mithramycin, vinblastine, vinorelbine, topotecan, razoxin, marimastat, COL-3, neovastat, BMS-275291 , squalamine, endostatin, SU5416, SU6668, EMD121974, interleukin-12, IM862, angiostatin, vitaxin, droloxifene, idoxyfene, spironolactone, finasteride, cimitidine, trastuzumab, denileukin diftitox,gefitinib, bortezimib, paclitaxel, cremophor-free paclitaxel, docetaxel, epithilone B, BMS- 247550, BMS-310705, droloxifene, 4-hydroxytamoxifen, pipendoxifene, ERA-923, arzoxifene, fulvestrant, acolbifene, lasofoxifene, idoxifene, TSE-424, HMR- 3339, ZK186619, topotecan, PTK787/ZK 222584, VX-745, PD 184352, rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, temsirolimus, AP- 23573, RAD001, ABT-578, BC-210, LY294002, LY292223, LY292696, LY293684,
LY293646, wortmannin, ZM336372, L-779,450, PEG-filgrastim, darbepoetin, erythropoietin, granulocyte colony-stimulating factor, zolendronate, prednisone, cetuximab, granulocyte macrophage colony-stimulating factor, histrelin, pegylated interferon alfa-2a, interferon alfa- 2a, pegylated interferon alfa-2b, interferon alfa-2b, azacitidine, PEG-L-asparaginase, lenalidomide, gemtuzumab, hydrocortisone, interleukin-11, dexrazoxane, alemtuzumab, all- transretinoic acid, ketoconazole, interleukin-2, megestrol, immune globulin, nitrogen mustard, methylprednisolone, ibritgumomab tiuxetan, androgens, decitabine, hexamethylmelamine, bexarotene, tositumomab, arsenic trioxide, cortisone, editronate, mitotane, cyclosporine, liposomal daunorubicin, Edwina-asparaginase, strontium 89, casopitant, netupitant, an NK-1 receptor antagonist, palonosetron, aprepitant, diphenhydramine, hydroxyzine,
metoclopramide, lorazepam, alprazolam, haloperidol, droperidol, dronabinol, dexamethasone, methylprednisolone, prochlorperazine, granisetron, ondansetron, dolasetron, tropisetron, pegfilgrastim, erythropoietin, epoetin alfa, darbepoetin alfa and mixtures thereof.
The term "anti-HIV agent" or "additional anti-HIV agent" includes, for example, nucleoside reverse transcriptase inhibitors (NRTI), other non-nucloeoside reverse
transcriptase inhibitors (i.e., those which are not representative of the present invention), protease inhibitors, fusion inhibitors, among others, exemplary compounds of which may include, for example, 3TC (Lamivudine), AZT (Zidovudine), (-)-FTC, ddl (Didanosine), ddC (zalcitabine), abacavir (ABC), tenofovir (PMPA), D-D4FC (Reverset), D4T (Stavudine), Racivir, L-FddC, L-FD4C, NVP (Nevirapine), DLV (Delavirdine), EFV (Efavirenz), SQVM (Saquinavir mesylate), RTV (Ritonavir), IDV (Indinavir), SQV (Saquinavir), NFV
(Nelfinavir), APV (Amprenavir), LPV (Lopinavir), fusion inhibitors such as T20, among others, fuseon and mixtures thereof, including anti-HIV compounds presently in clinical trials or in development.
Other anti-HIV agents which may be used in coadministration with compounds according to the present invention include, for example, other NNRTI's (i.e., other than the NNRTFs according to the present invention) may be selected from the group consisting of nevirapine (BI-R6-587), delavirdine (U-90152S/T), efavirenz (DMP-266), UC-781 (N-[4- chloro-3-(3-methyl-2-butenyloxy)phenyl]-2methyl3-furancarbothiamide), etravirine
(TMC125), Trovirdine (Ly300046.HCl), MKC-442 (emivirine, coactinon), HI-236, HI-240, HI-280, HI-281, rilpivirine (TMC-278), MSC-127, HBY 097, DMP266, Baicalin (TJN-151) ADAM-II (Methyl 3',3'-dichloro-4',4"-dimethoxy-5',5"-bis(methoxycarbonyl)-6,6- diphenylhexenoate), Methyl 3-Bromo-5-(l-5-bromo-4-methoxy-3- (methoxycarbonyl)phenyl)hept- 1 -enyl)-2-methoxybenzoate (Alkenyl diary lmethane analog, Adam analog), 5C13PhS-2IndolCONH2 (5-chloro-3-(phenylsulfmyl)-2'-indolecarboxamide), AAP-BHAP (U-104489 or PNU-104489), Capravirine (AG-1549, S-1153), atevirdine (U- 87201E), aurin tricarboxylic acid (SD-095345), l-[(6-Cyano-2-mdoyly)carbonyl]-4-[3- (isopropylamino)-2-pyridinyl]piperazine (piperazinel pyridine 4 indolyl derivative), l-[5- [[N-(methyl)methylsulfonylamino] -2-indolylcarbonyl-4- [3 -(isopropylamino)-2- pyridinyl]piperazine (piperazine 1 pyridine 5 indolyl derivative), l-[3-(Ethylamino)-2- [pyridinyl]-4-[(5-hydroxy-2-indolyl)carbonyl]piperazine, l-[(6-Formyl-2-indoyly)carbonyl]- 4-[3-(isopropylamino)-2-pyridinyl]piperazine, l-[[5-(Methylsulfonyloxy)-2- indoyly)carbonyl]-4-[3-(isopropylamino)-2-pyridinyl]piperazine, U88204E, Bis(2- nitrophenyl)sulfone (NSC 633001), Calanolide A (NSC675451), Calanolide B, 6-Benzyl-5- methyl-2-(cyclohexyloxy)pyrimidin-4-one (DABO-546), DPC 961, E-EBU, E-EBU-dm, E- EPSeU, E-EPU, Foscarnet (Foscavir), HEPT (l-[(2-Hydroxyethoxy)methyl]-6- (phenylthio)thymine), HEPT-M (l-[(2-Hydroxyethoxy)methyl]-6-(3- methylphenyl)thio)thymine), HEPT-S (1 -[(2-Hydroxyethoxy)methyl]-6-(phenylthio)-2- thiothymine), Inophyllum P, L-737,126, Michellamine A (NSC650898), Michellamine B (NSC649324), Michellamine F, 6-(3,5-Dimethylbenzyl)-l-[(2-hydroxyethoxy)methyl]-5- isopropyluracil, 6-(3,5-Dimethylbenzyl)-l-(ethyoxymethyl)-5-isopropyluracil, NPPS, E- BPTU (NSC 648400), Oltipraz (4-Methyl-5-(pyrazinyl)-3H-l,2-dithiole-3-thione), N-{2-(2- Chloro-6-fluorophenethyl]-N'-(2-thiazolyl)thiourea (PETT CI, F derivative), N-{2-(2,6- Difluorophenethyl]-N'-[2-(5-bromopyridyl)]thiourea {PETT derivative), N-{2-(2,6- Difluorophenethyl]-N'-[2-(5-methylpyridyl)]hiourea {PETT Pyridyl derivative), N-[2-(3- Fluorofuranyl)ethyl]-N'-[2-(5-chloropyridyl)]thiourea, N-[2-(2-Fluoro-6-ethoxyphenethyl)]- N'-[2-(5-bromopyridyl)]thiourea, N-(2-Phenethyl)-N'-(2-thiazolyl)thiourea (LY-73497), L- 697,639, L-697,593, L-697,661, 3-[2-(4,7-Difluorobenzoxazol-2-yl)ethyl}-5-ethyl-6- methyl(pypridin-2(lH)-thione (2-Pyridinone Derivative), 3-[[(2-Methoxy-5,6-dimethyl-3- pyridyl)methyl]amine]-5-ethyl-6-methyl(pypridin-2(lH)-thione (2-Pyridinone 3pyrid
3MeNH Derivative), R82150, R82913, R87232, R88703, R89439 (Loviride), R90385, S- 2720, Suramin Sodium, TBZ (Thiazolobenzimidazole, NSC 625487), Thiazoloisoindol-5-one, (+)(R)-9b-(3,5-Dimethylphenyl-2,3-dihydrothiazolo[2,3-a]isoindol-5(9bH)-one, Tivirapine (R86183), UC-38 and UC-84, among others.
The term "pharmaceutically acceptable salt" is used throughout the specification to describe, where applicable, a salt form of one or more of the compounds described herein which are presented to increase the solubility of the compound in the gastic juices of the patient's gastrointestinal tract in order to promote dissolution and the bioavailability of the compounds. Pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic bases and acids, where applicable. Suitable salts include those derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium, magnesium and ammonium salts, among numerous other acids and bases well known in the pharmaceutical art. Sodium and potassium salts are particularly preferred as neutralization salts of the phosphates according to the present invention.
The term "pharmaceutically acceptable derivative" is used throughout the
specification to describe any pharmaceutically acceptable prodrug form (such as an ester, amide other prodrug group), which, upon administration to a patient, provides directly or indirectly the present compound or an active metabolite of the present compound.
The term "independently" is used herein to indicate that the variable, which is independently applied, varies independently from application to application.
The term "hydrocarbyl" shall mean a compound which contains carbon and hydrogen and which may be fully saturated, partially unsaturated or aromatic and includes aryl groups, alkyl groups, alkenyl groups and alkynyl groups.
The term "alkyl" shall mean within its context a linear, branch-chained or cyclic fully saturated hydrocarbon radical or alkyl group, preferably a Cj-Cio, more preferably a Cj-C6, alternatively a Cj-C? alkyl group, which may be optionally substituted. Examples of alkyl groups are methyl, ethyl, n-butyl, sec-butyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, isopropyl, 2-methylpropyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclopentylethyl, cyclohexylethyl and cyclohexyl, among others. In certain preferred embodiments, compounds according to the present invention which may be used to covalently bind to dehalogenase enzymes. These compounds generally contain a side chain (often linked through a polyethylene glycol group) which terminates in an alkyl group which has a halogen substituent (often chlorine or bromine) on its distil end which results in covalent binding of the compound containing such a moiety to the protein. The term
"Alkenyl" refers to linear, branch-chained or cyclic C -Cio (preferably C2-C6) hydrocarbon radicals containing at least one C=C bond. The term "Alkynyl" refers to linear, branch- chained or cyclic C2-C10 (preferably C2-C6) hydrocarbon radicals containing at least one C≡C bond. The term "alkylene" when used, refers to a -(CH2)n- group (n is an integer generally from 0-6), which may be optionally substituted. When substituted, the alkylene group preferably is substituted on one or more of the methylene groups with a Ci-C6 alkyl group (including a cyclopropyl group or a t-butyl group), more preferably a methyl group, but may also be substituted with one or more halo groups, preferably from 1 to 3 halo groups or one or two hydroxyl groups, 0-(C!-C6 alkyl) groups or amino acid sidechains as otherwise disclosed herein. In certain embodiments, an alkylene group may be substituted with a urethane or alkoxy group (or other group) which is further substituted with a polyethylene glycol chain (of from 1 to 10, preferably 1 to 6, often 1 to 4 ethylene glycol units) to which is substituted (preferably, but not exclusively on the distal end of the polyethylene glycol chain) an alkyl chain substituted with a single halogen group, preferably a chlorine group. In still other embodiments, the alkylene (often, a methylene) group, may be substituted with an amino acid sidechain group such as a sidechain group of a natural or unnatural amino acid, for example, alanine, β-alanine, arginine, asparagine, aspartic acid, cysteine, cystine, glutamic acid, glutamine, glycine, phenylalanine, histidine, isoleucine, lysine, leucine, methionine, proline, serine, threonine, valine, tryptophan or tyrosine.
The term "unsubstituted" shall mean substituted only with hydrogen atoms. A range of carbon atoms which includes C0 means that carbon is absent and is replaced with H. Thus, a range of carbon atoms which is C0-C6 includes carbons atoms of 1, 2, 3, 4, 5 and 6 and for Co, H stands in place of carbon. The term "substituted" or "optionally substituted" shall mean independently (i.e., where more than substituent occurs, each substituent is independent of another substituent) one or more substituents (independently up to five substitutents, preferably up to three substituents, often 1 or 2 substituents on a moiety in a compound according to the present invention and may include substituents which themselves may be further substituted) at a carbon (or nitrogen) position anywhere on a molecule within context, and includes as substituents hydroxyl, thiol, carboxyl, cyano (C≡N), nitro (N02), halogen (preferably, 1 , 2 or 3 halogens, especially on an alkyl, especially a methyl group such as a trifluoromethyl), an alkyl group (preferably, C1-C10 ; more preferably, Q-C6), aryl (especially phenyl and substituted phenyl for example benzyl or benzoyl), alkoxy group (preferably, d- C6 alkyl or aryl, including phenyl and substituted phenyl), thioether (Q-Q alkyl or aryl), acyl (preferably, CrC6 acyl), ester or thioester (preferably, Q-C6 alkyl or aryl) including alkylene ester (such that attachment is on the alkylene group, rather than at the ester function which is preferably substituted with a Cj-C6 alkyl or aryl group), preferably, Cj-C6 alkyl or aryl, halogen (preferably, F or CI), amine (including a five- or six-membered cyclic alkylene amine, further including a C C6 alkyl amine or a Q-C6 dialkyl amine which alkyl groups may be substituted with one or two hydroxyl groups) or an optionally substituted -N(Co-C6 alkyl)C(0)(0-Ci-C6 alkyl) group (which may be optionally substituted with a polyethylene glycol chain to which is further bound an alkyl group containing a single halogen, preferably chlorine substituent), hydrazine, amido, which is preferably substituted with one or two Ci-C6 alkyl groups (including a carboxamide which is optionally substituted with one or two Ci-Ce alkyl groups), alkanol (preferably, C]-C6 alkyl or aryl), or alkanoic acid (preferably, C!-C6 alkyl or aryl). Substituents according to the present invention may include, for example -SiRiR2R3 groups where each of Ri and R2 is as otherwise described herein and R3 is H or a Ci-C6 alkyl group, preferably R1 ? R2, R3 in this context is a C!-C3 alkyl group (including an isopropyl or t-butyl group). Each of the above-described groups may be linked directly to the substituted moiety or alternatively, the substituent may be linked to the substituted moiety (preferably in the case of an aryl or heteraryl moiety) through an optionally substituted -(CH2)m- or alternatively an optionally substituted -(OCH2)m-, -(OCH2CH2)m- or - (CH2CH20)m- group, which may be substituted with any one or more of the above-described substituents. Alkylene groups -(CH2)m- or -(CH2)n- groups or other chains such as ethylene glycol chains, as identified above, may be substituted anywhere on the chain. Preferred substitutents on alkylene groups include halogen or C C6 (preferably C!-C3) alkyl groups, which may be optionally substituted with one or two hydroxyl groups, one or two ether groups (0-Ci-C6 groups), up to three halo groups (preferably F), or a sideshain of an amino acid as otherwise described herein and optionally substituted amide (preferably carboxamide substituted as described above) or urethane groups (often with one or two C0-C6 alkyl substitutents, which group(s) may be further substituted). In certain embodiments, the alkylene group (often a single methylene group) is substituted with one or two optionally substituted Ci-Ce alkyl groups, preferably C]-C4 alkyl group, most often methyl or O-methyl groups or a sidechain of an amino acid as otherwise described herein. In the present invention, a moiety in a molecule may be optionally substituted with up to five substituents, preferably up to three substituents. Most often, in the present invention moieties which are substituted are substituted with one or two substituents.
The term "substituted" (each substituent being independent of any other substituent) shall also mean within its context of use C!-C6 alkyl, C!-C alkoxy, halogen, amido, carboxamido, sulfone, including sulfonamide, keto, carboxy, Q-Q ester (oxyester or carbonylester), C Q keto, urethane -0-C(0)-NR1R2 or -N(R1)-C(0)-0-R1, nitro, cyano and amine (especially including a Q-Q alkylene-NRiR2, a mono- or di- Ci-C6 alkyl substituted amines which may be optionally substituted with one or two hydroxyl groups). Each of these groups contain unless otherwise indicated, within context, between 1 and 6 carbon atoms. In certain embodiments, preferred substituents will include for example, -NH-, -NHC(O)-, -0-, =0, -(CH2)m- (here, m and n are in context, 1, 2, 3, 4, 5 or 6), -S-, -S(O)-, S02- or -NH-C(O)- NH-, -(CH2)nOH, -(CH2)nSH, -(CH2)„COOH, C C6 alkyl,
Figure imgf000100_0001
alkyl), -(CH2)nOC(0)-(C!-C6 alkyl),
-(CH2)nC(0)O-(Ci-C6 alkyl), -(CH2)nNHC(0)-R!, -(CH^C^-NRiR,, -(OCH2)nOH, -(CH20)„COOH, Q-Q alkyl, -(OCH2)nO-(C1-C6 alkyl), -(CH20)„C(0)-(C1-C6 alkyl), -(OCH2)nNHC(0)-R1, -(CH20)nC(0)-NR1R2, -S(0)2-Rs, -S(0)-Rs (Rs is Ci-Q alkyl or a -(CH2)m-NR1R2 group), N02, CN or halogen (F, CI, Br, I, preferably F or CI), depending on the context of the use of the substituent. Ri and R2 are each, within context, H or a Ci-C6 alkyl group (which may be optionally substituted with one or two hydroxyl groups or up to three halogen groups, preferably fluorine). The term "substituted" shall also mean, within the chemical context of the compound defined and substituent used, an optionally substituted aryl or heteroaryl group or an optionally substituted heterocyclic group as otherwise described herein. Alkylene groups may also be substituted as otherwise disclosed herein, preferably with optionally substituted C!-C6 alkyl groups (methyl, ethyl or hydroxymethyl or
hydroxyethyl is preferred, thus providing a chiral center), a sidechain of an amino acid group as otherwise described herein, an amido group as described hereinabove, or a urethane group 0-C(0)-NR!R2 group where Rj and R2 are as otherwise described herein, although numerous other groups may also be used as substituents. Various optionally substituted moieties may be substituted with 3 or more substituents, preferably no more than 3 substituents and preferably with 1 or 2 substituents. It is noted that in instances where, in a compound at a particular position of the molecule substitution is required (principally, because of valency), but no substitution is indicated, then that substituent is construed or understood to be H, unless the context of the substitution suggests otherwise.
The term "aryl" or "aromatic", in context, refers to a substituted (as otherwise described herein) or unsubstituted monovalent aromatic radical having a single ring (e.g. , benzene, phenyl, benzyl) or condensed rings (e.g., naphthyl, anthracenyl, phenanthrenyl, etc.) and can be bound to the compound according to the present invention at any available stable position on the ring(s) or as otherwise indicated in the chemical structure presented. Other examples of aryl groups, in context, may include heterocyclic aromatic ring systems
"heteroaryl" groups having one or more nitrogen, oxygen, or sulfur atoms in the ring
(moncyclic) such as imidazole, furyl, pyrrole, furanyl, thiene, thiazole, pyridine, pyrimidine, pyrazine, triazole, oxazole or fused ring systems such as indole, quinoline, indolizine, azaindolizine, benzofurazan, etc., among others, which may be optionally substituted as described above. Among the heteroaryl groups which may be mentioned include nitrogen- containing heteroaryl groups such as pyrrole, pyridine, pyridone, pyridazine, pyrimidine, pyrazine, pyrazole, imidazole, triazole, triazine, tetrazole, indole, isoindole, indolizine, azaindolizine, purine, indazole, quinoline, dihydroquinoline, tetrahydroquinoline,
isoquinoline, dihydroisoquinoline, tetrahydroisoquinoline, quinolizine, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, imidazopyridine,
imidazotriazine, pyrazinopyridazine, acridine, phenanthridine, carbazole, carbazoline, perimidine, phenanthroline, phenacene, oxadiazole, benzimidazole, pyrrolopyridine, pyrrolopyrimidine and pyridopyrimidine; sulfur-containing aromatic heterocycles such as thiophene and benzothiophene; oxygen-containing aromatic heterocycles such as furan, pyran, cyclopentapyran, benzofuran and isobenzofuran; and aromatic heterocycles comprising 2 or more hetero atoms selected from among nitrogen, sulfur and oxygen, such as thiazole, thiadizole, isothiazole, benzoxazole, benzothiazole, benzothiadiazole, phenothiazine, isoxazole, furazan, phenoxazine, pyrazoloxazole, imidazothiazole, thienofuran, furopyrrole, pyridoxazine, furopyridine, furopyrimidine, thienopyrimidine and oxazole, among others, all of which may be optionally substituted.
The term "heterocycle" refers to a cyclic group which contains at least one
heteroatom, i.e., 0, N or S, and may be aromatic (heteroaryl) or non-aromatic. Thus, the heteroaryl moieties are subsumed under the definition of heterocycle, depending on the context of its use. Exemplary heteroaryl groups are described hereinabove. Exemplary non- aromatic heterocyclic groups for use in the present invention include, for example,
pyrrolidinyl, pyrrolinyl, piperidinyl, piperazinyl, N-methylpiperazinyl, pyrazolidinyl, imidazolidinyl, morpholinyl, tetrahydropyranyl, azetidinyl, oxetanyl, oxathiolanyl, pyridone, 2-pyrrolidone, ethyleneurea, 1,3-dioxolane, 1,3-dioxane, 1,4-dioxane, phthalimide and succinimide, among others, as described herein. The terms "treat", "treating", and "treatment", etc., as used herein, refer to any action providing a benefit to a patient for which the present compounds may be administered, including the treatment of any disease state or condition which is modulated through the protein to which the present compounds bind. Disease states or conditions, including cancer, which may be treated using compounds according to the present invention are set forth hereinabove.
The term "coadministration" or "combination therapy" shall mean that at least two compounds or compositions are administered to the patient at the same time, such that effective amounts or concentrations of each of the two or more compounds may be found in the patient at a given point in time. Although compounds according to the present invention may be co-administered to a patient at the same time, the term embraces both administration of two or more agents at the same time or at different times, provided that effective concentrations of all coadministered compounds or compositions are found in the subject at a given time. In certain preferred aspects of the present invention, one or more of the present compounds described above, are coadministered in combination with at least one additional bioactive agent, especially including an anticancer agent. In particularly preferred aspects of the invention, the co-administration of compounds results in synergistic therapeutic, including anticancer therapy.
Pharmaceutical compositions comprising combinations of an effective amount of at least one bifunctional compound according to the present invention, and one or more of the compounds otherwise described herein, all in effective amounts, in combination with a pharmaceutically effective amount of a carrier, additive or excipient, represents a further aspect of the present invention.
The present invention includes, where applicable, the compositions comprising the pharmaceutically acceptable salts, in particular, acid or base addition salts of compounds of the present invention. The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds useful in this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., l, -methylene-bis-(2-hydroxy-3 naphthoate)] salts, among numerous others.
Pharmaceutically acceptable base addition salts may also be used to produce pharmaceutically acceptable salt forms of the compounds or derivatives according to the present invention. The chemical bases that may be used as reagents to prepare
pharmaceutically acceptable base salts of the present compounds that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (eg., potassium and sodium) and alkaline earth metal cations (eg, calcium, zinc and magnesium), ammonium or water-soluble amine addition salts such as N- methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines, among others.
The compounds of the present invention may, in accordance with the invention, be administered in single or divided doses by the oral, parenteral or topical routes.
Administration of the active compound may range from continuous (intravenous drip) to several oral administrations per day (for example, Q.I.D.) and may include oral, topical, parenteral, intramuscular, intravenous, sub-cutaneous, transdermal (which may include a penetration enhancement agent), buccal, sublingual and suppository administration, among other routes of administration. Enteric coated oral tablets may also be used to enhance bioavailability of the compounds from an oral route of administration. The most effective dosage form will depend upon the pharmacokinetics of the particular agent chosen as well as the severity of disease in the patient. Administration of compounds according to the present invention as sprays, mists, or aerosols for intra-nasal, intra-tracheal or pulmonary
administration may also be used. The present invention therefore also is directed to pharmaceutical compositions comprising an effective amount of compound according to the present invention, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient. Compounds according to the present invention may be administered in immediate release, intermediate release or sustained or controlled release forms. Sustained or controlled release forms are preferably administered orally, but also in suppository and transdermal or other topical forms. Intramuscular injections in liposomal form may also be used to control or sustain the release of compound at an injection site. The compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers and may also be administered in controlled-release formulations. Pharmaceutically acceptable carriers that may be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as prolamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene- polyoxypropylene-block polymers, polyethylene glycol and wool fat.
The compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic,
intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously.
Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1, 3-butanediol.
Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are
conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as Ph. Helv or similar alcohol. The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
Alternatively, the pharmaceutical compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient, which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.
The pharmaceutical compositions of this invention may also be administered topically. Suitable topical formulations are readily prepared for each of these areas or organs. Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-acceptable transdermal patches may also be used.
For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. In certain preferred aspects of the invention, the compounds may be coated onto a stent which is to be surgically implanted into a patient in order to inhibit or reduce the likelihood of occlusion occurring in the stent in the patient.
Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more
pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2- octyldodecanol, benzyl alcohol and water.
For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with our without a preservative such as
benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical
compositions may be formulated in an ointment such as petrolatum.
The pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance
bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
The amount of compound in a pharmaceutical composition of the instant invention that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host and disease treated, the particular mode of administration.
Preferably, the compositions should be formulated to contain between about 0.05 milligram to about 750 milligrams or more, more preferably about 1 milligram to about 600 milligrams, and even more preferably about 10 milligrams to about 500 milligrams of active ingredient, alone or in combination with at least one other compound according to the present invention.
It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease or condition being treated.
A patient or subject in need of therapy using compounds according to the present invention can be treated by administering to the patient (subject) an effective amount of the compound according to the present invention including pharmaceutically acceptable salts, solvates or polymorphs, thereof optionally in a pharmaceutically acceptable carrier or diluent, either alone, or in combination with other known erythopoiesis stimulating agents as otherwise identified herein.
These compounds can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, including
transdermally, in liquid, cream, gel, or solid form, or by aerosol form.
The active compound is included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient a therapeutically effective amount for the desired indication, without causing serious toxic effects in the patient treated. A preferred dose of the active compound for all of the herein-mentioned conditions is in the range from about 10 ng/kg to 300 mg/kg, preferably 0.1 to 100 mg/kg per day, more generally 0.5 to about 25 mg per kilogram body weight of the recipient/patient per day. A typical topical dosage will range from 0.01 -5% wt/wt in a suitable carrier.
The compound is conveniently administered in any suitable unit dosage form, including but not limited to one containing less than lmg, 1 mg to 3000 mg, preferably 5 to 500 mg of active ingredient per unit dosage form. An oral dosage of about 25-250 mg is often convenient.
The active ingredient is preferably administered to achieve peak plasma
concentrations of the active compound of about 0.00001-30 mM, preferably about 0.1-30 μΜ. This may be achieved, for example, by the intravenous injection of a solution or formulation of the active ingredient, optionally in saline, or an aqueous medium or administered as a bolus of the active ingredient. Oral administration is also appropriate to generate effective plasma concentrations of active agent.
The concentration of active compound in the drug composition will depend on absorption, distribution, inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the
administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition. The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound or its prodrug derivative can be incorporated with excipients and used in the form of tablets, troches, or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the
composition.
The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a dispersing agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or enteric agents.
The active compound or pharmaceutically acceptable salt thereof can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
The active compound or pharmaceutically acceptable salts thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as erythropoietin stimulating agents, including EPO and darbapoietin alfa, among others. In certain preferred aspects of the invention, one or more compounds according to the present invention are coadministered with another bioactive agent, such as an erythropoietin stimulating agent or a would healing agent, including an antibiotic, as otherwise described herein. Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
If administered intravenously, preferred carriers are physiological saline or phosphate buffered saline (PBS).
In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release
formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
Liposomal suspensions may also be pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811 (which is incorporated herein by reference in its entirety). For example, liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the active
compound are then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
General Synthetic Approaches Generic scheme for the synthesis of ULM derivatives is described here. Briefly, the compounds according to the present invention are synthesized pursuant to the general solution phase synthetic scheme (presented hereinbelow) and/or general scheme I, which is directed to phase synthesis of compounds according to the present invention. Initially a hydroxyl-protected carboxy substituted (and protected) pyrrolidine compound is reacted with a carboxylic acid containing reagent, which introduces a carbonyl group at the amine of the pyrollidine ring to form an amide group. Alternatively, the pyrrolidine amine may be protected and the carboxylic acid moiety may be condensed with a nucleophilic group on a right hand fragment to provide an amide on the right hand portion of the pyrrolidine moiety. The left and right hand fragments to be condensed onto, respectively, the amine and carboxylic acid group of the pyrrolidine moiety are preferably prepared prior to condensing onto the pyrrolidine group, but other approaches may be taken to introduce groups onto the pyrrolidine group. The individual components which are combined to produce a ULM group can be prepared using blocking groups at preferred functional groups on the ULM group which can be removed so as to react with and covalently link a linker group which is prepared to accommodate a PTM moiety to which is already bound a protein binding moiety, or PTM group or may be further reacted to form a covalent bound with a PTM group, which may also may comprise a ULM' group as otherwise described herein. Thus, a carboxylic acid containing left hand fragment may be condensed onto the amine group of the pyrroline, thus forming an amide group with an R1 left hand fragment as depicted below. Onto the carboxyl group, any number of nucleophilic (preferably, amine containing) right hand fragments (pre-synthesized) may be condensed onto the carboxyl group to provide an amide group with an R2 right fragment as depicted below. Formation of the pre-synthesized groups to condense onto the amine and/or the carboxyl moiety of the pyrrolidine proceeds in a facile manner. Virtually any compound can be synthesized readily using this approach. The solid phase synthetic method can also be used and employs similar methods used in the solution phase synthesis, the major difference being that the hydroxyl group may be bound to a solid support as the other steps of the synthesis occur. The general synthetic methods are applicable to virtually all of the compounds of the present invention with facile modifications being made consistent with the state of chemical synthetic art as used directly or adapted from the specific teachings of the examples which follow. Scheme 1 Solution Phase Synthesis of UML Derivatives According to the Present Invention
Route B
Figure imgf000111_0001
H2NR. EDC, HOB!, HzN EDC. HOBt.
Route A DIPEA, DMF DIPEA, DMF
Figure imgf000111_0002
Scheme 2 Solid Phase Synthesis of Compounds According to the Present Invention
Figure imgf000111_0003
Alternative General Method for Solid Phase Synthesis of VHL Ligands according to the present invention (details for which are presented in the second set of examples), set forth herein:
Synthetic Approaches for Compound Generation to Screen for Target Protein Binding Elements (PTM) and Ubiquitination Ligand Moieties (ULM) of the Subject Invention Two basic methods which are used in combinatorial chemistry to identify PTM moieties and ULM moieties are solid-phase and solution-phase methods. Using these methods combinatorial compounds are created either by solution-phase synthesis or by producing compounds bound covalently to solid-phase particles. Once their moieties are identified they may be modified using appropriate groups (electrophilic and/or nucleophilic), and condensed onto linker groups to produce bifunctional compounds according to the present invention.
Solid Phase Methods
Solid Phase Methods rely on the teachings of Fruchtel, et al. 1996, Angew. Chem. Int. Ed. Engl. 35, 17-42; which is incorporated by reference in its entirety herein).
Solid-phase synthesis makes it easier to conduct multistep reactions and to drive reactions to completion, because excess reagents can be added and then easily washed away after each reaction step. Another key factor in favor of solid-phase synthesis is that it makes it possible to use split synthesis, a technique developed in 1982. Split synthesis produces large support-bound libraries in which each solid-phase particle holds a single compound, or soluble libraries produced by cleavage of compounds from the solid support. For example in a split synthesis method if you have 3 compound addition steps with 10 compounds used at each step i.e. 10 containers for those compounds. This will generate 103 compounds. Also, if you consider all the reaction steps included in a synthesis 10,000 compounds made via a solid phase methods using a three-step chemistry may only require about 22 containers for the chemistry and about 66 liquid handling steps relative to the 10,000 containers and 30,000 liquid handling steps. When you combine these advantages of solid phase synthesis with split synthesis, a significant level of synergy is achieved.
Solution Phase Methods
Solution phase chemistry is favored by many for library construction due to the wider range of organic reactions available for solution-phase synthesis, the technology used traditionally by most synthetic organic chemists, and products in solution can be more easily identified in standard drug target assays and characterized. A problem for solution-phase synthesis of one molecule at a time is the final purification that can be both expensive and slow. Chromatography is commonly a first resort since it usually works. In addition, the problems associated with solution chemistry are compounded when attempting to make tens of thousands of compounds to generate a library or a "book' for a library.
In the generation of libraries of compounds numerous methods have been devised resulting in the wide spread use of large libraries of chemicals to readily allow the discovery of potential drug candidates. The generation of chemical libraries that are free in solution is typically the goal of most of the pharmaceutical industry. This aim is due to the nature of many of the drug targets and the associated assays. Also the construction and utility of chemical libraries is typically facilitated but the generation of master plates of compounds in solution to form the basis of the chemical library. Thus the general advantages of the solid phase synthesis methods are typically not fully realized in the context of the current drug discovery efforts. The main reason for this is the interest not in binding of the compound to the drug target but to demonstrate that the activity of the drug target is altered, which typically requires compound free in solution. Further concerns with libraries of compounds on a solid phase arise from concerns of the potential influence of the linker and steric effects on the compounds bound to the solid phase.
Thus methods for the discovery of compounds, which bind to target molecules is known in the art. Also, the optimization of the initially discovered compound is well known in the art where the affinity is improved by generation of a pool of related compound via a more selective combinatorial chemistry approach.
The present invention provides a mechanism to overcome these problems in drug and small molecule discovery.
Addition of the Ubiquitin Ligase Binding Moiety (ULM)
At this point in the compound discovery path for the subject invention, the target protein-binding element of the compounds of the invention has been identified. These optimal binding molecules are then subjected to further chemistry to add the ubiquitin ligase binding moiety (ULM), pursuant to the disclosure of the present application. An alternative approach to the discovery of the target protein-binding moiety is based on solution phase screening. In such an example compounds (available either via synthesis, natural products or from companies such as ArQule (www.arqule.com), Pharmacopeia (www.pharmacopiea), and Cerep (www.cerep.com) are obtained and added to the target protein of interest and then subjected to size exclusion to remove the unbound compounds. The protein bound fraction is then subjected to GC/MS to identify the molecules. In this way the solution phase screening is made rapid and facile for compounds in solution.. There are numerous additional ways to determine ligand binding, including, for example, detecting changes in the Tm of the protein upon the ligand binding, among others.
Screening for Target Protein Binding Elements
Initially a target protein is selected, for example, an enzyme or protein involved in a particular biological process. Target protein for the subject invention come from numerous fields where small molecules are used to achieve modulation of a biological system in eukaryotic organisms. Examples of such fields are antivirals, antimicrobials, anti-parasitics, or other drug targets in a human patient, which may be rather diverse, etc.
The target protein is then either purified from a natural source in order to provide sufficient material for the screen or expressed via recombinant methods to provide sufficient material for the screens.
The target protein is then either labeled directly with a detectable species such as a radioactive, electrochemiluminescent, and chemiluminescent or fluorescent label or with an indirectly detectable species such as an enzyme, or particle. Alternatively an antibody or equivalent with binding activity to the target protein is labeled.
The next step is to provide a library of compounds for screening. A library of from 1,000 to 1,000,000 is typical of the size that is screened. These are available from a series of companies, which are well known in the art. These libraries of compounds are used to screen for the binding of the target protein. Ideally compounds are bought still bound to the solid phase or are screened for binding directly to immobilized target protein using methods as described below for screening. It is also possible to generate a chemical library of various potential binding molecules bound to a solid phase following conventional methods to give rise to differing potential compounds. The optimal methods for the construction of the chemical library is to employ the methods of split synthesis coupled to the solid phase (as outlined above). The library is generated using a series of solid phase chemistries such as to give rise to various compilations that form the basis of a library. The library is screened in the form of a library or in the form of the compilations. Typically one would take the products from the split synthesis and pool the solid phase and use this as the basis for the screen.
To the pool of beads used as the solid phase for the synthesis, a mixture of buffer, detergents, salts and blocking agents such as serum albumin or other proteins are added. This buffer addition step is used to block the beads or solid phase in such a way that any significant non-specific binding of the selected target protein does not occur. Following this blocking step the beads are washed and followed by the addition of the target protein either labeled or not. The beads or solid phase are then incubated to allow the binding of the target protein binding elements to the target protein. Following the incubation of the target molecule to the beads or solid phase the beads are washed and then the binding of the labeled target protein detected directly. In an alternative format, if the target protein is labeled with an indirectly detectable label such as an enzyme, the beads are then placed in to a substrate reaction solution to detect the presence of the enzyme label. In the case of an enzyme label, substrates for these detection methods are based on insoluble chromogenic products. In the case where the target protein is not labeled and an antibody or equivalent is available, the beads are subjected to another binding reaction where the antibody or equivalent, is labeled either directly or indirectly as suggested for the labeling of the target protein. It is also possible at this step to not use a labeled antibody or equivalent and to add a further step where the labeled antibody or equivalent is used. These additional steps can be detected using the same standard methods known in the art as suggested for the directly labeled target protein.
Following these steps a series of beads are identified and these beads are selected from the bead population and subject to analysis to determine the structure of the binding molecule that is able to bind the target protein as in this example. This is achieved by the use of GC/MS or via molecular tags used during the construction of the library as described earlier. Alternatively, a pool which was positive is re-made generating a series of sub pools for screening and further re-synthesis and dividing out of the various pooled compounds until a single compound is presented in a single well for analysis allowing the determination of the active compound.
This method can be repeated and/or adapted for identifying peptide target binding moieties (PTM) for virtually any target protein.
Screening for Binding Molecules from Chemical Libraries
The step of screening for specific molecules is made easy in the invention as only binding activity is desired and not specific modulation of the target protein as is required in traditional drug discovery.
One can buy a library of compounds for screening. A library of from 1 ,000 to
1,000,000 is typical of the size that might be screened. These are available from a number of companies. These libraries of compounds are used to screen for the binding of the target protein. Ideally, compounds are purchased still bound to the solid phase or are screened for binding directly to immobilized target protein using methods as described below for screening.
It is also possible to generate a library of from 1,000 to 100,000 compounds contained on a solid phase using split synthesis methods as described earlier. The library may be constructed using a series of chemical methods resulting in pools of the solid phase used during synthesis, which form the basis of the entries which make up the library. In addition at the final chemical coupling step used to construct the various entries the solid phase pools are stored in sub-pools in the libraries. These so called entries and sub-pools form the basis for screening as they contain not only pools of compounds but also a known chemical-coupling step used in synthesis.
The library can then be screened using two approaches. In both cases the solid phase from the chemical library to be screened is subjected incubation with assay buffers with blocking agents such as for example; proteins (i.e. BSA, gelatin), polyvinylpyrrolidone, ficoll, heparin, detergents (i.e. SDS, Tween, NP40, Triton X-100). This incubation step is to block the non-specific binding sites on the solid phase used in the generation of the library and allow the determination of specific binding events. This initial incubation is an art recognized step in various binding assays such as ELISA, southerns, westerns etc. Following this incubation with blocking agents the protein of interest is then added to a buffer which typically has the same composition as that during the blocking step but can also be modified using lower or no additional blocking agents with the exception of the detergents which are typically always present during a binding reaction.
In one of the screening methods the entries following the blocking step are then subjected to binding with the purified target protein. The solid phase from this incubation is then washed and subjected to a second binding step with a labeled reagent which binds to the tag sequence added to the receptor sub-unit during the recombinant engineering for the expression of the receptor sub-unit. Typically an antibody to this tag recognizes the tag sequence; examples that are in common use are the myc, flag, arid his epitopes. Following the incubation with the tag specific binding species the presence of the labeled binding species is detected by the presence of the label that is typically an enzyme such as alkaline phosphatase or peroxidase. The detection step typically makes use of an insoluble chromogenic substrate that is readily detected by eye or by image analysis systems.
In an alternative method soluble substrates can also be used and screened using ELISA plate readers, eye or other spectrophotometric methods. In its simplest form the various entries from the library are screened by eye to look for beads that have developed a color due to the enzymatic action on the chromogenic substrate. These colored beads indicate that the receptor subunit is binding to one of the compounds within the group of entries the next step is to determine if these so called positive group of entries contain specific binding or if binding is just to the tag binding reagent or some non-specific activation of the chromogenic substrate. To achieve this, the positive entries are screened with out the specific binding step to the receptor sub-unit. If these positive entries now become negative or show significantly reduced signals interms of positive solid phases with in the mixture then these are considered to be real positive hits in the screen. These real positive entries are then subjected to re-synthesis. In this re-synthesis the initial chemical steps to create the specific binding molecule is unknown only the last chemical coupling step in the compound synthesis is know, as this formed the last chemical step which constructed the group of entries. During the re-synthesis of the positive chapter the chemical step prior to the last chemical coupling is carried but as in the initial synthesis but the solid phase is not pooled and split for the final chemical coupling but are maintained as separate pools then subjected to the chemical coupling step know for that chapter. This resynthesis results in the formation of a new series of solid phase compound pools which have the last two chemical coupling steps known. This new series of solid phase compound pools are screened as in the initial screen and positive pools are checked as previously for the binding specificity to identify positive pools. The positive pool(s) now allow the re-synthesis of the pool(s) with the last two steps for the generation of the compound, which specifically binds to the receptor subunit. The positive pools are then subjected to the same cycle of re-synthesis and screening as just described but with the last two chemical coupling steps know the pools are maintained individually prior to the last know step. In this way the synthesis of the specific compound able to bind to the receptor sub-unit is deconvoluted from the chemical library and identified.
In an alternative method the positive solid phase is removed from the screen and collected. These are then subjected to the cleavage reaction, which removed the specific chemistry from the solid phase followed by the analysis of the various chemical species using GC to separate the individual compounds followed by MS to determine the molecular weight. This information coupled with the synthesis methods used is used to determine the compound identity. After the determination of these various candidate specific binding molecules they are then re-synthesized and subjected to the binding assay to check if these are the specific compounds that resulted in the positive solid phases.
Screening of the Ubiquitin Ligase Binding Moiety
This screening effort following methods and protocols known in the art allows the identification of compounds according to the present invention that bind to ubiquitin ligase. These compounds, already identified here, form the basis for the development of compounds of the invention. These compounds are then subjected to further chemistry based on the use of the linker group used in the development of the solid phase chemistry. To this linker group the various ubiquitin ligase binding moieties and/or protein binding moieties are added, generally through condensation reactions or other reactions to couple a ligand to a ubiquitin ligase binding moiety or a protein binding moiety. These reactions are well known in the art. Derivatization of linker groups is well-known in the art and can consist of providing a nucleophilic group (e.g., an alcohol, amine, thiol or other nucleophilic group) or an
electrophilic group (e.g., ester, carboxylic acid, acyl halide, halogen, etc.) at either or both ends of the linker group which may be used to condense an appropriately modified ULM group and/or PTM group onto the linker to produce a covalent bond. This final step of chemistry generates the compounds of the invention. The compounds of the invention are then subject to analysis to determine which of the compounds from the chemical library screen with which of the individual ubiquitin ligase binding moiety element is able to function most effectively in the targeted ubiquitination and/or degradation of the target protein. The ubiquitin ligase binding moiety may be determined by the methods as otherwise described in the examples section hereinbelow. In addition, the compounds of the invention can be tested in a mammalian tissue culture system where the target protein either intact or as an engineered fragment is expressed. In such a mammalian tissue culture system, the compounds effect on the target protein's level is determined by making use of the tag sequence which can be engineered into the recombinant expression of the target protein during the construction of the mammalian tissue culture test system. The tag sequence is used to determine the levels of the target protein during the incubation with the potential compounds screened and synthesized as described above. This assay for the tag sequence can take the form of a western blot or via an ELISA, for example. Other tags, which are valuable to use are those based on the green fluorescent protein, which allows the analysis of protein levels in living cells and/or organisms.
The compounds that show the optimal activity in the test systems will then form the basis for the next stage of drug development. In this next stage these selected compounds are subjected to the recognized drug development path. The drug development path determines the potential value of the compounds by evaluating a series of factors including
bioavailability; toxicology, pharmacology and efficacy in animal models before the compounds are considered for human testing.
Protein Level Control
This invention also relates to a method for the control of protein levels with a cell. This is based on the use of compounds of the invention, which are known to interact with a specific target protein such that degradation of a target protein in vivo will result in the control of the amount of protein in a biological system, prerferably to a particular therapeutic benefit. The following examples are used to assist in describing the present invention, but should not be seen as limiting the present invention in any way.
Examples
First Set
The inventors initially hypothesized that small molecule inhibitors of the VHL/HIF- la interaction could be rationally designed using hydroxyproline (Hyp) as a starting point, since residue Hyp564 on HIF- la makes key interactions with VHL14 and is crucial for HIF- l binding15. The inventors used the de-novo design software BOMB to guide the selection of plausible hydroxyproline analogs.16 1 and 2 were synthesized to test a promising design featuring an isoxazole moiety positioned to interact with a crystallographic water observed in the structure of VHL bound to the HIF peptide (549-582) 14 and a benzyl group stacked along the side chain of Tyr98. Their ability to bind to VHL was measured by the competition of a fluorescent HIF- la peptide using fluorescence polarization (FP).17 Both were able to displace the fluorescent peptide albeit at high concentrations (Table 1 A). While the smaller 3 was unable to fully displace the fluorescent peptide, the observed binding to VHL through the use of WaterLOGSY and saturation transfer difference (STD) NMR. As no binding was observed with hydroxyproline alone, this suggested that the inventors identified a minimal
pharmacophore (see Figure 2).
Table 1A. Binding of Initial Ligands to VHL OH
Figure imgf000120_0001
1 117 10
2 120.1 7.1
3 CH3 > 250 N/A
aAverage IC50 values were determined from three independent trials, each in triplicate.
Encouraged by these initial results, the inventors sought to increase the affinity of our VHL ligands by modifying the benzylamine moiety of 1 while maintaining the methyl- isoxazole fragment. In order to generate analogs rapidly, we developed a solid phase synthesis that involved the attachment of Fmoc-Hyp-OAllyl to Wang resin.18 Fmoc deprotection, coupling with 3-methyl-5-isoxazoleacetic acid followed by allyl ester deprotection and coupling with various amines and subsequent cleavage with trifluoroacetic acid led to the rapid generation of VHL ligands (Scheme l).19'20 These ligands were then tested for their ability to bind VHL using the HIF peptide FP displacement assay.
Incorporation of various halogenated benzylamines showed that para substitution yielded the highest affinity and that there were only slight differences of affinity between chlorides and bromides, although the corresponding fluoride was less potent. We also found that substitution with electron withdrawing groups such as esters, nitro groups, nitriles, and ketones led to more potent ligands than substitution with the electron donating methoxy and /-butyl substituents. Molecular dynamics simulations suggested that Arg 107 is flexible and could accommodate bulkier groups at the para position. Therefore, we considered larger heterocyclic substituents at the para position of the benzylamine moiety and synthesized 15, which was found to bind with a 4.1 μΜ IC50 value (Table 2, below).
Fluorescence Polarization Assay
Ability of VHL ligands to compete for the HIF la binding site on VCB was determined through a fluorescence polarization competition assay as described in the literature (Buckley et al. J ACS, 2012, 134, 4465^1468).
Table 2 Affinity Table- Most Compounds Showed Activity Within the Range of About 200 MicroMoles or Lower
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000123_0001
Figure imgf000124_0001
Figure imgf000125_0001
Figure imgf000126_0001
Figure imgf000127_0001
Figure imgf000128_0001
Figure imgf000129_0001
Figure imgf000130_0001
Figure imgf000131_0001
Figure imgf000132_0001
Figure imgf000133_0001
Figure imgf000134_0001
Figure imgf000135_0001
Figure imgf000136_0001
Figure imgf000137_0001
Figure imgf000138_0001
Figure imgf000139_0001
Figure imgf000140_0001
Synthetic Methods
General Chemistry
All reactions were performed in oven-dried or flame-dried glassware fitted with rubber septa under a positive pressure of nitrogen, unless otherwise noted. Air-and moisture-sensitive liquids were transferred via syringe or cannula. THF was distilled from
sodium/benzophenone. Dichloromethane was distilled from calcium hydride. Analytical thin layer chromatography (TLC) was performed using glass plates precoated with silica gel (0.25 mm). TLC plates were visualized by exposure to UV light (UV) or KMn04. Flash column chromatography was performed using silica gel 60 (230-400 mesh, Merck) with the indicated solvents.
1H and 13C spectra were recorded on Bruker Avance DPX-500 or Bruker Avance DPX- 400 NMR spectrometers. !H NMR spectra are represented as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad), integration, and coupling constant (J) in Hertz (Hz). 1H NMR chemical shifts are reported relative to CDC13 (7.26 ppm), d6- DMSO (2.50 ppm) and d4-MeOD (3.31 ppm). 1JC NMR was recorded relative to the central line of CDC13 (77.16 ppm), d6-DMSO (39.52 ppm) and d4-MeOD (49.00 ppm). In most cases, only peaks of the major rotamer are reported. Mass spectra were obtained using a Perkin-Elmer API 150 EX spectrometer. MALDI-TOF analyses of purified samples were performed in a Voyager-DE-PRO 6268 (Applied Biosystems) using cyano-4- hydroxycinnamic acid matrices. Unless otherwise noted, HPLC was performed using a Dynamax SD200 solvent delivery system connected to a Dynamax UV-1 Absorbance Detector with a YMC-Pack ODS-AM preparative column (250 x 20 mm, 5 μηι particle size, 12 nm pore size). A linear gradient of MeCN in H20 from 20% to 100% MeCN, with constant 0.1% TFA was run over 40 minutes.
General Methods of Chemical Synthesis
The following eight (8) general chemical synthetic methods (Methods A through F and Solid Phase Synthesis A and B, described hereinbelow) are provided for synthesizing numerous compounds according to the present invention which are set forth in Table 2 Affinity Table above. Each method is presented with reference to a specific compound, the synthetic details of which are presented hereinabove. All of the compounds numbered may be synthesized relatively easily using the straight-forward methods which are set forth hereinbelow. In certain instances, more synthetic details are provided for certain preferred embodiments in order to present that information such that it may serve as a template for synthesizing a number of other compounds as otherwise disclosed herein.
A
Figure imgf000141_0001
s an example, see the synthesis for compound VL133 of Table II, set forth below.
Figure imgf000142_0001
See the general synthesis for VLl 16 of Table II with protection of the hydroxyl group.
C
Figure imgf000142_0002
See the general synthesis for compound VL 217 of Table II, described below.
E
Figure imgf000142_0003
See the general synthesis for VL 219 of Table II, described below.
Figure imgf000143_0001
Method F subsumes methods C, D and E and is a general method which proceeds through commercially available amines.
Following the general synthetic methods set forth above and as previously described, the following compounds are synthesized by analogy.
Figure imgf000143_0002
(2S,4R)-l-((9H-fluoren-9-yl)methyl) 2-allyl 4-(tert-butoxy)pyrrolidine-l,2-dicarboxylate (Fmoc-Hyp(OtBu)-OAllyl)
Figure imgf000143_0003
Fmoc-Hyp(OtBu)OH (24.9 g, 60.8 mmol, 1 eq) was dissolved in DMF (300 mL) at room temperature. Sodium bicarbonate (12.8 g, 152 mmol, 2.5 eq) was added, followed by allyl bromide (25.3 mL, 300 mmol, 4.9 eq). The solution was fitted with an air condenser and heated to 50 °C for 20 hours. It was then cooled to room temperature, diluted with EtOAc, washed with aqueous 1 M HC1, saturated sodium bicarbonate, water and brine. The organic layer was dried with sodium sulfate, filtered and condensed.15 Purification by column chromatography (15 to 33% EtOAc hexanes) gave Fmoc-Hyp(OtBu)OAllyl (23.42 g, 52.1 mmol, 86%) as a faint yellow oil. 1H NMR (500 MHz, CDC13) δ 7.76 (t, J= 6.3 Hz, 2H), 7.63 - 7.54 (m, 2H), 7.43 - 7.37 (m, 2H), 7.31 (t, J= 7.0 Hz, 2H), 5.99 - 5.79 (m, 1H), 5.39 - 5.18 (m, 2H), 4.66 (d, J= 5.6 Hz, 1H), 4.63 - 4.13 (m, 6H), 3.81 (ddd, J= 16.6, 10.7, 6.2 Hz, 1H), 3.48 - 3.33 (m, 1H), 2.31 - 2.18 (m, 1H), 2.18 - 2.08 (m, 1H), 1.21 (d, J= 11.6 Hz, 9H). 13C NMR (126 MHz, CDC13) (mixture of rotamers) δ 172.49, 155.01, 154.49, 144.31, 144.18, 144.06, 143.84, 141.44, 141.41, 141.36, 131.91, 131.74, 127.80, 127.76, 127.20, 127.16, 125.31, 125.28, 125.11, 120.08, 120.05, 118.93, 118.61, 74.29, 69.37, 68.48, 67.73, 65.86, 58.09, 57.79, 54.01, 53.52, 47.40, 47.28, 38.90, 37.87, 28.41, 28.37. MS (ESI) 450.5 (M+H).
(2S,4R)-l-((9H-fluoren-9-yI)methyl) 2-allyl 4-hydroxypyrroIidine-l,2-dicarboxylate (Fmoc-Hyp(OH)-OAllyl)
Figure imgf000144_0001
Fmoc-Hyp(OtBu)-OAllyl (23.42 g, 52.1 mmol) was dissolved in DCM (306 mL) at room temperature. TFA (54 mL, 15% vol/vol) was added and the solution was stirred for 13 hours. The solution was poured into water, neutralized by slow addition of saturated aqueous sodium bicarbonate and extracted twice with DCM and once with EtOAc. The combined organic layers were dried with sodium sulfate, filtered and condensed. Purification by column chromatography (30 to 80% EtOAc/hexanes) gave Fmoc-Hyp(OH)-OAllyl as a yellowish oil (16.7 g, 42.4 mmol, 81%). !H and 13C NMR spectra matched those reported in the
literature.16
Figure imgf000144_0002
Fmoc-Hyp(OWang)-OAllyl W
Figure imgf000145_0001
Wang Resin (12.1 g, 1.1 mmol/g loading, 13.3 mmol, 1 eq) was swelled with DCM (90 mL) in a glass reaction vessel and cooled to 4°C. Trichloroacetonitirle (20 mL, 200 mmol, 15 eq) was added, followed by the addition of DBU (3 mL, 20 mmol, 1.5 eq) in 3 portions over 3 minutes, manually shaking the reaction vessel in between additions. The reaction vessel was nutated at 4°C for 1 hour, then washed with DCM, DMSO, THF, then twice with DCM at room temperature.17 A solution of Fmoc- Hyp(OH)-OAllyl (26.15 g, 66.5 mmol, 5 eq) in DCM (40 mL) and THF (40 mL) was then added, and shaken for 30 minutes and then washed twice with DCM, thrice with DCM and then twice with MeOH followed by DCM. The initial DCM washes were condensed, and purified by column chromatography (33% to 80% EtOAc) to recover the Fmoc-Hyp(OH)- OAllyl starting material (21.51 g, 54.67 mmol, 82%). The resin was dried in air, then dried under vacuum to give 15.5 g of Fmoc-Hyp(OWang)-OAllyl.18 The loading of the resin was
Figure imgf000145_0002
Solid Phase Synthesis General Method A
Fmoc-Hyp(OWang)-OAllyl resin (1 eq) was swelled DMF, then reacted with 20% piperidine in DMF for 30 minutes. The resin was then washed once with piperidine, and reacted again with 20% piperidine for 30 minutes to ensure complete deprotection. The resin was then washed twice with DMF and once with MeOH followed by DCM. The resulting free amine was then coupled with 3-methyl-5-isoxazoleacetic acid (4 eq), PyBOP (4 eq) HOBt (4 eq) and DIPEA (7 eq) in DMF for 4 hours. The resin was then washed thrice with DMF and twice with MeOH followed by DCM. The resin was then swelled with freshly distilled DCM, and reacted with Pd(PPh3)4 (0.1 eq) and PhSiH3 (10 eq) for 30 minutes. The resin was then washed once with DCM, and reacted again with Pd(PPh3)4 (0.1 eq) and PhSiH3 (10 eq) in distilled DCM for 30 minutes, after which the resin was washed twice with DMF and once with MeOH followed by DCM. The resulting carboxylic acid was then coupled with the appropriate amine (or a salt of the appropriate amine), RN¾ (4 eq) with PyBOP (4 eq), HOBt (4 eq) and DIPEA (7 eq for free amines, 8 eq for amine salts) in DMF for 4 hours. The resin was then washed 5 times with DMF, thrice with MeOH and 5 times with DCM. The resin was then reacted with 20% TFA in DCM for 2 hours. The reaction mixture was then drained and the resin was washed with DCM. Condensation under reduced pressure, and purification by column chromatography (1% to 10% 0.5M NH3 in MeOH/DCM desired VHL ligand.
Figure imgf000146_0001
Fmoc-Hyp(OWang)-OAIIyl
piperidine,
DMF
Figure imgf000146_0002
VHL Ligand
Solid Phase Synthesis General Method B
Briefly, Fmoc-Hyp-(OWang)-OAllyl resin (1 eq) was swelled with freshly distilled DCM, and reacted with Pd(PPh3)4 (0.1 eq) and PhSiH3 (10 eq) for 30 minutes. The resin was then washed once with DCM, and reacted again with Pd(PPh3)4 (0.1 eq) and PhSiH3 (10 eq) in distilled DCM for 30 minutes, after which the resin was washed twice with DMF and once with MeOH followed by DCM. The resulting carboxylic acid was then coupled with 4- chlorobenzylamine (4 eq), PyBOP (4 eq), HOBt (4 eq) and DIPEA (7 eq) in DMF for 4 hours. The resin was then reacted with 20% piperidine in DMF for 30 minutes. The resin was then washed once with DMF, and reacted again with 20% piperidine for 30 minutes to ensure complete deprotection. The resin was then coupled with the appropriate carboxylic acid (RC02H, 4 eq), PyBOP (4 eq), HOBt (4 eq) and DIPEA (7 eq) in DMF for 4 hours. The resin was then washed 4 times with DMF and twice with methanol followed by DCM. The resin was then reacted with 20% TFA in DCM for 2 hours. The reaction mixture was then drained and the resin was washed with DCM. Condensation under reduced pressure, and purification by column chromatography (1% to 10% 0.5M NH3 in MeOH/DCM or 1% to 10% MeOH in DCM) gave the desired VHL ligand. Yields are based upon the loading of the resin, which was estimated based upon its change in mass.
Figure imgf000147_0001
tert-Butyl 4-(methoxy(methyl)carbamoyl)benzylcarbamate (Boc-Amb-N(OMe)Me)
Boc-Amb-OH (2.55 g, 10.16 mmol, 1 eq) was dissolved in DCM (68 mL) and cooled to 4 °C in an ice bath. EDC (2.34 g, 12.2 mmol, 1.2 eq), HOBt (1.65 g, 12.2 mmol, 1.2 eq) and DIPEA (6.2 mL, 35.6 mmol, 3.5 eq) were added. The solution was stirred for 30 minutes and then Ν,Ο-Dimethylhydroxylamine hydrochloride (1.09 g, 11.2 mmol, 1.1 eq) was added. The solution warmed slowly to room temperature and after 21 hours was poured into brine, with a small amount of chloroform to break the resulting emulsion. After separation, the aqueous layer was extracted twice with EtOAc. The combined organic layer was dried over sodium sulfate, filtered and condensed. Purification by column chromatography (40 to 75% EtOAc/hexanes) gave a colorless oil (2.45 g, 8.33 mmol, 82%). *H NMR (500 MHz, CDC13) δ 7.65 (d, .7= 8.2 Hz, 2H), 7.31 (d, J= 8.1 Hz, 2H), 4.88 (s, 1H), 4.36 (d, J= 5.1 Hz, 2H), 3.55 (s, 3H), 3.35 (d, J= 4.7 Hz, 3H), 1.47 (s, 9H). 13C NMR (126 MHz, CDC13) δ 169.77, 156.04, 141.79, 133.21, 128.76, 127.03, 79.87, 61.20, 44.50, 33.88, 28.55. MS (ESI) 295.2 (M+H). tert-Butyl 4-formylbenzyIcarbamate (Boc-Amb-H)
BocHN
Figure imgf000148_0001
Boc-Amb-N(OMe)Me (2.45 g, 8.33 mmol, 1 eq) was dissolved in THF (83 mL) and cooled to -78 °C in a dry ice/acetone bath. Lithium aluminum hydride (0.41 g, 10.83 mmol, 1.3 eq) was added in 2 portions over 5 minutes. After 50 minutes, the suspension was warmed to 4 °C in an ice bath. After 3.5 hours, the reaction was deemed complete by TLC (mini workup in 10% potassium bisulfate and EtOAc, 50% EtOAc/hexanes) and the reaction was quenched by the slow addition of 10% potassium bisulfate at 4 °C. The mixture was warmed to room temperature, and stirred for 30 minutes. Most of the THF was removed under reduced pressure and mixture was diluted with water and extracted thrice with EtOAc. The combined organic layer was washed once with brine, dried over sodium sulfate, filtered and condensed. Purification by column chromatography (40 to 50% EtOAc/hexanes) gave Boc-Amb-H as a white solid (1.66 g, 7.1 mmol, 85%). 1H NMR (500 MHz, CDC13) δ 9.96 (s, 1H), 7.81 (d, J= 8.2 Hz, 2H), 7.41 (d, J= 8.0 Hz, 2H), 5.12 (s, 1H), 4.37 (d, J= 5.6 Hz, 2H), 1.44 (s, 9H). 13C NMR (126 MHz, CDC13) δ 191.94, 156.03, 146.30, 135.62, 130.14, 127.78, 79.92, 44.44, 28.46. MS (ESI) 235.9 (M+H), 180.2 (M-tBu). tert-Butyl 4-(oxazol-5-yl)benzylcarbamate
Figure imgf000149_0001
Potassium carbonate (0.13 g, 0.94 mmol, 1.2 eq) and toluenesulfonylmethyl isocyanide (0.184 g, 0.94 mmol, 1.2 eq) were added to MeOH (7.8 mL) at room temperature. The round bottom was fitted with a reflux condenser and heated to 45 °C. After 15 minutes, Boc-Amb- H (0.1835 g, 0.78 mmol, 1 eq) was added and the mixture was heated to 75 °C for 3 hours and then cooled to room temperature. The MeOH was removed under reduced pressure and the crude material was resuspended in EtOAc and 1 :2 mixture of saturated sodium carbonate to water and separated. The aqueous layer was then extracted once with EtOAc. The combined organic layer was dried over sodium sulfate, filtered and condensed. Purification by column chromatography (20 to 35% EtOAc/hexanes) gave a white solid. 1H NMR (400
MHz, CDC13) δ 7.91 (s, 1H), 7.62 (d, J= 8.3 Hz, 2H), 7.35 (ob d, 2H), 7.34 (ob s, 1), 4.88 (s, 1H), 1.47 (s, 9H). 13C NMR (126 MHz, CDC13) δ 156.02, 151.40, 150.47, 139.78, 128.01, 126.84, 124.67, 121.47, 79.68, 44.38, 28.47. MS (ESI) 275.5 (M+H).
(4-(OxazoI-5-yl)phenyl)methanamine trifluoroacetate salt
Figure imgf000149_0002
a solution of tert-butyl 4-(oxazol-5-yl)benzylcarbamate (1.09 g) in DCM (40 mL), TFA (4 mL) was added at room temperature. The solution was stirred for 16 hours and concentrated under reduced pressure to yield the trifluoroacetate salt of (4- (oxazol-5-yl)phenyl)methanamine (1.984 g) as a cream colored solid, which was used without further purification. Ή NMR (400 MHz, MeOD) δ 8.29 (s, 1H), 7.83 (d, J= 8.4 Hz, 2H), 7.60 (s, 1H), 7.56 (d, J= 8.5 Hz, 2H), 4.16 (s, 2H). MS (ESI) 175.3 (M- CF3CO2-).
(2S,4R)-N-(3-chlorobenzyl)-4-hydroxy-l-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2- carboxamide (VL4)
Figure imgf000150_0001
was synthesized according to General Method F as a white solid. 1H NMR (500MHz, MeOD):68.684 (1H, s); 7.33-7.23 (4H, m); 6.24 (1H, s); 4.56-4.53 (1H, t, J= 8 Hz); 4.51-4.50 (1H, m); 4.39-4.37 (2H, m); 3.96-3.92 (2H, m); 3.81- 3.3.78 (1H, dd, J= 9 Hz, 4 Hz); 3.64-3.62 (1H, m); 2.28-2.24 (4H, m); 2.09-2.04 (1H, m).13C NMR (125MHz, MeOD):5174.56, 168.67, 167.68, 161.58, 142.25, 135.35, 131.04, 128.43, 128.19, 126.76, 105.37, 70.86, 60.78, 56.96, 43.60, 39.33, 33.90, 11.21. MS (ESI) 378.2 (M+H).
(2S,4R)-4-hydroxy-N-(4-hydroxyphenethyl)-l-(2-(3-methylisoxazol-5- yl)acetyI)pyrrolidine-2-carboxainide (VL2) H
Figure imgf000150_0002
VL2 was synthesized according to General Method F. *H NMR (500 MHz, MeOD) d 8.33 & 8.13 (due to the rotamers, both s, 1H), 7.02 (d, J= 8.3 Hz, 2H), 6.69 & 6.65 (due to the rotamers, both d, J= 8.3 Hz, 2H), 6.22 & 6.10 (due to the rotamers, both s, 1H), 4.43 (d, J= 7.7 Hz, 2H), 3.89 (d, J= 4.7 Hz, 2H), 3.74 (dd, J= 11.0, 4.3 Hz, 1H), 3.57 (d, 7= 11.0 Hz, 1H), 3.42-3.36 (m, 2H), 2.73-2.63 (m, 2H), 2.25 (s, 3H), 2.16-2.12 (m, 1H), 1.96-1.91 (m, 1H). 13C NMR (asterisk denotes the signals of the minor rotamer, 125 MHz, MeOD) d 174.2, 174.1, * 173.9, *173.8, *169.0, 168.6, 167.6, *167.4, 161.6, *161.5, *157.0, 156.9, *131.2, 130.8, *116.2, 116.1, *105.6, 105.4, 70.7, *69.2, *61.0, *60.9, 60.7, 60.6, 56.9, *56.2, 42.4, 42.3, *42.0, *41.9, 41.5, 39.3, 35.5, *35.3, 33.9, *32.9, 11.2. MS (ESI) [M+H] 374.1,
[2M+Na] 769.6.
(2S,4R)-4-hydroxy-N-methyI-l-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2- carboxamide (VL26)
Figure imgf000151_0001
VL26 was synthesized according to General Method F and was isolated as a colorless oil (28 mg, 0.105 mmol, 80%). 1H NMR (500 MHz, MeOD) δ 6.23 (s, 1H), 4.47 (dt, J= 16.3, 5.2 Hz, 2H), 3.91 (d, J= 5.7 Hz, 2H), 3.78 (dd, J= 10.9, 4.2 Hz, 1H), 3.61 (dd, J= 11.0, 1.8 Hz, 1H), 2.73 (s, 3H), 2.26 - 2.18 (m, 4H), 2.05 (dd, J= 8.3, 4.7 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 174.82, 168.66, 167.67, 161.58, 105.40, 70.79, 60.67, 56.91, 39.30, 33.89, 26.35, 11.20. MS (ESI) 291.1 (M+Na), 268.7 (M+H).
VL34
Figure imgf000151_0002
was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.3 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a white solid (14.7 mg). 1H NMR (400 MHz, MeOD) δ 7.31 (dd, J= 5.9, 5.1 Hz, 4H), 7.27 - 7.17 (m, 1H), 6.23 (s, 1H), 4.55 (t, J= 8.0 Hz, 1H), 4.50 (s, 1H), 4.39 (s, 2H), 3.92 (d, J= 1.8 Hz, 2H), 3.80 (dd, J= 10.9, 4.3 Hz, 1H), 3.61 (dd, J= 7.3, 5.5 Hz, 1H), 2.33 - 2.19 (m, 4H), 2.12 - 2.03 (m, 1H). 13C NMR (101 MHz, MeOD) δ 174.29, 168.68, 167.68, 161.60, 139.73, 129.51, 128.40, 128.14, 105.36, 70.84, 60.73, 56.97, 44.05, 39.36, 33.95, 11.21. MS (ESI) 344.3 (M+H), 366.2 (M+Na).
VL28
Figure imgf000151_0003
synthesized from Fmoc-Hyp(OWang)-OAllyl (0.3 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a yellow solid (19.1 mg). 1H NMR (500 MHz, MeOD) δ 8.66 (t, J= 5.5 Hz, 1H), 7.48 - 7.34 (m, 2H), 7.31 - 7.21 (m, 2H), 6.23 (s, 1H), 4.58 (t, J= 8.0 Hz, 1H), 4.48 (qd, J= 15.8, 5.9 Hz, 3H), 3.99- 3.87 (m, 2H), 3.80 (dd, J= 10.9, 4.3 Hz, 1H), 3.66 - 3.60 (m, 1H), 2.31 - 2.22 (m, 4H), 2.09 (ddd, J= 13.0, 8.2, 4.7 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 174.60, 168.72, 167.65, 161.59, 136.79, 134.01, 130.29, 130.08, 129.67, 128.21, 105.37, 70.84, 60.74, 56.96, 42.08, 39.34, 33.95, 11.22. MS (ESI) 378.3 (M+H).
VL21
Figure imgf000152_0001
VL21 was synthesized from Fmoc-Hyp(OWang)-OAllyl (0.2 mmol) using Solid Phase Synthesis General Method A. It was isolated as a white solid (15.9 mg). 1H NMR (500 MHz, MeOD) δ 8.65 (s, 1H), 7.32 - 7.26 (m, 4H), 6.22 (s, 1H), 4.58 - 4.47 (m, 2H), 4.43 - 4.32 (m, 2H), 3.92 (d, J= 4.2 Hz, 2H), 3.80 (dd, J= 10.9, 4.3 Hz, 1H), 3.66 - 3.58 (m, 1H), 2.30 - 2.22 (m, 4H), 2.08 (dd, J= 8.3, 4.7 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 174.48, 168.71, 167.66, 161.60, 138.67, 133.85, 129.99, 129.53, 105.37, 70.85, 60.80, 56.99, 43.45, 39.33, 33.95, 11.20. MS (ESI) 378.4 (M+H).
VL20
Figure imgf000152_0002
was synthesized from Fmoc-Hyp(OWang)-OAllyl
(0.15 mmol) using Solid Phase Synthesis General Method A. It was isolated as a white solid (9.9 mg). 1H NMR (400 MHz, MeOD) δ 8.64 (t, J= 5.6 Hz, 1H), 7.37 - 7.26 (m, 2H), 7.07 - 6.99 (m, 2H), 6.23 (s, 1H), 4.57 - 4.47 (m, 2H), 4.37 (dd, J= 8.4, 5.8 Hz, 2H), 3.93 (d, J = 3.0 Hz, 2H), 3.80 (dd, 7 = 11.0, 4.2 Hz, 1H), 3.66 - 3.58 (m, 1H), 2.28 - 2.22 (m, 4H), 2.08 (dd, J= 8.3, 4.7 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 174.31, 168.69, 167.67, 163.44 (d, J= 243.5 Hz), 161.60, 135.78, 130.27 (d, J= 8.1 Hz), 116.09 (d, J= 21.6 Hz), 105.37, 70.85, 60.75, 56.99, 43.32, 39.33, 33.95, 11.20. MS (ESI) 362.3 (M+H).
VL29
Figure imgf000153_0001
was synthesized from Fmoc-Hyp(OWang)-OAllyl
(0.3 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a light yellow solid (16.4 mg). 1H NMR (400 MHz, MeOD) δ 7.45 (dq, J= 9.0, 2.2 Hz, 2H), 7.23 (d, J= 8.5 Hz, 2H), 6.22 (s, 1H), 4.58 - 4.47 (m, 2H), 4.35 (dt, J= 18.9, 15.4 Hz, 2H), 3.92 (d, J = 2.6 Hz, 2H), 3.80 (dd, J= 10.9, 4.2 Hz, 1H), 3.63 (d, J= 11.0 Hz, 1H), 2.30 - 2.21 (m, 4H), 2.11 - 2.02 (m, 1H). 13C NMR (101 MHz, MeOD) δ 174.41, 168.71, 167.66, 161.61, 139.15, 132.55, 130.32, 121.77, 105.37, 70.85, 60.75, 56.99, 43.37, 39.33, 33.94, 11.22. MS (ESI) 424.1 (M+H).
VL31
Figure imgf000154_0001
was synthesized from Fmoc-Hyp(OWang)-OAllyl
(0.3 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a white solid (19.8 mg). 1H NMR (500 MHz, MeOD) δ 8.56 (s, 1H), 7.35 (d, J= 8.2 Hz, 2H), 7.22 (d, J= 8.2 Hz, 2H), 6.24 (s, 1H), 4.53 (dd, J= 18.3, 10.3 Hz, 2H), 4.36 (d, J- 5.7 Hz, 2H), 3.92 (d, J= 3.0 Hz, 2H), 3.80 (dd, J= 10.9, 4.2 Hz, 1H), 3.62 (d, J= 11.1 Hz, 1H), 2.29 - 2.21 (m, 4H), 2.12 - 2.02 (m, 1H), 1.29 (d, J= 7.9 Hz, 9H). 13C NMR (126 MHz, MeOD) δ 174.29, 168.67, 167.68, 161.59, 151.18, 136.67, 128.19, 126.39, 105.38, 70.83, 60.77, 56.97, 43.88, 39.37, 35.28, 33.95, 31.79, 31.74, 11.23. MS (ESI) 400.5 (M+H).
VL47
Figure imgf000154_0002
was synthesized from Fmoc-Hyp(OWang)-OAUyl
(0.156 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a white solid (9.1 mg). 1H NMR (500 MHz, MeOD) δ 7.22 (dd, J= 8.4, 3.9 Hz, 2H), 6.86 (dd, J= 8.8, 2.2 Hz, 2H), 6.22 (s, 1H), 4.63 - 4.45 (m, 2H), 4.37 - 4.26 (m, 2H), 3.92 (d, J= 2.6 Hz, 2H), 3.83 - 3.70 (m, 4H), 3.61 (d, J= 11.2 Hz, 1H), 2.28 - 2.20 (m, 4H), 2.06 (ddd, J= 13.0, 8.1, 4.7 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 174.13, 168.66, 167.68, 161.60, 160.39, 131.67, 129.76, 114.89, 105.37, 70.83, 60.74, 56.97, 55.67, 43.57, 39.34, 33.95, 1 1.21. MS (ESI) 374.5 (M+H). VL35
Figure imgf000155_0001
was synthesized from Fmoc-Hyp(OWi
OAllyl (0.156 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a white solid (14.1 mg). 1H NMR (500 MHz, DMSO) δ 7.90 - 7.85 (m, 2H), 7.39 (d, J = 8.4 Hz, 2H), 6.23 (s, 1H), 5.17 (s, 1H), 4.37 (dd, J= 17.9, 10.4 Hz, 4H), 3.88 (s, 2H), 3.84 (s, 3H), 3.70 (dd, J= 10.5, 4.6 Hz, 1H), 3.47 (dd, J= 10.4, 2.5 Hz, 1H), 2.20 (d, J= 10.2 Hz, 3H), 2.11 - 2.03 (m, 1H), 1.92 (ddd, J= 12.5, 7.2, 4.9 Hz, 1H). 13C NMR (126 MHz, DMSO) δ 171.66, 166.66, 166.10, 165.66, 159.35, 145.22, 129.08, 127.99, 127.06, 103.94, 68.62, 58.76, 55.20, 52.02, 41.49, 38.17, 32.73, 10.95.MS (ESI) 402.6 (M+H).
VL48
Figure imgf000155_0002
was synthesized from Fmoc-Hyp(OWang)-OAllyl
(0.156 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a white solid (11.4 mg). 1H NMR (400 MHz, MeOD) δ 8.28 - 8.05 (m, 2H), 7.55 (d, J= 8.8 Hz, 2H), 6.23 (s, 1H), 4.64 - 4.36 (m, 4H), 3.94 (d, J= 3.8 Hz, 2H), 3.81 (dd, J= 10.9, 4.2 Hz, 1H), 3.65 (dt, J= 11.0, 1.7 Hz, 1H), 2.34 - 2.21 (m, 4H), 2.09 (td, J= 8.5, 4.2 Hz, 1H) 13C NMR (101 MHz, MeOD) δ 174.70, 168.79, 167.65, 161.63, 148.48, 147.72, 129.13, 124.56, 105.40, 70.88, 60.79, 57.03, 43.41, 39.32, 33.94, 11.20. MS (ESI) 389.3 (M+H), 411.4 (M+Na). VL88
Figure imgf000156_0001
synthesized from Fmoc-Hyp(OWang)-OAllyl
(0.156 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a clear oil (8.0 mg). 1H NMR (500 MHz, MeOD) δ 8.77 (s, 1H), 7.58 (dd, J= 88.0, 8.1 Hz, 4H), 6.23 (d, J= 4.4 Hz, 1H), 4.61 - 4.33 (m, 4H), 3.93 (d, J= 9.7 Hz, 2H), 3.83 - 3.74 (m, 1H), 3.63 (dd, J= 10.4, 9.0 Hz, 1H), 2.33 - 2.27 (m, 1H), 2.26 (d, J= 3.7 Hz, 3H), 2.15— 2.03 (m, 1H). 13C NMR (126 MHz, MeOD) δ 175.33, 168.76, 167.64, 161.61, 145.83, 133.39, 129.12, 1 19.74, 111.79, 105.28, 70.87, 70.87, 59.32, 57.02, 43.61, 38.79, 33.94, 11.21, 11.19. MS (ESI) 391.2 (M+Na).
VL95
Figure imgf000156_0002
was synthesized from Fmoc-Hyp(OWang)-OAllyl
(0.156 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a white solid (23 mg). 1H NMR (400 MHz, MeOD) δ 8.71 (s, 1H), 7.96 - 7.91 (m, 2H), 7.43 (d, J= 8.5 Hz, 2H), 6.22 (s, 1H), 4.56 (t, J= 8.0 Hz, 1H), 4.49 (ddd, J= 18.6, 8.6, 4.1 Hz, 3H), 3.91 (s, 2H), 3.80 (dd, J= 10.9, 4.2 Hz, 1H), 3.65 - 3.58 (m, 1H), 2.58 (d, J= 1.6 Hz, 3H), 2.28 - 2.22 (m, 4H), 2.10 (dd, J= 8.3, 4.7 Hz, 1H). 13C NMR (101 MHz, MeOD) δ 200.08, 174.34, 168.43, 167.36, 161.39, 145.50, 136.96, 129.62, 128.28, 105.26, 70.65, 60.57, 56.83, 43.72, 39.14, 33.87, 26.73, 1 1.30. MS (ESI) 386.0 (M+H). VL111
Figure imgf000157_0001
was synthesized from Fmoc-Hyp(OWang)- OAllyl (0.2 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a white solid (18.2 mg). 1H NMR (500 MHz, MeOD) δ 8.23 (s, 1H), 7.68 (d, J= 8.1 Hz, 2H), 7.49 (s, 1H), 7.41 (d, J= 8.1 Hz, 2H), 6.23 (s, 1H), 4.59 - 4.37 (m, 4H), 3.93 (d, J= 3.4 Hz, 2H), 3.81 (dd, J= 10.9, 4.1 Hz, 1H), 3.63 (d, J= 11.0 Hz, 1H), 2.32 - 2.17 (m, 4H), 2.09 (ddd, J= 13.0, 8.0, 4.6 Hz, 1H). 13C NMR (126 MHz, MeOD) δ 174.43, 168.72, 167.67, 161.60, 153.14, 152.75, 140.78, 129.06, 127.74, 125.61, 121.81, 105.37, 70.86, 60.78, 57.00, 43.72, 39.35, 33.96, 11.20. MS (ESI) 411.3 (M+H).
VL116 Right Hand Fragment (Representative Method B Synthesis)
Figure imgf000157_0002
Figure imgf000157_0003
2-(trimethylsilyl)ethyl 4-bromobenzylcarbamate
TeocHN
Figure imgf000157_0004
4-Bromobenzylamine hydrochloride (354 mg, 1.59 mmol, 1 eq) was dissolved in DMF (6.4 mL) and water (2.1 mL) and stirred at room temperature. Triethylamine (0.33 mL, 2.39 mmol, 1.5 eq) and TeocOSu (454 mg, 1.75 mmol, 1.1 eq) were then added. After 12 hours, the mixture was diluted with EtOAc, washed with 1M HC1, saturated sodium bicarbonate, water and brine. The organic layer was then dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification by column chromatography (10 to
20% EtOAc/hexanes) gave a colorless oil (0.4158 g, 1.26 mmol, 79%). 1H NMR (500 MHz, CDC13) δ 7.48 - 7.43 (m, 2H), 7.17 (d, J= 8.1 Hz, 2H), 4.94 (s, 1H), 4.31 (d, J= 6.0 Hz, 2H), 4.23 - 4.15 (m, 2H), 1.04 - 0.93 (m, 2H), 0.04 (s, 9H). 13C NMR (126 MHz, CDC13) δ 156.91, 137.95, 131.88, 129.32, 121.43, 63.53, 44.53, 17.92, -1.32. MS (ESI) 354.1 (M+H).
2-(trimethylsilyl)ethyl 4-(4-methylthiazol-5-yl)benzylcarbamate
Figure imgf000158_0001
2-(trimethylsilyl)ethyl 4-bromobenzylcarbamate (132 mg, 0.4 mmol, 1 eq), 4- methylthiazole-5-carboxylic acid (114.5 mg, 0.8 mmol, 2 eq), tetrabutylammonium chloride hydrate (118 mg, 0.4 mmol, 1 eq), cesium carbonate (196 mg, 0.6 mmol, 1.5 eq) and
Pd(P(tBu)3)2 (40.8 mg, 0.08 mmol, 0.2 eq) were dissolved in DMF (4 mL).1 The reaction was heated to 170°C in a microwave reactor for 16 minutes. The mixture was then cooled to room temperature, diluted with EtOAc and washed thrice with brine, once with saturated sodium bicarbonate, water, and then brine. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by coulm chromatography (10 to 35% EtOAc/hexanes) gave a colorless oil (61.7 mg, 0.177 mmol, 44%). Ή NMR (400 MHz, CDCI3) δ 8.67 (s, 1H), 7.43 - 7.37 (m, 2H), 7.34 (d, J= 8.1 Hz, 2H), 5.09 (s, 1H), 4.39 (d, J= 6.0 Hz, 2H), 4.28 - 4.02 (m, 2H), 2.52 (s, 3H), 1.10 - 0.90 (m, 2H), 0.14 - -0.09 (m, 9H). 13C NMR (101 MHz, CDC13) δ 156.98, 150.42, 148.66, 138.76, 131.67, 131.18, 129.66, 127.89, 63.46, 44.71, 17.90, 16.18, -1.34. MS (ESI) 349.0 (M+H).
!thylthiazol-5-yl)phenyl)methanamine
Figure imgf000158_0002
2-(trimethylsilyl)ethyl 4-(4-methylthiazol-5-yl)benzylcarbamate (51.8 mg, 0.149 mmol, 1 eq) was dissolvd in acetonittile (6 mL) at room temperature. A one molar solution of
tetrabutylammonium fluoride in THF (0.45 mL, 0.45 mmol, 3 eq) was added and the solution was stirred for 24 hours. The mixture was concentrated under reduced pressure. Purification by column chromatography (0.5 to 4% 0.5N NH3 (MeOH)/DCM) gave a light yellow oil (27.2 mg, 0.133 mmol, 89%). 1H NMR (500 MHz, MeOD) δ 8.87 (s, 1H), 7.44 (s, 4H), 3.85 (s, 2H), 2.47 (s, 3H). 13C NMR (126 MHz, MeOD) δ 152.77, 149.07, 143.63, 133.42, 131.46, 130.49, 129.05, 46.23, 15.79. MS (ESI) 205.0 (M+H).
Alternate Route:
4-bromobenzonitrile (5.1 g, 28 mmol, 1 eq), 4-methylthiazole (5.56 g, 56 mmol, 2 eq) potassium acetate (5.5 g, 56 mmol, 2 eq), palladium (II) acetate (63 mg, 0.28 mmol, 1 mol %) were dissolved in dimethylacetamide and stirred under argon. (CITE JOC, 2009, 74, 1 179) The mixture was heated to 150 °C and stirred for 19 hours, then diluted with 500 mL EtOAc, and washed 4 times with 300 mL water. The first wash was then back extracted with 300 mL EtOAc, and then washed 4 times with 100 mL water. The combined organic layer was dried over sodium sulfate, filtered and concentrated under vacuum to give a beige solid (5.55 g, 27.7 mmol, 99%) that matched the reported spectral data.ra The solid was then dissolved in MeOH (280 mL) and cooled to 4 °C. Cobalt chloride (9.9 g, 41.6 mmol, 1.5 eq) was added, followed by the slow, portionwise addition of sodium borohydride (5.2 g, 139 mmol, 5 eq), which was accompanied by vigorous bubbling. After 90 minutes, the reaction was quenched by the addition of water and ammonium hydroxide. The mixture was extracted 4 times with chloroform, and purified by column chromatography (10 to 30% 0.5M NH3 (MeOH)/DCM) to give a darker oil (4.12 g, 20.2 mmol, 73%).
General Solution Phase Synthesis
(2S,4R)-allyl 4-(fert-butoxy)pyrroIidine-2-carboxylate
Figure imgf000159_0001
(2S,4R)-l-((9H-fluoren-9-yl)methyl) 2-allyl 4-(tert-butoxy)pyrrolidine-l,2-dicarboxylate (7.0 g, 15.57 mmol, 1 eq) was dissolved in DCM (156 mL) and cooled to 4°C. Tris(2- aminoethyl)amine (5.8 mL, 38.9 mmol, 2.5 eq) was added, and the solution was stirred for 1 hour at 4°C and 4.5 hours at room temperature. The mixture was then mixed with silica gel (roughly 20 g), and concentrated under reduced pressure, and purified by column
chromatography (1 to 5% 0.5N NH3 (MeOH)/DCM) to give an opaque oil (3.44 g, 15.1 mmol, 97%). JH NMR (400 MHz, MeOH) δ 6.03 - 5.88 (m, 1H), 5.25 (dq, J= 17.2, 1.8 Hz, 1H), 5.09 (dq, J= 10.5, 1.6 Hz, 1H), 4.33 - 4.23 (m, 1H), 4.06 (dt, J= 5.1, 1.6 Hz, 2H), 3.86 (t, J= 8.0 Hz, 1H), 3.18 (dd, J= 11.4, 5.7 Hz, 1H), 2.70 (dd, J= 11.4, 3.8 Hz, 1H), 2.00 (dd, J= 8.0, 5.0 Hz, 2H), 1.19 (s, 9H). 13C NMR (101 MHz, MeOH) δ 175.89, 138.93, 114.88, 74.93, 72.93, 63.97, 59.77, 55.44, 40.18, 28.65. MS (ESI) 228.0 (M+H).
(2S,4R)-aIIyI 4-(tert-butoxy)-l-(2-(3-methylisoxazol-5-yl)acetyI)pyrrolidine-2- carboxylate
Figure imgf000160_0001
(2S,4R)-allyl 4-(tert-butoxy)pyrrolidine-2-carboxylate ( 0.148 g, 0.65 mmol, 1 eq) was dissolved in DMF (6.5 mL) and cooled to 4°C. 2-(3-methylisoxazol-5-yl)acetic acid (0.12 g, 0.85 mmol, 1.3 eq), EDC (0.163 g, 0.85 mmol, 1.3 eq), HOBt (0.123 g, 0.91 mmol, 1.4 eq), and DIPEA (0.283 mL, 1.63 mmol, 2.5 eq) were added, and the solution was allowed to warm slowly to room temperature. After 12 hours, the mixture was poured into brine and extracted four times with EtOAc. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (1 to 3% MeOH/DCM) gave a light yellow oil (0.2008 g, 0.573 mmol, 88%). 1H NMR (500 MHz, CDC13) δ 6.17 (s, 1H), 5.95 - 5.85 (m, 1H), 5.29 (ddd, J= 13.8, 1 1.7, 1.3 Hz, 2H), 4.69 - 4.55 (m, 3H), 4.40 - 4.32 (m, 1H), 3.84 - 3.75 (m, 3H), 3.37 (dd, J= 10.0, 4.7 Hz, 1H), 2.27 (s, 3H), 2.15 (ddd, J= 18.5, 12.0, 5.9 Hz, 2H), 1.18 (s, 9H). I3C NMR (126 MHz, CDC13) δ 171.87, 165.94, 165.63, 160.30, 131.84, 118.72, 104.04, 74.53, 69.55, 65.98, 57.96, 54.53, 37.31, 33.58, 28.35, 11.62. MS (ESI) 351.5 (M+H). (2S,4R)-4-(tert-butoxy)-l-(2-(3-methyIisoxazol-5-yI)acetyI)pyrroIidine-2-carboxylic acid
Figure imgf000161_0001
(2S,4R)-allyl 4-(tert-butoxy)- 1 -(2-(3-methylisoxazo.l-5-yl)acetyl)pyrrolidine-2-carboxylate (1.67 g, 4.77 mmol, 1 eq) was dissolved in THF (48 mL) at room temperature. Pd(PPh3)4 (0.55 g, 0.48 mmol, 0.1 eq) and morpholine (4.2 mL, 48 mmol, 10 eq) were then added. After 35 minutes, the solution was concentrated under reduced pressure, redissolved in DCM, and washed four times with 1M HC1 (aq). The aqueous layer was then back extracted once with DCM. The combined organic layer was then dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (1 to 20%
MeOH/DCM) gave a yellow solid (1.27 g, 4.1 mmol, 86%). 1H NMR (500 MHz, MeOH) δ 6.23 (s, 1H), 4.47 (t, J= 6.0 Hz, 2H), 3.94 - 3.80 (m, 3H), 3.48 (dd, J= 10.6, 3.8 Hz, 1H), 2.28 - 2.11 (m, 5H), 1.21 (s, 9H)/3C NMR (126 MHz, MeOH) δ 175.53, 168.41, 167.68, 161.59, 105.25, 75.57, 71.00, 59.36, 55.81, 38.49, 33.88, 28.48, 11.20. MS (ESI) 311.2
(M+H).
General Method B Representative Procedure (with hydroxyl group protection): VL116
(2S,4R)-4-(tert-butoxy)-l-(2-(3-methylisoxazol-5-yl)acetyl)-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide
Figure imgf000161_0002
(2S,4R)-4-(tert-butoxy)-l-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylic acid (53.7 mg, 0.173 mmol, 1.3 eq), (4-(4-methylthiazol-5-yl)phenyl)methanamine (27.2 mg, 0.133 mmol, 1 eq), EDC (33.2 mg, 0.173 mmol, 1.3 eq), and HOBt (23.4 mg, 0.173 mmol, 1.3 eq) were dissolved in DMF (3.5 mL) at 4°C. DIPEA (0.07 mL, 0.4 mmol, 3 eq) was added, and the solution was allowed to slowly warm to room tmeprature. After 19 hours, the mixture was poured into brine and extracted four times with EtOAc. The organic layer was dried with sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (1 to 5% MeOH/DCM) gave a colorless oil (58.1 mg, 0.117 mmol, 88%). 1H NMR (400 MHz, CDC13) δ 8.67 (s, 1H), 7.42 - 7.27 (m, 5H), 6.06 (s, 1H), 4.69 (dd, J= 8.4, 2.6 Hz, 1H), 4.59 - 4.35 (m, 3H), 3.82 - 3.71 (m, 3H), 3.34 (dd, J= 9.9, 6.3 Hz, 1H), 2.59 - 2.46 (m, 4H), 2.25 (s, 3H), 1.91 (dd, J= 8.2, 4.4 Hz, 1H), 1.25 - 1.14 (m, 9H). 13C NMR (101 MHz, CDC13) δ 170.70, 167.35, 165.30, 160.24, 150.42, 148.59, 138.09, 131.74, 131.05, 129.66, 127.85, 104.19, 74.48, 70.02, 59.12, 54.20, 43.25, 35.59, 33.49, 28.38, 16.19, 11.57. MS (ESI) 497.4 (M+H).
(2S,4R)-4-hydroxy-l-(2-(3-methylisoxazol-5-yl)acetyl)-N-(4-(4-methyIthiazol-5- yl)benzyI)pyrrolidine-2-carboxamide (VL116)
Figure imgf000162_0001
(2S,4R)-4-(tert-butoxy)-l-(2-(3-methylisoxazol-5-yl)acetyl)-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide (58.1 mg, 0.117 mmol) was dissolved in DCM (8 mL). TFA (2 mL, 20% vol/vol) was added and the solution was stirred for 12 hours at room temperature, after which it was concentrated under reduced pressure. Purification by column chromatography (1 to 10% 0.5N NH3 (MeOH)/DCM) gave a colorless oil (28.4 mg, 0.065 mmol, 56%). 1H NMR (400 MHz, MeOH) δ 8.87 (d, J= 2.1 Hz, 1H), 7.50 - 7.34 (m, 4H), 6.23 (s, 1H), 4.57 (t, J= 8.0 Hz, 1H), 4.54 - 4.38 (m, 3H), 3.93 (d, J= 2.4 Hz, 2H), 3.81 (dd, J= 10.9, 4.3 Hz, 1H), 3.63 (dd, J= 7.2, 5.5 Hz, 1H), 2.46 (d, J= 8.8 Hz, 3H), 2.33 - 2.20 (m, 4H), 2.10 (ddd, J= 13.1, 8.2, 4.7 Hz, 1H). 13C NMR (101 MHz, MeOH) δ 174.43, 168.71, 167.66, 161.58, 152.83, 149.04, 140.14, 133.39, 131.56, 130.43, 128.88, 105.39, 70.86, 60.78, 57.00, 43.65, 39.36, 33.96, 15.81, 1 1.22. MS (ESI) 441.3 (M+H). General Method A Representative Procedure: VL133
(2S,4R)-4-hydroxy-l-(2-(3-methylisoxazol-5-yI)acetyl)pyrroIidine-2-carboxylic acid
Figure imgf000163_0001
(2S,4R)-4-(tert-butoxy)- 1 -(2-(3 -methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylic acid (124.9 mg, 0.4 mmol,l eq) was dissolved in DCM (18 mL) at room temperature. TFA (2 mL, 10%) was added, and the solution was stirred for 12 hours. It was then concentrated under reduced pressure and purified by column chromatography (4 to 20% MeOH/DCM) to give a yellow oil (99.7 mg, 0.39 mmol, 98%). 1H NMR (500 MHz, MeOD) δ 6.24 (s, 1H), 4.55 - 4.46 (m, 2H), 3.89 (d, J= 28.3 Hz, 2H), 3.77 (dd, J= 10.9, 4.3 Hz, 1H), 3.62 (d, 7= 11.0 Hz, 1H), 2.36 - 2.22 (m, 4H), 2.10 (ddd, J= 13.1, 8.0, 4.8 Hz, 1H). 13C NMR (126 MHz, CDC13) δ 175.33, 168.51, 167.61, 161.61, 105.28, 70.86, 59.33, 56.60, 38.78, 33.85, 11.20. MS (ESI) 255.1 (M+H).
(2S,4R)-N-(4-(lH-pyrrol-3-yl)benzyl)-4-hydroxy-l-(2-(3-methylisoxazol-5- yI)acetyI)pyrrolidine-2-carboxamide (VL133)
Figure imgf000163_0002
(2S,4R)-4-hydroxy-l-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylic acid (52.6 mg, 0.207 mmol, 1.3 eq), (4-(lH-pyrrol-3-yl)phenyl)methanamine (27.3 mg, 0.159 mmol, 1 eq), EDC (39.7 mg, 0.207 mmol, 1.3 eq) and HOBt (28 mg, 0.207 mmol, 1.3 eq) were dissolved in DMF (4.1 mL) and cooled to 4°C. DIPEA (0.083 mL, 0.477 mmol, 3 eq) was added and the solution was allowed to slowly warm to room temperature. After 16 hours, the mixture was poured into half saturated sodium chloride (aqueous) and extracted 3 times with EtOAc. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. Purification by column chromatography (1 to 10%» 0.5N NH3 (MeOH)/DCM) gave an off white solid (41.5 mg, 0.102 mmol, 64%). Ή NMR (400 MHz, DMSO) δ 8.40 (d, J= 6.0 Hz, 1H), 7.52 - 7.39 (m, 2H), 7.22 - 7.12 (m, 3H), 6.82 - 6.72 (m, 1H), 6.41 (d, J= 1.7 Hz, 1H), 6.24 (s, 1H), 5.17 (d, J= 3.9 Hz, 1H), 4.31 (ddd, J= 17.1 , 13.7, 6.4 Hz, 4H), 3.88 (s, 2H), 3.75 - 3.65 (m, 1H), 3.52 - 3.41 (m, 1H), 2.18 (d, J = 18.0 Hz, 3H), 2.12 - 1.99 (m, 1H), 1.94 - 1.85 (m, 1H). 13C NMR (101 MHz, DMSO) δ 171.36, 166.69, 165.54, 159.38, 135.66, 134.68, 127.20, 124.21, 123.00, 1 18.86, 114.71, 105.22, 103.99, 68.61, 58.76, 55.18, 41.63, 38.27, 32.78, 1 1.00. MS (ESI) 431.5 (M+Na).
For further reference see the following articles and the references cited therein:
(1) Buckley DL et al. J. Am. Chem. Soc 2012, 134, 4465-4468.
(2) Van Molle I et al. A Chemistry & Biology 2012, 19, 1300-1312
(3) Buckley, D Angew. Chem. Int. Ed., 2012, 51, 11463-11467
(4) Buckley, D. Let al. Angew. Chem. 2012, 124, 11630-11634.
Examples Second Set
VL50
Figure imgf000164_0001
VL50 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.156 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (29.8 mg, 0.084 mmol, 54%). 1H NMR (400MHz, CD3OD):87.34-7.27 (m, 4H); 5.43-5.35 (m, 4H); 3.81-3.78 (dd, J=8 Hz, 4 Hz, 1H); 3.61-3.57 (m, 1H); 2.65-2.61 (m, 2H); 2.57-2.51 (m, 2H); 2.28-2.21 (m, 1H); 2.08-2.02 (m, 1H). 13C NMR (100MHz, CD3OD):5 177.53, 174.74, 173.76, 138.75, 133.76, 129.96, 129.49, 70.71, 60.55, 56.47, 43.25, 39.33, 30.97, 30.64. MS (ESI) 354.2 (M+H). VL52
OH
Figure imgf000165_0001
VL52 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.156 mmol) according to the Solid Phase Synthesis General Method B. It was isolated as a white solid (7.7 mg, 0.021 mmol, 14%). JH NMR (500MHz, CD3OD):57.41 (d, J= 2 Hz, IH); 7.30 (s, 4H); 6.35-6.34 (dd, J= 3 Hz, 2 Hz, IH); 6.26-6.25 (d, J= 3 Hz, IH); 4.49-4.32 (m, 4H); 3.82-3.73 (m, 3H); 3.65-2.62 (m, IH); 2.23-2.22 (m, IH); 2.09-2.06 (m, 1H).13C NMR (125MHz, CD3OD):6174.54, 170.58, 149.67, 143.24, 138.68, 133.84, 129.98, 129.53, 111.50, 108.98, 70.88, 60.75, 56.95, 43.31, 39.24, 35.58. MS (ESI) 365.2 (M+H), 385.3 (M+Na).
VL73
Figure imgf000165_0002
VL73 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a clear oil (38.9 mg, 0.099 mmol, 55%).^ NMR (500 MHz, CD3OD ) δ 7.51 - 6.99 (m, 8H), 4.72 (t, J = 8.2, IH), 4.55 - 4.33 (m, 3H), 3.60 (dd, J = 3.7, 11.3, IH), 3.19 (dd, J = 1.5, 11.3, IH), 2.36 - 2.25 (m, IH), 2.21 - 2.03 (m, 1H).13C NMR (126 MHz, CD3OD) δ 174.03, 169.66, 138.62, 137.31, 133.87, 132.12, 130.92, 130.48, 129.98, 129.56, 129.16, 128.53, 70.64, 60.38, 43.39, 39.25, 24.21. MS (ESI) 395.3 (M+H).
VL64 OH
Figure imgf000166_0001
VL64 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.156 mmol) according to the Solid Phase Synthesis General Method B. It was isolated as a white solid (27.5 mg, 0.077 mmol, 49%).1H NMR (500 MHz, CD3OD) δ 7.66 - 7.59 (m, 2H), 7.54 - 7.22 (m, 7H), 4.75 (t, J = 8.6, 1H), 4.55 - 4.33 (m, 3H), 3.85 (dd, J = 3.0, 11.5, 1H), 3.43 (d, J = 11.5, 1H), 2.38 - 2.26 (m, 1H), 2.14 - 2.05 (m, 1H).13C NMR (126 MHz, CD3OD) δ 174.72, 172.78, 138.73, 137.14, 133.83, 131.74, 129.93, 129.55, 129.49, 128.56, 71.04, 60.85, 59.80, 43.34, 39.28. MS (ESI) 359.1 (M+H).
VL69
Figure imgf000166_0002
VL69 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.156 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (26.1 mg, 0.62 mmol, 40%). 1H NMR (500 MHz, DMSO) δ 7.30 (dt, J = 8.2, 25.1, 4H), 7.20 (dd, J - 1.7, 8.3, 1H), 7.13 (d, J = 1.7, 1H), 7.01 (d, J = 8.4, 1H), 4.98 (s, 1H), 4.56 (t, J = 8.6, 1H), 4.29 (d, J = 2.6, 2H), 3.76 (dd, J = 15.5, 30.6, 7H), 3.36 (d, J = 11.1, 1H), 2.14 (dd, J = 7.7, 12.8, 1H), 1.96 - 1.83 (m, 1H). 13C NMR (126 MHz, DMSO) δ 171.91, 168.82, 150.39, 148.08, 138.70, 131.10, 128.68, 128.09, 121.00, 111.44, 110.75, 99.56, 68.90, 59.33, 59.30, 58.68, 55.57, 41.17, 38.01. MS (ESI) 418.8 (M+H). VL70
OH
Figure imgf000167_0001
VL70 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.156 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a colorless oil (31.1mg, 0.083 mmol, 53%).1H NMR (500 MHz, CD3OD) δ 7.38 - 7.17 (m, 6H), 6.85 - 6.73 (m, 2H), 4.76 (t, J = 8.5, 1H), 4.53 - 4.31 (m, 3H), 3.85 (dd, J = 3.2, 11.6, 1H), 3.37 (d, J = 11.6, 1H), 2.50 - 2.24 (m, 1H), 2.08 (ddd, J = 4.3, 9.1, 13.3, 1H).13C NMR (126 MHz, CD3OD) δ 174.72, 172.14, 145.18, 138.67, 133.87, 132.18, 129.97, 129.56, 128.80, 122.39, 1 18.87, 1 17.94, 71.01, 60.29, 58.54, 43.40, 39.40. MS (ESI) 374.5 (M+H).
VL71
Figure imgf000167_0002
VL71 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.156 mmol) according to the Solid Phase Synthesis General Method B. It was isolated as a colorless oil (31.1 mg, 0.080 mmol, 51%). 1H NMR (500 MHz, CD3OD) δ 7.40 - 7.32 (m, 4H), 7.24 (t, J = 7.6, 1H), 7.09 (d, J - 7.9, 1H), 7.03 (d, J = 7.1, 1H), 4.74 (t, J = 8.2, 1H), 4.59 - 4.33 (m, 3H), 3.54 (d, J = 11.0, 1H), 3.20 (d, J = 11.2, 1H), 2.35 (dd, J = 8.7, 12.4, 1H), 2.26 (s, 3H), 2.14 (dd, J = 4.3, 9.3, 1H). 13C NMR (126 MHz, CD3OD) δ 174.37, 172.44, 140.91, 139.29, 138.69, 133.84, 129.93, 129.55, 128.37, 124.30, 121.45, 120.64, 70.73, 60.11, 43.36, 39.44, 13.89. MS (ESI) 388.1, 390.3 (M+H). VL72
OH
Figure imgf000168_0001
VL72 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.156 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a yellow oil (31.3 mg, 0.084 mmol, 54%). 1H NMR (500 MHz, CD3OD) 6 7.48 (d, J = 8.3, 2H), 7.30 (s, 4H), 6.79 (d, J = 8.3, 2H), 4.79 - 4.69 (m, 1H), 4.53 - 4.29 (m, 3H), 3.95 - 3.83 (m, 1H), 3.54 (d, J = 1 1.4, 1H), 2.35 - 2.24 (m, 1H), 2.07 (ddd, J = 3.9, 10.1, 13.5, 1H). 13C NMR (126 MHz, CD3OD) δ 175.03, 173.02, 149.95, 138.75, 133.80, 130.79, 129.91, 129.54, 126.23, 1 15.89, 71.16, 61.03, 60.12, 43.31 , 39.16. MS (ESI) 375.0 (M+H).
VL74
Figure imgf000168_0002
VL74 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (36.3 mg, 0.092 mmol, 51%)}U NMR (500 MHz, CD3OD) δ 7.67 - 7.56 (m, 2H), 7.52 - 7.44 (m, 2H), 7.34 - 7.28 (m, 4H), 4.74 (dd, J = 7.7, 9.6, 1H), 4.55 - 4.30 (m, 3H), 3.85 (dd, J = 3.5, 1 1.4, 1H), 3.42 (d, J = 1 1.4, 1H), 2.37 - 2.28 (m, 1H), 2.15 - 2.05 (m, 1H). 13C NMR (126 MHz, CD3OD) 6 174.59, 171.54, 138.69, 137.75, 135.66, 133.84, 130.38, 129.92, 129.70, 129.55, 71.04, 60.92, 59.75, 43.34, 39.29. MS (ESI) 394.6 (M+H). VL75
Figure imgf000169_0001
VL75 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (25.0 mg, 0.066 mmol, 37%). 1H NMR (500 MHz, CD3OD) δ 7.64 - 6.87 (m, 8H), 4.73 (dd, J = 7.7, 9.6, 1H), 4.54 - 4.31 (m, 3H), 3.84 (dd, J = 3.5, 11.5, 1H), 3.42 (d, J = 11.4, 1H), 2.33 (ddd, J = 1.6, 7.6, 13.0, 1H), 2.13 - 2.05 (m, 1H). 13C NMR (126 MHz, CD3OD) δ 174.64, 171.20, 163.83 (d, J = 246.5), 139.35, 138.72, 133.86, 131.60, 129.94, 129.56, 124.51, 118.51 (d, J=21.3), 115.56 (d, J=23.4), 71.02, 60.94, 59.70, 43.47, 39.31. MS (ESI) 377.4 (M+H).
VL76
Figure imgf000169_0002
VL76 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (29.6 mg, 0.067 mmol, 38%). *H NMR (400 MHz, CD3OD) δ 7.82 (s, 1H), 7.70 - 7.58 (m, 2H), 7.40 (t, J = 7.9, 1H), 7.36 - 7.18 (m, 4H), 4.73 (dd, J = 7.9, 9.4, 1H), 4.53 - 4.31 (m, 3H), 3.82 (dt, J = 5.2, 10.4, 1H), 3.40 (d, J = 11.4, 1H), 2.33 (dd, J = 7.6, 13.2, lH), 2.09 (ddd, J = 4.1, 9.7, 13.7, 1H). 13C NMR (101 MHz, CD3OD) δ 174.53, 170.95, 139.22, 138.68, 134.68, 133.85, 131.56, 131.44, 129.92, 129.56, 127.31, 123.35, 71.02, 60.90, 59.70, 43.33, 39.31. MS (ESI) 439.4 (M+H). VL77
Figure imgf000170_0001
VL77 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (31.0 mg, 0.081 mmol, 45%). 1H NMR (500 MHz, DMSO) δ 8.07 (t, J = 1.4, 1H), 8.01 - 7.95 (m, 1H), 7.93 - 7.88 (m, 1H), 7.69 (t, J = 7.8, 1H), 7.40 - 7.23 (m, 4H), 4.56 (dd, J = 8.3, 16.4, 1H), 4.30 (dd, J = 8.1, 15.4, 3H), 3.79 (dd, J = 3.6, 11.0, 1H), 3.24 (d, J = 11.0, 1H), 2.23 - 2.15 (m, 1H), 1.92 (ddd, J - 4.2, 9.3, 13.2, 1H). 13C NMR (126 MHz, DMSO) δ 171.51, 167.29, 138.64, 137.27, 133.88, 132.29, 131.16, 131.08, 129.73, 128.68, 128.15, 118.25, 111.40, 68.82, 59.39, 59.36, 58.28, 38.19. MS (ESI) 383.8 (M+H).
VL79
Figure imgf000170_0002
VL79 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (34.9 mg, 0.090 mmol, 50%). 1H NMR (500 MHz, CD3OD) δ 7.41 - 7.15 (m, 6H), 7.08 - 6.90 (m, 2H), 4.73 (dd, J = 7.7, 9.6, 1H), 4.54 - 4.31 (m, 3H), 3.87 - 3.74 (m, 4H), 3.43 (d, J = 11.5, 1H), 2.37 - 2.27 (m, 1H), 2.14 - 2.05 (m, 1H). 13C NMR (126 MHz, CD3OD) 5 174.72, 172.59, 161.07, 138.72, 138.40, 133.83, 130.67, 129.93, 129.56, 120.58, 117.52, 113.77, 71.01, 60.82, 59.80, 55.87, 43.33, 39.29. MS (ESI) 389.0 (M+H). VL80
OH
Figure imgf000171_0001
VL80 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a white solid (41.2 mg, 0.110 mmol, 61%). 1H NMR (500 MHz, CD3OD) δ 7.36 - 6.76 (m, 8H), 4.72 (dd, J = 7.8, 9.4, 1H), 4.53 - 4.31 (m, 3H), 3.82 (dd, J = 3.5, 11.6, 1H), 3.45 (d, J = 11.6, 1H), 2.34 - 2.27 (m, 1H), 2.14 - 2.03 (m, 1H). 13C NMR (126 MHz, CD3OD) δ 174.81, 172.77, 158.73, 138.74, 138.36, 133.83, 130.64, 129.93, 129.56, 119.39, 118.62, 115.26, 71.01, 60.81, 59.80, 43.46, 39.24. MS (ESI) 375.4 (M+H).
VL81
Figure imgf000171_0002
VL81 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.18 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a colorless oil (42.9 mg, 0.091 mmol, 50%). 1H NMR (500 MHz, CD3OD) δ 7.77 - 7.27 (m, 6H), 7.04 (d, J = 8.3, 1H), 4.71 (t, J = 8.2, 1H), 4.56 - 4.30 (m, 3H), 3.59 (dd, J = 3.7, 11.2, 1H), 3.17 (d, J = 11.3, 1H), 2.37 - 2.25 (m, 1H), 2.19 - 2.09 (m, 1H). 13C NMR (126 MHz, CD3OD) δ 173.87, 169.41, 138.18, 137.15, 133.71, 130.60, 130.36, 130.00, 129.69, 129.56, 129.40, 120.48, 70.62, 69.41, 60.48, 43.53, 39.23. MS (ESI) 472.1 (M+H). VL96
OH
Figure imgf000172_0001
VL96 was synthesized from Fmoc-Hyp(OWang)-OAUyl resin (0.155 mmol) according to Solid Phase Synthesis General Method B. It was isolated as a light yellow oil (36.6 mg, 0.102 mmol, 66%). 1H NMR (500 MHz, CD3OD) δ 8.81 (s, 1H), 8.66 (dd, J = 4.6, 1.5 Hz, 2H), 7.60 (dd, J = 4.5, 1.6 Hz, 2H), 7.32 - 7.25 (m, 4H), 4.70 (dd, J = 9.3, 7.9 Hz, 1H), 4.46 (dd, J = 15.3, 6.3 Hz, 1H), 4.39 (s, 1H), 4.33 (dd, J = 15.4, 5.5 Hz, 1H), 3.78 (dd, J = 11.4, 3.5 Hz, 1H), 3.27 (dt, J = 3.2, 1.6 Hz, 1H), 2.31 (dd, J = 13.2, 7.6 Hz, 1H), 2.08 (ddd, J = 13.5, 9.6, 4.2 Hz, 1H). 13C NMR (126 MHz, CD3OD) 6 174.32, 169.63, 150.65, 145.83, 138.68, 133.88, 129.96, 129.56, 123.32, 70.99, 60.88, 59.33, 43.49, 39.33. MS (ESI) 360.5 (M+H).
VL112
Figure imgf000172_0002
VL112 was synthesized from Fmoc-Hyp(OWang)-OAllyl resin (0.2 mmol) according to Solid Phase Synthesis General Method A. It was isolated as a cream colored solid (22.6 mg, 0.055 mmol, 28%). XH NMR (500 MHz, CD3OD) δ 7.98 (d, J = 7.1 Hz, 3H), 7.46 (d, J = 8.0 Hz, 2H), 7.28 (s, 1H), 6.23 (s, 1H), 4.62 - 4.39 (m, 4H), 3.93 (d, J = 2.9 Hz, 2H), 3.81 (dd, J = 10.9, 4.1 Hz, 1H), 3.64 (d, J = 11.0 Hz, 1H), 2.33 - 2.17 (m, 4H), 2.15 - 2.04 (m, 1H). 13C NMR (126 MHz, CD3OD) δ 174.50, 168.72, 167.68, 163.41, 161.60, 142.96, 140.75, 129.45, 128.96, 127.53, 127.15, 105.36, 70.87, 60.78, 56.99, 43.72, 39.36, 33.95, 11.20. MS (ESI) 410.9 (M+H). VLl 15
Figure imgf000173_0001
VLl 15 was synthesized according to General Method B. 1H NMR (500 MHz, CD3OD) δ 8.87 (s, 1H), 7.46 - 7.40 (m, 2H), 7.36 (dd, J= 8.8, 4.3 Hz, 2H), 6.20 (s, 1H), 4.55 (t, J = 8.0 Hz, 1H), 4.50 (d, J= 6.3 Hz, 1H), 4.48 - 4.42 (m, 2H), 3.92 (d, J= 4.5 Hz, 2H), 3.80 (dd, J= 10.9, 4.3 Hz, 1H), 3.62 (d, J= 11.0 Hz, 1H), 2.48 (d, J= 10.2 Hz, 3H), 2.31 - 2.21 (m, 4H), 2.08 (ddd, J= 13.0, 8.2, 4.7 Hz, 1H). 13C NMR (126 MHz, CD3OD) δ 174.48, 168.60, 167.70, 161.57, 152.92, 149.26, 140.81, 133.50, 133.09, 130.13, 129.24, 129.09, 128.34, 105.35, 70.86, 60.75, 56.95, 43.81, 39.38, 33.92, 15.87, 11.23. MS (ESI) 441.4 (M+H).
VL154
Figure imgf000173_0002
VLl 54 was synthesized according to General Method B. 1H NMR (500 MHz, CD3OD) δ 8.95 (s, 1H), 8.44 (t, J= 5.6, 1H), 7.84 (d, J= 8.2, 2H), 7.70 (d, J= 1.9, 1H), 7.35 (d, J = 8.2, 2H), 6.19 (s, 1H), 4.56 (t, J = 7.9, 1H), 4.51 (s, 1H), 4.43 (d, J= 5.7, 2H), 3.87 (s, 2H), 3.78 (dd, J= 10.9, 4.3, 1H), 3.58 (d, J= 10.8, 1H), 2.24 (obscured s, 4H), 2.16 - 2.07 (m, 1H); 13C NMR (126 MHz, CD3OD) δ 176.66, 170.98, 169.94, 164.15, 159.72, 157.62, 142.33, 136.89, 131.58, 130.33, 117.00, 108.05, 73.36, 63.27, 59.60, 46.75, 41.78, 36.80, 14.39; TLC: (EtOAC) Rr0.5; LRMS (ESI) 427.6 (M+H)+. VL155
Figure imgf000174_0001
VL155 was synthesized according to General Method B. 1H NMR (500 MHz, CD3OD) δ 8.87 (d, J= 5.2, 1H), 8.54 (t, J= 5.7, 1H), 8.07 (s, 1H), 7.56 (d, J= 8.2, 2H), 7.36 (d, J= 8.2, 2H), 6.20 (s, 1H), 4.56 (t, J= 8.0, 1H), 4.51 (s, 1H), 4.42 (qd, J = 5.5, 15.5, 2H), 3.78 (dt, J = 9.2, 18.5, 1H), 3.60 (d, J= 11.1, 1H), 2.28 - 2.21 (m, 4H), 2.10 (ddd, J= 4.7, 8.0, 13.0, 1H); I3C NMR (126 MHz, CD3OD) 8 176.72, 171.03, 169.98, 164.12, 142.98, 142.96, 133.45, 132.34 131.86, 130.07, 108.02, 100.0, 73.37, 63.29, 59.60, 46.52, 41.81, 36.74, 14.27. TLC: (EtOAC) R =0.5 ; LRMS (ESI) 427.4 (M+H)+.
VL118
Figure imgf000174_0002
VL118 was synthesized according to General Method A. 1H NMR (500 MHz, CD3OD) δ 7.37 - 7.31 (m, 2H), 7.27 (d, J = 7.7 Hz, 1H), 7.22 (d, J - 7.5 Hz, 1H), 6.74 - 6.68 (m, 1H), 6.20 (s, 1H), 6.14 (dd, J= 3.5, 1.8 Hz, 1H), 6.10 - 6.05 (m, 1H), 4.55 (t, J= 8.0 Hz, 1H), 4.49 (s, 1H), 4.45 - 4.39 (m, 2H), 3.89 (t, J = 8.4 Hz, 1H), 3.79 (dd, J = 10.9, 4.3 Hz, 1H), 3.67 - 3.55 (m, 5H), 2.26 - 2.22 (m, 4H), 2.07 (ddd, J = 13.0, 8.1, 4.7 Hz, 1H). 13C NMR (126 MHz, CD3OD) δ 174.35, 168.57, 167.66, 161.57, 139.94, 135.44, 135.24, 129.58, 128.35, 128.22, 126.62, 124.93, 109.56, 108.54, 105.37, 70.84, 60.72, 56.91, 44.04, 39.36, 35.34, 33.88, 11.23. MS (ESI) 422.8 (M+H). VL119
Figure imgf000175_0001
VL119 was synthesized according to General Method A. 1H NMR (500 MHz, CD3OD) δ 7.38 - 7.30 (m, 4H), 6.76 - 6.67 (m, 1H), 6.23 (s, 1H), 6.10 (dd, J = 3.5, 1.8 Hz, 1H), 6.09 - 6.05 (m, 1H), 4.56 (t, J= 8.1 Hz, 1H), 4.51 (s, 1H), 4.47 - 4.39 (m, 2H), 3.93 (d, J= 3.0 Hz, 2H), 3.81 (dd, J= 10.9, 4.3 Hz, 1H), 3.63 (q, J= 5.8 Hz, 4H), 2.31 - 2.22 (m, 4H), 2.10 (ddd, J = 13.0, 8.1 , 4.7 Hz, 1H). 13C NMR (101 MHz, -1 :1 CD30D:CDC13) 8 172.63, 167.39, 166.19, 160.68, 136.80, 132.70, 129.06, 128.99, 127.75, 124.09, 108.75, 107.93, 104.62, 69.88, 59.64, 56.15, 43.36, 37.98, 35.19, 33.53, 11.37. MS (ESI) 423.6 (M+H).
VL131
Figure imgf000175_0002
VL131 was synthesized according to General Method B. lU NMR (400 MHz, CD3OD) δ 9.02 (d, J= 5.2 Hz, 1H), 8.02 (d, J= 8.4 Hz, 2H), 7.41 (d, J= 8.4 Hz, 2H), 6.17 (s, 1H), 4.52 - 4.38 (m, 4H), 3.84 (s, 2H), 3.76 (dd, J= 10.8, 4.3 Hz, 1H), 3.56 (d, J= 9.5 Hz, 1H), 2.30 - 2.18 (m, 4H), 2.14 (td, J= 8.1, 3.9 Hz, 1H). 13C NMR (101 MHz, CD3OD) δ 173.25, 167.86, 167.57, 166.44, 166.18, 160.85, 142.53, 128.33, 128.14, 125.56, 104.77, 70.04, 59.87, 56.31, 43.52, 38.30, 33.60, 11.39. MS (ESI) 413.3 (M+H). VL138
Figure imgf000176_0001
VL138 was synthesized according to General Method B. 1H NMR (400 MHz, CD3OD) δ 7.42 (d, J= 8.2 Hz, 2H), 7.32 - 7.24 (m, 2H), 6.24 (s, 1H), 4.69 - 4.33 (m, 5H), 3.94 (d, J = 3.0 Hz, 1H), 3.82 (dd, J= 10.9, 4.3 Hz, 1H), 3.64 (d, J= 11.1 Hz, 1H), 2.38 (s, 3H), 2.31 - 2.24 (m, 4H), 2.23 (s, 3H), 2.10 (ddd, J= 13.1, 8.2, 4.7 Hz, 1H). 13C NMR (126 MHz, CD3OD) 6 174.41, 168.72, 167.67, 166.87, 161.59, 160.02, 139.46, 130.38, 129.37, 128.89, 117.72, 105.38, 70.87, 60.78, 57.01, 43.74, 39.37, 33.97, 11.38, 11.20, 10.66. MS (ESI) 438.6 (M+H).
VL139
Figure imgf000176_0002
VL139 was synthesized according to General Method B. 1H NMR (400 MHz, -1 : 1 CD30D:CDC13) δ 7.89 (s, 2H), 7.49 (d, J = 8.1 Hz, 2H), 7.28 (d, J = 7.9 Hz, 2H), 6.20 (s, 1H), 4.54 (dd, J = 17.4, 9.5 Hz, 2H), 4.39 (d, J = 5.3 Hz, 2H), 3.93 - 3.46 (m, 4H), 2.32 - 2.16 (m, 4H), 2.16 - 2.05 (m, 1H). 13C NMR (126 MHz, -1 : 1 CD30D:CDC13) δ 173.80, 168.23, 167.21, 161.29, 137.35, 132.66, 129.24, 128.77, 126.60, 126.48, 105.16, 70.53, 60.42, 56.73, 43.71, 39.00, 33.85, 11.30. MS (ESI) 410.0 (M+H). W
VL152
Figure imgf000177_0001
VL152 was synthesized according to General Method B. 1H NMR (400 MHz, CD3OD) δ 7.38 (d, J= 8.2 Hz, 2H), 7.25 (d, J = 8.2 Hz, 2H), 6.17 (d, J = 55.2 Hz, 1H), 4.65 - 4.30 (m, 4H), 4.05 - 3.72 (m, 3H), 3.64 (d, J = 11.1 Hz, 1H), 2.32 - 2.19 (m, 10H), 2.10 (ddd, J = 13.1, 8.2, 4.7 Hz, 1H). 13C NMR (101 MHz, CD3OD) 6 174.37, 168.72, 167.67, 161.59, 143.18, 138.27, 132.85, 130.54, 129.12, 128.64, 105.40, 70.86, 60.78, 57.01, 43.80, 39.38, 33.96, 11.21, 11.07. MS (ESI) 438.5 (M+H).
VL158
Figure imgf000177_0002
VL158 was synthesized according to General Method B. *H NMR (500 MHz, CD3OD) δ 8.03 (s, 1H), 7.62 (t, J = 8.7 Hz, 2H), 7.43 (d, J = 6.6 Hz, 1H), 7.33 (t, J = 6.5 Hz, 2H), 6.19 (s, 1H), 4.62 - 4.48 (m, 2H), 4.48 - 4.32 (m, 2H), 3.93 - 3.68 (m, 3H), 3.58 (s, 1H), 2.29 - 2.19 (m, 4H), 2.11 (ddd, J= 13.0, 8.0, 4.8 Hz, 1H). 13C NMR (126 MHz, CD3OD) δ 173.59, 168.01, 166.92, 161.11, 138.84, 135.95, 130.48, 129.06, 128.64, 125.89, 116.23, 105.04, 70.35, 60.24, 56.60, 43.56, 38.76, 33.78, 11.33. MS (ESI) 410.1 (M+H). VL160
Figure imgf000178_0001
VL160 was synthesized according to General Method B. Ή NMR (500 MHz, CD3OD) δ 7.68 (d, J = 8.1 Hz, 2H), 7.63 (s, 1H), 7.33 (d, J = 8.0 Hz, 2H), 6.63 (s, 1H), 6.19 (s, 1H), 4.54 (t, J= 8.0 Hz, 1H), 4.47 (s, 1H), 4.38 (d, J= 4.6 Hz, 2H), 3.89 (d, J= 3.1 Hz, 2H), 3.78 (dd, J = 10.9, 4.3 Hz, 1H), 3.60 (d, J = 11.1 Hz, 1H), 2.28 - 2.14 (m, 4H), 2.06 (ddd, J = 13.0, 8.1, 4.7 Hz, 1H). 13C NMR (126 MHz, CD3OD) δ 174.32, 168.69, 167.67, 161.61, 139.59, 132.31, 129.33, 128.86, 127.00, 126.87, 105.49, 105.38, 70.84, 60.78, 56.97, 43.80, 39.35, 33.95, 11.19. MS (ESI) 409.2 (M+H), 431.8 (M+Na).
(2S,4R)-(9H-fluoren-9-yl)methyl 4-(tert-butoxy)-2-((4- chlorobenzyI)carbamoyl)pyrrolidine-l-carboxylate
Figure imgf000178_0002
Fmoc-Hyp(OtBu)-OH (1.23 g, 3 mmol, 1 eq) was dissolved in DCM (15 mL) and cooled to 4 °C. EDC (0.69g, 3.6 mmol, 1.2 eq) and HOBt (0.49 g, 3.6 mmol, 1.2 eq) were then added. After 20 minutes, 4-chlorobenzylamine (0.48 mL, 3.9 mmol, 1.3 eq) was added and the solution was allowed to warm slowly to room temperature. After 15 hours, the mixture was diluted with EtOAc and washed with 1M HCl, sodium bicarbonate, water and brine. The organic layer was dried with sodium sulfate, filtered and condensed. Purification by column chromatography (25 to 100% EtOAc/hexanes) gave a white foam (1.42 g, 2.66 mmol, 89%). 1H NMR (400 MHz, CDC13) δ 7.77 (d, J= 7.2 Hz, 2H), 7.57 (s, 2H), 7.40 (t, J= 7.3 Hz, 2H), 7.31 (t, J = 7.3 Hz, 2H), 7.17 (dd, J = 27.2, 19.5 Hz, 4H), 4.58 - 3.94 (m, 7H), 3.60 (d, J = 6.7 Hz, 1H), 3.31 (d, J = 6.6 Hz, 1H), 2.50 (s, 1H), 1.96 (s, 1H), 1.28 - 1.10 (m, 9H). 13C NMR (101 MHz, CDC13) δ 171.54, 156.13, 143.74, 141.32, 136.81, 133.02, 128.79, 128.71, 127.83, 127.12, 125.04, 120.07, 74.15, 69.63, 67.87, 59.17, 53.26, 47.10, 42.72, 36.34, 28.31. MS (ESI) 534.8 (M+H).
(2S,4R)-4-(te ,i-butoxy)-N-(4-chlorobenzyl)pyrrolidine-2-carboxamide
Figure imgf000179_0001
(25',4i?)-(9H-fluoren-9-yl)methyl 4-(tert-butoxy)-2-((4-chlorobenzyl)carbamoyl)pyrrolidine- 1-carboxylate (0.5 g, 0.94 mmol, 1 eq) was dissolved in DCM (15 mL) and cooled to 4 °C. Tris(2-aminoethyl)amine (0.35 mL, 2.34 mmol, 2.5 eq) was added slowly, dropwise. After 30 minutes, the reaction was warmed to room temperature and stirred for an additional 14 hours. It was loaded directly onto a silica column, and purified by column chromatography (1 to 7% 0.5N methanolic ammonia/DCM) to give a white solid (0.2871 g, 0.92 mmol, 98%). *H NMR (400 MHz, CD3OD) δ 7.27 (dd, J = 20.1, 8.4 Hz, 4H), 4.35 (s, 2H), 4.22 (s, 1H), 3.84 (t, J = 8.0 Hz, 1H), 3.08 (dd, J = 11.4, 5.1 Hz, 1H), 2.76 (dd, J = 1 1.4, 2.8 Hz, 1H), 2.14 - 1.98 (m, 1H), 1.97 - 1.81 (m, 1H), 1.17 (s, 9H). 13C NMR (126 MHz, CD3OD) δ 176.48, 138.81, 133.83, 130.00, 129.52, 74.76, 73.37, 60.80, 55.61, 43.04, 40.76, 28.67.
General Method C: Representative Procedure: VL156
Figure imgf000179_0002
Figure imgf000180_0001
IH-Imidazol-l-ylacetic acid (20.6 mg, 0.163 mmol, 1.3 eq), EDC (31.2 mg, 0.163 mmol, 1.3 eq) and HOBt (22 mg, 0.163 mmol, 1.3 eq) were dissolved in DCM (2.5 mL) and DMF (0.4 mL) at room temperature in a 1 dram vial. After stirring for 15 minutes, DIPEA (0.055 mL, 0.313 mmol, 2.5 eq) was added, followed by (2S,4i?)-4-( rt-butoxy)-N-(4- chlorobenzyl)pyrrolidine-2-carboxamide (38.9 mg, 0.125 mmol, 1 eq) after an additional 30 minutes. The mixture was stirred for 14 hours, then diluted with EtOAc and washed with , brine. The organic layer was dried over sodium sulfate, filtered and condensed. Purification by column chromatography (1 to 10 % MeOH/DCM) gave a white solid, which was used directly in the following step. 1H NMR (400 MHz, CD3OD) δ 7.65 (s, 1H), 7.28 (td, J= 10.9, 8.4 Hz, 4H), 7.06 (d, J= 43.6 Hz, 2H), 4.99 (dd, J= 38.1, 17.1 Hz, 2H), 4.51 (t, J= 6.6 Hz, 2H), 4.35 (q, J= 15.4 Hz, 2H), 3.86 (dd, J= 10.2, 5.6 Hz, 1H), 3.45 (dd, J= 10.3, 4.1 Hz, 1H), 2.22 - 2.02 (m, 2H), 1.21 (d, J= 13.8 Hz, 9H). MS (ESI) 419.7 (M+H).
The white solid was dissolved in DCM (9 mL) at room temperature. TFA (1 mL) was added and the mixture was stirred for 12 hours and condensed. Purification by column
chromatography (1 to 20% 0.5 N methanolic ammonia/DCM) gave a white solid (39.8 mg, 0.11 mmol, 88% over 2 steps. 1H NMR (400 MHz, CD3OD) δ 8.73 (s, 1H), 7.47 (d, J= 16.9 Hz, 2H), 7.26 (s, 4H), 5.25 (dd, J= 37.5, 16.9 Hz, 2H), 4.56 (t, J= 7.9 Hz, 2H), 4.44 - 4.27 (m, 2H), 3.82 (dd, J= 10.8, 4.1 Hz, 1H), 3.63 (d, J= 10.8 Hz, 1H), 2.36 - 2.22 (m, 1H), 2.07 (ddd, J= 13.1, 8.3, 4.6 Hz, 1H). 13C NMR (126 MHz, CD3OD) δ 174.14, 166.34, 138.56, 138.20, 133.87, 129.97, 129.49, 124.55, 121.47, 70.94, 61.00, 55.75, 51.33, 43.35, 39.21. MS (ESI) 364.8 (M+H). VL120
Figure imgf000181_0001
VL120 was synthesized according to General Method C. 1H NMR (500 MHz, CD3OD) δ 8.67 (d, J= 1.2 Hz, 1H), 7.36 (s, 1H), 7.29 (d, J= 9.2 Hz, 4H), 4.62 - 4.47 (m, 2H), 4.47 - 4.24 (m, 2H), 3.87 (ddd, J= 18.3, 15.1, 10.8 Hz, 3H), 3.66 (d, J= 11.0 Hz, 1H), 2.37 - 2.20 (m, 1H), 2.07 (ddd, J = 13.1, 8.4, 4.6 Hz, 1H). 13C NMR (126 MHz, CD3OD) δ 174.56, 169.45, 138.62, 135.15, 133.89, 129.98, 129.72, 129.52, 118.80, 70.89, 60.70, 56.84, 43.35, 39.46, 31.70. MS (ESI) 362.3 (M+H).
VL157
Figure imgf000181_0002
VL157 was synthesized according to General Method C. 1H NMR (500 MHz, CD3OD) δ 7.49 (s, 1H), 7.39 (s, 1H), 7.34 - 7.22 (m, 4H), 4.52 (t, J= 8.1 Hz, 1H), 4.50 - 4.45 (m, 1H), 4.37 (dt, J= 22.8, 15.4 Hz, 2H), 3.87 - 3.80 (m, 3H), 3.77 (dd, J= 11.0, 4.2 Hz, 1H), 3.66 - 3.52 (m, 3H), 2.30 - 2.18 (m, 1H), 2.04 (ddd, J= 13.1, 8.3, 4.7 Hz, 1H). 13C NMR (126 MHz, CD3OD) 8 174.67, 172.70, 140.18, 138.71, 133.81, 131.62, 129.95, 129.51, 115.17, 70.91, 60.65, 56.93, 43.29, 39.28, 38.76, 31.51. MS (ESI) 377.0 (M+H). VL173
Figure imgf000182_0001
VL173 was synthesized according to General Method C. 1H NMR (400 MHz, CDC13/CD30D) 6 7.63-7.53 (m, 3H); 7.49 (d, J= 7.6 Hz, 1H); 7.26 (q, J= 8.3 Hz, 4H); 4.60- 4.51 (m, 2H); 4.42-4.32 (m, 2H); 3.84-3.75 (m, 3H); 3.59 (d, J= 11.3 Hz, 1H); 3.42-3.32 (m, 1H); 2.29-2.19 (m, 1H); 2.17-2.08 (m, 1H). 13C NMR (100MHz, CDC13/CD30D) δ 173.4, 170.7, 137.4, 136.8, 134.8, 133.6, 131.1, 129,9, 129.3, 129.0, 1 19.2, 112.7, 70.1, 59.8, 56.3, 43.0, 41.1, 38.4. TLC (10% MeOH in CH2C12), Rf 0.38 (UV, CAM), MS (ESI+): calculated for C21H21N303C1 [M+H]+ 398.1, found 398.2.
Figure imgf000182_0002
Azidoacetic acid
N3 / C02H
To a solution of ethyl azidoacetate (530 mg, 4.107 mmol) in THF-H20 (12 mL/12 mL) at rt was added LiOH H20 (345 mg, 8.214 mmol). The reaction mixture was stirred at rt for 17 h, evaporated, and diluted with H20 (10 mL), cooled to 0 °C, and adjusted to pH 4 with 1N-HC1. The resulting mixture was extracted twice with diethyl ether, washed with brine, dried over anhydrous Na2S0 , and evaporated. The concentrate was purified by short column chromatography (eluting with 100% hexane initially, grading to 2% ethyl acetate in hexane) on silica gel to give azidoacetic acid 1 (372 mg, 89%») as a pale-yellow oil. 1H NMR (500 MHz, CDC13) δ 9.73 (brs, 1H), 3.97 (s, 2H). 13C NMR (125 MHz, CD3OD) d 174.2, 50.0.
(2S,4R)-l-(2-azidoacetyl)-4-(te 'i-butoxy)-N-(4-chlorobenzyl)pyrrolidine-2-carboxamide
Figure imgf000183_0001
To a solution of azidoacetic acid (32 mg, 0.315 mmol) in CH2Cl2-DMF (1.5 mL/1.5 mL)) at room temperature were added (25',4i?)-4-(tert-butoxy)-iV-(4-chlorobenzyl)pyrrolidine-2- carboxamide (93 mg, 0.300 mmol), DIPEA (0.19 mL, 1.080 mmol), and HOBt (48 mg, 0.360 mmol). The mixture was cooled to 0 °C, and then EDC (69 mg, 0.360 mmol) was added to the mixture at 0 °C. The reaction mixture was allowed to warm to rt, stirred at rt for 17 h, and cooled to 0 °C. The resulting mixture was quenched with H20 (5 mL) and extracted twice with ethylacetate. The combined extracts were washed with brine, dried over anhydrous Na2S04, filtered, and evaporated. The concentrate was purified by column chromatography (eluting with 5% ethyl acetate in hexane initially, grading to 40% ethyl acetate in hexane) on silica gel to afford the coupled product (110 mg, 93%). lH NMR (400 MHz, CDC13) δ 7.31 (brs, 1H), 7.27 (d, J= 8.5 Hz, 2H), 7.18 (d, J= 8.5 Hz, 2H), 4.66 (dd, J= 8.4, 2.2 Hz, 1H), 4.58-4.52 (m, 1H), 4.41 (dd, J= 15.1, 6.1 Hz, 1H), 4.30 (dd, J= 15.1, 5.8 Hz, 1H), 3.87 (dd, J= 16.0, 16.0 Hz, 1H), 3.84 (dd, J= 16.0, 16.0 Hz, 1H), 3.61 (dd, J= 9.8, 7.0 Hz, 1H), 3.14 (dd, J= 9.8, 6.4 Hz, 1H), 2.50 (ddd, J= 12.6, 6.3, 2.3 Hz, 1H), 1.86 (dt, J= 12.6, 8.2 Hz, 1H), 1.19 (s, 9H). 13C NMR, 100 MHz, CDC13) δ 170.3, 167.4, 162.5, 136.5, 133.1, 128.8, 128.7, 74.3, 69.9, 59.0, 52.7, 50.9, 42.8, 36.4, 35.1, 31.4, 28.2. MS (ESI) [M+H]+ 394.3. (2S,4R)-4-(te/-/-butoxy)-N-(4-chlorobenzyl)-l-(2-(4-(methoxymethyI)-lH-l,2,3-triazol-l- yl)acetyl)pyrrolidine-2-carboxamide
Figure imgf000184_0001
To a solution of methyl propargyl ether (7 mg, 0.067 mmol) and (2S,4i?)-l-(2-azidoacetyl)-4- (tert-butoxy)-N-(4-chlorobenzyl)pyrrolidine-2-carboxamide (25 mg, 0.0636 mmol) in t- BuOH-H20 (1 :1, 1 mL) and THF (1 mL) at rt were added CuS04-5H20 (1.5 mg, 0.006 mmol) and sodium ascorbate (1.0 M in H20, 2 drops). The reaction mixture was stirred at rt for 19 h and evaporated. The residue was diluted with H20 (5 mL) and the mixture was extracted three times with ethyl acetate. The combined extracts were washed with brine, dried over Na2S04, filtered, and concentrated. The crude residue was purified by flash
chromatography on silica gel to give the desired triazole (25 mg, 85%). l NMR (500 MHz, CD3OD) d 7.91 (s, 1H), 7.30-7.22 (m, 4H), 5.43 (d, J= 16.8 Hz, 1H), 5.34 (d, J= 16.7 Hz, 1H), 4.54 (s, 2H), 4.53-4.49 (m, 2H), 4.37 (d, J= 15.4 Hz, 1H), 4.31 (d, J= 15.4 Hz, 1H), 3.90 (dd, J= 10.3, 5.6 Hz, 1H), 3.49 (dd, J= 10.4, 4.3 Hz, 1H), 3.37 (s, 3H), 2.19-2.13 (m, 1H), 2.11-2.07 (m, 1H), 1.22 (s, 9H). 13C NMR (asterisk denotes the signals of the minor rotamer, 125 MHz, CD3OD) d 174.1, * 173.4, *166.9, 166.7, 145.7, *138.6, 138.5, *134.2, 133.8, *130.4, 129.9, * 129.7, 129.5, 126.7, 75.6, *75.5, 71.1, *69.2, 66.3, *66.2, 60.8, *60.3, 58.4, *58.3, *55.5, 54.8, 52.6, *51.9, *43.7, 43.3, *41.1, 38.7, 28.5. MS (ESI) [M+H]+ 464.2.
VL141
Figure imgf000184_0002
To a stirred solution of the corresponding t-butyl ether (22 mg, 0.0475 mmol) in CH2C12 (1.5 mL) at 0 °C was added TFA (0.2 mL). The reaction mixture was stirred at rt for 12 h and concentrated. The residue was chromatographed (eluting with 100% CH2C12 initially, grading to 7% CH3OH in CH2C12) on silica gel to provide 5 (18.5 mg, 96%). 1H NMR (500 MHz, CD3OD/CDCI3 = 2: 1) d 8.83 & 8.46 (due to the rotamers, both t, J= 5.7 Hz, 1H), 7.85 & 7.76 (due to the rotamers, both s, 1H), 7.23 (d, J= 8.5 Hz, 2H), 7.18 (d, J= 8.5 Hz, 2H), 5.36 (d, J= 16.6 Hz, 1H), 5.27 (d, J= 16.6 Hz, 1H), 4.54 (s, 2H), 4.54-4.50 (m, 2H), 4.33 & 4.32 (due to the rotamers, both s, 2H), 3.77 (dd, J= 10.8, 4.2 Hz, 1H), 3.60 (d, J= 10.8 Hz, 1H), 3.37 & 3.36 (due to the rotamers, both s, 3H), 2.26-2.21 (m, 1H), 2.09-2.04 (m, 1H). 13C NMR (asterisk denotes the signals of the minor rotamer, 125 MHz, CD30D/CDC13 = 2: 1) d ♦173.4, 173.3, * 166.2, 165.9, 145.2, 137.5, *133.9, 133.5, 129.9, 129.4, 129.1, 126.0, * 125.9, 70.4, *68.5, 66.0, *65.9, *60.4, 60.3, 58.4, *58.3, *56.1, 55.4, 52.2, *51.5, *43.2, 43.1, *41.1, 38.4. MS (ESI) [M+H]+ 408.3. TLC (10% MeOH in CH2C12), Rf 0.48 (UV, CAM).
VL167
Figure imgf000185_0001
VL167 was synthesized according to General Method C. lH NMR (500 MHz, CDC13) d 7.86 (s, 1H), 7.71 (d, J= 9.5 Hz, 1H), 7.61 (d, J= 7.4 Hz, 2H), 7.56 (d, J= 7.6 Hz, 1H), 7.51 (d, J = 7.6 Hz, 1H), 7.42 (dd, J= 7.4, 7.4 Hz, 2H), 7.38-7.30 (m, 2H), 7.30-7.26 (m, 3H), 4.66- 4.42 (m, 2H), 4.42-4.27 (m, 2H), 3.85 (dd, J= 11 A, 3.5 Hz, 1H), 3.49 (d, J= 11.4 Hz, 1H), 2.33-2.29 (m, 1H), 2.15-2.09 (m, 1H). 13C NMR (asterisk denotes the signals of the minor rotamer, 125 MHz, CDC13) d 172.5, 170.6, 162.7, 140.7, 139.3, 136.4, 135.6, 131.9, 128.2, *128.1, 128.0, 127.9, 127.6, *127.5, 126.8, 126.1, *126.0, 125.2, 125.1, 68.9, *67.4, *60.2, 58.7, 57.8, 41.5, *39.5, 37.2, 35.2, 30.0. MS (ESI) [M+H]+ 435.5. VL216
Figure imgf000186_0001
C.
Figure imgf000186_0002
(2S,4R)-(9H-fluoren-9-yl)methyl 4-(tert-butoxy)-2-((4-(oxazol-5-yl)benzyl)carbamoyl) pyrrolidine-l-carboxylate
Figure imgf000186_0003
To a round bottom flask with stir bar was charged (2S,4i?)-l-(((9H-fluoren-9- yl)methoxy)carbonyl)-4-(tert-butoxy)pyrrolidine-2-carboxylic acid (0.587, 1.4 mmol 1.0 equiv)'EDC (380 mg, 2.0 mmol, 1.4 equiv), HOBt (310 mg, 2.0 mmol, 1.4 equiv) and (4- (oxazol-5-yl)phenyl)methanamine (250 mg, 1.4 mmol, 1.0 equiv). Upon stirring for 18 h the reaction was diluted with 25 ml DCM, and washed with citric acid (2X 50 mL), and saturated NaHC03 (2X 50 mL). The organic layer was dried with Na2S04, concentrated down then purified via silica gel chromatography (DCM to 2% MeOH (0,5 N NH3) to yield 515 mg (65% yield) of product as a viscous oil 1H NMR (400 MHz, CDC13) δ 7.89 (s, 1H), 7.85 - 7.70 (m, 2H), 7.68 - 7.49 (m, 4H), 7.47 - 7.37 (m, 2H), 7.35 - 7.20 (m, 5H), 4.54 - 4.35 (m, 4H), 4.35 - 4.14 (m, 2H), 3.72 - 3.58 (m, 1H), 3.49 - 3.27 (m, 1H), 2.53 (s, 1H), 2.00 (dd, J = 8.1, 20.2, 1H), 1.25 (s, 9H); TLC: (9: 1 DCM:MeOH (0.5 N NH3)) R/=0.5; LRMS (ESI) 565.9(M+H)+.
(2S,4R)-l-(3-ethoxybenzoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2- carboxamide
Figure imgf000187_0001
To (2S,4i?)-(9H-fluoren-9-yl)methyl 4-(tert-butoxy)-2-((4-(oxazol-5-yl)benzyl)carbamoyl) pyrrolidine- 1-carboxylate (2,5 g, 3.61 mmol, 1.0 equiv) in 36 mL DCM was charged tris(2- aminoethyl)amine mol, 9.0 mmol, 2.5 equiv).□ (400 upon stirring for 3 h the cloudy mixture was diluted with silica gel and concentrated down. The material was then dry loaded to a silica gel column and purified (DCM to 5% MeOH (0.5 N NH3) in DCM) to yield 820 mg (67% yield) as a white solid. 1H NMR (501 MHz, CDC13) δ 8.02 (s, 1H), 7.90 (s, 1H), 7.60 (d, J= 8.1, 2H), 7.33 - 7.29 (m, 3H), 4.44 (d, J= 6.1, 2H), 4.21 - 4.07 (m, 1H), 3.97 (dd, J = 7.2, 8.7, 1H), 2.87 (d, J= 1 1.6, 1H), 2.80 (dd, J = 4.3, 11.6, 1H), 2.17 (dd, J= 10.2, 12.4, 1H), 2.11 - 1.94 (m, 1H), 1.16 (s, 9H); 13C NMR (126 MHz, CDC13) δ 174.88, 151.27, 150.40, 139.33, 128.07, 126.79, 124.63, 121.43, 73.65, 72.30, 59.95, 54.97, 42.51, 39.27, 28.38; TLC: (9:1 DCM MeOH (0.5 N NH3)) R 0.42; LRMS (ESI) 344.2 (M+H)+.
1H NMR (400 MHz, CD3OD) δ 7.42 - 7.28 (m, 4H), 7.28 - 7.12 (m, 2H), 7.10 - 6.77 (m, 2H), 4.71 (dt, J= 30.7, 15.3 Hz, 1H), 4.58 - 4.30 (m, 3H), 4.18 - 3.92 (m, 2H), 3.87 - 3.77 (m, 1H), 3.44 (d, J= 11.4 Hz, 1H), 2.38 - 2.24 (m, 1H), 2.15 - 2.03 (m, 1H), 1.55 - 1.23 (m, 3H). 13C NMR (126 MHz, CD3OD) δ 174.72, 172.63, 160.34, 138.72, 138.35, 133.82, 130.65, 130.11, 129.92, 129.55, 120.47, 118.08, 114.27, 113.89, 71.01, 64.71, 60.81, 59.80, 43.33, 39.29, 15.09. MS (ESI) 403.2 (M+H). General Method D: Representative Procedure:
VL217
Figure imgf000188_0001
(2S,4R)-4-(te/'i-butoxy)-l-(3-ethoxybenzoyl)-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2- carboxamide
Figure imgf000188_0002
3-Ethoxybenzoic acid (13.3 mg, 0.08 mmol, 1 eq), EDC (16.9 mg, 0.088 mmol, 1.1 eq) and HOBt (11.9 mg, 0.88 mmol, 1.1 eq) were dissolved in DCM (0.8 mL) at room temperature. DIPEA (0.0279 mL, 0.16 mmol, 2 eq) was added, followed by (2S,4i?)-4-(tert-butoxy)-N-(4- (oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide (33.0 mg, 0.096 mmol, 1.2 eq). The solution was stirred for 21 hours then diluted with EtO Ac and washed with 10% citric acid, saturated sodium bicarbonate and brine. The organic layer was dried over sodium sulfate, filtered and condensed. Purification by column chromatography (1 to 5% MeOH/DCM) gave a colorless oil (36.1 mg, 0.073 mmol, 92%). 1H NMR (400 MHz, CDC13) δ 7.90 (s, 1H), 7.61 (dd, J= 16.6, 6.9 Hz, 3H), 7.38 - 7.27 (m, 4H), 6.98 (dd, J= 16.0, 6.4 Hz, 3H), 4.92 (dd, J= 8.3, 4.7 Hz, 1H), 4.48 (d, J= 6.0 Hz, 2H), 4.43 - 4.31 (m, 1H), 4.03 (q, J= 7.0 Hz, 2H), 3.61 (dd, J = 10.9, 5.7 Hz, 1H), 3.31 (dd, J= 10.9, 4.4 Hz, 1H), 2.73 - 2.55 (m, 1H), 2.05 - 1.92 (m, 1H), 1.40 (t, J= 7.0 Hz, 3H), 1.13 (s, 9H). MS (ESI) 492.4 (M+H). VL217
Figure imgf000189_0001
(2S,4i?)-4-(tert-butoxy)-l-(3-ethoxybenzoyl)-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2- carboxamide (36.1 mg, 0.073 mmol, 1 eq) was dissolved in DCM (9 mL) at room temperature. TFA (1 mL) was added and the solution was stirred for 13 hours, then condensed. Purification by column chromatography (1 to 10% MeOH/DCM) gave a colorless oil (22.9 mg, 0.053 mmol, 72 %). 1H NMR (400 MHz, CD3OD) δ 8.24 (d, J= 12.0 Hz, 1H), 7.65 (dd, J= 28.0, 8.3 Hz, 2H), 7.47 (dd, J = 18.8, 10.6 Hz, 3H), 7.23 (ddd, J = 9.4, 4.6, 4.1 Hz, 3H), 7.09 - 6.87 (m, 2H), 4.75 (dd, J= 9.6, 7.7 Hz, 1H), 4.48 (dd, J= 49.7, 15.5 Hz, 3H), 4.06 (q, J = 7.0 Hz, 2H), 3.84 (dd, J = 11.5, 3.5 Hz, 1H), 3.44 (d, J = 11.5 Hz, 1H), 2.42 - 2.29 (m, 1H), 2.21 - 2.05 (m, 1H), 1.36 (dt, J = 24.0, 7.0 Hz, 3H). 13C NMR (101 MHz, CD3OD) δ 174.78, 172.66, 160.35, 153.14, 152.74, 140.85, 138.38, 130.66, 129.00, 127.71, 125.62, 121.77, 120.50, 118.08, 114.30, 71.02, 64.71, 60.85, 59.82, 43.72, 39.32,
Figure imgf000189_0002
(2S,4R)-tert-butyl 4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl) pyrrolidine- 1-carboxylate
Figure imgf000189_0003
(2>S',4i-)-l-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (366 mg, 1.58 mmol, 1 equiv.) was dissolved in 15 mL DMF and charged with EDC (380 mg, 2.0mmol 1.3 equiv,), and HOBt (310 mg, 2.0 mmol, 1.5 equiv) after 5 minutes of stirring (4-(4- methylthiazol-5-yl)phenyl)methanamine (325 mg, 1.58 mmol, 1 equiv) was added. Upon stirring for 15 h the reaction was diluted with 25 mL EtOAc, and washed with 25 mL brine (2X), followed by 25 mL Sat. NaHC03 (2X). The organic layer was concentrated down to yield 650 mg (98 % yield) of the product as a yellow oil. 1H NMR (400 MHz, CDC13) δ 8.67 (s, 1H), 7.43 - 7.29 (m, 4H), 4.49 (d, J= 16.7 Hz, 4H), 3.51 (dd, J= 11.0, 4.7 Hz, 2H), 2.61 - 2.45 (m, 4H), 2.03 (d, J= 7.4 Hz, 2H), 1.42 (s, 9H).TLC: (9:1 DCM:MeOH (0.5 N NH3)) Rr0.20; MS (ESI) 417.5 (M+H)+.
(2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
Figure imgf000190_0001
To (2S,4R)-tert-butyl 4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl) pyrrolidine- 1-carboxylate ( 650 mg, 1.40 mmol, 1 equiv) in a round bottom flask was charged 9 mL 4M HCL in dioxanes (36 mmol, 26 equiv). The reaction was left to stir for lh upon which time N2 was bubbled through for 1 h and the volatiles were removed by vacuum. The resulting viscous oil was washed dissolved in water and washed with 50 mL EtOAC. The aqueous layer was then basified to pH 12 with 1 M NaOH, and then extracted with 50 mL EtOAC (3X). The organic layer was dried and concentrated down to yield 250 mg (79% yield) of product as a brown viscous oil. 1H NMR (501 MHz,CDCl3) δ 8.66 (s, 1H), 8.18 (t, J= 6.0, 1H), 7.38 (d, J= 8.1, 2H), 7.30 (d, J= 8.1, 2H), 4.48 - 4.37 (m, 3H), 4.08 (t, J= 8.4, 1H),
3.02 (d, J= 13.3, 1H), 2.79 (dd, J= 3.2, 12.3, 1H), 2.51 (s, 3H), 2.33 (dd, J= 8.6, 13.9, 1H),
2.03 - 1.87 (m, 1H); 13C NMR (126 MHz, CDC13) δ 174.89, 150.35, 148.46, 138.30, 131.54, 130.95, 129.51, 127.92, 72.90, 59.72, 55.35, 42.53, 39.98, 16.06; TLC: (9:1 DCM:MeOH) R ).l ; LRMS (ESI) 317.4 (M+H)+. General Method E: Representative Procedure: VL219
Figure imgf000191_0001
3-ethoxybenzoic acid (17 mg, 0.1 mmol, 1 equiv.) was dissolved in 1 mL 10:1 DCM:DMF and charged with EDC (25 mg, 0.13 mmol 1.3 equiv,), and HOBt (21 mg, 0.13 mmol, 1.3 equiv). After 5 minutes of stirring (2S,4i?)-4-hydroxy-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide (31 mg, 0.095 mmol, 1 equiv) was added. Upon stirring for 18 h the reaction was diluted with 15 mL EtO Ac and washed with 25 mL 10% aqueous citric acid and 25 mL saturated NaHC03. The organic layer was dried with Na2S04 and concentrated by vacuum. The resultant oil was purified by silica gel chromatography (DCM to 9% MeOH (0.5 N NH3) in DCM) to yield 25 mg (56 % yield) of the product as a white solid. 1H NMR (501 MHz, CD3OD) 5 8.87 (s, 1H), 7.51 - 7.42 (m, 4H), 7.37 (t, J= 8.1, 1H), 7.23 - 7.14 (m, 2H), 7.05 (dd, J= 2.2, 8.4, 1H), 4.79 (dd, J= 7.7, 9.5, 1H), 4.63 - 4.40 (m, 3H), 4.08 (q, J= 7.0, 2H), 3.86 (dt, J= 3.8, 7.6, 1H), 3.47 (d, J= 11.5, 1H), 2.47 (s, 3H) 2.36 (dd, J= 7.6, 13.2, 1H), 2.14 (ddd, J= 5.3, 10.2, 16.4, 1H), 1.41 (t, J= 7.0, 3H); 13C NMR (126 MHz, CD3OD) δ 174.74, 172.64, 160.34, 152.78, 149.05, 140.21, 138.40, 133.39, 131.55, 130.65, 130.44, 128.83, 120.49, 118.07, 1 14.32, 71.02, 64.71, 60.83, 59.81, 43.67, 39.30, 15.79, 15.06; TLC: (9:1 DCM:MeOH (0.5 N NH3)) R/=0.25; LRMS (ESI) 466.1(M+H)+.
VL210
Figure imgf000192_0001
VL210 was synthesized according to General Method D. 1H NMR (500 MHz, CD3OD) δ 8.23 (s, 1H), 7.82 (t, J = 1.7, 1H), 7.73 - 7.58 (m, 4H), 7.49 - 7.33 (m, 4H), 4.76 (dd, J = 7.6, 9.6, 1H), 4.59 - 4.32 (m, 3H), 3.84 (dd, J = 3.5, 11.4, 1H), 3.41 (d, J = 11.3, 1H), 2.43 - 2.30 (m, 1H), 2.18 - 2.07 (m, 1H); 13C NMR (126 MHz, CD3OD) δ 173.14, 169.54, 151.35, 139.41, 137.87, 133.28, 130.18, 130.01, 127.92, 127.61, 126.31, 125.93, 124.23, 121.93, 120.36, 69.62, 59.53, 58.30, 42.31, 37.95; LRMS (ESI) 471.5 (M+H)+.
VL224
Figure imgf000192_0002
VL224 was synthesized according to General Method E. *H NMR (501 MHz, CD3OD) δ 8.87 (s, 1H), 7.83 (d, J= 1.5, 1H), 7.67 (d, J= 7.1, 1H), 7.61 (d, J= 6.7, 1H), 7.48 - 7.36 (m, 5H), 4.77 (t, J= 8.5, 1H), 4.60 - 4.39 (obscured m, 3H), 3.90 - 3.78 (m, 1H), 3.42 (d, J= 11.4, 1H), 2.47 (s, 3H), 2.41 - 2.30 (m, 1H), 2.19 - 2.06 (m, 1H); 13C NMR (126 MHz, CD3OD) 5 173.15, 169.55, 151.41, 147.64, 138.77, 137.85, 133.26, 132.78, 131.98, 130.16, 130.02, 129.05, 127.43, 125.91, 121.93, 69.64, 59.53, 58.32, 42.27, 37.94, 14.41; TLC: (9:1 DCM:MeOH (0.5 N NH3)) R/=0.7; LRMS (ESI) 499.8(M+H)+.
VL215
OH
Figure imgf000193_0001
VL215 was synthesized according to General Method D. 1H NMR (501 MHz, CD3OD) δ 8.24 (dd, J= 13.4, 7.1 Hz, 1H), 7.87 - 7.58 (m, 3H), 7.58 - 7.31 (m, 4H), 7.16 (s, 1H), 4.73 (d, J= 7.8 Hz, 1H), 4.63 - 4.50 (m, 1H), 4.49 - 4.29 (m, 2H), 3.80 (d, J= 10.5 Hz, 1H), 3.60 (s, 1H), 2.31 (s, 1H), 2.17 (s, 1H). 13C MR (126 MHz, CD3OD) δ 179.37, 169.61, 153.12, 152.75, 140.72, 138.21, 137.16, 133.72, 130.38, 129.70, 129.40, 129.08, 127.76, 125.63, 121.80, 70.64, 60.46, 58.42, 43.80, 39.27. MS (ESI) 504.2 (M+H).
VL228
Figure imgf000193_0002
VL228 was synthesized according to General Method E. NMR (400 MHz, CD3OD) δ 8.88 (d, J= 9.3 Hz, 1H), 7.75 (d, J= 1.9 Hz, 1H), 7.48 (ddd, J= 13.9, 8.4, 4.1 Hz, 5H), 7.17 (d, J = 8.3 Hz, 1H), 4.74 (t, J= 8.2 Hz, 1H), 4.63 - 4.33 (m, 3H), 3.61 (dd, J= 11.3, 3.8 Hz, 1H), 3.18 (d, J= 11.3 Hz, 1H), 2.49 (d, J= 9.6 Hz, 3H), 2.33 (ddd, J= 7.8, 4.8, 2.1 Hz, 1H), 2.19 (ddd, J= 11.9, 7.8, 4.6 Hz, 1H). 13C NMR (126 MHz, CD3OD) δ 173.93, 169.45, 152.84, 149.07, 140.11, 138.21, 137.17, 133.73, 131.62, 130.53, 130.48, 130.39, 129.52, 129.41, 128.93, 70.65, 60.48, 58.39, 43.75, 39.26, 15.81. MS (ESI) 534.4 (M+H).
VL177 OH
Figure imgf000194_0001
VL177 was synthesized according to General Method D. 'H NMR (500 MHz,
CDC13/CD30D) δ 7.89 (s, 1H); 7.84 (s, 1H); 7.80-7.75 (m, 2H); 7.69 (d, J= 7.8 Hz, 1H); 7.57-7.48 (m, 3H); 7.31 (d, J= 8.1 Hz, 2H); 4.76 (t, J= 8.3 Hz, 1H); 4.49-4.39 ( m, 3H); 3.72 (dd, J= 11.2, 3.5 Hz, 1H); 3.36 (d, J= 1 1.2 Hz, 1H); 2.93 (s, 1H); 2.31 (ddd, J= 13.2, 8.8, 4.4 Hz, 1H); 2.21 (dd, J= 13.5, 7.8 Hz, 1H). 13C NMR (125MHz, CDC13/CD30D) 6 171.8, 169.0, 151.5, 150.6, 138.9, 137.0, 133.9, 131.9, 131.3, 129.5, 128.1, 126.7, 124.7, 121.1, 117.9, 112.7, 69.9, 59.3, 58.5, 43.3, 37.4. TLC (10% MeOH in CH2C12), Rf 0.17 (UV,
CAM), MS (ESI+): calculated for C23H21N404 [M+H]+ 417.2, found 417.1.
VL226
Figure imgf000194_0002
VL226 was synthesized according to General Method E. 1H NMR (500 MHz,
CDC13/CD30D) δ 8.65 (s, 1H); 7.84 (s, 1H); 7.74 (dd, J= 13.3, 7.8 Hz, 2H); 7.53 (t, J= 7.8 Hz, 1H); 7.40-7.28 (m, 5H); 4.92 (t, J= 8.1 Hz, 1H); 4.53 (s, 1H); 4.48 (d, J= 5.9 Hz, 2H); 3.72 (dd, J= 11.3, 3.5 Hz, 1H); 3.52-3.44 (m, 1H); 2.85 (br s, 1H); 2.67-2.56 (m, 1H); 2.48 (s, 3H); 2.21 (dd, J= 13.5, 7.8 Hz, 1H). 13C NMR (125MHz, CDC13/CD30D) δ 170.8, 169.4, 150.5, 148.6, 138.0, 137.0, 134.1, 131.9, 131.4, 129.7, 129.6, 127.0, 118.0, 113.0, 70,4, 59.1, 58.6, 43.5, 36.8, 16.2. TLC (10% MeOH in CH2C12), Rf 0.32 (UV, CAM), MS (ESI+):
calculated for C24H23N403S [M+H]+ 447.2, found 447.0.
VL211
Figure imgf000195_0001
VL211 was synthesized according to General Method D. 1H NMR (500 MHz, CD3OD) δ 8.11 (s, 1H), 7.58 (dd, J = 23, 8.2, 2H), 7.42 - 7.30 (m, 3H), 7.16 (t, J = 7.9, 1H), 6.96 (d, J= 7.7, 1H), 6.92 (s, 1H), 6.80 (dd, J = 2.3, 8.1, 1H), 4.65 (t, J = 8.6, 1H), 4.47 - 4.26 (m, 3H), 3.71 (dt, J = 4.0, 8.0, 1H), 3.36 (d, J = 1 1.6, 1H), 2.32 - 2.16 (m, 1H), 2.08 - 1.94 (m, 1H); 13C NMR (126 MHz, CD3OD) δ 174.74, 172.77, 158.71, 153.14, 152.70, 140.83, 138.38, 130.62, 128.98, 127.69, 125.62, 121.75, 119.39, 118.61, 115.27, 71.01, 60.77, 59.79, 43.73, 39.25; TLC: (9:1 DCM:MeOH R =0.15; LRMS (ESI) 408.3 (M+H)+.
VL225
Figure imgf000195_0002
V1225 was synthesized according to General Method E. 1H NMR (501 MHz, CD3OD) δ 8.86 (s, 1H), 7.49 - 7.34 (m, 4H), 7.27 (t, J= 7.8, 1H), 7.11 - 7.00 (m, 2H), 6.93 - 6.84 (m, 1H), 4.77 (t, J= 8.5, 1H), 4.57- 4.38 (m, 3H), 3.84 (dd, J= 3.3, 11.5, 1H), 3.47 (d, J= 11.5, 1H), 2.46 (S, 3H) 2.34 (dd, J= 7.1, 12.5, 1H), 2.18 - 2.06 (m, 1H); I3C NMR (126 MHz, CD3OD) δ 173.35, 171.36, 157.31, 151.39, 147.62, 138.81, 136.95, 130.12, 129.21, 129.04, 127.62, 127.41 , 1 17.97, 117.19, 113.84, 69.61, 59.37, 58.41, 42.24, 37.85, 14.37; TLC: (9:1
DCM:MeOH) R 0.3; LRMS (ESI) 437.0 (M+H)+. VL178
Figure imgf000196_0001
VL178 was synthesized according to General Method D. 1H NMR (400 MHz, CD3OD) δ 8.84 (t, J= 5.9, 1H), 8.26 (d, J= 5.9, 1H), 7.73 (d, J= 8.3, 2H), 7.55 - 7.45 (m, 3H), 7.06 (t, J= 7.8, 1H), 6.86 - 6.76 (m, 1H), 6.68 (d, J= 7.3, 1H), 4.75 (t, J= 8.4, 1H), 4.66 - 4.35 (m, 3H), 3.55 (dd, J = 3.5, 11.6, 1H), 3.24 (d, J= 11.4, 1H), 2.41 - 2.26 (m, 1H), 2.21 - 2.10 (m, 4H); 13C NMR (126 MHz, CD3OD) δ 173.21, 172.03, 151.32, 145.03, 139.46, 137.30, 130.95, 127.61, 126.53, 126.29, 124.22, 123.96, 120.35, 116.31, 115.97, 74.46, 69.35, 58.72, 42.46, 38.02, 23.61; LRMS (ESI) 420.4 (M+H)+.
VL229
Figure imgf000196_0002
(25,4i?)-4-hydroxy-N-(4-(4-rnethylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (24mg, 0.0756 mmol, 1 eq), 3-amino-2-methylbenzoic acid (13 mg, 0.083 mmol, 1.1 eq), EDC (16 mg, 0.083 mmol, 1.1 eq) and HOBt (1 1 mg, 0.083 mmol, 1.1 eq) were dissolved in DMF (0.76 mL) at room temperature. DIPEA (0.02 mL, 0.113 mmol, 1.5 eq) was added, and the solution was stirred for 17 hours. The solution was then partitioned between 1M NaOH and EtOAc, separated, and extracted twice more with EtOAc. The combined organic layer was dried over sodium sulfate, filtered and condensed. Purification by column chromatography (1 to 10 % 0.5N methanolic ammonia/DCM) gave a white solid (20.5 mg, 0.045 mmol, 60%). 1H NMR (501 MHz, CD3OD) δ 8.87 (t, J= 6.6 Hz, 1H), 7.45 (dt, J= 20.5, 7.7 Hz, 4H), 7.03 (t, J= 7.6 Hz, 1H), 6.78 (d, J= 7.8 Hz, 1H), 6.65 (s, 1H), 4.74 (t, J= 8.1 Hz, 1H), 4.67 - 4.34 (m, 3H), 3.53 (d, J= 11.3 Hz, 1H), 3.21 (d, J= 9.3 Hz, 1H), 2.48 (d, J= 3.1 Hz, 3H), 2.32 (d, J = 7.6 Hz, 1H), 2.14 (dd, J = 31.4, 20.5 Hz, 4H). 13C NMR (126 MHz, CD3OD) δ 174.56, 173.67, 152.89, 152.81, 149.04, 147.80, 140.23, 138.57, 133.44, 131.54, 130.46, 128.86, 127.83, 117.01, 1 16.36, 70.77, 69.66, 60.09, 43.70, 39.41, 15.81, 13.92. MS (ESI) 450.6 (M+H), 473.4 (M+Na).
For further reference see the following articles and the references cited therein:
(1) Buckley DL et al. J. Am. Chem. Soc 2012, 134, 4465-4468.
(2) Van Molle I et al. A Chemistry & Biology 2012, 19, 1300-1312
(3) Buckley, D Angew. Chem. Int. Ed., 2012, 51, 11463-11467
(4) Buckley, D. Let al. Angew. Chem. 2012, 124, 11630-11634.
Examples- Compounds 165-266 of Affinity Table II
The following compounds were synthesized according to the stated General Method, were purified by standard chromatographic methods and had !H and 13C NMR and MS data consistent with the desired structure.
VL165:
Figure imgf000197_0001
VL165 was synthesized according to General Method B. VL168 & 169
The chiral RHS amine fragment was synthesized using the procedure from Surya Prakash, G.
K.; Mandal, M.; Olah, G. A. Angew. Chem. Int. Ed. 2001, 40, 589-690.
Figure imgf000197_0002
I VL168 was synthesized according to General Method F
Figure imgf000198_0001
VL169 was synthesized according to General Method F VL174
Figure imgf000198_0002
VL174 General Method C
VL175: General Method C
Figure imgf000198_0003
C
Figure imgf000198_0004
VL190: General Method B
Figure imgf000199_0001
ı98
Figure imgf000200_0001
VL187: General Method B
Figure imgf000200_0002
VL188: General Method B
Figure imgf000200_0003
VL189: General Method B
Figure imgf000200_0004
VL192-VL205: Solid Phase Synthesis General Method B
C
Figure imgf000200_0005
VL207 General Method C
Figure imgf000201_0001
VL212 General Method C
Figure imgf000201_0002
VL214 General Method C
Figure imgf000201_0003
VL218 General Method C
Figure imgf000201_0004
VL221 General Method C
Figure imgf000202_0001
201
Figure imgf000203_0001
VL230: General Method D
Figure imgf000203_0002
VL231: General Method E
Figure imgf000203_0003
VL238 : General Method B
Figure imgf000203_0004
VL240: General Method E
HO
AcHN o O
VL241 : General Method B
Figure imgf000204_0001
VL242: General Method E
Figure imgf000204_0002
VL243: General Method E
Figure imgf000204_0003
VL244: General Method B
Figure imgf000204_0004
VL245: General Method E
Figure imgf000204_0005
3-hydroxy-2-methylbenzoic acid (26.3 mg, 0.173 mmol, 1.1 eq), EDC (33.2 mg) and HOBt (23.4 mg) were dissolved in DCM (0.8 mL) and DMF (0.1 mL) at 4 °C. After 10 minutes, (2iS',4i?)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (0.5 mL of a 100 mg/mL solution in DCM) was added and the mixture was warmed to room temperature. After 21 hours, the mixture was diluted with 10 mL of half saturated sodium chloride and extracted thrice with 10 mL of EtOAc. The combined organic layer was dried over sodium sulfate, filtered and condensed. Purification by column chromatography (1 to 10%
MeOH/DCM) gave a white solid (29.2 mg, 0.0647, 41%). 1H NMR (400 MHz, MeOD) δ 8.93 - 8.82 (m, 1H), 7.55 - 7.36 (m, 4H), 7.10 (t, J= 7.8 Hz, 1H), 6.83 (dd, J= 10.3, 7.9 Hz, 2H), 4.76 (t, J= 8.4 Hz, 1H), 4.66 - 4.38 (m, 3H), 3.56 (dd, J= 11.6, 3.6 Hz, 1H), 3.22 (d, J = 11.6 Hz, 1H), 2.54 - 2.47 (m, 3H), 2.41 - 2.31 (m, 1H), 2.19 (dt, J= 11.3, 10.9 Hz, 4H). 13C NMR (126 MHz, MeOD) δ 174.50, 173.09, 157.22, 152.89, 152.80, 149.01, 140.21, 139.18, 133.42, 131.52, 130.44, 128.85, 127.94, 117.84, 116.42, 70.73, 69.62, 60.12, 43.69, 39.38, 15.79, 12.70. MS (ESI) 452.5 (M+H).
VL247: General Method C
Figure imgf000205_0001
VL249: General Method E
Figure imgf000205_0002
VL250: General Method E
Figure imgf000205_0003
VL253: General Method C
Figure imgf000205_0004
VL254: General Method C
Figure imgf000206_0001
VL257: General Method C
Figure imgf000206_0002
VL258: General Method C
Figure imgf000206_0003
VL259: General Method C
Figure imgf000206_0004
VL260: General Method E
Figure imgf000206_0005
VL261 : General Method E
Figure imgf000206_0006
VL262: General Method E
Figure imgf000207_0001
VL263: General Method E
Figure imgf000207_0002
VL264: General Method E
Figure imgf000207_0003
VL265: General Method E
Figure imgf000207_0004
VL251
(25,,4i?)-l-((5)-2-((5 -2-acetarnido-4-rnethylpentanamido)propanoyl)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
Figure imgf000207_0005
tert-butyl ((S)- 1 -((25',4^)-4-hydroxy-2-((4-(4-methylthiazol-5 -yl)benzyl)carba- moyl)pyrrolidin- 1 -yl)- 1 -oxopropan-2-yl)carbamate
Figure imgf000208_0001
Boc-Ala-OH (189 mg, 1.0- mmol) was dissolved in 10 mL DCM and charged with EDC (248 mg, 1.2 mmol), and HOBt (202 mg, 1.3 mmol) after 5 minutes of stirring (25',4i?)-4-hydroxy- N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carb-oxamide (317 mg, 1.0 mmol) was added. Upon stirring for 18 h the reaction was diluted with 10 mL DCM and washed with 10 mL 10% aqueous citric acid followed by 5 mL saturated NaHC03. The mixture was concentrated down and purified by silica gel chromatography (DCM/MeOH gradient) to yield 210 mg (43 % yield) of the product as a white solid. 1H NMR (501 MHz, CDC13) δ
8.65 (s, 1H), 7.58 (s, 1H), 7.31 (d, J= 8.1, 2H), 7.26 (d, J= 8.0, 2H), 5.44 (d, J= 7.4, 1H),
4.66 (t, J= 7.6, 1H), 4.52 (s, 1H), 4.39 (m, 3H), 3.78 (d, J= 10.9, 1H), 3.59 (d, J= 7.0, 1H), 2.47 (s, 3H), 2.30 (s, 1H), 2.10 (s, 1H), 1.54 - 1.31 (m, 9H), 1.26 (d, J= 6.9, 3H); 13C NMR (126 MHz, CDC13) δ 173.1, 171.2, 155.5, 150.5, 148.2, 138.2, 130.7, 129.4, 127.6, 80.1, 70.1, 58.8, 55.2, 48.0, 42.3, 36.5, 28.3, 18.0, 16.0; LRMS (ESI) 489.4 (M+H)+.
VL251
(21S,,4i?)-l-((,S)-2-((S)-2-acetamido-4-methylpentanamido)propanoyl)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
Figure imgf000208_0002
Boc-Ala-Hyp-benzyl thiazole (116 mg, 0.225 mmol) was dissolved in 1 mL DCM and charged with 2.3 mL 4M HCL in dioxanes. Upon stirring for one hour Nitrogen gas was sparged through the mixture for 15 minutes and the remaining volatiles removed by roto vap. The resultant foam was then dissolved in 5 mL 1 : 1 DCM: DMF and charged with EDC (56 mg, 0.29 mmol), HOBt (45 mg, 0.29 mmol), and Ac-Leu-OH (43 mg, 0.25 mmol) were added. After stirring for 5 minutes triethyl amine was added. Upon stirring for 18 h the reaction was diluted with 10 mL EtOAc and washed with 10 mL 10% aqueous citric acid followed by 5 mL saturated NaHC03 The aqueous layer was then back extracted 2 X 10 mL DCM. The organic layers were combined and the mixture was concentrated down and purified by silica gel chromatography (DCM/MeOH gradient) to yield 35 mg (29 % yield) of the product as a white solid. 1H NMR (501 MHz, CDC13) δ 8.68 (s, 1H), 8.05 (s, 1H), 7.70 (s, 1H), 7.36 (d, J= 7.3, 2H), 7.28 (d, J= 8.6, 2H), 6.50 (s, 1H), 4.85 - 4.73 (m, 2H), 4.68 (s, 1H), 4.59 (s, 1H), 4.40 (d, J= 32.4, 2H), 3.84 (d, J= 10.7, 1H), 3.70 (d, J= 10.5, 1H), 2.51 (s, 3H), 2.30 (s, 1H), 2.21 (s, 1H), 1.85 (s, 3H), 1.59 (s, 1H), 1.50 (s, 2H), 1.34 (d, J = 6.7, 3H), 0.86 (t, J = 6.7, 6H); 13C NMR (126 MHz, CDC13) 5 172.1, 172.0, 171.2, 170.8, 150.4, 148.4, 138.1, 129.5, 129.4, 127.8, 110.0, 70.36, 58.9, 55.5, 51.8, 46.9, 43.1, 41.8, 36.9, 24.7, 23.2, 23.1, 21.8, 17.9, 16.0; LRMS (ESI) 545.1 (M+H)+.
VL252
(2S,4i?)-l-((S)-2-((5)-2-amino-4-methylpentanamido)propanoyl)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
Figure imgf000209_0001
Boc-Ala-Hyp-benzyl thiazole (116 mg, 0.225 mmol) was dissolved in 1 mL DCM and charged with 2.3 mL 4M HCL in dioxanes. Upon stirring for one hour Nitrogen gas was sparged through the mixture for 15 minutes and the remaining volatiles removed by roto vap. The resultant foam was then dissolved in 5 mL 1 : 1 DCM: DMF and charged with EDC (56 mg, 0.29 mmol), HOBt (45 mg, 0.29 mmol), and Boc-Leu-OH (62 mg, 0.25 mmol) were added. After stirring for 5 minutes triethyl amine was added. Upon stirring for 18 h the reaction was diluted with 10 mL EtOAc and washed with 10 mL 10% aqueous citric acid followed by 5 mL saturated NaHC03. The organic layers were combined and the mixture was concentrated to yield 55 mg (40 % yield) of the product as a white solid. LRMS (ESI) 602.0 (M+H)+. Upon confirmation by mass spec the product was dissolved in 2 mL 1 : 1
DCM:MeOH and charged with 3 mL 4M HC1 in dioxanes. Upon stirring for 45 minutes the reaction was quenched with 5 ml 0,5 N ammonia in methanol. The solvents were evaporated down and purified by silica gel chromatography (gradient of DCM/MeOH (0.5 N NH3) to yield 50 mg of pure product as a white solid. 1H NMR (501 MHz, CDC13) δ 8.25 (s, 1H), 6.91 (dd, J= 7.3, 18.0, 4H), 4.17 (d, J= 7.5, 2H), 4.06 (d, J= 22.4, 2H), 3.95 (d, J= 15.3, 1H), 3.56 - 3.42 (m, 2H), 3.24 (d, J= 7.8, 1H), 2.05 (s, 3H), 1.86 - 1.77 (m, 1H), 1.77 - 1.65 (m, 1H), 1.35 - 1.19 (m, 2H), 1.13 (s, 1H), .0.93 (d, J= 6.8, 3H), 0.50 (dd, J= 6.3, 9.8, 6H); 13C NMR (126 MHz, CDC13) δ 171.6, 171.5, 150.3, 147.7, 137.9, 131.4, 130.1, 129.0, 127.3, 109.9, 69.7, 58.6, 55.11, 46.9, 42.5, 36.7, 24.1, 22.4, 22.2, 16.2, 15.3; LRMS (ESI) 502.0 (M+H)+.
VL253: General Method C
Figure imgf000210_0001
VL254: General Method C
Figure imgf000210_0002
VL257: General Method C
Figure imgf000210_0003
VL258: General Method C
Figure imgf000211_0001
VL259: General Method C
Figure imgf000211_0002
VL260: General Method E
Figure imgf000211_0003
VL261 : General Method E
Figure imgf000211_0004
VL262: General Method E
Figure imgf000211_0005
VL263: General Method E
Figure imgf000212_0001
VL264: General Method E
Figure imgf000212_0002
VL265: General Method E
Figure imgf000212_0003
Examples for Compounds of Figure 15
The following procedures were used to synthesize and/or characterize compounds according to the present invention as indicated
LCMS Method :
The analysis was conducted on an Acquity UPLC BEH CI 8 column (50mm x 2.1mm internal diameter 1.7μηι packing diameter) at 40°C.
The solvents employed were:
A = 0.1% v/v solution of formic acid in water.
B = 0.1% v/v solution of formic acid in acetonitrile.
The gradient employed was as follows: Time Flow Rate
% A % B
(minutes) (mL/min)
0 1 97 3
1.5 1 0 100
1.9 1 0 100
2.0 1 97 3
The UV detection was an averaged signal from wavelength of 210nm to 350nm and mass spectra were recorded on a mass spectrometer using alternate-scan positive and negative mode electrospray ionization.
The following illustrates the mobile phases and gradients used when compounds underwent purification by mass-directed autopreparative HPLC.
Mass-Directed Autopreparative HPLC (Formic Acid Modifier)
The HPLC analysis was conducted on a Sunfire CI 8 column (150mm x 30mm internal diameter, 5μηι packing diameter) at ambient temperature.
The solvents employed were:
A = 0.1% v/v solution of formic acid in water.
B = 0.1% v/v solution of formic acid in acetonitrile.
Mass-Directed Autopreparative HPLC (Trifluoroacetic Acid Modifier)
The HPLC analysis was conducted on a Sunfire CI 8 column (150mm x 30mm internal diameter, 5μηι packing diameter) at ambient temperature.
The solvents employed were:
A = 0.1% v/v solution of trifluoroacetic acid in water. B = 0.1% v/v solution of trifluoroacetic acid in acetonitrile.
Mass-Directed Autopreparative HPLC (Ammonium Bicarbonate Modifier)
The HPLC analysis was conducted on an XBridge CI 8 column (150mm x 30mm internal diameter, 5μηι packing diameter) at ambient temperature.
The solvents employed were:
A = 10 mM ammonium bicarbonate in water adjusted to pH 10 with ammonia solution.
B = acetonitrile.
For each of the mass-directed autopreparative purifications, irrespective of the modifier used, the gradient employed was dependent upon the retention time of the particular compound undergoing purification as recorded in the analytical LCMS, and was as follows:
For compounds with an analytical LCMS retention time below 0.6 minutes the following gradient was used:
For compounds with an analytical LCMS retention time between 0.6 and 0.9 minutes the following gradient was used:
Figure imgf000214_0002
1 40 85 15
10 40 45 55
11 40 1 99
15 40 1 99
For compounds with an analytical LCMS retention time between 0.9 and 1.2 minutes the following gradient was used:
Figure imgf000215_0001
For compounds with an analytical LCMS retention time between 1.2 and 1.4 minutes the following gradient was used:
Figure imgf000215_0002
The UV detection was an averaged signal from wavelength of 210nm to 350nm and mass spectra were recorded on a mass spectrometer using alternate-scan positive and negative mode electrospray ionization. The chemical names were generated using ACD Name Pro version 6.02 from Advanced Chemistry Development, Inc.
Examples
(2S,4R)-l-(2-ethoxybenzoyl)-4-hydroxy-N-(4-(oxazol-5-yl)benzyl)pyrroIidine-2- carboxamide
Figure imgf000216_0001
A solution of 2-ethoxybenzoic acid (commercially available from for example Aldrich) (29 mg, 0.17 mmol), (2S,4R)-4-hydroxy-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide (50 mg, 0.17 mmol) and DIPEA (0.061 mL, 0.35 mmol) in DMF (1 mL) was treated with HATU (80 mg, 0.21 mmol) and the mixture was stirred at ambient temperature for 2 hours. The product was then subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (38 mg, 0.087 mmol, 50% yield). LCMS RT= 0.72 min, ES+ve m/z 436 [M+H]+.
Using a method analogous to that for (2S,4R)-l-(2-ethoxybenzoyl)-4-hydroxy-N-(4-(oxazol- 5-yl)benzyl)pyrrolidine-2-carboxamide, the following compounds were prepared:
Figure imgf000216_0002
HQ
(2S,4R)-1 -(3-cyanobenzoyl)- 4-hydroxy-N-(4-(oxazol-5- 0.64
57% 417 yl)benzyl)pyrrolidine-2- min
carboxamide
(2S,4R)-4-hydroxy-l-(3- HQ
isopropoxybenzoyl)-N-(4-
0.78
(oxazol-5- 53% 450 min yl)benzyl)pyrrolidine-2- carboxamide
HQ
(2S,4R)-1 -(3-acetylbenzoyl)- 4-hydroxy-N-(4-(oxazol-5- 0.63
47% 434 yl)benzyl)pyrrolidine-2- min carboxamide
(2S,4R)-4-hydroxy-l-(3- morpholinobenzoyl)-N-(4-
0.66
(oxazol-5- 63%
min 477 yl)benzyl)pyrrolidine-2- carboxamide
(2S,4R)-4-hydroxy-l-(3- HQ
isopropylbenzoyl)-N-(4-
0.82
(oxazol-5- 69% 434 min yl)benzyI)pyrrolidine-2- carboxamide
HQ
(2S,4R)-l-(3-chlorobenzoyl)- 4-hydroxy-N-(4-(oxazol-5- 0.73
65% 426 yl)benzyl)pyrrolidine-2- min carboxamide
HQ_
(2S.4R)- 1 -(3-bromobenzoyl)- 4-hydroxy-N-(4-(oxazol-5- 0.75 470,47
66%
yl)benzyl)pyrrolidine-2- min 2 carboxamide
(2S,4R)-l-(3-ethylbenzoyI)-4- hydroxy-N-(4-(oxazol-5- 0.77
55%
yl)benzyl)pyrrolidine-2- 420 min carboxamide
HQ
(2S,4R)-l-(3,5- diethoxybenzoyl)-4-hydroxy-
0.81
N-(4-(oxazol-5- 65% 480 min yl)benzyl)pyrrolidine-2- carboxamide
HQ
(2S,4R)-4-hydroxy-N-(4- (oxazol-5-yl)benzyl)- 1 -(3- 0.80
52% 450 propoxybenzoyl)pyrrolidine- min
2-carboxamide
(S)-l-((2S,4R)-4-hydroxy-2-((4-(oxazol-5-yl)benzyl)carbamoyl)pyrroIidin-l-yl)-l- oxopropan-2-yl acetate and (2S,4R)-4-hydroxy-l-((S)-2-hydroxypropanoyl)-N-(4- (oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide
Figure imgf000218_0001
A stirred mixture of (2S,4R)-4-hydroxy-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride (60 mg, 0.19 mmol) and (S)-2-acetoxypropanoic acid (commercially available from for example Aldrich) (25 mg, 0.19 mmol) in DMF (1.2 mL) was treated with DIPEA (0.13 mL, 0.74 mmol) and then with HATU (85 mg, 0.22 mmol) and the mixture was stirred at ambient temperature for 30 minutes. Half of the reaction mixture was then subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford (S)- 1 -((2S,4R)-4-hydroxy-2-((4-(oxazol-5-yl)benzyl)carbamoyl)pyrrolidin-l -yl)- 1 - oxopropan-2-yl acetate (21 mg, 0.052 mmol, 28 % yield). LCMS RT= 0.58 min, ES+ve m/z 402 [M+H]+.
The remaining half of the reaction mixture was treated with ammonia (2M solution in methanol) (2 mL), sealed and allowed to stand for 1 day. The solution was then evaporated to dryness and the product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford (2S,4R)-4-hydroxy-l-((S)-2-hydroxypropanoyl)-N-(4- (oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide (18 mg, 0.050 mmol, 27 % yield). LCMS RT= 0.53 min, ES+ve m/z 360 [M+H]+.
-benzyl 4-hydroxy-l-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylate
Figure imgf000218_0002
-cooled mixture of 2-(3-methylisoxazol-5-yl)acetic acid (commercially available from for example Aldrich) (0.91 g, 6.4 mmol) and (2S,4R)-benzyl 4-hydroxypyrrolidine-2- carboxylate, hydrochloride (1.67 g, 6.5 mmol) in DMF (9 mL) was treated with DIPEA (3.4 mL, 19 mmol) and then with HATU (2.56 g, 6.7 mmol) over 20 minutes. The mixture was stirred with cooling for 30 minutes and then overnight at ambient temperature. The mixture was then treated with saturated aqueous sodium bicarbonate (50 mL), extracted with dichloromethane (4 x 60 mL) and the combined organic phase was filtered through a hydrophobic frit and evaporated to dryness The product was purified by flash
chromatography (100 g cartridge) using a gradient elution from 0% to 15% methanol in dichloromethane to afford the title compound (2.3 g, 6.7 mmol, quantitative). LCMS RT= 0.75 min, ES+ve m/z 345 [M+H]+.
(2S,4R)-N-((3,4-dihydro-2H-benzo[b][l,4]oxazin-2-yl)methyl)-4-hydroxy-l-(2-(3- methylisoxazol-5-yI)acetyl)pyrrolidine-2-carboxamide
Figure imgf000219_0001
A solution of (2S,4R)-4-hydroxy-l-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylic acid (90 mg, 0.35 mmol), (3,4-dihydro-2H-benzo[b][l,4]oxazin-2-yl)methanamine
(commercially available from for example Fluorochem) (58 mg, 0.35 mmol) and DIPEA (0.155 mL, 0.89 mmol) in DMF (2 mL) was treated with HATU (139 mg, 0.37 mmol) and stirred for 1 hour. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (84 mg, 0.21 mmol, 60 % yield) LCMS RT= 0.61 min, ES+ve m/z 401 [M+H]+.
(2S,4R)-N-(4-chlorobenzyl)-4-hydroxy-l-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2- carboxamide
Figure imgf000219_0002
A solution of (4-chlorophenyl)methanamine (commercially available from for example Aldrich) (0.021 mL, 0.17 mmol) and (2S,4R)-4-hydroxy-l-(2-(3-methylisoxazol-5- yl)acetyl)pyrrolidine-2-carboxylic acid (40 mg, 0.16 mmol) in DMF (1 mL) was treated with DIPEA (0.082 mL, 0.47 mmol) then with HATU (66 mg, 0.17 mmol) and the mixture was stirred at ambient temperature for 2 hours. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (24 mg, 0.064 mmol, 40 % yield). LCMS RT= 0.73 min, ES+ve m/z 378 [M+H]+.
(2S,4R)-4-hydroxy-l-(2-(3-methylisoxazol-5-yl)acetyl)-N-(4-(2-oxo-2,3- dihy drobenzo [d] oxazol-5-y l)benzyl)py rrolidine-2-carboxamide
Figure imgf000220_0001
A mixture of (2S,4R)-4-hydroxy-l-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylic acid (60 mg, 0.24 mmol) and 5-(4-(aminomethyl)phenyl)benzo[d]oxazol-2(3H)-one, hydrochloride (65 mg, 0.24 mmol) in DMF (1.6 mL) was treated with DIPEA (0.124 mL, 0.71 mmol) and HATU (99 mg, 0.26 mmol) and the mixture was stirred for 30 minutes. The product was then subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (64 mg, 0.13 mmol, 57% yield). LCMS RT= 0.70 min, ES+ve m/z 477 [M+H]+.
(2S,4R)-N-(l-(benzofuran-2-yl)ethyI)-4-hydroxy-l-(2-(3-methyIisoxazol-5- yl)acetyl)pyrrolidine-2-carboxamide
Figure imgf000220_0002
A stirred solution of (2S,4R)-4-hydroxy-l-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2- carboxylic acid (90 mg, 0.35 mmol), l-(benzofuran-2-yl)ethanamine (commercially available from for example Enamine) (57 mg, 0.35 mmol) and DIPEA (0.155 mL, 0.89 mmol) in DMF (2 mL) was treated with HATU (139 mg, 0.37 mmol). After 1 hour the product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (91 mg, 0.21 mmol, 65 % yield) LCMS RT= 0.79 min, ES+ve m/z 398 [M+H]+.
(2S,4R)-N-([l,l'-biphenyl]-4-ylmethyI)-4-hydroxy-l-(2-(3-methylisoxazol-5- yl)acetyl)pyrrolidine-2-carboxamide
Figure imgf000220_0003
A stirred mixture of (2S,4R)-4-hydroxy-l-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2- carboxylic acid (30 mg, 0.12 mmol) and [l,l'-biphenyl]-4-ylmethanamine (commercially available from for example Aldrich) (22 mg, 0.12 mmol) in DMF (0.8 mL) was treated with DIPEA (0.08 mL, 0.47 mmol) and then with HATU (49 mg, 0.13 mmol) and the mixture was stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (40 mg, 81% yield). LCMS RT= 0.86 min, ES+ve m/z 420 [M+H]+.
Using a method analogous to that for (2S,4R)-N-([l,l'-biphenyl]-4-ylmethyl)-4-hydroxy-l-
(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxamide the following compounds were prepared:
Figure imgf000221_0001
benzo[d] imidazol- 5- yl)methyl)pyrroli
dine-2- carboxamide
(2S,4R)-4- hydroxy-l-(2-(3- methylisoxazol-5- yl)acetyl)-N- 19% 0.39 min 395 (quinolin-7- ylmethyl)pyrrolidi
ne-2-carboxamide
(2S,4R)-4- hydroxy-l -(2-(3- methylisoxazol-5- yl)acetyl)-N-((4-
34% 0.72 min 427 phenylthiazol-2- yl)methyl)pyrroli
dine-2- carboxamide
(2S,4R)-4- hydroxy-l-(2-(3- methylisoxazol-5- yl)acetyl)-N-((l- phenylpyrrolidin- 35% 0.72 min 413 3- yl)methyl)pyrroli
dine-2- carboxamide
(2S,4R)-4- hydroxy-l-(2-(3- methylisoxazol-5- yl)acetyl)-N-((5- phenyl- 1,2,4- 31% 0.67 min 412 oxadiazol-3- yl)methyl)pyrroli
dine-2- carboxamide (2S,4R)-4- hydroxy-l -(2-(3- methylisoxazol-5- yl)acetyl)-N-((3- (p-tolyl)isoxazol- 56% 0.78 min 426 5- yl)methyl)pyrroli
dine-2- carboxamide
(2S,4R)-N-((S)-1- (4- chlorophenyl)ethy
l)-4-hydroxy-l -
58% 0.78 min 392 (2-(3- methylisoxazol-5- yl)acetyl)pyrrolidi
ne-2-carboxamide
(2S,4R)-N-((3-(4- chlorophenyl)- l,2,4-oxadiazol-5- yl)methyl)-4-
57% 0.81 min 446 hydroxy-l-(2-(3- methylisoxazol-5- yl)acetyl)pyrrolidi
ne-2-carboxamide
(2S,4R)-4- hydroxy-l-(2-(3- methylisoxazol-5- yl)acetyl)-N-((5-
66% 0.72 min 411 phenylisoxazol-3- yI)methyl)pyrroli
dine-2- carboxamide
(2S,4R)-4- hydroxy-l-(2-(3- methylisoxazol-5- yl)acetyl)-N-(4- 43% 0.60 min 413 (pyrrolidin-1- yl)benzyl)pyrrolid
ine-2- carboxamide
(2S,4R)-l-((S)-2-acetamidopropanoyl)-4-hydroxy-N-phenethylpyrrolidine-2- carboxamide
Figure imgf000224_0001
A stirred mixture of (2S,4R)-l-((S)-2-acetamidopropanoyl)-4-hydroxypyrrolidine-2- carboxylic acid (24 mg, 0.10 mmol) and 2-phenylethanamine (commercially available from for example Aldrich) (0.012 mL, 0.10 mmol) in DMF (0.8 mL) was treated with DIPEA (0.07 mL, 0.39 mmol) and then with HATU (45 mg, 0.12 mmol), and the mixture was stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass- directed automated preparative HPLC (formic acid modifier) to afford the title compound (25 mg, 72% yield). LCMS RT= 0.56 min, ES+ve m/z 348 [M+H]+.
Using a method analogous to that for (2S,4R)-l-((S)-2-acetamidopropanoyl)-4-hydroxy-N- phenethylpyrrolidine-2-carboxamide the following compounds were prepared:
Figure imgf000224_0002
Figure imgf000225_0001
(S)-l-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyI)carbamoyl)pyrrolidin-l-yl)- l-oxopropan-2-yl acetate & (2S,4R)-l-acetyl-4-hydroxy-N-(4-(4-methylthiazol-5- yl)benzyl)pyrroIidine-2-carboxamide
Figure imgf000225_0002
An ice-cooled mixture of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine- 2-carboxamide, hydrochloride (31 mg, 0.088 mmol) and (S)-2-acetoxypropanoic acid (commercially available from for example Aldrich) (8 xh, 0.09 mmol) in DMF (0.8 mL) was treated with DIPEA (0.074 mL, 0.42 mmol). HATU (34 mg, 0.088 mmol) was then added portion- wise over 10 minutes and the mixture was stirred at ambient temperature for 1 hour. The products were separated and purified by mass-directed automated preparative HPLC (formic acid modifier) to afford (S)-l-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidin-l-yl)-l-oxopropan-2-yl acetate (15 mg, 0.035 mmol, 41 % yield) LCMS RT= 0.64 min, ES+ve m/z 432 [M+H]+ and (2S,4R)-l-acetyl-4-hydroxy-N-(4- (4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (9 mg, 0.025 mmol, 30 % yield) LCMS RT= 0.57 min, ES+ve m/z 360 [M+H]+.
(2S,4R)-l-(2-(cyanomethyl)benzoyl)-4-hydroxy-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide
Figure imgf000226_0001
A stirred mixture of (2S,4R)-4-hydroxy-N-(4-(thiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (50 mg, 0.17 mmol) and 2-(cyanomethyl)benzoic acid (commercially available from for example Aldrich) (29 mg, 0.18 mmol) in DMF (0.7 niL) was treated with DIPEA (0.086 mL, 0.49 mmol) and then with HATU (69 mg, 0.18 mmol) and the mixture was stirred at ambient temperature for 10 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (31 mg, 0.067 mmol, 41 % yield). LCMS RT= 0.73 min, ES+ve m/z 461 [M+H]+.
Using a method analogous to that for (2S,4R)-l-(2-(cyanomethyl)benzoyl)-4-hydroxy-N-(4- (4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide the following compounds were prepared:
Figure imgf000226_0002
22S
Figure imgf000227_0001
carboxamide (2S,4R)-4-hydroxy- 1 -((S)-2- methoxypropanoyl)-N-(4-(4- HO,
methylthiazoI-5- f t 0.57
69% 404 yl)benzyl)pyrrolidine-2- min
carboxamide
(2S,4R)-4-hydroxy-l-(3- methoxybenzoyl)-N-(4-(4- HQ
methylthiazol-5- f t 0.71
67% 452 yl)benzyl)pyrrolidine-2- min
carboxamide
(2S,4R)-4-hydroxy-l-(2- methylbenzoyl)-N-(4-(4- HQ
methylthiazol-5- f t 77% 0.74
436 yl)benzyl)pyrrolidine-2- min
carboxamide
(2S,4R)-4-hydroxy-l-(3- methoxy-2-methylbenzoyl)-N- HQ.
(4-(4-methylthiazol-5 - f 0.76
61% 466 yl)benzyl)pyrrolidine-2- min
carboxamide
(2S,4R)-l-(3-chloro-5- HQ,
methoxybenzoyl)-4-hydroxy- Π S
N-(4-(4-methylthiazol-5 - 69% 0.80
486 yl)benzyl)pyrrolidine-2- min
carboxamide
Ci
(2S,4R)-4-hydroxy-l-(3- hydroxy-2-methylbenzoyl)-N- HQ f t
(4-(4-methylthiazol-5- 84% 0.64
452 yl)benzyl)pyrrolidine-2- min
carboxamide
Single
enantiomer,
stereochemistr
(2S,4R)-4-hydroxy-N-(4-(4- y unknown at
methylthiazol-5-yl)benzyl)- 1 - H¾ the unspecified
(2-(3- Π chiral centre, 32% 0.59
473 oxomorphoIino)propanoyl)pyr min
eluted first
rolidine-2-carboxamide during HPLC
0 1 purification
(formic acid
modifier)
Figure imgf000229_0001
modifier)
Figure imgf000230_0001
Figure imgf000231_0001
(2S,4R)-l-(2- QH
cyclohexylpropanoyl)-4-
Mixture of
hydroxy-N-(4-(4- diastereoisome 0.87 methylthiazol-5- 68% 456 min rs
yl)benzyl)pyrrolidine-2- carboxamide
(2S,4R)- l-(2-((4- HI?
fluorophenyl)amino)propanoyl
Mixture of
)-4-hydroxy-N-(4-(4- .77
diastereoisome 41% 0 methylthiazol-5- 483 min rs
yl)benzyl)pyrrolidine-2- carboxamide
(2S,4R)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)- 1 - (2-( 1 -oxoisoindolin-2- 0.69
49% 491 min yl)acetyl)pyrrolidine-2- carboxamide
OH
(2S,4R)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)- 1 - Mixture of
(2-(pyrazolo[ 1 ,5-a]pyridin-3- diastereoisome 0.70
61% 490 yl)propanoyl)pyrrolidine-2- min
rs
carboxamide V-i 0 0 /
(2S,4R)-l-(2-(3- cyanophenyl)propanoyl)-4-
Mixture of
hydroxy-N-(4-(4- 0.77
diastereoisome 54%
methylthiazol-5- 475 min rs
yl)benzyl)pyrrolidine-2- carboxamide
Single
enantiomer,
stereochemistr
(2S,4R)-4-hydroxy-l-(2- y unknown at
methyl-4-oxo-4- the undefined
phenylbutanoyl)-N-(4-(4- 0.80
chiral centre, 35%
methylthiazol-5- 492 min eluted first
yl)benzyl)pyrrolidine-2- during HPLC
carboxamide
purification
(formic acid
modifier)
Single
enantiomer,
stereochemistr
(2S,4R)-4-hydroxy-l-(2- methyI-4-oxo-4- r y unknown at
phenylbutanoyl)-N-(4-(4- the undefined
0.82 chiral centre, 26%
methylthiazol-5- 492 min eluted second
yl)benzyl)pyrrolidine-2- u o during HPLC
carboxamide I
purification
(formic acid
modifier)
Single
QH enantiomer,
(2S,4R)-4-hydroxy-N-(4-(4- stereochemistr
methylthiazol-5-yl)benzyl)- 1 - y unknown at 0.78 (2- 44%
the undefined 450 min phenylpropanoyl)pyrrolidine- chiral centre,
2-carboxamide
eluted first
during HPLC purification
(formic acid
modifier)
Single
enantiomer,
QH stereochemistr
(2S,4R)-4-hydroxy-N-(4-(4- y unknown at
methylthiazol-5-yl)benzyl)- 1 - the undefined
0.80 (2- chiral centre, 41% 450 min phenylpropanoyl)pyrrolidine- eluted second
2-carboxamide during HPLC
purification
(formic acid
modifier)
Single
enantiomer,
QH stereochemistr
(2S,4R)-4-hydroxy-N-(4-(4- y unknown at
methylthiazol-5-yl)benzyl)- 1 - the undefined
0.62
(2-(2-oxopyridin- 1 (2H)- chiral centre, 33% 467 yl)propanoyl)pyrrolidine-2- min
eluted first
carboxamide during HPLC
purification
(formic acid
modifier)
Single
enantiomer,
stereochemistr
QH
(2S,4R)-4-hydroxy-l-(2- y unknown at
(indolin- 1 -yl)propanoyl)-N-(4- the undefined
(4-methylthiazol-5- 0.86
chiral centre, 35% 491 min yl)benzyl)pyrrolidine-2- eluted first
carboxamide during HPLC
purification
(formic acid
modifier)
Single
enantiomer,
stereochemistr
QH
(2S,4R)-4-hydroxy-l -(2- y unknown at
(indolin- 1 -yl)propanoyl)-N-(4- the undefined
0.88 (4-methylthiazol-5- chiral centre, 40% 491 yl)benzyi)pyrrolidine-2- min
eluted second
carboxamide during HPLC
purification
(formic acid
modifier)
(2S,4R)-4-hydroxy-l-(2- HO
methyl-3-
Mixture of
morpholinopropanoyl)-N-(4- 0.52
diastereoisome 57% 472 (4-methylthiazol-5- min
rs
yl)benzyl)pyrrolidine-2- carboxamide 0 0
(2S,4R)-4-hydroxy-N-(4-(4- HQ
methylthiazol-5-yl)benzyl)- 1 - (pyrazolo[ 1 ,5-a]pyridine-2- 0.68
64% 463 min carbonyl)pyrrolidine-2- carboxamide |
Figure imgf000234_0001
(2S,4R)-l-((S)-2-cyclopropyl- pH
2-( 1 -oxoisoindolin-2- yl)acetyl)-4-hydroxy-N-(4-(4- Single 0.80
62% 531 methylthiazol-5- enantiomer min yl)benzyl)pyrrolidine-2- carboxamide
(2S,4R)-4-hydroxy- 1 -((S)-3 - QH
methyl-2-( 1 -oxoisoindolin-2- yl)butanoyl)-N-(4-(4- Single 0.83
58% 533 methylthiazol-5- enantiomer min yl)benzyl)pyrrolidine-2- carboxamide
(2S,4R)-l -((S)-3,3-dimethyl- QH
2-( 1 -oxoisoindolin-2- yl)butanoyl)-4-hydroxy-N-(4- Single 0.91
52% 547 (4-methylthiazoI-5- enantiomer min yl)benzyl)pyrrolidine-2- carboxamide
3-(2-(2-(2-(3-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazoI-5- yl)benzyl)carbamoyl)pyrrolidine-l-carbonyl)phenoxy)ethoxy)ethoxy)ethoxy)propanoic acid
Figure imgf000235_0001
An ice-cooled mixture of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine- 2-carboxamide, hydrochloride (682 mg, 2.2 mmol), 3-((14,14-dimethyl-12-oxo-3,6,9,13- tetraoxapentadecyl)oxy)benzoic acid (778 mg, 2.0 mmol), DIPEA (1.36 mL, 7.8 mmol) in
DMF (12 mL) was treated with HATU (817 mg, 2.2 mmol). The mixture was allowed to
warm to ambient temperature and stirred for 30 minutes then treated with water (70 mL) and extracted with ethyl acetate (3 x 70 mL). The combined organic phase was washed with
saturated aqueous sodium bicarbonate (100 mL), water (100 mL), brine (100 mL), dried over magnesium sulfate, filtered and evaporated to dryness. The crude product was dissolved in
dichloromethane (6 mL) and treated with TFA (2.0 mL). After 1 hour, the reaction mixture was evaporated to dryness and the product was purified by flash chromatography (60 g CI 8 cartridge) using a gradient elution from 10 to 95% acetonitrile (+ 0.1% formic acid) in water
(+ 0.1% formic acid) to afford the title compound (568 mg, 45% yield). LCMS RT= 0.73 min, ES+ve m/z 642 [M+H]+.
(2S,4R)-4-hydroxy-l-(3-(2-methoxyethoxy)benzoyl)-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide
Figure imgf000236_0001
A mixture of (2S,4R)-4-hydroxy-l-(3-hydroxybenzoyl)-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide (55 mg, 0.13 mmol) and potassium carbonate (55 mg, 0.40 mmol) in DMF (0.8 mL) was treated with l-bromo-2-methoxyethane (commercially available from for example Aldrich) (0.024 mL, 0.25 mmol) and stirred at 50°C for 2.5 hours. Additional l-bromo-2-methoxyethane (0.024 mL, 0.25 mmol) was added and the mixture stirred at 50°C overnight. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (41 mg, 0.083 mmol, 66 % yield) LCMS RT= 0.74 min, ES+ve m/z 496 [M+H]+
(2S,4R)-4-hydroxy-l-(3-(2-(2-methoxyethoxy)ethoxy)benzoyI)-N-(4-(4-methyIthiazol-5- yl)benzyl)pyrrolidme-2-carboxamide
Figure imgf000236_0002
A mixture of (2S,4R)-4-hydroxy-l-(3-hydroxybenzoyl)-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide (55 mg, 0.13 mmol) and potassium carbonate (55 mg, 0.40 mmol) in DMF (0.8 mL) was treated with l-bromo-2-(2-methoxyethoxy)ethane
(commercially available from for example Aldrich) (0.034 mL, 0.25 mmol) and the reaction stirred at 50°C for 2.5 hours. Additional l-bromo-2-(2-methoxyethoxy)ethane (0.034 mL, 0.25 mmol) was added and the mixture stirred at 50°C overnight. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (40 mg, 0.074 mmol, 59 % yield) LCMS RT= 0.74 min, ES+ve m/z 540 [M+H]+. (2S,4R)-l-((S)-2-((S)-2-acetamido-4-methylpentanamido)propanoyl)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
Figure imgf000237_0001
A stirred mixture of (2S,4R)-l-((S)-2-aminopropanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (50 mg, 0.12 mmol) and (S)-2- acetamido-4-methylpentanoic acid (commercially available from for example Aldrich) (22 mg, 0.12 mmol) in DMF (0.7 mL) was treated with DIPEA (0.062 mL, 0.35 mmol) and then with HATU (49 mg, 0.13 mmol) and the mixture was stirred at ambient temperature for 10 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (42 mg, 0.077 mmol, 66 % yield). LCMS RT= 0.68 min, ES+ve m/z 544 [M+H]+.
(2S,4R)-l-((S)-2-acetamido-3-methylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide
Figure imgf000237_0002
A solution of tert-butyl ((S)-l-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidin-l-yl)-3 -methyl- l-oxobutan-2-yl)carbamate (120 mg, 0.23 mmol) in dichloromethane (2 mL) and treated with 4 M hydrochloric acid in 1,4-dioxane (1 mL). The mixture was stirred at ambient temperature for 30 minutes and was then evaporated to dryness. The residue was dissolved in DMF (1 mL) and treated with triethylamine (0.08 mL, 0.58 mmol), followed by acetic anhydride (0.02 mL, 0.21 mmol) and the mixture was stirred at ambient temperature for 1 hour. The product was subjected to purification by mass- directed automated preparative HPLC (formic acid modifier) to afford the title compound (53 mg, 49% yield). LCMS RT= 0.65 min, ES+ve m/z 460 [M+H]+.
Using a method analogous to that for (2S,4R)-l-((S)-2-acetamido-3-methylbutanoyl)-4- hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, the following compounds were prepared:
Figure imgf000238_0001
(2S,4R)-l-((S)-2-(3-ethoxy-N-methylbenzamido)propanoyl)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyI)pyrrolidine-2-carboxamide
Figure imgf000238_0002
A mixture of (2S,4R)-4-hydroxy-l-((S)-2-(methylamino)propanoyl)-N-(4-(4-methylthiazol- 5-yl)benzyl)pyrrolidine-2-carboxamide (20 mg, 0.05 mmol), DIPEA (0.043 mL, 0.25 mmol) and 3 -ethoxy benzoic acid (commercially available from for example Aldrich) (8 mg, 0.05 mmol) in DMF (1 mL) was treated with HATU (19 mg, 0.05 mmol) and the mixture was stirred for 20 minutes. The product was purified by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (14 mg, 0.025 mmol, 50 % yield). LCMS RT= 0.82 min, ES+ve m/z 551 [M+H]+.
(2S,4R)-4-hydroxy-l-((S)-2-(3-methoxypropanamido)propanoyl)-N-(4-(4-methylthiazol- 5-yl)benzyl)pyrroIidine-2-carboxamide
Figure imgf000239_0001
A solution of a mixture of (2S,4i?)-l-((S)-2-aminopropanoyl)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (107 mg, 0.25 mmol), 3-methoxypropionic acid (commercially available from for example Aldrich) (0.028 mL, 0.30 mmol) and DIPEA (0.2 mL, 1.15 mmol) in dry DMF (3 mL) was treated with HATU (115 mg, 0.30 mmol). The mixture was stirred at ambient temperature for 30 minutes. The mixture was loaded onto a methanol-preconditioned aminopropyl solid-phase extraction cartridge (2g), which was eluted with methanol (3 column volumes). The resulting eluant was evaporated to dryness and the product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (57 mg, 0.12 mmol, 48 % yield). LCMS RT= 0.62 min, ES+ve m/z 475 [M+H]+.
(2S,4R)-4-hydroxy-l-(2-(3-methoxypropanamido)-2-methylpropanoyI)-N-(4-(4- methylthiazol-5-yl)benzyl)pyrroIidine-2-carboxamide
Figure imgf000239_0002
A solution of a mixture of (2S,4i?)-l-(2-amino-2-methylpropanoyl)-4-hydroxy-7V-(4-(4- methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (95 mg, 0.24 mmol), 3- methoxypropionic acid (0.028 mL, 0.30 mmol) and DIPEA (0.2 mL, 1.15 mmol) in dry DMF (3 mL) was treated with HATU (115 mg, 0.30 mmol) and the mixture was stirred at ambient temperature for 30 minutes The mixture was loaded onto a methanol-preconditioned aminopropyl solid-phase extraction cartridge (NH2) which was eluted with methanol (3 column volumes). The resulting eluant was evaporated to dryness and the product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (45 mg, 0.09 mmol, 37 % yield). LCMS RT= 0.68 min, ES+ve m/z 489 [M+H]+.
(2S,4R)-4-hydroxy-l-((S)-2-(2-methoxyacetamido)-3-methylbutanoyl)-N-(4-(4- methylthiazoI-5-yI)benzyl)pyrrolidine-2-carboxamide
Figure imgf000240_0001
A mixture of (25,,4i?)-l-((S)-2-amino-3-methylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (20 mg, 0.044 mmol), 2-methoxyacetic acid (3 iL, 0.039 mmol) and DIPEA (0.035 mL, 0.20 mmol) in DMF (1 mL) was treated with HATU (18 mg, 0.047 mmol) and stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (14 mg, 0.029 mmol, 73 % yield). LCMS RT= 0.70 min, ES+ve m/z 489 [M+H]+.
(2S,4R)-4-hydroxy-l-((S)-2-(2-methoxy-iV-methylacetamido)-3-methylbutanoyI)-A'-(4-(4- methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
Figure imgf000240_0002
A mixture of (25,,4i?)-4-hydroxy-l-((S)-3-methyl-2-(methylamino)butanoyl)-N-(4-(4- methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (19 mg, 0.041 mmol), 2-methoxyacetic acid (3 μΕ, 0.039 mmol) and DIPEA (0.035 mL, 0.20 mmol) in DMF (1 mL) was treated with HATU (18 mg, 0.047 mmol) and stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (16 mg, 0.032 mmol, 81 % yield). LCMS RT= 0.70 min, ES+ve m/z 503 [M+H]+. (2S,4R)-l-((S)-2-( ,3-dimethyloxetane-3-carboxamido)propanoyI)-4-hydroxy-N-(4-(4-
Figure imgf000241_0001
A mixture of (2S,4R)-4-hydroxy-l-((S)-2-(methylamino)propanoyl)-N-(4-(4-methylthiazol- 5-yl)benzyl)pyrrolidine-2-carboxamide (15 mg, 0.037 mmol), DIPEA (0.032 mL, 0.18 mmol) and 3-methyloxetane-3-carboxylic acid (commercially available from for example
Fluorochem) (3 yLt 0.037 mmol) in DMF (1 mL) was treated with HATU (14 mg, 0.037 mmol) and the mixture was stirred for 1 hour. The product was purified by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (9 mg, 0.019 mmol, 51 % yield). LCMS RT= 0.62 min, ES+ve m/z 501 [M+H]+. boxamido)propanoyI)-N-(4-(4- de
Figure imgf000241_0002
A stirred mixture of (2S,4R)-l-((S)-2-aminopropanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide (21 mg, 0.043 mmol), DIPEA (0.043 mL, 0.25 mmol) and 3-methyloxetane-3-carboxylic acid (commercially available from for example
Fluorochem) (6 mg, 0.05 mmol) in DMF (2 mL) was treated with HATU (19 mg, 0.05 mmol) and stirred for 30 minutes. The product was purified by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (14 mg, 0.029 mmol, 60 % yield). LCMS RT= 0.59 min, ES+ve m/z 487 [M+H]+.
(2S,4R)-l-((S)-2-(3-ethoxybenzamido)propanoyl)-4-hydroxy-N-(4-(4-methyIthiazol-5- yI)benzyI)pyrrolidine-2-carboxamide
Figure imgf000241_0003
A stirred mixture of 3-ethoxybenzoic acid (commercially available from for example
Aldrich) (20 mg, 0.12 mmol) and (2S,4R)-l-((S)-2-aminopropanoyl)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (56 mg, 0.13 mmol) in DMF (3.2 mL) was treated with DIPEA (0.063 mL, 0.36 mmol) and then with HATU (50 mg, 0.13 mmol) and the mixture was stirred at ambient temperature for 30 minutes. The product was then subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (36 mg, 0.067 mmol, 56 % yield). LCMS RT= 0.80 min, ES+ve m/z 537 [M+H]+.
(2S,4R)-N-((lH-indol-3-yl)methyI)-4-hydroxy-l-((S)-2-(l-oxoisoindolin-2- yl)propanoyl)pyrrolidine-2-carboxamide
Figure imgf000242_0001
A solution of (2S,4R)-4-hydroxy-l-((S)-2-(l-oxoisoindolin-2-yl)propanoyl)pyrrolidine-2- carboxylic acid (10 mg, 0.031 mmol), DIPEA (0.038 mL, 0.22 mmol) and (lH-indol-3- yl)methanamine (commercially available from for example Fluorochem) (6 mg, 0.041 mmol) in DMF (0.8 mL) was treated with HATU (15 mg, 0.039 mmol) and stirred for 1 hour. The product was purified by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (3.1 mg, 6.9 μιηοΐ, 22 % yield). LCMS RT= 0.75 min, ES+ve m/z 447 [M+H]+.
(2S,4R)-N-((R)-2,3-dihydrobenzofuran-3-yl)-4-hydroxy-l-((S)-2-(l-oxoisoindolin-2- -yl)-
Figure imgf000242_0002
A mixture of 2,3 -dihydrobenzofuran-3 -amine (commercially available from for example Chem-Impex International, Inc.) (13 mg, 0.094 mmol) and (2S,4R)-4-hydroxy-l-((S)-2-(l- oxoisoindolin-2-yl)propanoyl)pyrrolidine-2-carboxylic acid (25 mg, 0.079 mmol) in DMF (0.8 mL) was treated with DIPEA (0.055 mL, 0.31 mmol) and then HATU (33 mg, 0.086 mmol) and the mixture was stirred at ambient temperature for 30 minutes. The product mixture was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compounds: Isomer 1 (first-eluting) (12 mg, 0.027 mmol, 35 % yield). LCMS RT= 0.73 min, ES+ve m/z 436 [M+H]+. Isomer 2 (second-eluting) (13 mg, 0.030 mmol, 38% yield). LCMS RT= 0.74 min, ES+ve m/z 436 [M+H]+. Using a method analogous to that for the two diastereoisomers of (2S,4R)-N-(2,3- dihydrobenzofuran-3 -yl)-4-hydroxy- 1 -((S)-2-( 1 -oxoisoindolin-2-yl)propanoyl)pyrrolidine-2- carboxamide, the following compounds were prepared:
Figure imgf000243_0001
Figure imgf000244_0001
(2S,4R)-4-hydroxy-N-(2-hydroxy-4-(4-methylthiazol-5-yI)benzyI)-l-((S)-3-methyl-2-(l- oxoisoindolin-2-yl)butanoyl)pyrrolidine-2-carboxamide
Figure imgf000244_0002
A mixture of (2S,4R)-4-hydroxy-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)pyrrolidine- 2-carboxamide, hydrochloride (125 mg, 0.34 mmol) and (S)-3-methyl-2-(l-oxoisoindolin-2- yl)butanoic acid (83 mg, 0.36 mmol) in DMF (1.6 mL) was treated with DIPEA (0.24 mL, 1.4 mmol) and HATU (140 mg, 0.37 mmol) and the mixture was stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (120 mg, 0.22 mmol, 65 % yield). LCMS RT= 0.81 min, ES+ve m/z 549 [M+H]+.
(2S,4R)-4-hydroxy-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)-l-((R)-3-methyl-2-(l- oxoisoindoIin-2-yl)butanoyl)pyrrolidine-2-carboxamide
Figure imgf000244_0003
A mixture of (2S,4R)-4-hydroxy-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)pyrrolidine- 2-carboxamide, hydrochloride (65 mg, 0.18 mmol) and (R)-3-methyl-2-(l-oxoisoindolin-2- yl)butanoic acid (43 mg, 0.19 mmol) in DMF (1.6 mL) was treated with DIPEA (0.123 mL, 0.70 mmol) and HATU (74 mg, 0.19 mmol) and the mixture was stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (64 mg, 0.12 mmol, 66 % yield). LCMS RT= 0.80 min, ES+ve m/z 549 [M+H]+. tert-butyl ((S)-l-((2R,4S)-4-hydroxy-2-((4-(4-methyIthiazol-5- yl)benzyl)carbamoyl)pyrrolidin-l-yl)-l-oxopropan-2-yl)(methyl)carbamate
Figure imgf000245_0001
A stirred mixture of (S)-2-((tert-butoxycarbonyl)(methyl)amino)propanoic acid (115 mg, 0.57 mmol) and (2R,4S)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (200 mg, 0.57 mmol) in DMF (0.7 mL) was treated with DIPEA (0.4 mL, 2.3 mmol) and then with HATU (215 mg, 0.57 mmol) and the mixture was stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (146 mg, 0.29 mmol, 51 % yield). LCMS RT= 0.84 min, ES+ve m/z 503 [M+H]+.
(2S,4R)-4-hydroxy-l-((S)-2-(3-methoxy-N-methylpropanamido)propanoyl)-N-(4-(4- methylthiazol-5-yl)benzyl)pyrroIidine-2-carboxamide
Figure imgf000245_0002
A stirred mixture of (2S,4R)-4-hydroxy-l-((S)-2-(methylamino)propanoyl)-N-(4-(4- methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (50 mg, 0.12 mmol) and 3- methoxypropanoic acid (commercially available from for example Aldrich) (0.013 mL, 0.14 mmol) in DMF (0.8 mL) was treated with DIPEA (0.087 mL, 0.50 mmol) and then with HATU (52 mg, 0.14 mmol). The mixture was stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (43 mg, 71% yield). LCMS RT= 0.61 min, ES+ve m/z 489 [M+H]+. (2S,4R)-4-hydroxy-l-((S)-2-((2-methoxyethyl)(methyl)amino)propanoyl)-N-(4-(4- methylthiazol-5-yI)benzyl)pyrrolidine-2-carboxamide
Figure imgf000246_0001
A stirred mixture of l-bromo-2-methoxy ethane (commercially available from for example Aldrich) (0.013 mL, 0.14 mmol) and (2S,4R)-4-hydroxy-l-((S)-2-(methylamino)propanoyl)- N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (50 mg, 0.12 mmol) in DMF (0.8 mL) was treated with DIPEA (0.054 mL, 0.31 mmol) and the mixture was stirred at 85 °C for 18 hours. The reaction mixture was cooled and the product was subjected to purification by mass-directed automated preparative HPLC (ammonium bicarbonate modifier) to afford the title compound (44 mg, 77% yield). LCMS RT= 0.51 min, ES+ve m/z 461 [M+H]+.
(2S,4R)-4-hydroxy-l-((S)-4-(2-methoxyacetyl)morpholine-3-carbonyl)-N-(4-(4- methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
Figure imgf000246_0002
A mixture of (2,S,4i?)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)-l-((S)-morpholine-3- carbonyl)pyrrolidine-2-carboxamide, hydrochloride (19 mg, 0.041 mmol), 2-methoxyacetic acid (3 μΐ, 0.039 mmol) and DIPEA (0.035 mL, 0.20 mmol) in DMF (1 mL) was treated with HATU (18 mg, 0.047 mmol) and stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (13 mg, 0.026 mmol, 66 % yield). LCMS RT= 0.60 min, ES+ve m/z 503 [M+H]+. (2S,4R)-N-(4-(2,4-dimethylthiazol-5-yI)benzyI)-4-hydroxy-l-(2-(3-methylisoxazol-5- yl)acetyl)pyrrolidine-2-carboxamide
Figure imgf000247_0001
A stirred mixture of (2S,4R)-N-(4-(2,4-dimethylthiazol-5-yl)benzyl)-4-hydroxypyrrolidine-2- carboxamide (30 mg, 0.09 mmol) and 2-(3-methylisoxazol-5-yl)acetic acid (commercially available from for example Aldrich) (13 mg, 0.09 mmol) in DMF (0.8 mL) was treated with DIPEA (0.063 mL, 0.36 mmol) and then with HATU (41 mg, 0.1 1 mmol) and stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass- directed automated preparative HPLC (formic acid modifier) to afford the title compound (26 mg, 63% yield). LCMS RT= 0.66 min, ES+ve m/z 455 [M+H]+.
(2S,4R)-l-((S)-2-acetamidopropanoyl)-N-(4-(2,4-dimethylthiazol-5-yl)benzyl)-4- hydroxypyrrolidine-2-carboxamide
Figure imgf000247_0002
A stirred mixture of (2S,4R)-N-(4-(2,4-dimethylthiazol-5-yl)benzyl)-4-hydroxypyrrolidine-2- carboxamide (30 mg, 0.09 mmol) and (S)-2-acetamidopropanoic acid (commercially available from for example Aldrich) (12 mg, 0.09 mmol) in DMF (0.8 mL) was treated with DIPEA (0.063 mL, 0.36 mmol) and then with HATU (41 mg, 0.11 mmol), and the mixture was stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (30 mg, 75% yield). LCMS RT= 0.58 min, ES+ve m/z 445 [M+H]+.
(2S,4R)-N-(4-bromobenzyl)-l-(3-ethoxybenzoyl)-4-hydroxypyrrolidine-2-carboxamide
Figure imgf000247_0003
An ice-cooled mixture of (2S,4R)-l-(3-ethoxybenzoyl)-4-hydroxypyrrolidine-2-carboxylic acid (73 mg, 0.26mmol) and (4-bromophenyl)methanamine, hydrochloride (commercially available from for example Aldrich) (58 mg, 0.26 mmol) in DMF (0.5 mL) was treated with a solution of DIPEA (0.145 mL, 0.83 mmol) in DMF (1 mL) and then with HATU (105 mg, 0.28 mmol) and stirred overnight at ambient temperature. The product was then subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (62 mg, 53% yield). LCMS RT= 0.90 min, ES+ve m/z 447,449 [M+H]+.
(2S,4R)-N-([l, -biphenyl]-4-ylmethyl)-l-(3-ethoxybenzoyl)-4-hydroxypyrrolidine-2- carboxamide
Figure imgf000248_0001
A mixture of (2S,4R)-l-(3-ethoxybenzoyl)-4-hydroxypyrrolidine-2-carboxylic acid (30 mg, 0.11 mmol) and [l,r-biphenyl]-4-ylmethanamine (commercially available from for example Aldrich) (20 mg, 0.11 mmol) in DMF (0.8 mL) was treated with DIPEA (0.075 mL, 0.43 mmol) and then with HATU (45 mg, 0.12 mmol) and stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (26 mg, 55% yield). LCMS RT= 0.98 min, ES+ve m/z 445 [M+H]+.
Using a method analogous to that for 2S,4R)-N-([l,l'-biphenyl]-4-ylmethyl)-l-(3- ethoxybenzoyl)-4-hydroxypyrrolidine-2-carboxamide, the following compounds were prepared:
Figure imgf000248_0002
Figure imgf000249_0001
(2S,4R)-4-hydroxy-l-(2-(3-methoxypropanamido)acetyl)-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide
Figure imgf000249_0002
A mixture of (2S,4R)-l-(2-aminoacetyl)-4-hydroxy-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide (134 mg, 0.33 mmol) and 3-methoxypropanoic acid (commercially available from for example Aldrich) (37 mg, 0.36 mmol) in DMF (0.8 mL) was treated with DIPEA (0.23 mL, 1.3 mmol) and then with HATU (136 mg, 0.36 mmol) and stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (36 mg, 24% yield). LCMS RT= 0.56 min, ES+ve m/z 461 [M+H]+.
(2S,4R)-l-((S)-3,3-dimethyl-2-(3-methyloxetane-3-carboxamido)butanoyl)-4-hydroxy-N- (4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
Figure imgf000250_0001
A stirred mixture of (2S,4R)-l-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (20 mg, 0.04 mmol) and 3-methyloxetane-3-carboxylic acid (commercially available from for example
Chemgenx) (5 mg, 0.04 mmol) in DMF (0.6 mL) was treated with DIPEA (0.03 mL, 0.17 mmol) and then with HATU (20 mg, 0.05 mmol), and the mixture was stirred at ambient temperature for 1 hour. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to give the title compound (18 mg, 80% yield). LCMS RT= 0.76 min, ES+ve m/z 529 [M+H]+.
Using a method analogous to that for (2S,4R)-l-((S)-3,3-dimethyl-2-(3-methyloxetane-3- carboxamido)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2- carboxamide, the following compounds were prepared:
Figure imgf000250_0002
Figure imgf000251_0001
carboxamide
(S)-N-((S)-l-((2S,4R)-4-hydroxy-2-((4-(4-methyIthiazoI-5- yl)benzyl)carbamoyl)pyrrolidin-l-yl)-3,3-dimethyl-l-oxobutan-2-yI)morpholine-3- carboxamide, hydrochloride
Figure imgf000251_0002
A mixture of (2S,4R)-l-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (40 mg, 0.086 mmol) and (S)-4-(tert- butoxycarbonyl)morpholine-3-carboxylic acid (commercially available from for example Astatech, Inc.) (20 mg, 0.086 mmol) in DMF (0.6 mL) was treated with DIPEA (0.06 mL, 0.35 mmol) and then with HATU (40 mg, 0.10 mmol) and stirred at ambient temperature for 1 hour. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to give the intermediate Boc-protected product. The intermediate was then dissolved in a mixture of dichloromethane (1 mL) and methanol (0.5 mL) and treated with 4M hydrochloric acid in 1,4-dioxane (0.4 mL, 1.6 mmol), After stirring at ambient temperature for 1 hour, the mixture was evaporated to dryness to afford the title compound (31 mg, 62% yield). LCMS RT= 0.60 min, ES+ve m/z 544 [M+H]+.
Using a method analogous to that for (S)-N-((S)-l-((2S,4R)-4-hydroxy-2-((4-(4- methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin- 1 -yl)-3,3-dimethyl- 1 -oxobutan-2- yl)morpholine-3-carboxamide, hydrochloride, the following compounds were prepared:
Figure imgf000251_0003
(S)-N-((S)-l-((2S,4R)-4- hydroxy-2-((4-(4- methylthiazol-5-
0.62
yl)benzyl)carbamoyl)pyrrolidi 54% 544
min
n-l-yl)-3,3-dimethyl-l- oxobutan-2-yI)morpholine-2- H Π
carboxamide, hydrochloride
0
N-((S)- 1 -((2S,4R)-4-hydroxy-
2-((4-(4-methylthiazol-5-
0.62- yl)benzyl)carbamoyl)pyrrolidi
52% 0.64 544 n-l-yl)-3,3-dimethyl-l - min
oxobutan-2-yl)morpholine-2- carboxamide, hydrochloride
° ^\
tert-butyl 4-((S)-l-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidin-l-yl)-l-oxopropan-2-yl)piperazine-l-carboxylate & tert-butyl 4-((R)-l-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazoI-5- yl)benzyl)carbamoyl)pyrroIidin-l-yl)-l-oxo ropan-2-yl) i erazine-l-carboxylate
Figure imgf000252_0001
A stirred mixture of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2- carboxamide, hydrochloride (100 mg, 0.28 mmol) and 2-(4-(tert-butoxycarbonyl)-2- oxopiperazin-l-yl)propanoic acid (85 mg, 0.31 mmol) in DMF (0.8 mL) was treated with DIPEA (0.20 mL, 1.13 mmol) and then with HATU (129 mg, 0.34 mmol) and then stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass- directed automated preparative HPLC (ammonium bicarbonate modifier) to afford the title compounds: Isomer 1 (first-eluting) (48 mg, 30 % yield). LCMS RT= 0.85 min, ES+ve m/z 572 [M+H]+. Isomer 2 (second-eluting) (51 mg, 32 % yield). LCMS RT= 0.86 min, ES+ve m/z 572 [M+H]+.
(2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)-l-((S)-2-(piperazin-l- yl)propanoyl)pyrrolidine-2-carboxamide, hydrochloride & (2S,4R)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)-l-((R)-2-(piperazin-l-yl)propanoyl)pyrrolidine-2- carboxamide, hydrochloride
Figure imgf000253_0001
Isomer 1 and isomer 2 of tert-butyl 4-(l-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidin- 1 -yl)- 1 -oxopropan-2-yl)piperazine- 1 -carboxylate (48 mg, 0.08 mmol) were separately dissolved in a mixture of dichloromethane (0.3 mL) and methanol (0.1 mL) and treated with 4M hydrochloric acid in 1,4-dioxane (0.3 mL, 1.2 mmol) respectively. After stirring at ambient temperature for 1 hour, the reaction mixtures were evaporated to dryness to afford the title compounds as hydrochloride salts. Isomer 1 (42 mg, 99 % yield). LCMS RT= 0.62 min, ES+ve m/z 472 [M+H]+. Isomer 2 (42 mg, 99 % yield). LCMS RT= 0.60 min, ES+ve m/z 472 [M+H]+.
(S)-N-((S)-l-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidin-l-yl)-3,3-dimethyl-l-oxobutan-2-yl)-4-(2- methoxyethyl)morpholine-2-carboxamide
Figure imgf000253_0002
A mixture of 1 -bromo-2-methoxyethane (4 xL, 0.04 mmol), (S)-N-((S)-l-((2S,4R)-4- hydroxy-2-((4-(4-methylthiazol-5 -yl)benzyl)carbamoyl)pyrrolidin- 1 -yl)-3 ,3 -dimethyl- 1 - oxobutan-2-yl)morpholine-2-carboxamide, hydrochloride (20 mg, 0.04 mmol) and DIPEA (0.019 mL, 0.11 mmol) in DMF (0.5 mL) was stirred at 85 °C for 6 hours. The cooled product was subjected to purification by mass-directed automated preparative HPLC (ammonium bicarbonate modifier) to afford the title compound (9 mg, 41% yield). LCMS RT= 0.88 min, ES+ve m/z 602 [M+H]+.
Using a method analogous to that for (S)-N-((S)-l-((2S,4R)-4-hydroxy-2-((4-(4- methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-l-yl)-3,3-dimethyl-l-oxobutan-2-yl)-4-(2- methoxyethyl)mo holine-2-carboxamide the following compounds were prepared:
Figure imgf000254_0001
Methyl 4-(((5)-l-(((S)-l-((2S,4R)-4-hydroxy-2-((4-(4-methyIthiazol-5- yl)benzyl)carbamoyl)pyrrolidin-l-yl)-l-oxopropan-2-yl)amino)-4-methyl-l-oxopentan-
2-yl)amino)-4-oxobutanoate
Figure imgf000255_0001
A mixture of (21S',4i?)-l-((S)-2-((1S)-2-amino-4-methylpentanamido)propanoyl)-4-hydroxy-N- (4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (102 mg, 0.19 mmol), DIPEA (0.165 mL, 0.95 mmol) and 4-methoxy-4-oxobutanoic acid (commercially available from for example Aldrich) (25 mg, 0.19 mmol) in DMF (2 mL) was treated with HATU (64 mg, 0.17 mmol) and the mixture was stirred at ambient temperature for 20 minutes. Brine (10 mL) was added and the product was extracted with ethyl acetate (20 mL). The organic phase was washed with brine (2 x 20 mL), dried using a hydrophobic frit and evaporated to dryness. The product was purified by chromatography on reverse phase silica using a gradient elution from 5% to 70% acetonitrile(+ 0.1% formic acid) in water(+ 0.1% formic acid) to afford the title compound (73 mg, 0.12 mmol, 63 % yield). LCMS RT= 0.74 min, ES+ve m/z 616 [M+H]+.
4-(3-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyI)pyrrolidine-l- carbonyl)phenoxy)butanoic acid (
Figure imgf000255_0002
A solution of tert-bv y\ 4-(3-((2S,4#)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-l-carbonyl)phenoxy)butanoate (130 mg, 0.22 mmol) in dichloromethane (3 mL) was treated with TFA (0.5 mL, 6.5 mmol) and stirred at ambient temperature for 5 hours. The solvent was evaporated to dryness and the product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (65 mg, 0.12 mmol, 55 % yield). LCMS RT= 0.70 min, ES+ve m/z 524 [M+H]+. 4-(((S)-l-(((5)-l-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyI)pyrrolidin-l-yl)-l-oxopropan-2-yl)amino)-4-methyl-l-oxopentan- 2-yl)amino)-4-oxobutanoic acid
Figure imgf000256_0001
A solution of methyl 4-(((5)-l-(((S)-l-((2S,4i?)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbanioyl)pyrrolidin- 1 -yl)- 1 -oxopropan-2-yl)amino)-4-methyl- 1 -oxopentan-2- yl)amino)-4-oxobutanoate (73 mg, 0.12 mmol) in methanol (3 mL) was treated with aqueous sodium hydroxide (2M, 0.6 mL, 1.2 mmol) and the mixture was stirred at ambient temperature for 2 hours. The mixture was evaporated to dryness and the product was purified by chromatography on reverse phase silica using a gradient elution from 5% to 60% acetonitrile(+ 0.1% formic acid) in water(+ 0.1% formic acid) to afford the title compound
(53 mg, 0.088 mmol, 74 % yield). LCMS RT= 0.69 min, ES+ve m/z 602 [M+H]+.
(2S,4R)-4-hydroxy-l-((5)-2-((S)-2-(2-methoxyacetamido)-4- methyIpentanamido)propanoyl)-iV-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2- carboxamide
Figure imgf000256_0002
A mixture of (25,,4i?)-l-((5)-2-((5)-2-amino-4-methylpentanamido)propanoyl)-4-hydroxy-N- (4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (30 mg, 0.056 mmol), 2-methoxyacetic acid (commercially available from for example Aldrich) (4.3 uL, 0.056 mmol) and DIPEA (0.05 mL, 0.29 mmol) in DMF (1 mL) was treated with HATU (25 mg, 0.066 mmol) and stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (18 mg, 0.031 mmol, 56 % yield). LCMS RT= 0.73 min, ES+ve m/z SI [M+H]+. W
(2S,4R)-4-hydroxy-l-((S)-2-((S)-2-(3-methoxypropanamido)-4- methylpentanamido)propanoyI)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2- carboxamide
Figure imgf000257_0001
A mixture of (2S',4i?)-l-((S)-2-((>S)-2-amino-4-methylpentanamido)propanoyl)-4-hydroxy-N- (4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (30 mg, 0.056 mmol), 3-methoxypropanoic acid (commercially available from for example Aldrich) (5.2 uL, 0.056 mmol) and DIPEA (0.05 mL, 0.29 mmol) in DMF (1 mL) and stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (20 mg, 0.034 mmol, 61 % yield). LCMS RT= 0.72 min, ES+ve m/z 588 [M+H]+. roxy-N-(4-(4-methylthiazol-5-
Figure imgf000257_0002
A mixture of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2- carboxamide, hydrochloride (58 mg, 0.16 mmol) and 6-fluoropicolinonitrile (commercially available from for example Aldrich) (20 mg, 0.16 mmol) in DMSO (1 mL) was treated with DIPEA (0.10 mL, 0.57 mmol), sealed and heated in a Biotage "Initiator" microwave at 100°C for 60 minutes. The product was purified by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (23 mg, 0.055 mmol, 34 % yield). LCMS RT= 0.74 min, ES+ve m/z 420 [M+H]+.
Intermediates
-(oxazol-5-yl)benzonitrile
Figure imgf000257_0003
A mixture of 4-formylbenzonitrile (commercially available from for example Aldrich) (5.32 g, 41 mmol), l-((isocyanomethyl)sulfonyl)-4-methylbenzene (commercially available from for example Aldrich) (8.83 g, 45 mmol) and potassium carbonate (7.3 g, 53 mmol) in methanol (200 mL) was stirred at ambient temperature for 80 minutes. The mixture was then evaporated to dryness; the residue was treated with saturated aqueous sodium bicarbonate (100 mL) and extracted with dichloromethane (3 x 100 mL). The combined organics were washed with brine (75 mL), passed through a hydrophobic frit and then evaporated to dryness to afford the title compound (7.19 g, 42 mmol, quantitative). LCMS RT= 0.48 min, ES+ve m/z \l\ [M+H]+.
(4-(oxazol-5-yl)phenyI)methanamine
Figure imgf000258_0001
Under an atmosphere of nitrogen, an ice-cooled mixture of 4-(oxazol-5-yl)benzonitrile (900 mg, 5.29 mmol) and cobalt(II) chloride hexahydrate (commercially available from for example Aldrich) (1.8 g, 7.9 mmol) in methanol (50 mL) was treated portion-wise over 5 minutes with sodium borohydride (1 g, 26 mmol). The mixture was stirred for 30 minutes and then treated with water (50 mL) and concentrated aqueous ammonia (20 mL). The mixture was extracted with chloroform (3 x 150 mL), the combined organics were evaporated to dryness and the product was purified by chromatography on silica using a gradient elution from 0% to 30% methanol in dichloromethane (+ 0.1% triethylamine) to afford the title compound (580 mg, 3.3 mmol, 63 % yield). LCMS RT= 0.35 min, ES+ve m/z 175 [M+H]+.
(2S,4R)-tert-butyl 4-hydroxy-2-((4-(oxazol-5-yl)benzyl)carbamoyI)pyrrolidine-l- carboxylate
Figure imgf000258_0002
To a stirred solution of (2S,4R)-l-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (0.66 g, 2.9 mmol) in dry DMF (20 mL) were added (4-(oxazol-5- yl)phenyl)methanamine (0.5 g, 2.87 mmol) and DIPEA (1 mL, 5.7 mmol). This solution was then ice-cooled and HATU (1.09 g, 2.9 mmol) was added. The reaction mixture was stirred with cooling for an additional hour then treated with water (30 mL) and extracted with ethyl acetate (3x100 mL). The combined organic phase was washed with saturated aqueous sodium bicarbonate (60 mL), brine (60 mL), dried over magnesium sulfate, filtered and evaporated to dryness. The product was purified by chromatography on silica using a gradient elution from 0% to 25% methanol in dichloromethane to afford the title compound (758 mg, 1.96 mmol, 68 % yield). LCMS RT= 0.73 min, ES+ve m/z 388 [M+H]+.
(2S,4R)-4-hydroxy-N-(4-(oxazol-5-yI)benzyl)pyrrolidine-2-carboxamide, hydrochloride
Figure imgf000259_0001
A solution of (2S,4R)-tert-butyl 4-hydroxy-2-((4-(oxazol-5-yl)benzyl)carbamoyl)pyrrolidine- 1-carboxylate (2.74 g, 7.1 mmol) in methanol (10 mL) and dichloromethane (15 mL) was treated with hydrochloric acid (4 M in 1,4-dioxane) (8.8 mL, 35 mmol) and the mixture was stirred at ambient temperature for 24 hours. The mixture was evaporated to dryness. The residue was suspended in methanol, filtered and dried under vacuum to afford the title compound (2.24 g, 6.9 mmol, 98 % yield). LCMS RT= 0.44 min, ES+ve m/z 288 [M+H]+. -tert-butyl 2-((4-bromobenzyl)carbamoyl)-4-hydroxypyrrolidine-l-carboxylate
Figure imgf000259_0002
An ice-cooled mixture of (2S,4R)-l-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (commercially available from for example Aldrich) (7.95 g, 34 mmol) and (4- bromophenyl)methanamine (commercially available from for example Fluorochem) (6.4 g, 34 mmol) in DMF (200 mL) was treated with DIPEA (18 mL, 103 mmol) and then with HATU (14.4 g, 38 mmol) and the mixture was stirred at ambient temperature for 30 minutes. The mixture was treated with water (200 mL) and extracted with ethyl acetate (2 x 200 mL). The combined organic phase was washed with saturated aqueous sodium bicarbonate (2 x 300 mL), water (100 mL), brine (200 mL), dried over magnesium sulfate and evaporated to dryness. The product was purified by flash chromatography (750 g silica cartridge) using a gradient elution from 0% to 10% methanol in dichloromethane to afford the title compound (12.9 g, 94% yield). LCMS RT= 0.87 min, ES+ve m/z 401 [M+H]+.
(2S,4R)-tert-butyl 4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine- 1-carboxylate
Figure imgf000260_0001
Under an atmosphere of nitrogen, a mixture of (2S,4R)-tert-butyl 2-((4- bromobenzyl)carbamoyl)-4-hydroxypyrrolidine-l-carboxylate (12.9 g, 32 mmol), 4- methylthiazole (commercially available from for example Aldrich) (5.9 mL, 65 mmol), palladium(II) acetate (commercially available from for example Aldrich) (0.145 g, 0.65 mmol) and potassium acetate (6.34 g, 65 mmol) in N-methyl-2-pyrrolidone (80 mL) was stirred at 120 °C for 18 hours. After cooling to ambient temperature, water (100 ml) was added and the product was extracted with ethyl acetate (4 x 300 mL). The combined organic phase was washed with brine (5 x 200 mL), dried over magnesium sulfate and evaporated to dryness. The product was purified by flash chromatography (750 g silica cartridge) using a gradient elution from 0% to 10% methanol in dichloromethane to afford the title compound (8.0 g, 59% yield). LCMS RT= 0.75 min, ES+ve m/z 418 [M+H]+.
(2S,4R)-4-hydroxy-N-(4-(4-methyIthiazol-5-yI)benzyl)pyrrolidine-2-carboxamide, hydrochloride
Figure imgf000260_0002
A solution of (2S,4R)-tert-butyl 4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-l-carboxylate (8 g, 19 mmol) in a mixture of methanol (30 mL) and dichloromethane (20 mL) was treated with 4M hydrochloric acid in 1,4-dioxane (8 mL, 32 mmol). The mixture was stirred at ambient temperature for 2 hours. The solvent was evaporated to dryness and the residue was triturated in dichloromethane, filtered and dried under vacuum to afford the title compound (6.7 g, 99 % yield). LCMS RT= 0.51 min, ES+ve m/z 318 [M+H]+. (2S,4R)-l-(3-ethoxybenzoyl)-4-hydroxypyrrolidine-2-carboxylic acid
Figure imgf000261_0001
3-Ethoxybenzoic acid (commercially available from for example Aldrich) (4 g, 24 mmol) was dissolved in thionyl chloride (24 mL, 329 mmol) and stirred at 60 °C for 1 hour and then at 50 °C for 18 hours. After cooling to ambient temperature the mixture was evaporated to dryness and the residue was treated with diethyl ether (5 mL). The mixture was then ice- cooled and treated with a solution of (2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid, hydrochloride (commercially available from for example Aldrich) (4.44 g, 27 mmol) in 1M aqueous sodium hydroxide (27 mL, 27 mmol). The reaction was warmed to ambient temperature and stirred for 18 hours. The mixture was separated; the aqueous phase was washed with diethyl ether and then acidified with 2M aqueous hydrochloric acid. The product was extracted in diethyl ether (2 x 70 mL) and the combined ethereal phase was evaporated to dryness. The product was purified by flash chromatography (340 g CI 8 cartridge), using a gradient elution from 10 to 30% acetonitrile (+ 0.1% formic acid) in water (+ 0.1% formic acid) to afford the title compound (3.5 g, 52% yield). LCMS RT= 0.55 min, ES+ve m/z 280 [ +H]+.
-benzyl l-((S)-2-acetamidopropanoyl)-4-hydroxypyrrolidine-2-carboxylate
Figure imgf000261_0002
An ice-cooled mixture of (S)-2-acetamidopropanoic acid (commercially available from for example Aldrich) (2.80 g, 21 mmol) and (2S,4R)-benzyl 4-hydroxypyrrolidine-2-carboxylate, hydrochloride (commercially available from for example Aldrich) (5 g, 19 mmol) in DMF (5 mL) was treated with DIPEA (14.mL, 78 mmol), followed by HATU (8.11 g, 21 mmol) over 10 min. The mixture was warmed to ambient temperature and stirred for 1 hour then treated with saturated aqueous sodium bicarbonate (30 mL) and stirred for 5 min. The mixture was then extracted with ethyl acetate (3 x 100 mL) and the combined organic phase was washed with water (100 mL), brine (100 mL), dried over magnesium sulfate and evaporated to dryness. The product was purified by flash chromatography (330 g silica cartridge) using a gradient elution from 0 to 10% methanol in dichloromethane to afford the title compound (2.0 g, 31% yield). LCMS RT= 0.63 min, ES+ve m/z 335 [M+H]+.
-l-((S)-2-acetamidopropanoyl)-4-hydroxypyrrolidine-2-carboxylic acid
Figure imgf000262_0001
A solution of (2S,4R)-benzyl-l -((S)-2-acetamidopropanoyl)-4-hydroxypyrrolidine-2- carboxylate (2 g, 6.0 mmol) in ethanol (10 mL) was added to a flask containing palladium on carbon (1.27 g, 1.2 mmol) (10%), Degussa type) under an atmosphere of nitrogen. The flask was filled with hydrogen and the solution was stirred at ambient temperature for 2 hours. The catalyst was removed by filtration through celite and the filtrate was evaporated under reduced pressure to afford the title compound (1.37 g, 94% yield). LCMS RT= 0.28 min, ES+ve m/z 244 [M+H]+.
(2S,4R)-4-hydroxy-l-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylic acid
Figure imgf000262_0002
Under an atmosphere of nitrogen, a solution of (2S,4R)-benzyl 4-hydroxy-l-(2-(3- methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylate (2.3 g, 6.7 mmol) in ethanol (60 mL) was added to palladium on carbon (0.071 g, 0.67 mmol) (10 %, Degussa type) and then stirred under an atmosphere of hydrogen. After 2 hours, the mixture was filtered through celite. The filtrate was evaporated to dryness and the residue was triturated with cyclohexane and dried under vacuum to afford a white solid. The product was purified by mass-directed automated preparative HPLC (TFA modifier) to afford the title compound (650 mg, 2.6 mmol, 38 % yield). LCMS RT= 0.38 min, ES+ve m/z 255 [M+H]+.
(2S,4R)-methyl 4-hydroxy-l-((S)-2-(l-oxoisoindolin-2-yl)propanoyl)pyrrolidine-2- carboxylate
Figure imgf000262_0003
A mixture of (2S,4R)-methyl 4-hydroxypyrrolidine-2-carboxylate, hydrochloride (commercially available from for example Aldrich) (1.77 g, 9.8 mmol) and (S)-2-(l- oxoisoindolin-2-yl)propanoic acid (2 g, 9.8 mmol) in DMF (4 mL) was treated with DIPEA (5.11 mL, 29 mmol) and then with HATU (4.08 g, 10.7 mmol), and stirred at ambient temperature for 30 minutes. The mixture was treated with saturated aqueous sodium bicarbonate (100 mL) and extracted with ethyl acetate (2 x 200 mL). The combined organic phase was washed with water (100 mL), brine (100 mL), dried over magnesium sulfate and evaporated to dryness. The product was purified by flash chromatography (120 g CI 8 cartridge), using a gradient elution from 10% to 50% acetonitrile (+ 0.1% formic acid) in water (+ 0.1% formic acid) to afford the title compound (1.0 g, 31% yield). LCMS RT= 0.60 min, ES+ve m/z 333 [M+H]+.
(2S,4R)-4-hydroxy-l-((S)-2-(l-oxoisoindolin-2-yl)propanoyl)pyrrolidine-2-carboxyIic acid
Figure imgf000263_0001
A solution of (2S,4R)-methyl 4-hydroxy-l-((S)-2-(l-oxoisoindolin-2- yl)propanoyl)pyrrolidine-2-carboxylate (1 g, 3.0 mmol) in methanol (2 mL) was treated with 2M aqueous sodium hydroxide (5 mL, 10 mmol) and the mixture was stirred at ambient temperature for 2 hours then acidified with 2M aqueous hydrochloric acid (6 mL). The mixture was then evaporated to about one half of the original volume and then ice-cooled. The resulting precipitate was filtered off and dried under vacuum to afford the title compound (615 mg, 64% yield). LCMS RT= 0.51min, ES+ve m/z 319 [M+H]+.
Methyl 3-(4-(/erf-butoxy)-4-oxobutoxy)benzoate
Figure imgf000263_0002
A solution of methyl 3-hydroxybenzoate (commercially available from for example Aldrich) (1 g, 6.6 mmol) and K2C03 (1.82 g, 13.2 mmol) in DMF (10 mL) was treated with tert-butyl 4-bromobutanoate (commercially available from for example Aldrich) (2.2 g, 9.9 mmol) and the mixture was stirred at 60 °C for 16 hours. A further aliquot of K2C03 (1.82 g, 13.2 mmol) and tert-butyl 4-bromobutanoate (2.2 g, 9.9 mmol) were added and the mixture was heated at 60 °C for further 6 hours. The mixture was cooled to ambient temperature and partitioned between ethyl acetate (50 mL) and water (50 mL). The organic phase was washed with brine (2 x 50 mL), dried (hydrophobic frit) and evaporated to dryness. The product was purified by chromatography on silica using a gradient elution from 0% to 100% methyl tert-butyl ether in cyclohexane to afford the title compound (1.4 g, 4.8 mmol, 72 % yield). LCMS RT= 1.26 min, ES+ve m/z 312 [M+H]+.
3-(4-(7¾/*i-butoxy)-4-oxobutoxy)benzoic acid
Figure imgf000264_0001
A mixture of methyl 3-(4-(tert-butoxy)-4-oxobutoxy)benzoate (1.4 g, 4.8 mmol) and aqueous sodium hydroxide (2M, 4.8 mL, 9.6 mmol) in methanol (10 mL) was stirred at ambient temperature for 5 hours. The methanol was removed under reduced pressure (no heat) and the aqueous phase was acidified to pH 3 with saturated aqueous citric acid. The product was extracted with ethyl acetate (60 mL) and the organic extract was washed with brine (20 mL), dried using a hydrophobic frit and evaporated to dryness. The product was purified by chromatography on silica using a gradient elution from 0% to 25% methanol in
dichloromethane to afford the title compound (625 mg, 2.2 mmol, 47 % yield). LCMS RT= 1.06 min, ES+ve m/z 279 [M-H]'.
Meth l 3-((14,14-dimethyl-12-oxo-3,6,9,13-tetraoxapentadecyl)oxy)benzoate
Figure imgf000264_0002
An ice-cooled mixture of tert-butyl 3-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)propanoate (commercially available from for example Aldrich) (2.0 g, 7.2 mmol), triphenylphosphine (2.3 g, 8.6 mmol) and methyl 3-hydroxybenzoate (commercially available from for example Aldrich) (1.2 g, 7.9 mmol) in THF (40 mL) was treated dropwise over 5 minutes with diisopropyl azodicarboxylate (1.68 mL, 8.6 mmol). The mixture was warmed to ambient temperature and stirred for 18 hours. The mixture was then evaporated to dryness and purified by flash column chromatography (100 g silica cartridge) using a gradient elution from 0 to 100% methyl tert-butyl ether in cyclohexane over 40 minutes to afford the title compound (2.53 g, 85% yield). LCMS RT= 1.14 min, ES+ve m/z 430 [M+NH4]+.
3-((14,14-dimethyl-12-oxo-3,6,9,13-tetraoxapentadecyl)oxy)benzoic acid (
Figure imgf000265_0001
A solution of methyl 3-((14,14-dimethyl-12-oxo-3,6,9,13-tetraoxapentadecyl)oxy)benzoate
(2.53 g, 4.9 mmol) in methanol (25 mL) was treated with 1M aqueous sodium hydroxide (0.3 g, 7.6 mmol) in water (7 mL), and the mixture was stirred at ambient temperature for 1 hour.
Acetic acid (0.45 mL, 7.9 mmol) was slowly added and the mixture was evaporated to dryness and purified by flash chromatography (100 g silica cartridge) using a gradient elution from 0% to 15% methanol in dichloromethane (+1% triethylamine) to afford the title compound (1.37 g, 70% yield). LCMS RT= 0.99 min, ES+ve m/z 399 [M+H]+.
tert-butyl ((S)-l-((2S,4R)-4-hydroxy-2-((4-(4-methyIthiazol-5- yl)benzyI)carbamoyl)pyrrolidin-l-yl)-3-methyl-l-oxobutan-2-yl)carbamate
Figure imgf000265_0002
A stirred mixture of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2- carboxamide, hydrochloride (125 mg, 0.35 mmol) and (S)-2-((tert-butoxycarbonyl)amino)-3- methylbutanoic acid (commercially available from for example Aldrich) (77 mg, 0.35 mmol) in DMF (0.9 mL) was treated with DIPEA (0.22 mL, 1.3 mmol) and then with HATU (134 mg, 0.35 mmol) and the mixture was stirred at ambient temperature for 1 hour. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (120 mg, 72% yield). LCMS RT= 0.87 min, ES+ve m/z 511 [M+H]+.
Using a method analogous to that for tert-butyl-((S)-l-((2S,4R)-4-hydroxy-2-((4-(4- methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin- 1 -yl)-3-methyl- 1 -oxobutan-2-yl)carbamate, the following compounds were prepared:
Figure imgf000266_0001
(2S,4R)-l-(2-aminoacetyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yI)benzyl)pyrrolidine-2- carboxamide
Figure imgf000267_0001
A stirred mixture of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2- carboxamide, hydrochloride (100 mg, 0.28 mmol) and 2-((tert-butoxycarbonyl)amino)acetic acid (commercially available from for example Aldrich) (49 mg, 0.28 mmol) in DMF (3 mL) was treated with DIPEA (0.20 mL, 1.1 mmol) and then with HATU (118 mg, 0.31 mmol) and the mixture was stirred at ambient temperature for 30 minutes. Water (20 ml) was added and the product was extracted with ethyl acetate (3 x 20 mL). The combined organic phase was washed with saturated aqueous sodium bicarbonate (20 mL), water (20 mL), brine (20 mL) filtered through a hydrophobic frit and evaporated to dryness. The residue was then dissolved in dichloromethane (3 mL) and treated with TFA (1 mL, 13 mmol). After stirring at ambient temperature for 10 minutes, the reaction mixture was evaporated to dryness. The residue was dissolved in the minimum amount of methanol and then loaded onto a pre-conditioned (methanol) aminopropyl solid-phase extraction cartridge (5 g). The column was eluted with methanol (3 volumes) and the product-containing fractions were evaporated to dryness to afford the title compound (104 mg, 99 % yield). LCMS RT= 0.44 min, ES+ve m/z 375
[M+H]+.
(2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)-l-((S)-morpholine-3- carbonyl)pyrrolidine-2-carboxamide
Figure imgf000267_0002
A solution of (S)-tert-butyl 3-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-l-carbonyl)morpholine-4-carboxylate (115 mg, 0.22 mmol) in dichloromethane (0.5 mL) was treated with TFA (0.5 mL) and the reaction mixture was stirred at ambient temperature for 1 hour. The mixture was evaporated to dryness and the residue was then dissolved in the minimum amount of a mixture of
methanol: dichloromethane (1 :1), and loaded onto a pre-conditioned (methanol) aminopropyl solid-phase extraction cartridge (2 g). The column was eluted with methanol (3 volumes) and the product-containing fractions were evaporated under reduced pressure to afford the title compound (89 mg, 94% yield). LCMS RT= 0.47 min, ES+ve m/z 431 [M+H]+.
(2S,4R)-4-hydroxy-l-((S)-3-methyl-2-(methylamiiio)butanoyI)-N-(4-(4-methylthiazoI-5- yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride
Figure imgf000268_0001
A mixture of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2- carboxamide, hydrochloride (100 mg, 0.28 mmol), (S)-2-((tert- butoxycarbonyl)(methyl)amino)-3-methylbutanoic acid (commercially available from for example Aldrich) (65 mg, 0.28 mmol) and DIPEA (0.247 mL, 1.41 mmol) in DMF (2 mL) was treated with HATU (118 mg, 0.31 mmol) and stirred at ambient temperature for 30 minutes. The Boc protected intermediate was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier). The purified intermediate was dissolved in methanol :dichloromethane (1 :1, 3 mL), treated with hydrochloric acid in 1,4-dioxane (4M, 3 mL, 12 mmol) and allowed to stand for 1 hour. The mixture was then evaporated to dryness to afford the title compound (107 mg, 0.23 mmol, 81 % yield). LCMS RT= 0.55 min, ES+ve m/z 431 [M+H]+.
(2S,4R)-l-((S)-2-amino-3-methylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride
Figure imgf000268_0002
A solution of tert-butyl ((5)-l-((25',4i?)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidin-l-yl)-3 -methyl- l-oxobutan-2-yl)carbamate (287 mg, 0.56 mmol) in THF (5 mL) and treated with 4M hydrochloric acid in 1,4-dioxan (10 mL) and stirred at ambient temperature for 2 hours. The mixture was evaporated to dryness to afford the title compound (224 mg, 0.49 mmol, quantitative). LCMS RT= 0.55 min, ES+ve m/z 417 [M+H]+.
(2S,4R)-l-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride
Figure imgf000269_0001
A stirred mixture of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2- carboxamide, hydrochloride (70 mg, 0.20 mmol) and (S)-2-((tert-butoxycarbonyl)amino)-3,3- dimethylbutanoic acid (commercially available from for example Fluka) (50 mg, 0.22 mmol) in DMF (1 mL) was treated with DIPEA (0.14 mL, 0.79 mmol) and then with HATU (90 mg, 0.24 mmol), and stirred at ambient temperature for 30 minutes. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to give the intermediate boc-protected product. The intermediate was then dissolved in a mixture of dichloromethane (0.5 mL) and methanol (0.1 mL) and treated with 4M hydrochloric acid in 1,4-dioxane (0.25 mL, 1,0 mmol), After stirring at ambient temperature for 1 hour, the reaction mixture was evaporated to dryness and the residue triturated to a solid with dichloromethane and dried under vacuum to afford the title compound (76 mg, 82 % yield). LCMS RT= 0.58 min, ES+ve m/z 431 [M+H]+.
(2S,4R)-l-((S)-2-((S)-2-amino-4-methylpentanamido)propanoyl)-4-hydroxy-N-(4-(4- methylthiazoI-5-yI)benzyl)pyrroIidine-2-carboxamide, hydrochloride
Figure imgf000269_0002
HCI
A solution of a mixture of (2S,4i?)-l-((S)-2-aminopropanoyl)-4-hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (507 mg, 1.2 mmol), DIPEA (0.868 mL, 4.97 mmol) and (5)-2-((tert-butoxycarbonyl)amino)-4-methylpentanoic acid (commercially available from for example Aldrich) (230 mg, 0.99 mmol) in DMF (5 mL) was treated with HATU (416 mg, 1.1 mmol) and stirred at ambient temperature for 2 hours. Water (50 mL) was added and the product was extracted with ethyl acetate (50 mL). The organic phase was washed with brine (2 x 50 mL), dried using a hydrophobic frit and evaporated to dryness. The residue was dissolved in methanol :dichloromethane (1 : 1, 15 mL), treated with hydrochloric acid in 1,4-dioxane (4M, 5 mL, 20 mmol) and stirred at ambient temperature for 3 hours. The mixture was evaporated to dryness and the residue was suspended in dichloromethane (10 mL), sonicated, filtered and dried under vacuum to afford the title compound (280 mg, 0.56 mmol, 56 % yield). LCMS RT= 0.55 min, ES+ve m/z 502
[M+H]+.
(2S,4R)-tert-butyl 2-((4-(2,4-dimethylthiazol-5-yl)benzyl)carbamoyl)-4- hydroxypyrrolidine-l-carboxylate
Figure imgf000270_0001
Under an atmosphere of nitrogen, a mixture of (2S,4R)-tert-butyl 2-((4- bromobenzyl)carbamoyl)-4-hydroxypyrrolidine-l-carboxylate (200 mg, 0.50 mmol), 2,4- dimethylthiazole (commercially available from for example Avocado) (113 mg, 1.0 mmol), palladium(II) acetate (commercially available from for example Aldrich) (2 mg, 10 μηιοΐ) and potassium acetate (98 mg, 1.0 mmol) in N-methyl-2-pyrrolidone (2 mL) was stirred at 120 °C for 18 hours. The cooled mixture was treated with water (25 ml) and the product was extracted with ethyl acetate (4 x 30 mL). The combined organic phase was washed with brine (5 x 20 mL), filtered through a hydrophobic frit and evaporated to dryness. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (142 mg, 66% yield). LCMS RT= 0.77 min, ES+ve m/z 432 [M+H]+.
(2S,4R)-N-(4-(2,4-dimethylthiazol-5-yl)benzyl)-4-hydroxypyrrolidine-2-carboxamide, hydrochloride
Figure imgf000270_0002
A solution of (2S,4R)-tert-butyl 2-((4-(2,4-dimethylthiazol-5-yl)benzyl)carbamoyl)-4- hydroxypyrrolidine-l-carboxylate (142 mg, 0.33 mmol) in a mixture of methanol (0.5 mL) and dichloromethane (1.5 mL) was treated with 4M hydrochloric acid in 1,4-dioxane (0.63 mL, 2.5 mmol) and stirred at ambient temperature for 2 hours. The solvent was evaporated to dryness and the residue was triturated to a solid with diethyl ether and dried under vacuum to afford the title compound (120 mg, 99% yield). LCMS RT= 0.49 min, ES+ve m/z 332
[M+H]+.
-3-methyl-2-(3-methyl-2,5-dipxo-2,5-dihydro-lH-pyrrol-l-yl)butanoic acid
Figure imgf000271_0001
A mixture of 3-methylfuran-2,5-dione (commercially available from for example Aldrich) (0.12 mL, 1.3 mmol) and (S)-2-amino-3-methylbutanoic acid (commercially available from for example Apollo Scientific) (150 mg, 1.3 mmol). in acetic acid (1 mL) was sealed and heated in a Biotage "Initiator" microwave at 120°C for 1 hour. The mixture was evaporated to dryness to afford the title compound (253 mg, 94% yield). LCMS RT= 0.75 min, ES+ve m/z
212 [M+H]+
benzyl 2-(3-oxomorphoIino)propanoate
Figure imgf000271_0002
Under an atmosphere of nitrogen, an ice-cooled solution of morpholin-3-one (commercially available from for example Aldrich) (100 mg, 1.0 mmol) in DMF (2 mL) was treated with sodium hydride (60% w/w in mineral oil) (40 mg, 1.0 mmol). After 5 minutes, benzyl 2- bromopropanoate (commercially available from for example Aldrich) (240 mg, 1.0 mmol) was added and the mixture was stirred with cooling for 30 minutes and then at ambient temperature for a further 18 hours. The reaction mixture was cautiously treated with saturated aqueous sodium bicarbonate (10 mL) and then extracted with ethyl acetate (2 x 40 mL). The combined organic phase was washed with brine (25 mL), filtered through a hydrophobic frit, and evaporated to dryness. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to give the title compound (105 mg, 40% yield). LCMS RT= 0.80 min, ES+ve m/z 264 [M+H]+.
-(3-oxomorpholino)propanoic acid
Figure imgf000271_0003
Under an atmosphere of nitrogen, a solution of benzyl 2-(3-oxomorpholino)propanoate (90 mg, 0.34 mmol) in ethanol (3 mL) was added to a flask containing palladium on carbon (36 mg, 0.034 mmol) (10%, Degussa type). The flask was then filled with hydrogen and the mixture was stirred at ambient temperature for 1 hour. The catalyst was removed by filtration through celite and the filtrate was evaporated under reduced pressure to afford the title compound (55 mg, 93% yield). LCMS RT= 0.33 min, ES+ve m/z 174 [M+H]+.
tert-butyl 4-(l-(benzyloxy)-l-oxopropan-2-yl)-3-oxopiperazine-l-carboxylate
Figure imgf000272_0001
Under an atmosphere of nitrogen, an ice-cooled solution of tert-butyl 3-oxopiperazine-l- carboxylate (commercially available from for example Aldrich) (200 mg, 1.0 mmol) in DMF (4 mL) was treated with sodium hydride (60% w/w in mineral oil) (44 mg, 1.1 mmol). After 5 minutes, benzyl 2-bromopropanoate (commercially available from for example Aldrich) (255 mg, 1.05 mmol) was added. The mixture was stirred at 0 °C for 30 minutes and then at ambient temperature for a further 18 hours. The mixture was cautiously treated with saturated aqueous sodium bicarbonate (20 mL) and then extracted with ethyl acetate (2 x 40 mL). The combined organic phase was washed with brine (25 mL), filtered through a hydrophobic frit, and evaporated to dryness. The product was purified by flash column chromatography (20 g silica cartridge) using a gradient elution from 0% to 100% ethyl acetate in cyclohexane to afford the title compound (230 mg, 64% yield). LCMS RT= 1.05 min, ES+ve m/z 363
[M+H]+.
2-(4-(tert-butoxycarbonyl)-2-oxopiperazin-l-yl)propanoic acid
Figure imgf000272_0002
Under an atmosphere of nitrogen, a solution of tert-butyl 4-(l-(benzyloxy)-l-oxopropan-2- yl)-3-oxopiperazine-l-carboxylate (230 mg, 0.64 mmol) in ethanol (3 mL) was added to a flask containing palladium on carbon (68 mg, 0.063 mmol) (10%, Degussa type). The flask was filled with hydrogen and the mixture was stirred at ambient temperature for 1 hour. The catalyst was removed by filtration through celite and the filtrate was evaporated under reduced pressure to afford the title compound (171 mg, 99% yield). LCMS RT= 0.62 min, ES+ve m/z 290 [M+H]+.
tert-butyl 4-(2-oxo-2,3-dihydrobenzo [d] oxazoI-5-yl)benzylcarbamate
Figure imgf000273_0001
Under an atmosphere of nitrogen, a mixture of (4-(((tert- butoxycarbonyl)amino)methyl)phenyl)boronic acid (commercially available from for example Aldrich) (387 mg, 1.54 mmol), 5-bromobenzo[d]oxazol-2(3H)-one (commercially available from for example Aldrich) (300 mg, 1.40 mmol) and sodium carbonate (446 mg, 4.21 mmol) in DMF (4 mL) was treated with dicholoro[l,l'- bis(diphenylphosphino)ferrocene]palladium(II) (commercially available from for example Aldrich) (72 mg, 0.098 mmol) then sealed and heated in a Biotage "Initiator" microwave at 110 °C for 1 hr. The cooled product mixture was treated with dichloromethane (50 mL) and water (10 mL). The mixture was separated and the organic fraction was evaporated to dryness. The product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (178 mg, 0.52 mmol, 37 % yield). LCMS RT= 1.03 min, ES+ve m/z 341 [M+H]+.
5-(4-(aminomethyl)phenyI)benzo[d]oxazol-2(3H)-one, hydrochloride
Figure imgf000273_0002
A solution of tert-butyl 4-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)benzylcarbamate (130 mg, 0.38 mmol) in THF (10 mL) was treated with hydrochloric acid (4M in 1,4-dioxan) (1 mL, 4 mmol) and the mixture was stirred at ambient temperature ovemight. The mixture was treated with diethyl ether (40 mL); the resulting precipitate was filtered off and dried under vacuum to afford the title compound (87 mg, 0.31 mmol, 82 % yield). LCMS RT= 0.49 min, ES+ve m/z 241 [M+H]+.
(2S,4R)-4-hydroxy-l-(3-hydroxybenzoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine- 2-carboxamide
Figure imgf000273_0003
An ice-cooled solution of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine- 2-carboxahiide, hydrochloride (217 mg, 0.61 rnmol), 3-hydroxybenzoic acid (85 mg, 0.61 mmol) and DIPEA (0.321 mL, 1.84 mmol) in DMF (4 mL) was treated portion- wise with HATU (240 mg, 0.63 mmol) over 1 minute and then stirred at ambient temperature for 1 hour. The mixture was treated with saturated aqueous sodium bicarbonate (20 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic phase was washed with brine (3 x 30 mL), filtered through a hydrophobic frit and then evaporated to dryness. The product was purified by flash chromatography (50 g silica cartridge) using a gradient elution from 0 to 25% methanol in dichloromethane to afford the title compound (234 mg, 0.53 mmol, 87 % yield). LCMS RT= 0.49 min, ES+ve m/z 241 [M+H]+.
-2-(l-oxoisoindolin-2-yl)propanoic acid
Figure imgf000274_0001
A mixture of phthalaldehyde (commercially available from for example Aldrich) (4 g, 30 mmol) and (S)-2-aminopropanoic acid (commercially available from for example Aldrich) (2.39 g, 27 mmol) in acetonitrile (150 mL) was heated at reflux for 5 hr then allowed to cool to ambient temperature and stood overnight. The resulting crystalline precipitate was filtered off, washed with acetonitrile and dried under vacuum to afford the title compound (4.46 g, 22 mmol, 73 % yield). LCMS RT= 0.59 min, ES+ve m/z 206 [M+H]+.
Using a method analogous to that for (S)-2-(l-oxoisoindolin-2-yl)propanoic acid, the following compounds were prepared:
Figure imgf000274_0002
(S)-3-methyl-2-(l-
0.74
oxoisoindolin-2- CQ H 9% 234
min
yl)butanoic acid 0^ 5
0
(S)-3,3-dimethyl-2-(l-
0.82
oxoisoindolin-2- 69% 248
min
yI)butanoic acid 0 0
Ethyl 2-(5-methoxy-l-oxoisoindolin-2-yI)-3-methylbutanoate
Figure imgf000275_0001
Under an atmosphere of nitrogen, an ice-cooled solution of 5-methoxyisoindolin-l-one (commercially available from for example Chem Impex) (105 mg, 0.64 mmol) in DMF (2.5 mL) was treated with sodium hydride (60% w/w in mineral oil) (31 mg, 0.77 mmol). The mixture was warmed to ambient temperature, treated with ethyl 2-bromo-3-methylbutanoate (commercially available from for example Alfa Aesar) (135 mg, 0.64 mmol), stirred at ambient temperature for 2 hours and then heated to 70 °C for a further 18 hours. The mixture was then ice-cooled and treated with additional sodium hydride (60% w/w in mineral oil) (31 mg, 0.77 mmol), followed by ethyl 2-bromo-3-methylbutanoate (135 mg, 0.64 mmol) and stirred at 70 °C for a further 24 hours. The cooled mixture was then cautiously treated with saturated aqueous ammonium chloride (20 mL) and the product was extracted with ethyl acetate (2 x 25 mL). The combined organic phase was washed with water (20 mL), brine (20 mL), filtered through a hydrophobic frit and evaporated to dryness. The product was purified by flash chromatography (20 g silica cartridge) using a gradient elution from 0% to 50% ethyl acetate in cyclohexane to afford the title compound (44 mg, 23% yield). LCMS RT= 1.01 min, ES+ve m/z 292 [M+H]+
Ethyl 2-(6-methoxy-l-oxoisoindolin-2-yl)-3-methylbutanoate
Figure imgf000275_0002
Under an atmosphere of nitrogen, an ice-cooled solution of 6-methoxyisoindolin-l-one (commercially available from for example Astatech) (105 mg, 0.64 mmol) in DMF (2.5 mL) was treated with sodium hydride (60% w/w in mineral oil) (31 mg, 0.77 mmol) and the mixture was allowed to warm to ambient temperature. The mixture was then treated with ethyl 2-bromo-3-methylbutanoate (commercially available from for example Alfa Aesar) (135 mg, 0.64 mmol) and the mixture was stirred for 18 hours then cautiously treated with saturated aqueous ammonium chloride (20 mL). The product was extracted with ethyl acetate (2 x 25 mL) and the combined organic phase was washed with water (20 mL), brine (20 mL), filtered through a hydrophobic frit and evaporated to dryness. The product was purified by flash chromatography (20 g silica cartridge) using a gradient elution from 0 to 50% ethyl acetate in cyclohexane to afford the title compound (40 mg, 21% yield). LCMS RT= 1.03 min, ES+ve m/z 292 [M+H]+
-(6-methoxy-l-oxoisoindoIin-2-yl)-3-methylbutanoic acid
Figure imgf000276_0001
A solution of ethyl 2-(6-methoxy-l-oxoisoindolin-2-yl)-3-methylbutanoate (40 mg, 0.14 mmol) in ethanol (0.4 mL) was treated with 2M aqueous sodium hydroxide (0.20 mL, 0.41 mmol) and the mixture was stirred at ambient temperature for 2 hours. The reaction mixture was evaporated to dryness, treated with water (lOmL) and acidified to pH 3 using 2M aqueous hydrochloric acid. The product was extracted with ethyl acetate (2 x10 mL), and the combined organic phase was filtered through a hydrophobic frit and evaporated to dryness to afford the title compound (34 mg, 94% yield). LCMS RT= 0.80 min, ES+ve m/z 264 [M+H]+. -(5-methoxy-l-oxoisoindolin-2-yl)-3-methylbutanoic acid
Figure imgf000276_0002
A solution of ethyl 2-(5-methoxy-l-oxoisoindolin-2-yl)-3-methylbutanoate (40 mg, 0.14 mmol) in ethanol (0.4 mL) was treated with 2M aqueous sodium hydroxide (0.20 mL, 0.41 mmol) and the mixture was stirred at ambient temperature for 2 hours. The mixture was then evaporated to dryness; the residue was treated with water (10 mL) and acidified to pH 3 using 2M aqueous hydrochloric acid. The product was extracted with ethyl acetate (2 x10 mL), and the combined organic phase was filtered through a hydrophobic frit and evaporated to dryness to afford the title compound (33 mg, 93% yield). LCMS RT= 0.76 min, ES+ve m/z 264 [M+H]+.
Ethyl 2-(7-chloro- 1 -oxoisoindolin-2-y l)-3-methy Ibutanoate
Figure imgf000277_0001
Under a nitrogen atmosphere, an ice-cooled solution of 7-chloroisoindolin-l-one
(commercially available from for example JW Pharm) (150 mg, 0.90 mmol) in DMF (2.5 mL) was treated with sodium hydride (60% w/w in mineral oil) (50 mg, 1.25 mmol). The mixture was allowed to warm to ambient temperature, then treated with ethyl 2-bromo-3- methylbutanoate (commercially available from for example Alfa Aesar) (187 mg, 0.90 mmol) and stirred for 5 hours. The mixture was then ice-cooled, treated with additional sodium hydride (60% w/w in mineral oil) (50 mg, 1.25 mmol) and ethyl 2-bromo-3-methylbutanoate (187 mg, 0.90 mmol) and the mixture was stirred at ambient temperature for a further 24 hours. The mixture was then cautiously treated with saturated aqueous ammonium chloride (20 mL), and the product was extracted with ethyl acetate (2 x 25 mL). The combined organic phase was washed with water (20 mL), brine (20 mL), filtered through a hydrophobic frit and evaporated to dryness. The product was purified by flash chromatography (20 g silica cartridge) using a gradient elution from 0 to 50% ethyl acetate in cyclohexane to afford the title compound (40 mg, 15% yield). LCMS RT= 1.07 min, ES+ve m/z 296 [M+H]+. -(7-chloro-l-oxoisoindolin-2-yl)-3-methylbutanoic acid
Figure imgf000277_0002
A solution of ethyl 2-(7-chloro-l-oxoisoindolin-2-yl)-3 -methylbutanoate (40 mg, 0.14 mmol) in ethanol (0.4 mL) was treated with 2M aqueous sodium hydroxide (0.22 mL, 0.45 mmol) and the mixture was stirred at ambient temperature for 2 hours. The mixture was then evaporated to dryness, treated with water (10 mL) and then acidified to pH 3 using 2M aqueous hydrochloric acid. The product was extracted with ethyl acetate (2 xlO mL) and the combined organic phase was filtered through a hydrophobic frit and evaporated to dryness to afford the title compound (34 mg, 94% yield). LCMS RT= 0.82 min, ES+ve m/z 268 [M+H]+. -Hydroxy-4-(4-methylthiazol-5-yl)benzonitrile
Figure imgf000278_0001
Under an atmosphere of nitrogen, a mixture of 4-bromo-2-hydroxybenzonitrile
(commercially available from for example Fluorochem) (15 g, 76 mmol), 4-methylthiazole (commercially available from for example Aldrich) (14 mL, 152 mmol), potassium acetate (14.9 g, 152 mmol) and palladium(II) acetate (0.34 g, 1.52 mmol) in l-methyl-2-pyrrolidone (125 mL) was heated at 110°C for 3 hours. The mixture was then cooled to 50°C, poured into water (300 mL) and extracted with ethyl acetate (3 x 350 mL). The combined organic fraction was filtered and the filtrate was then washed with brine (3 x 400 mL), filtered through a hydrophobic frit and evaporated to dryness. The residue was re-evaporated from toluene then from diethyl ether and then slurried in methanol to precipitate a yellow solid which was filtered off. The filtrate was evaporated to dryness and slurried in ice-cooled methanol to afford a second batch of yellow solid. The combined solid was dried under vacuum to afford the title compound (12 g, 56 mmol, 73 % yield). LCMS RT= 0.75 min, ES+ve m/z 217
[M+H]+. -(Aminomethyl)-5-(4-methylthiazol-5-yl)phenol
Figure imgf000278_0002
An ice-cooled solution of 2-hydroxy-4-(4-methylthiazol-5-yl)benzonitrile (12 g, 56 mmol) in THF (550 mL) was treated dropwise with lithium aluminium hydride (1M in THF, 140 mL, 140 mmol) over 5 minutes. The resulting mixture was then heated at 50°C for 30 minutes and additional lithium aluminium hydride (1M in THF, 20 mL, 20 mmol) was added. After a further 30 minutes the mixture was cooled in an ice bath and treated cautiously with water (14 mL), followed by aqueous sodium hydroxide (4M, 42 mL, 168 mmol) and finally water (14 mL). After standing for 3 days, the mixture was filtered and the filtered solid was washed with THF. The combined filtrate was evaporated to dryness and the residue was slurried in dichloromethane:methanol (4:1) with Celite (about 20g) and filtered. The filtered solid was washed three times with dichloromethane/methanol (4:1) and the combined filtrate was evaporated to dryness. The product was purified by flash chromatography (330 g silica cartridge) using a gradient elution from 0 to 15 % methanol in dichloromethane (+1 % triethylamine) to afford the title compound (6.2 g, 28 mmol, 51 % yield). LCMS RT= 0.41 min, ES+ve m/z 221 [M+H]+.
(2S,4R)-tert-Butyl 4-hydroxy-2-((2-hydroxy-4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-l -carboxylate
Figure imgf000279_0001
An ice-cooled solution of 2-(aminomethyl)-5-(4-methylthiazol-5-yl)phenol (3.05 g, 13.8 mmol) and (2S,4R)-l-(tert-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (2.94 mL, 13.8 mmol) in DMF (35 mL) was treated with DIPEA (7.25 mL, 42 mmol) followed by HATU (5.79 g, 15.2 mmol) and the mixture was stirred at ambient temperature for 1 hour. The mixture was treated with saturated aqueous sodium bicarbonate (50 mL) and extracted with ethyl acetate (3 x 80 mL). The combined organic phase was washed with brine (60 mL), filtered through a hydrophobic frit and evaporated to dryness. The product was purified by flash chromatography (330 g silica cartridge) using a gradient from 0 to 15% methanol in dichloromethane to afford the title product (4.8 g, 11 mmol, 80 % yield). LCMS RT= 0.76 min, ES+ve m/z 434 [M+H]+.
(2S,4R)-4-Hydroxy-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2- carboxamide, hydrochloride
Figure imgf000279_0002
A solution of (2S,4R)-tert-butyl 4-hydroxy-2-((2-hydroxy-4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-l-carboxylate (4.8 g, 11 mmol) in
dichloromethane:methanol 20:1 (50 mL) was treated with hydrochloric acid (4M in 1,4- dioxane) (35 mL, 140 mmol) and the mixture was stirred overnight at ambient temperature. The mixture was then evaporated to dryness and the residual solid was suspended in dichloromethane and filtered. The filtered solid was washed with further dichloromethane and dried under vacuum to afford the title compound (4 g, 10.8 mmol, 98 % yield). LCMS RT= 0.46 min, ES+ve m/z 334 [M+H]+. (2S,4R)-l-((S)-2-Aminopropanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride
Figure imgf000280_0001
A stirred mixture of (2S,4i?)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2- carboxamide, hydrochloride (100 mg, 0.28 mmol), (S)-2-((tert- butoxycarbonyl)amino)propanoic acid (commercially available from for example Aldrich) (64 mg, 0.34 mmol) and DIPEA (0.197 mL, 1.13 mmol) in dry DMF (3 mL) was treated with HATU (129 mg, 0.34 mmol and stirred at ambient temperature for 30 minutes. The mixture was then partitioned between ethyl acetate (30 mL) and water (30 mL) and the organic phase was washed with brine (30 mL), dried (hydrophobic frit) and evaporated to dryness. The residue was dissolved in methanol and added to a methanol-preconditioned aminopropyl solid-phase extraction cartridge (2g) eluting with methanol (3 column volumes). The resulting eluant was evaporated to dryness and the residue was dissolved in
dichloromethane:methanol (1 :1, 8 mL) and treated with hydrochloric acid, (4M in 1,4- dioxane) (1 mL, 4 mmol). The mixture was stirred at ambient temperature for 16 hours and then evaporated to dryness to afford the title compound (107 mg, 0.25 mmol, 89 % yield). LCMS RT= 0.51 min, ES+ve m/z 389 [M+H]+.
(2S,4R)-l-(2-Amino-2-methylpropanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide
Figure imgf000280_0002
A solution of a mixture of (2S,4i?)-4-hydroxy-iV-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine- 2-carboxamide, hydrochloride (100 mg, 0.28 mmol), 2-((tert-butoxycarbonyl)amino)-2- methylpropanoic acid (commercially available from for example Aldrich) (69 mg, 0.34 mmol) and DIPEA (0.197 mL, 1.13 mmol) in dry DMF (3 mL) was treated with HATU (129 mg, 0.34 mmol, stirred at ambient temperature for 30 minutes and then partitioned between ethyl acetate (30 mL) and water (30 mL). The organic phase was washed with brine (30 mL), dried (hydrophobic frit) and evaporated to dryness. The residue was dissolved in methanol and added to a methanol-preconditioned aminopropyl solid-phase extraction cartridge (2g) eluting with methanol. The resulting eluant was evaporated to dryness and the residue was dissolved in dichloromethane methanol (1 :1, 8 mL) and treated with hydrochloric acid, 4M in 1,4-dioxane (1 mL, 4 mmol). The reaction mixture was stirred at ambient temperature for 16 hours and then evaporated to dryness. The residue was suspended in dichloromethane (4 mL) and treated with TFA (1 mL) and the mixture was stirred at ambient temperature for 4 hours. The mixture was evaporated to dryness and the residue was dissolved in methanol and added to a methanol-preconditioned sulfonic acid solid-phase extraction cartridge (2g) and eluted with methanol (3 column volumes) and then with ammonia in methanol (2M, 3 column volumes). The product-containing fractions were evaporated to dryness to afford the title compound (95 mg, 0.24 mmol, 84 % yield). LCMS RT= 0.53 min, ES+ve m/z 403 [M+H]+.
(2S,4R)-4-Hydroxy-l-((S)-2-(methylamino)propanoyl)-N-(4-(4-methylthiazol-5- yl)benzyl)pyrrolidine-2-carboxamide
Figure imgf000281_0001
A stirred mixture of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2- carboxamide, hydrochloride (120 mg, 0.34 mmol) and (S)-2-((tert- butoxycarbonyl)(methyl)amino)propanoic acid (commercially available from for example Aldrich) (76 mg, 0.37 mmol) in DMF (2 mL) was treated with DIPEA (0.24 mL, 1.36 mmol) and then with HATU (155 mg, 0.41 mmol), and the mixture was stirred at ambient temperature for 30 minutes. The crude product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to give the intermediate Boc-protected product. The intermediate was suspended in dichloromethane (0.5 mL) and treated with TFA (0.5 mL). The mixture was stirred at ambient temperature for 1 hour and was then evaporated to dryness. The residue was dissolved in the minimum amount of a mixture of
methanol: dichloromethane (1 :1), and then loaded onto a pre-conditioned (methanol) aminopropyl solid-phase extraction cartridge (5 g). The column was eluted with methanol (3 volumes) and the product-containing fractions were combined and evaporated to dryness to afford the title compound (103 mg, 75% yield). LCMS RT= 0.47 min, ES+ve m/z 403
[M+H]+. (2S,4R)-4-Hydroxy-N-(4-(4-methylthiazol-5-yl)benzyI)-l-((S)-morpholine-3- carbonyl)pyrrolidine-2-carboxamide, hydrochloride
Figure imgf000282_0001
A mixture of (2S,4R)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2- carboxamide, hydrochloride (100 mg, 0.28 mmol), (S)-4-(tert-butoxycarbonyl)morpholine-3- carboxylic acid (commercially available from for example Astatech) (65 mg, 0.28 mmol) and DIPEA (0.247 mL, 1.41 mmol) in DMF (2 mL) was treated with HATU (1 18 mg, 0.31 1 mmol) and stirred at ambient temperature for 30 minutes. The Boc protected intermediate was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier). The intermediate was dissolved in methanol :dichloromethane (1 :1, 3 mL), treated with hydrochloric acid in 1,4-dioxane (4M, 3 mL, 12 mmol) and allowed to stand for 1 hour. The mixture was evaporated to dryness to afford the title compound (110 mg, 0.24 mmol, 83 % yield). LCMS RT= 0.50 min, ES+ve m/z 431/432 [M+H]+.
J^-butyl 4-(3-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5- yl)benzyl)carbamoyl)pyrrolidine-l-carbonyl)phenoxy)butanoate
Figure imgf000282_0002
A solution of a mixture of 3-(4-(fert-butoxy)-4-oxobutoxy)benzoic acid (95 mg, 0.34 mmol), (2S,4i?)-4-hydroxy- V-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (100 mg, 0.28 mmol) and DIPEA (0.2 mL, 1.15 mmol) in dry DMF (3 mL) was treated with HATU (129 mg, 0.34 mmol) and the mixture was stirred at ambient temperature for 30 minutes. The mixture was added to an aminopropyl solid-phase extraction cartridge and eluted with methanol (3 column volumes). The resulting eluant was evaporated to dryness and the product was subjected to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (130 mg, 0.22 mmol, 79 % yield). LCMS RT= 0.98 min, ES+ve m/z 580 [M+H]+. Example- VHL Protac Which Binds Estrogen Receptor (Estrogen Protacts)
Abbreviations:
DCM: dichloromethane.
DIPEA: NJJ-diisopropylethylamine.
DMF: N,N-dimethylformamide.
HA TU: 2-(7-aza- 1 H-benzotriazole- 1 -yl)- 1 , 1 ,3 ,3 -tetramethyluronium hexafluorophosphate.
HPLC: high-performance liquid chromatography.
LCMS: liquid chromatography-mass spectrometry
Min: minutes.
RT: retention time.
tBu: tert-butoxide.
TFA: trifluoroacetic acid.
THF: tetrahydrofuran.
LCMS Method ;
The analysis was conducted on an Acquity UPLC BEH CI 8 column (50mm x 2.1mm internal diameter 1.7μπι packing diameter) at 40°C.
The solvents employed were:
A = 0.1% v/v solution of formic acid in water.
B = 0.1% v/v solution of formic acid in acetonitrile.
The gradient employed was as follows:
Figure imgf000283_0001
The UV detection was an averaged signal from wavelength of 210nm to 350nm and mass spectra were recorded on a mass spectrometer using alternate-scan positive and negative mode electrospray ionization. The following illustrates the mobile phases and gradients used when compounds underwent purification by mass-directed autopreparative HPLC.
Mass-Directed Autopreparative HPLC (Formic Acid Modifier)
The HPLC analysis was conducted on a Sunfire C18 column (150mm x 30mm internal diameter, 5μηι packing diameter) at ambient temperature.
The solvents employed were:
A = 0.1% v/v solution of formic acid in water.
B = 0.1% v/v solution of formic acid in acetonitrile.
Mass-Directed Autopreparative HPLC (Trifluoroacetic Acid Modifier)
The HPLC analysis was conducted on a Sunfire CI 8 column (150mm x 30mm internal diameter, 5μηι packing diameter) at ambient temperature.
The solvents employed were:
A = 0.1% v/v solution of trifluoroacetic acid in water.
B = 0.1% v/v solution of trifluoroacetic acid in acetonitrile.
Mass-Directed Autopreparative HPLC (Ammonium Bicarbonate Modifier)
The HPLC analysis was conducted on an XBridge CI 8 column (150mm x 30mm internal diameter, 5μπι packing diameter) at ambient temperature.
The solvents employed were:
A = 10 mM ammonium bicarbonate in water adjusted to pH 10 with ammonia solution. B = acetonitrile. For each of the mass-directed autopreparative purifications, irrespective of the modifier used, the gradient employed was dependent upon the retention time of the particular compound undergoing purification as recorded in the analytical LCMS, and was as follows:
For compounds with an analytical LCMS retention time below 0.6 minutes the following gradient was used:
Figure imgf000285_0001
For compounds with an analytical LCMS retention time between 0.6 and 0.9 minutes the following gradient was used:
Figure imgf000285_0002
For compounds with an analytical LCMS retention time between 0.9 and 1.2 minutes the following gradient was used:
Figure imgf000285_0003
1 40 70 30
10 40 15 85
11 40 1 99
15 40 1 99
For compounds with an analytical LCMS retention time between 1.2 and 1.4 minutes the following gradient was used:
Figure imgf000286_0001
For compounds with an analytical LCMS retention time greater than 1.4 minutes (LCMS method A) or greater than 3.6 minutes (LCMS method B) the following gradient was used:
Figure imgf000286_0002
The UV detection was an averaged signal from wavelength of 210nm to 350nm and mass spectra were recorded on a mass spectrometer using alternate-scan positive and negative mode electrospray ionization. The chemical names were generated using ACD Name Pro version 6.02 from Advanced Chemistry Development, Inc.
8/?,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-
7, 8,9, 11 , 12, 13,14,15,16, 17-decahydro-6H-cyclopenta[a]phenanthren-6-one
Figure imgf000287_0001
(8f?,9S, 13S, 14S, 17S)-3, 17-bis(methoxymethoxy)-13-methyl- 7,8,9, 11 , 12, 13, 14, 15, 16, 17-decahydro-6 - -cyclopenta[a]phenanthren-6-one can be prepared according to the process described by Xiang-Rong Jiang, J. Walter Sowell, Bao Ting Zhu, Steroids, 2006, 71, 334-342. (doi: 10.1016/j.steroids.2005.1 1.008). 15-Bromo-1 -phenyl-2,5,8,11 -tetraoxapentadecane
Figure imgf000287_0002
To a suspension of sodium hydride, 60 % w/w in mineral oil (0.250 g, 6.24 mmol) in DMF (2 mL) was added a solution of 2-(2-(2-(benzyloxy)ethoxy)ethoxy)ethanol (1 g, 4.16 mmol) (commercially available from for example Fluorochem) in DMF (2 mL) at 0 °C. After stirring for 25 minutes, 1,4-dibromobutane (commercially available from for example Aldrich) (4.04 g, 18.73 mmol) dissolved in DMF (2 mL) was added dropwise to the mixture. The reaction was stirred under an atmosphere of nitrogen for 2.5 hours. A further aliquot of sodium hydride, 60 % w/w in mineral oil (0.250 g, 6.24 mmol) was added and the reaction was stirred at 0 °C for 30 minutes. The reaction was warmed to room temperature and stirred for 30 minutes. A final aliquot of sodium hydride, 60 % w/w in mineral oil (0.250 g, 6.24 mmol) was added and the reaction stirred at room temperature for 2 hours then left standing over the weekend. The reaction mixture was filtered through celite and the solid washed with DCM. The filtrate was partitioned between DCM (30 mL) and water (30 mL). The organic extract was washed with brine (2 x 30 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 100% methyl tert-butyl ether in cyclohexane to afford the title compound (711 mg, 1.89 mmol, 46% yield). LCMS RT= 1.16 min, ES+ve m/z 375.2/377.1 [M+H]+. 15-Iodo-l-phenyI-2,5,8,ll-tetraoxapentadecane
Figure imgf000288_0001
A mixture of 15-bromo-l -phenyl -2,5,8,11-tetraoxapentadecane (711 mg, 1.894 mmol) and sodium iodide (568 mg, 3.79 mmol) in acetone (10 mL) was heated under reflux conditions for 4 hours. The reaction was cooled to room temperature. The mixture was filtered through celite and the solid washed with acetone. The solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate (30 mL) and washed with water (30 mL) and brine (2 x 30 mL). The organic extract was dried using a hydrophobic frit and concentrated under reduced pressure to afford the title compound (759 mg, 1.797 mmol, 95% yield). LCMS RT= 1.23 min, ES+ve m/z 440.0 [M+NH4]+.
(7S,8R,9S 3 4S,17S)-3,17-Bis(methoxymethoxy)-13-methyl-7-(l-phenyl-2,5,8,ll- tetraoxapentadecan-15-yl)-7,8,9,ll,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-6-one
Figure imgf000288_0002
A solution of KOtBu in THF (1M, 1.282 mL, 1.282 mmol) was added to a cooled solution (0 °C) of (SR,9S, 13S, 14S, 17S)-3 , 17-bis(methoxymethoxy)- 13 -methyl- 7,8,9,11, 12,13, 14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one (240 mg, 0.641 mmol) in anhydrous THF (2 mL). The reaction mixture was stirred at 0 °C for 45 minutes and then cooled to -78 °C. A solution of 15-iodo-l-phenyl-2,5, 8,11-tetraoxapentadecane (789 mg, 1.868 mmol) in THF (1 mL) was added dropwise. The solution was stirred at -78 °C for 2 minutes, allowed to warm to 0 °C and stirred for 1.5 hours at that temperature. The reaction was partitioned between water (30 mL) and ethyl acetate (30 mL). The organic extract was dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 100% ethyl acetate in cyclohexane to afford the title compound (234 mg, 0.350 mmol, 55% yield). LCMS RT= 1.48 min, ES+ve m/z 669.3 [M+H]+, 686.4 [M+NH4]+. (7S,8R,9S,13 ,14S,17S)-3,17-Dihydroxy-13-methyI-7-(l-phenyl-2,5,8,ll- tetraoxapentadecan-15-yI)-7,8,9,ll»12,13,14,15,16,17-decahydro-6H- cyclopenta [a] phenanthren-6-one
Figure imgf000289_0001
A solution of aqueous HC1 (6M, 2.3 mL, 13.80 mmol) was added to a solution of
(7S,8i?,9S,l 3S,14S, 17S)-3,17-bis(methoxymethoxy)-l 3-methyl-7-(l -phenyl-2,5,8, 11 - tetraoxapentadecan- 15-yl)-7,8,9, 11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-6-one (234 mg, 0.350 mmol) in THF (2.3 mL). The reaction mixture was stirred at room temperature for 16 hours. Water (30 mL) was added and the product was extracted with ethyl acetate (50 mL). The organic extract was washed with brine (2 x 30 mL), dried using a hydrophobic frit and concentrated under reduced pressure to afford the title compound (200 mg, 0.344 mmol, 98% yield). LCMS RT= 1.07 min, ES+ve m/z 581.3 [M+H]+, 598.3 [M+NH4]+.
(7R,8R,9S,135,14S,17S)-13-Methyl-7-(l-phenyl-2,5,8,ll-tetraoxapentadecan-15-yI)- 7,8,9,ll,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
Figure imgf000289_0002
Triethylsilane (commercially available from for example Aldrich) (0.550 mL, 3.44 mmol) was added to a solution of (7S,8i?,9S,13S,145,175)-3,17-dihydroxy-13-methyl-7-(l-phenyl- 2,5,8, 11 -tetraoxapentadecan- 15-yl)-7,8,9, 11 , 12, 13, 14, 15, 16, 17-decahydro-6H- cyclopenta[a]phenanthren-6-one (200 mg, 0.344 mmol) in TFA (2 mL, 26.0 mmol). The reaction was stirred at room temperature under an atmosphere of nitrogen for 16 hours. The mixture was partitioned between ethyl acetate (30 mL) and brine (30 mL). The organic extract was washed with brine (2 x 30 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The residue was dissolved in MeOH (5 mL) and treated with aqueous NaOH (2M, 5 mL, 10.00 mmol). The reaction mixture was stirred at room temperature for 3 hours. The solvent was removed under reduced pressure. The residue was partitioned between ethyl acetate (30 mL) and a 10 % citric acid solution (30 mL). The organic extract was washed with brine (30 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by reverse phase
chromatography using a gradient elution from 5% to 95% acetonitrile (+ 0.1% formic acid) in water (+ 0.1% formic acid) to afford the title compound (150 mg, 0.265 mmol, 77% yield). LCMS RT= 1.18 min, ES+ve m/z 567.3 [M+H]+, 584.3 [M+NH4]+.
15-((7R,8R,9S,135,14S,17S)-3,17-Bis(methoxymethoxy)-13-methyl- 7,8,9,ll,12,13,14,15,16,l'7-decahydro-6Jy-cyclopenta[a]phenanthreii-7-yI)-l-phenyl- 2,5,8»! 1-tetraoxapentadecane
Figure imgf000290_0001
A vial was charged with (7i?,8i?,9S,135,14S,17S)-13-methyl-7-(l-phenyl-2,5,8,l 1- tetraoxapentadecan- 15-yl)-7,8,9, 11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthrene-3,17-diol (150 mg, 0.265 mmol) and DIPEA (0.555 mL, 3.18 mmol) in THF (10 mL). The vial was sealed, the solution was cooled to 0 °C and
chloro(methoxy)methane (commercially available from for example Aldrich) (0.2 mL, 2.63 mmol) was added. The reaction mixture was warmed to room temperature, stirred for 1 hour and heated at 70 °C for 40 hours. The reaction was cooled to room temperature. The reaction was partitioned between ethyl acetate (100 mL) and water (100 mL). The organic extract was washed with brine (2 x 50 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 100% methyl tert-butyl ether in cyclohexane to afford the title compound (122 mg, 0.186 mmol, 70% yield). LCMS RT= 1.60 min, ES+ve m/z 672.5 [M+NH4]+. 2-(2-(2-(4-((7R,8R,9S,13S,14S,17S)-3,17-Bis(methoxymethoxy)-13-methyl-
7,8,9,ll,12,13,14,15,16,17-decahydro-6JH-cyclopenta[a]phenanthren-7- yl)butoxy)ethoxy)ethoxy)ethanol
Figure imgf000291_0001
A mixture of 15-((7i?,8i?,9^,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl- 7,8,9, 11 , 12, 13 , 14, 15 , 16, 17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)- 1 -phenyl-2,5 ,8 , 11 - tetraoxapentadecane (115 mg, 0.176 mmol) and 10 % w/w palladium on carbon (100 mg, 0.094 mmol) in ethanol (4 mL) was stirred at room temperature under an atmosphere of hydrogen for 1.5 hours. The palladium on carbon was filtered through celite and the filtrate evaporated under reduced pressure. The residue was partitioned between ethyl acetate (15 mL) and brine (15 mL). The organic extract was dried using a hydrophobic frit and
concentrated under reduced pressure to afford the title compound (81 mg, 0.143 mmol, 82% yield). LCMS RT= 1.36 min, ES+ve m/z 582.4 [M+NH4]+.
7¾rf-butyl 16-((7i?,8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl-
7,8,9,ll,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-3,6,9,12- tetraoxahexadecan-l-oate
Figure imgf000291_0002
Sodium hydride, 60 % w/w in mineral oil (10 mg, 0.250 mmol) was added to a cooled solution (0 °C) of 2-(2-(2-(4-((7i?,8i?,9S,13S,145,175)-3,17-bis(methoxymethoxy)-13-methyl- 7,8,9, 11 , 12, 13 , 14, 15, 16, 17-decahydro-6H-cyclopenta[a]phenanthren-7- yl)butoxy)ethoxy)ethoxy)ethanol (81 mg, 0.143 mmol) in DMF (2 mL). The reaction was stirred at that temperature for 10 minutes and fert-butyl 2-bromoacetate (commercially available from for example Aldrich) (32 μί, 0.217 mmol) was added. The reaction was stirred at 0 °C for 1 hour and at room temperature for further 2 hours. The reaction mixture was partitioned between ethyl acetate (30 mL) and water (30 mL). The organic layer was washed with brine (30 mL), dried (hydrophobic frit) and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 100% methyl tert-b tyl ether in cyclohexane to afford the title compound (60 mg, mmol, 62% yield). LCMS RT= 1.57 min, ES+ve m/z 696.5 [M+N¾]+.
16-((7R,8R,9S,13S,14S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,ll,12,13,14,15,16,17- decahydro-6JH-cyclopenta[a]phenanthren-7-yl)-3,6,9,12-tetraoxahexadecaii-l-oic acid
Figure imgf000292_0001
Tert-butyl 16-((7R,8R,9S, 13S, 14S, 17S)-3 , 17-bis(methoxymethoxy)- 13 -methyl- 7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-3 ,6,9, 12- tetraoxahexadecan-l-oate (133 mg, 0.196 mmol) was dissolved in THF (1.5 mL) and treated with aqueous HC1 (6M, 1.5 mL, 9.00 mmol). The reaction mixture was stirred at room temperature for 8 hours. The reaction mixture was subjected directly to purification by mass- directed automated preparative HPLC (formic acid modifier) to afford the title compound (60 mg, 0.112 mmol, 57% yield). LCMS RT= 0.89 min, ES+ve m/z 535.3 [M+H]+, 552.3
[M+NH4]+.
(2S,4R)-l-((S)-19-((7R,8R,9S,13S,14S,17S)-3,17-Dihydroxy-13-methyI- 7,8,9,ll>12,13,14,15,16,l'7-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-2-isopropyl-4- oxo-6,9,12,15-tetraoxa-3-azanonadecan-l-oyI)-4-hydroxy-N-(4-(4-methylthiazol-5- yl)benzyI)pyrrolidine-2-carboxamide
Figure imgf000292_0002
methylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (25 mg, 0.055 mmol), 16-((7i?,8i?,9S,13S,145,17S)-3,17-dihydroxy-13-methyl- 7,8,9, 11 , 12, 13 , 14, 15 , 16, 17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-3 ,6,9, 12- tetraoxahexadecan-l-oic acid (15 mg, 0.028 mmol) and DIPEA (0.05 mL, 0.286 mmol) in DMF (1 mL). The reaction was stirred at room temperature for 30 minutes. The reaction mixture was subjected directly to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (20 mg, 0.021 mmol, 76% yield). LCMS RT= 0.99 min, ES+ve m/z 933.3 [M+H]+.
(2S,4R)-l-((S)-2-(rert-butyl)-19-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl- 7,8,9,ll»12,13,14,15,16,17-decahydro-6JfiT-cyclopenta[a]phenanthren-7-yl)-4-oxo- 6,9,12,15-tetraoxa-3-azanonadecan-l-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5- yI)benzyI)pyrroIidine-2-carboxamide
Figure imgf000293_0001
HATU (22 mg, 0.058 mmol) was added to a mixture of (2S,47?)-l-((S)-2-amino-3,3- dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (25 mg, 0.054 mmol), 16-((7i?,8i?,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl- 7,8,9,11, 12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-3 ,6,9, 12- tetraoxahexadecan-l-oic acid (23 mg, 0.043 mmol) and DIPEA (0.040 mL, 0.229 mmol) in DMF (1 mL). The reaction was stirred at room temperature for 10 minutes. The reaction mixture was subjected directly to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (26 mg, 0.027 mmol, 64% yield). LCMS RT= 1.02 min, ES+ve m/z 947.8 [M+H]+. -(2-(4-Bromobutoxy)ethoxy)ethoxy)methyl)benzene
Figure imgf000293_0002
To a suspension of sodium hydride, 60 % w/w in mineral oil (0.92 g, 22.9 mmol) in DMF (5 mL) was added a solution of 2-(2-(benzyloxy)ethoxy)ethanol (commercially available from for example Aldrich) (2.74 mL, 15.29 mmol) in DMF (5 mL) at 0 °C. After stirring for 25 min, 1 ,4-dibromobutane (commercially available from for example Aldrich) (14.9 g, 68.8 mmol) dissolved in DMF (5 mL) was added dropwise to the mixture. The reaction was warmed to ambient temperature and stirred under an atmosphere of nitrogen for 2.5 hours. A further aliquot of sodium hydride, 60 % w/w in mineral oil (0.92 g, 22.9 mmol) was added and the reaction was stirred at 0 °C for 30 minutes and at ambient temperature for 30 minutes A final aliquot of sodium hydride, 60 % w/w in mineral oil (0.92 g, 22.9 mmol) was added and the reaction stirred at ambient temperature for 2 hours then left standing overnight. The reaction mixture was filtered through celite and the solid washed with DCM. The filtrate was partitioned between DCM (30 mL) and water (30 mL). The organic extract was washed with brine (2 x 30 mL), dried using a hydrophobic frit, and concentrated under reduced pressure. The product was purified by chromatography on silica using a using a gradient elution from 0% to 80% methyl tert-butyl ether in cyclohexane to afford the title compound (3 g, 9.06 mmol, 59% yield). LCMS RT= 1.19 min, ES+ve m/z 331.2/333.2 [M+H]+. -(2-(4-Iodobutoxy)ethoxy)ethoxy)methyl)benzene
Figure imgf000294_0001
A mixture of ((2-(2-(4-bromobutoxy)ethoxy)ethoxy)methyl)benzene (3 g, 9.06 mmol) and sodium iodide (2.72 g, 18.11 mmol) in acetone (10 mL) was heated under reflux conditions for 3 hours. The reaction was cooled to room temperature. The mixture was filtered through celite and the solid washed with acetone. The solvent was removed under reduced pressure and the residue was dissolved in ethyl acetate (30 mL) and washed with water (30 mL) and brine (2 x 30 mL). The organic extract was dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by chromatography on silica using a using a gradient elution from 0% to 50% methyl tert-butyl ether in cyclohexane to afford the title compound (3 A g, 8.2 mmol, 90% yield). LCMS RT= 1.25 min, ES+ve m/z 379.2 [M+H]+.
(7S,8R,9S,135,14S,17S)-7-(4-(2-(2-(Benzyloxy)ethoxy)ethoxy)butyl)-3,17- bis(methoxymethoxy)-13-methyl-7,8,9,ll,12,13,14,15,16,17-decahydro-6Ji-r- cyclopenta[a]phenanthren-6-one
Figure imgf000294_0002
A solution of KOtBu, in THF (1M, 3.2 mL, 3.2 mmol) was added to a cooled solution (0 °C) of (SR,9S, 13S, 1 AS, 175)-3 , 17-bis(methoxymethoxy)- 13 -methyl-7,8,9, 11 , 12, 13 , 14, 15, 16, 17- decahydro-6H-cyclopenta[a]phenanthren-6-one (600 mg, 1.6 mmol) in anhydrous THF (6 mL). The reaction mixture was stirred at 0 °C for 45 minutes and then cooled to -78 °C. A solution of ((2-(2-(4-Iodobutoxy)ethoxy)ethoxy)methyl)benzene (910 mg, 2.4 mmol) in THF (3 mL) was added dropwise. The solution was stirred at -78 °C for 2 minutes then allowed to warm to 0 °C and stirred for 1.5 hours at that temperature. The reaction was partitioned between water (30 mL) and ethyl acetate (30 mL). The organic extract was separated, dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 50% ethyl acetate in cyclohexane to afford the title compound (450 mg, 0.72 mmol, 45% yield). LCMS RT= 1.49 min, ES+ve m/z 625.5 [M+H]+.
(7S,8R,9S,135,14S,17S)-7-(4-(2-(2-(Benzyloxy)ethoxy)ethoxy)butyl)-3,17-dihydroxy-13- methyI-7,8,9,ll,12,13,14,15,16,n-decahydro-6H-cyclopenta[a]phenanthreii-6-one
Figure imgf000295_0001
A solution of aqueous HC1 (6M, 4.6 mL, 27.6 mmol) was added to a solution of
(7S,8i?,9S,l 3S, 14S, 17S)-7-(4-(2-(2-(benzyloxy)ethoxy)ethoxy)butyl)-3, 17- bis(methoxymethoxy)- 13 -methyl-7,8,9, 11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-6-one (470 mg, 0.752 mmol) in THF (4.6 mL). The reaction mixture was stirred at room temperature for 18 hours. Water (30 mL) was added and the product was extracted with ethyl acetate (50 mL). The organic extract was washed with brine (2 x 30 mL), dried using a hydrophobic frit and concentrated under reduced pressure to afford the title compound (390 mg, 0.727 mmol, 97% yield). LCMS RT= 1.08 min, ES+ve m/z 537.2 [M+H]+, 554.2 [M+NH4]+. (7R,8R,9S,13S,14S,17S)-7-(4-(2-(2-(Benzyloxy)ethoxy)ethoxy)butyI)-13-methyl- 7,8,9,ll512,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
Figure imgf000296_0001
Triethylsilane (commercially available from for example Aldrich) 1.161 mL, 7.27 mmol) was added to a solution of (7S,SR,9S, US, 145,17S)-7-(4-(2-(2-(benzyloxy)ethoxy)ethoxy)butyl
3,17-dihydroxy- 13-methyl-7,8,9, 11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-6-one (390 mg, 0.727 mmol) in TFA (4.2 mL, 54.5 mmol). The reaction was stirred at room temperature under an atmosphere of nitrogen for 18 hours. The mixture was partitioned between ethyl acetate (50 mL) and brine (50 mL). The organic extract was washed with brine (2 x 30 mL), saturated sodium bicarbonate (30 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The residue was dissolved in MeOH (10 mL) and treated with aqueous NaOH (2M, 5 mL, 10.0 mmol). The reaction mixture was stirred at room temperature for 1 hour. The solvent was removed under reduced pressure. The residue was partitioned between ethyl acetate (30 mL) and aqueous HC1 solution (1M, 20 mL). The organic extract was washed with brine (20 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by reverse phase chromatography using a gradient elution from 5% to 95% acetonitrile (+ 0.1% formic acid) in water (+ 0.1% formic acid) to afford the title compound (270 mg, 0.517 mmol,
71% yield). LCMS RT= 1.18 min, ES+ve m/z 523.5 [M+H]+, 540.5 [M+NH4]+.
(7R,8^,9S,13S,14S,17S)-7-(4-(2-(2-(Benzyloxy)ethoxy)ethoxy)butyl)-3,17- bis(methoxymethoxy)-13-methyl-7,8,9,ll,12,13,14,15,16,17-decahydro-6Hr- cy clopenta [a] phenanthrene
Figure imgf000296_0002
Chloro(methoxy)methane (commercially available from for example Aldrich) (0.390 mL, 5.14 mmol) was added to a cooled (0 °C) solution of (7i?,8i?,9S,13S, 145,175)-7-(4-(2-(2- (benzyloxy)ethoxy)ethoxy)butyl)- 13 -methyl-7,8,9, 11 , 12, 13 , 14, 15, 16, 17-decahydro-6H- cyclopenta[a]phenanthrene-3,17-diol (270 mg, 0.517 mmol) and DIPEA (1.083 mL, 6.20 mmol) in THF (16 mL). The reaction mixture was warmed to room temperature, stirred for 1 hour and then heated at 70 °C for 40 hours. The reaction mixture was cooled to 0 °C, additional DIPEA (0.271 mL, 1.550 mmol) and chloro(methoxy)methane (0.098 mL, 1.291 mmol) was added. The reaction was heated to 70 °C and stirred for a further 24 hours. The reaction was cooled to room temperature, and was partitioned between ethyl acetate (100 mL) and water (100 mL). The organic extract was washed with brine (2 x 50 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 100% methyl fert-butyl ether in cyclohexane to afford the title compound (220 mg, 0.36 mmol, 70%) yield). LCMS RT= 1.62 min, ES+ve m/z 628.6 [M+NH4]+.
2-(2-(4-((7R,8R,9S,13S,14S,17S)-3,17-Bis(methoxymethoxy)-13-methyl-
7,8,9,ll,12,13,14,15,16,17-decahydro-6Jfi -cyclopenta[a]phenanthren-7- yI)butoxy)ethoxy)ethanol
Figure imgf000297_0001
A mixture of (7R,SR,9S, 13S, 14S, 17S)-7-(4-(2-(2-(benzyloxy)ethoxy)ethoxy)butyl)-3 , 17- bis(methoxymethoxy)- 13-methyl-7,8,9, 11 , 12, 13 , 14, 15, 16, 17-decahydro-6H- cyclopenta[a]phenanthrene (220 mg, 0.36 mmol) and 10 % w/w palladium on carbon (100 mg, 0.094 mmol) in ethanol (4 mL) was stirred at room temperature under an atmosphere of hydrogen for 1 hour. The palladium on carbon was filtered through celite, washed with ethanol (50 ml) and the filtrate was evaporated under reduced pressure to afford the title compound (186 mg, 0.357 mmol, 99% yield) LCMS RT= 1.36 min, ES+ve m/z 521.5
[M+H]+, 538.5 [M+NH4]+.
Tert- vtyl 2-(2-(2-(4-((7R,8R,9S,13S,14S,17S)-3,17-is(methoxymethoxy)-13-methyI-
7,8,9,ll,12,13,14,15,16,l'7-decahydro-6H-cyclopenta[a]phenanthren-7- yl)butoxy)ethoxy)ethoxy)acetate
Figure imgf000297_0002
Sodium hydride, 60 % w/w mineral oil (25.0 mg, 0.625 mmol) was added to a cooled solution (0 °C) of 2-(2-(4-((7i?,8i?,9S, 135,145, 17S)-3,17-bis(methoxymethoxy)- 13 -methyl- 7,8,9, 11, 12,13, 14, 15, 16,17-decahydro-6H-cyclopenta[a]phenanthren-7- yl)butoxy)ethoxy)ethanol (186 mg, 0.357 mmol) in DMF (4.5 mL). The reaction was stirred at 0 °C for 10 minutes and tert-butyl 2-bromoacetate (commercially available from for example Aldrich) (79 μί, 0.536 mmol) was added. The reaction was stirred at 0 °C for 1 hour and at room temperature for a further 6 hours. The reaction was cooled to 0 °C and additional sodium hydride, 60 % w/w in mineral oil (15.72 mg, 0.393 mmol), followed by tert-butyl 2- bromoacetate (0.053 mL, 0.357 mmol) was added. The reaction was stirred at room temperature for a further 18 hours. The reaction mixture was partitioned between ethyl acetate (30 mL) and water (30 mL). The organic layer separated, washed with brine (30 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 100% methyl tert- butyl ether in cyclohexane to afford the title compound (90 mg, 0.142 mmol, 40% yield). LCMS RT= 1.56 min, ES+ve m/z 652.6 [M+NH4]+, 657.5 [M+Na]+.
2-(2-(2-(4-((7R,8R,9S,13S,145,17S)-3,17-Dihydroxy-13-methyl- 7,8,9,ll512,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7- yl)butoxy)ethoxy)ethoxy)acetic acid
Figure imgf000298_0001
7¾rt-butyl 2-(2-(2-(4-((7i?,8i?,9S, 13S, 14S, 17S)-3 , 17-bis(methoxymethoxy)- 13-methyl- 7,8,9,11, 12,13, 14,15, 16,17-decahydro-6H-cyclopenta[a]phenanthren-7- yl)butoxy)ethoxy)ethoxy)acetate (80 mg, 0.126 mmol) was dissolved in THF (1 mL) and treated with aqueous HC1 (6M, 1 mL, 6.0 mmol). The reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was subjected directly to purification by mass- directed automated preparative HPLC (formic acid modifier) to afford the title compound (23 mg, 0.047 mmol, 37% yield). LCMS RT= 0.89 min, ES+ve m/z 491.4 [M+H]+. (25,4R)-l-((S -16-((7R,8R,9S,13S,145,17S)-3,17-Dihydroxy-13-methyl- 7,8,9 1 2,13,14,15,16,17-decahydro-6i3r-cyclopenta[a]phenanthreii-7-yl)-2-isopropyl-4- oxo-6,9,12-trioxa-3-azahexadecan-l-oyl)-4-hydroxy-iV-(4-(4-methylthiazol-5- l)benzyl)pyrrolidine-2-carboxamide
Figure imgf000299_0001
HATU (12 mg, 0.03 mmol) was added to a mixture of (2S,4i?)-l-((5 -2-amino-3- methylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (23 mg, 0.05 mmol), 2-(2-(2-(4-((7i?,8i?,9S,13S,14S,175)-3,17-dihydroxy-13- methyl-7,8,9, 11 , 12, 13, 14, 15, 16, 17-decahydro-6H-cyclopenta[a]phenanthren-7- yl)butoxy)ethoxy)ethoxy)acetic acid (10 mg, 0.02 mmol) and DIPEA (0.04 mL, 0.20 mmol) in DMF (0.8 mL). The reaction was stirred at room temperature for 30 min. The reaction mixture was subjected directly to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (15 mg, 0.017 mmol, 84% yield). LCMS RT= 0.98 min, ES+ve m/z 889.7 [M+H]+. -Bromo-l-phenyl-2,5,8,ll514-pentaoxaoctadecane
Figure imgf000299_0002
To a suspension of sodium hydride, 60 % w/w in mineral oil (0.85 g, 21.3 mmol) in DMF (8 mL) was added a solution of l-phenyl-2,5,8,1 l-tetraoxatridecan-13-ol (commercially available from for example TCI Europe Fine Chemicals) (4.0 g, 14.2 mmol) in DMF (8 mL) at 0 °C. After stirring for 25 minutes, 1,4-dibromobutane (commercially available from for example Aldrich) (7.62 mL, 63.8 mmol) dissolved in DMF (8 mL) was added dropwise to the mixture. The reaction was warmed to room temperature and stirred under an atmosphere of nitrogen for 30 minutes. A further aliquot of sodium hydride, 60 % w/w in mineral oil (0.85 g, 21.3 mmol) was added and the reaction was stirred at room temperature overnight. Another aliquot of sodium hydride, 60 % w/w in mineral oil (0.85 g, 21.3 mmol) was added and the reaction stirred at room temperature for 2 hours. A final aliquot of sodium hydride, 60 % w/w in mineral oil (0.43 g, 10.6 mmol) was added and the reaction stirred at room temperature for 1 hour. The reaction mixture was filtered through celite and the solid washed with DCM. The filtrate was partitioned between DCM (50 mL) and water (50 mL). The organic extract was washed with brine (2 x 50 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 85% methyl tert-butyl ether iii cyclohexane to afford the title compound (3.93 g, 9.37 mmol, 63% yield). LCMS RT= 1.16 min, ES+ve m/z 419.3/421.2 [M+H]+. -Iodo-l-phenyl-2,5,8,ll,14-pentaoxaoctadecane
Figure imgf000300_0001
A mixture of 18-bromo-l-phenyl-2,5,8,l 1,14-pentaoxaoctadecane (2.08 g, 4.91 mmol) and sodium iodide (1.47 g, 9.82 mmol) in acetone (10 mL) was heated under reflux conditions for 3 hours. The reaction was cooled to room temperature, filtered through celite and the solid was washed with acetone. The solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate (30 mL), and washed with water (30 mL) and brine (2 x 30 mL). The organic extract was dried using a hydrophobic frit and concentrated under reduced pressure to afford the title compound (759 mg, 1.80 mmol, 95% yield).LCMS RT= 1.21 min, ES+ve m/z 467.0 [M+H]+, 484.0 [M+NH4]+.
(7S,8R,9S,135 4S 7S)-3 7-Bis(methoxymethoxy)-13-methyl-7-(l^henyl-2,5,8 1 4^ pentaoxaoctadecan-18-yI)-7,8,9,H,12,13,14,15,16,l'7-decahydro-6H- cy clopenta [a] phenanthren-6-one
Figure imgf000300_0002
A solution of KOtBu in THF (1M, 5.34 mL, 5.34 mmol) was added to a cooled solution (0 °C) of (ZR,9S, 13S, 1 S, 17S)-3 , 17-bis(methoxymethoxy)- 13 -methyl-
7,8,9,11,12,13, 14,15, 16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one (1 g, 2.67 mmol) in anhydrous THF (10 mL). The reaction mixture was stirred at 0 °C for 45 minutes and then cooled to -78 °C. 18-Iodo-l-phenyl-2,5, 8,11,14-pentaoxaoctadecane (1.87 g, 4.01 mmol) in THF (5 mL) was added dropwise. The solution was stirred at -78 °C for 2 minutes, allowed to warm to 0 °C and stirred for 1.5 hours at that temperature. The reaction was partitioned between water (50 mL) and ethyl acetate (2 x 50 mL). The organic extracts were dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 100% ethyl acetate in cyclohexane to afford the title compound (883 mg, 1.24 mmol, 46% yield). LCMS RT= 1.47 min, ES+ve m/z 713.5 [M+H]+.
(7S,8R,9S,13 ,14S,17S)-3,17-Dihydroxy-13-methyI-7-(l-phenyl-2,5,8,ll,14- pentaoxaoctadecan-18-yl)-7,8,9,ll,12,13,14,15,16,17-decahydro-6H- cyclopenta [a] phenanthren-6-one
Figure imgf000301_0001
A solution of aqueous HC1 (6M, 9.2 mL, 55.2 mmol) was added to a solution of
(7S,SR,9S, 135", 14S, 17S)-3 , 17-bis(methoxymethoxy)- 13-methyl-7-(l -phenyl-2,5,8, 11,14- pentaoxaoctadecan- 18-yl)-7,8,9, 11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-6-one (883 mg, 1.24 mmol) in THF (9.2 mL). The reaction mixture was stirred at room temperature for 18 hours. Water (30 mL) was added and the product was extracted with ethyl acetate (50 mL). The organic extract was washed with brine (2 x 30mL), dried using a hydrophobic frit and concentrated under reduced pressure to afford the title compound (772 mg, 1.23 mmol, 99% yield). LCMS RT= 1.06 min, ES+ve m/z 625.3 [M+H]+, 642.3 [M+NH4]+.
(7R,8R,9S,135,14S,17S)-13-Methyl-7-(l-phenyl-2,5,8,ll,14-pentaoxaoctadecan-18-yl)- 7,8,9,ll,12,13,14,15,16,17-decahydro-6Hr-cyclopenta[a]phenanthrene-3,17-diol
Figure imgf000301_0002
Triethylsilane (commercially available from for example Aldrich) (2.0 mL, 12.9 mmol) was added to a solution of (7S,8i?,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7-(l-phenyl- 2,5,8, 11 , 14-pentaoxaoctadecan- 18-yl)-7,8,9, 11 , 12, 13, 14, 15, 16, 17-decahydro-6H- cyclopenta[a]phenanthren-6-one (830 mg, 1.29 mmol) in TFA (8.5 mL, 110 mmol). The reaction was stirred at room temperature under an atmosphere of nitrogen for 16 hours. The mixture was partitioned between ethyl acetate (50 mL) and brine (50 niL). The organic extract was washed with brine (2 x 50 mL), saturated sodium bicarbonate (50 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The residue was dissolved in MeOH (10 mL) and treated with aqueous NaOH (2M, 10 mL, 20.0 mmol). The reaction mixture was stirred at room temperature for 1 hour. The solvent was removed under reduced pressure. The residue was partitioned between ethyl acetate (40 mL) and 1M HC1 solution (20 mL). The organic extract was washed with brine (20 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by reverse phase chromatography using a gradient elution from 5% to 90% acetonitrile (+ 0.1% formic acid) in water (+ 0.1% formic acid) to afford the title compound (375 mg, 0.614 mmol, 47% yield). LCMS RT= 1.17 min, ES+ve m/z 611.5 [M+H]+, 628.6 [M+NH4]+.
18-((7R,8R,9S,13S,14S,17S)-3,17-Bis(methoxymethoxy)-13-methyl- 7,8,9,ll,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-l-phenyl- 2,5,8,11,14-pentaoxaoctadecane
Figure imgf000302_0001
Chloro(methoxy)methane (commercially available from for example Aldrich) (0.5 mL, 6.58 mmol) was added to a cooled (0 °C) solution of (7i?,8i?,9S,13S,14S,175)-13-methyl-7-(l- phenyl-2,5,8, 11,14-pentaoxaoctadecan- 18-yl)-7,8,9, 11 , 12, 13 , 14, 15, 16, 17-decahydro-6H- cyclopenta[a]phenanthrene-3,17-diol (375 mg, 0.614 mmol) and DIPEA (1.5 mL, 8.59 mmol) in THF (20 mL). The reaction mixture was warmed to room temperature, stirred for 1 hour and heated at 70 °C for 72 hours. The reaction was cooled to room temperature. The reaction was partitioned between ethyl acetate (100 mL) and water (100 mL). The organic extract was washed with brine (2 x 50 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 100%) methyl tert-butyl ether in cyclohexane to afford the title compound (357 mg, 0.51 mmol, 72% yield). LCMS RT= 1.60 min, ES+ve m/z 716.7 [M+NH4]+, 721.7 [M+Na]+.
16-((7R,8R,9S,13S,14S,175)-3,17-Bis(methoxymethoxy)-13-methyl- 7,8,9,ll,12,13,14,15,16,17-decahydro-6Jfir-cyclopenta[a]phenanthren-7-yl)-3,6,9,12- tetraoxahexadecan- 1 -ol
Figure imgf000303_0001
A mixture of 18-((7i?,8i?,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl- 7,8,9,1 1,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)- 1 -phenyl- 2,5,8,11,14-pentaoxaoctadecane (357 mg, 0.444 mmol) and 10 % w/w palladium on carbon (157 mg, 0.148 mmol) in ethanol (5 mL) was stirred at room temperature under an atmosphere of hydrogen for 1.5 hours. The palladium on carbon was filtered through celite and the filtrate evaporated under reduced pressure to afford the title compound (300 mg, 0.41 mmol, 93% yield) LCMS RT= 1.37 min, ES+ve m/z 609.6 [M+H]+, 631.6 [M+Na]+.
Jert-butyl 19-((7R,8R,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl- 7,8,9,ll,12,13,14,15,16,17-decahydro-6^-cyclopenta[a]phenanthren-7-yl)-3,6,9,12,lS- pentaoxanonadecan-l-oate
Figure imgf000303_0002
Sodium hydride, 60 % w/w in mineral oil (30 mg, 0.75 mmol) was added to a cooled solution (0 °C) of 16-((7i?,8i?,9S,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl- 7,8,9, 11 , 12, 13 , 14, 15, 16, 17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-3 ,6,9,12- tetraoxahexadecan-l-ol (300 mg, 0.43 mmol) in DMF (5 mL). The reaction was stirred at that temperature for 10 minutes and tert-butyl 2-bromoacetate (0.095 mL, 0.643 mmol) was added. The reaction was stirred at 0 °C for 1 hour and then at room temperature for a further 18 hours. The reaction mixture was partitioned between ethyl acetate (30 mL) and water (30 mL). The water layer was extracted with additional ethyl acetate (2 x 30 mL), and the combined organic layers were washed with brine (2 x 30 mL), dried (hydrophobic frit) and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 100% methyl tert-butyl ether in cyclohexane to afford the title compound (177 mg, 0.245 mmol, 57% yield). LCMS RT= 1.58 min, ES+ve m/z 740.6 [M+NH4]+, 745.6 [M+Na]+. 19-((7R,8R,9S,13S,14S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,ll,12,13,14,15,16,17- decahydro-6H-cyclopenta[a]phenanthren-7-yl)-3,6,9,12,15-pentaoxanonadecan-l-oic acid
Figure imgf000304_0001
Tert-butyl 19-((7tf,8i?,9S, 13S, 1 AS, 17S)-3 , 17-bis(methoxymethoxy)- 13 -methyl- 7,8,9, 11 , 12, 13 , 14, 15, 16, 17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-3 ,6,9, 12,15- pentaoxanonadecan-l-oate (177 mg, 0.189 mmol) was dissolved in THF (2 mL) and treated with aqueous HC1 (6M, 2 mL, 12.0 mmol). The reaction mixture was stirred at room temperature for 7 hours. The reaction mixture was subjected directly to purification by mass- directed automated preparative HPLC (formic acid modifier) to afford the title compound (64 mg, 0.111 mmol, 59% yield). LCMS RT= 0.92 min, ES+ve m/z 579.4 [M+H]+, 596.5
[M+NH4]+.
(2S,4R)-l-((S)-22-((7R,8^,95,13S,14S,17S)-3,17-Dihydroxy-13-methyl- 7,8,9,ll,12,13,14,15,16,17-decahydro-6 i-cyclopenta[a]phenanthren-7-yl)-2-isopropyl-4- oxo-6,9,12,15,18-pentaoxa-3-azadocosan-l-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5- yI)benzyl)pyrrolidine-2-carboxamide
Figure imgf000304_0002
HATU (16 mg, 0.04 mmol) was added to a mixture of (2S,4i?)-l-((5)-2-amino-3- methylbutanoyl)-4-hydroxy-7V-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (25 mg, 0.06 mmol), 19-((7i?,8i?,95,13S,145,17S)-3,17-dihydroxy-13-methyl- 7,8,9, 11 , 12, 13 , 14, 15, 16, 17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-3 ,6,9, 12, 15- pentaoxanonadecan-l-oic acid (16 mg, 0.03 mmol) and DIPEA (0.048 mL, 0.28 mmol) in DMF (0.8 mL). The reaction was stirred at room temperature for 30 minutes. The reaction mixture was subjected directly to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (17.7 mg, 0.018 mmol, 65% yield).
LCMS RT= 0.99 min, ES+ve m/z 977.4 [M+H]+. (2S 4R)-l-((S)-2-(r^-butyl)-22-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl- 7,8,9,H,12,13,14,15,16,l7-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-4-oxo- 6,9,12,15,18-pentaoxa-3-azadocosan-l-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5- yl)ben^I)pyrrolidine-2-carboxamide
Figure imgf000305_0001
HATU (16 mg, 0.04 mmol) was added to a mixture of (2S,4i?)-l-((5)-2-amino-3,3- dimemylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (25 mg, 0.05 mmol), 19-((7i?,8i?,9S,13S,14S,17,S)-3,17-dihydroxy-13-methyl- 7,8,9, 11 , 12, 13 , 14, 15, 16, 17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-3,6,9, 12,15- pentaoxanonadecan-l-oic acid (16 mg, 0.03 mmol) and DIPEA (0.048 mL, 0.28 mmol) in DMF (0.8 mL). The reaction was stirred at room temperature for 30 minutes. The reaction mixture was subjected directly to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (17.5 mg, 0.017 mmol, 63% yield).
LCMS RT= 1.03 min, ES+ve m/z 991.4 [M+H]+.
(7S,8R,95,13S,14S,17S)-7-(5-(Benzyloxy)pentyl)-3,17-dihydroxy-13-methyl- 7,8,9,ll,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one
Figure imgf000305_0002
A solution of KO/Bu in THF (1M, 4.81 mL, 4.81 mmol) was added to a cooled solution (0 °C) of (8i?,9S, 13S, \4S, 17S)-3, 17-bis(methoxymethoxy)- 13-methyl- 7,8,9,1 l,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-6-one (900 mg, 2.403 mmol) in anhydrous THF (10 mL). The reaction mixture was stirred at 0 °C for 45 minutes and then cooled to -78 0 °C. (((5-Iodopentyl)oxy)methyl)benzene (can be prepared following the procedure described in J. Chem. Soc, Perkin Trans. 1 1990, 129-132) (2.193 g, 7.21 mmol) in THF (0.5 mL) was added dropwise. The solution was stirred at -78 °C for 2 minutes and allowed to warm to room temperature and stirred for 1 hour at that temperature. The reaction was partitioned between water (70 mL) and ethyl acetate (70 mL). The organic extract was dried using a hydrophobic frit and concentrated under reduced pressure. The intermediate was purified by chromatography on silica using a gradient elution from 0% to 50% ethyl acetate in cyclohexane. The residue was dissolved in THF (16 mL) and aqueous HC1 (6M, 16 mL, 96 mmol) was added. The reaction was stirred at room temperature for 16 hours. The reaction mixture was partitioned between ethyl acetate (20 mL) and water (20 mL). The organic extract was dried (hydrophobic frit) and concentrated under reduced pressure. The product was purified by reverse phase chromatography using a gradient elution from 5%> to 85% acetonitrile (+ 0.1 % formic acid) in water (+ 0.1 % formic acid) to afford the title compound^! mg, 1.053 mmol, 44% yield). LCMS RT= 1.16 min, ES+ve m/z 463.4 [M+H]+.
(7R R,9S,13S 4S475)-7-(5-(Beni^loxy)pentyl)-13-methyl-7,8,9,ll,12,13,14,15,16,17- decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
Figure imgf000306_0001
Triethylsilane (1.681 mL, 10.53 mmol) was added to a solution of (7S,8i?,9S,13S,14S,17S)-7- (5-(benzyloxy)pentyl)-3 , 17-dihydroxy- 13-methyl-7,8,9, 11 , 12, 13, 14, 15, 16, 17-decahydro-6H- cyclopenta[a]phenanthren-6-one (487 mg, 1.053 mmol) in TFA (6 mL, 78 mmol). The reaction was stirred at room temperature under an atmosphere of nitrogen for 16 hours. The mixture was partitioned between ethyl acetate (30 mL) and brine (30 mL). The organic extract was washed with brine (2 x 30 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The residue was dissolved in MeOH (4 mL) and treated with aqueous NaOH (2M, 4 mL, 8.00 mmol). The reaction mixture was stirred at room
temperature for 3 hours. The solvent was removed under reduced pressure. The residue was partitioned between ethyl acetate (30 mL) and water (30 mL). The organic extract was washed with brine (30 mL), dried (hydrophobic frit) and concentrated under reduced pressure. The product was purified by reverse phase chromatography using a gradient elution from 10%) to 95% acetonitrile (+ 0.1%) formic acid) in water (+ 0.1 % formic acid) to afford the title compound (410 mg, 0.914 mmol, 87% yield). LCMS RT= 1.30 min, ES+ve m/z 449.1
[M+H]+. (7R,8R,9S,13S,14S,17S)-7-(5-(Benzyloxy)pentyI)-3,17-bis(methoxymethoxy)-13-methyl- 7,8,9,ll512,13,14,15,16,17-decahydro-6iy-cyclopenta[a]phenaiithrene
Figure imgf000307_0001
Chloro(methoxy)methane (0.7 mL, 9.22 mmol) was added to solution of
(7R,8R,9S, 13S, 1 AS, 17£)-7-(5-(benzyloxy)pentyl)- 13-methyl-7,8,9, 11 , 12, 13, 14, 15, 16, 17- decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol (410 mg, 0.914 mmol) and DIPEA (2 mL, 11.45 mmol) in THF (8 mL). The reaction vessel was sealed, placed under an
atmosphere of nitrogen and heated at 70 °C for 2 days. The reaction was cooled to room temperature. The reaction was partitioned between ethyl acetate (50 mL) and brine (50 mL). The organic extract was washed with brine (2 x 50 mL), dried using a hydrophobic frit and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 100% methyl tert-butyl ether in cyclohexane to afford the title compound (474 mg, 0.883 mmol, 97% yield). LCMS RT= 1.72 min, ES+ve m/z 554.5
[M+NH4]+.
5-((7R,8R,9S,13S,14S,17S)-3,17-Bis(methoxymethoxy)-13-methyl- 7,8,9,ll,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yI)pentan-l-ol
Figure imgf000307_0002
A mixture of (7i?,8i?,9S, 13S, 14S, 17S)-7-(5-(benzyloxy)pentyl)-3, 17-bis(methoxymethoxy)- 13-methyl-7,8,9,l 1,12,13, 14,15, 16,17-decahydro-6H-cyclopenta[a]phenanthrene (474 mg, 0.883 mmol) and 10% w/w palladium on carbon (100 mg, 0.094 mmol) in ethanol (5 mL) and methyl tert-butyl ether (2 mL) was stirred at room temperature under an atmosphere of hydrogen for 1.5 hours. The palladium was filtered through celite and the filtrate
concentrated under reduced pressure to afford the title compound (371 mg, 0.831 mmol, 94% yield). LCMS RT= 1.39 min, ES+ve m/z 447.5 [M+H]+ (weak ionisation). 5-((7R,8R,9S 3S 4S47S)-3,17-Bis(methoxymethoxy)-13-methyl- 7,8,9,ll,12,13,14,15,16,17-decahydro-6iT-cyclopenta[a]phenanthren-7-yl)pentyl 4- methylbenzenesulfonate
Figure imgf000308_0001
4-Methylbenzene-l-sulfonyl chloride (400 mg, 2.098 mmol) was added to 5- ((7R,8R,9S, 13S, 14S, 175)-3 , 17-bis(methoxymethoxy)- 13 -methyl-7,8,9, 11 , 12, 13 , 14, 15 , 16, 17- decahydro-6H-cyclopenta[a]phenanthren-7-yl)pentan-l-ol (371 mg, 0.831 mmol) in pyridine (5 mL). The reaction mixture was stirred at room temperature for 20 hours. The reaction mixture was partitioned between ethyl acetate (30 mL) and aqueous HC1 (2M, 30 mL). The organic extract was washed with sat Na2C03 (30 mL), brine (30 mL), dried (hydrophobic frit) and concentrated under reduced pressure. The product was purified by chromatography on silica using a gradient elution from 0% to 100% methyl tert-butyl ether in cyclohexane to afford the title compound (401 mg, 0.667 mmol, 80% yield). LCMS RT= 1.60 min, ES+ve
Figure imgf000308_0002
Tert-butyl 18-((7R,8R,95,13S,14S,17S)-3,17-bis(methoxymethoxy)-13-methyl- 7,8,9,ll,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yI)-13-methyl- 4,7,10-trioxa-13-azaoctadecan-l-oate, formic acid salt
Figure imgf000308_0003
A microwave vial was charged with 5-((7J?,8i?,9S,13S,14S,175)-3,17-bis(methoxymethoxy)- 13 -methyl-7,8,9, 11 , 12, 13 , 14, 15 , 16, 17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)pentyl 4-methylbenzenesulfonate (100 mg, 0.166 mmol), tert-butyl 5,8,1 l-trioxa-2-azatetradecan- 14-oate (can be prepared following the procedure described in WO2012054110A2) (145 mg, 0.499 mmol) and DIPEA (0.291 mL, 1.664 mmol) in THF (2 mL). The vial was sealed and placed under an atmosphere of nitrogen using a vacuum purge. The reaction was heated at 75 °C for 48 hours. The reaction was cooled to room temperature. The reaction mixture was subjected directly to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (102 mg, 0.133 mmol, 80% yield). LCMS RT= 1.22 min, ES+ve m/z 720.6 [M+H]+. ,12,13,14,15,16,17- 0-trioxa-13-
Figure imgf000309_0001
7¾rf-butyl 18-((7i?,8i?,9S, 135, 1 AS, 17S)-3 , 17-bis(methoxymethoxy)- 13 -methyl- 7,8,9, 11 , 12, 13, 14, 15, 16, 17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)- 13-methyl-4,7, 10- trioxa-13-azaoctadecan-l-oate, formic acid salt (100 mg, 0.131 mmol) was dissolved in THF (1 mL) and treated with aqueous HC1 (6M, 1 mL, 6.00 mmol). The reaction was stirred at room temperature for 6 hours. The reaction mixture was subjected directly to purification by mass-directed automated preparative HPLC (formic acid modifier) to afford the title compound (24 mg, 0.039 mmol, 30% yield). LCMS RT= 0.74 min, ES+ve m/z 576.5 [M+H]+.
(2S,4R)-l-((S)-2-(re^-butyl)-21-((7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl- 7,8,9,ll,12,13,14,15,16,17-decahydro-6JfiT-cyclopenta[a]phenanthren-7-yl)-16-methyl-4- oxo-7,10,13-trioxa-3,16-diazahenicosan-l-oyl)-4-hydroxy-N-(4-(4-methylthiazoI-5-
Figure imgf000309_0002
HATU (13 mg, 0.034 mmol) was added to a mixture of (2S,4i?)-l-((S)-2-amino-3,3- dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide, hydrochloride (13 mg, 0.028 mmol), 18-((7i?,8i?,95,135,145',175)-3,17-dihydroxy-13-methyl- 7,8,9, 1 1 , 12, 13 , 14, 15, 16, 17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)- 13 -methyl-4,7, 10- trioxa-13-azaoctadecan-l-oic acid, formic acid salt (12 mg, 0.019 mmol) and DIPEA (0.03 mL, 0.172 mmol) in DMF (0.8 mL). The reaction was stirred at room temperature for 10 minutes. The reaction mixture was subjected directly to two purifications by mass-directed automated preparative HPLC (formic acid modifier followed by ammonium carbonate modifier) to afford the title compound (13 mg, 0.013 mmol, 68 % yield). LCMS RT= 0.84 min, ES+ve m/z 988.8 [M+H]+.

Claims

Claims:
1. A compound according to the chemical structure:
ULM
Where L is a linker group and
ULM
is a ubiquitin ligase binding moiety, wherein said linker group is optionally further
PTM
linked to a group.
2. A compound according to the chemical structure:
Figure imgf000311_0001
ULM
is a ubiquitin ligase binding moiety;
Figure imgf000311_0002
is a chemical moiety (protein target moiety) which binds to a target protein or polypeptide which is to be degraded by ubiquitin ligase and is chemically linked directly to
ULM PTM ULM
the group or through a linker moiety L, or is alternatively a
group which is also a ubiquitin ligase binding moiety, which may be the same or different
ULM ULM
than the group and is linked directly to the group directly or through the linker moiety; and
L is a linker moiety which is may be present or absent and when present, chemically
(covalently) links
Figure imgf000311_0003
or
a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate or polymorph thereof.
3. The compound according to claim 2 wherein
Figure imgf000311_0004
group. ULM
4. A compound according to any of claims 1-3 wherein is a group according to the chemical structure:
Figure imgf000312_0001
Where R1 is an optionally substituted Cj-Q alkyl group, an optionally substituted
-(CH2)nOH, an optionally substituted -(CH2)nSH, an optionally substituted (CH2)n-0-(C1- C6)alkyl group, an optionally substituted (CH2)n- WCHOCHW-(Co-C6)alkyl group containing an epoxide moiety where W is independently absent or H, an optionally substituted
-(CH2)nCOOH, an optionally substituted -(CH2)nC(0)-(C1-C6 alkyl), an optionally substituted -(CH2)nNR!R2,an optionally substituted -(CH2)nNHC(0)-Rl5 an optionally substituted
-(CH2)„C(0)-lSI iR2, an optionally substituted -(CH2)nOC(0)-NR1R2, -(CH20)nH, an optionally substituted -(CH2)nOC(0)-(C1-C6 alkyl), an optionally substituted -(CH2)nC(0)-0- (Ci-C6 alkyl), an optionally substituted -(CH20)nCOOH, an optionally substituted - (OCH2)nO-(C1-C6 alkyl), an optionally substituted -(CH20)nC(0)-(C1-C6 alkyl), an optionally substituted -(OCH2)nNHC(0)-R1, an optionally substituted -(CH20)nC(0)-NR1R2, - (CH2CH20)nH, an optionally substituted -(CH2CH20)nCOOH, an optionally substituted - (OCH2CH2)nO-(C1-C6 alkyl), an optionally substituted -(CH2CH20)„C(0)-(C1-C6 alkyl), an optionally substituted -(OCH2CH2)nNHC(0)-Rl5 an optionally substituted
-(CH2CH20)nC(0)-NR1R2,an optionally substituted -S02Rs, an optionally substituted S(0)Rs, N02, CN or halogen (F, CI, Br, I, preferably F or CI);
R\ and R2 are each independently H or a Q-C6 alkyl group which may be optionally substituted with one or two hydroxyl groups or up to three halogen groups (preferably fluorine);
Rs is a Cj-C6 alkyl group, an optionally substituted aryl, heteroaryl or heterocycle group or a -(CFt NR^ group,
X and X' are each independently C=0, C=S, -S(O), S(0)2 , (preferably X and X' are both C=0); R2 is an optionally substituted -(CH2)n-(C=0)u(NRi)v(S02)w(Ci-C6)alkyl group, an optionally substituted RINR2N -(CH2)n-(C=0)u(NR1)v(S02)wNR1NR2N group, an optionally substituted -(CH2)n-(C=0)u(NR1)v(S02)w-Aryl, an optionally substituted
-(CH2)n-(C=0)u(NR1)v(S02)w-Heteroaryl, an optionally substituted
-(CH2)n-(C=0)vNRi(S02)w-Heterocycle, an optionally substituted
-NR1-(CH2)n-C(0)u(NR1)v(S02)w-Ci-C6 alkyl, an optionally substituted
-NR1-(CH2)n-C(0)u(NR1)v(S02)w- NRiNR2N, an optionally substituted
-NR1-(CH2)„-C(0)u(NR1)v(S02)w-NR1C(0)R1N, an optionally substituted
-NR1-(CH2)n-(C=0)u(NR1)v(S02)w-Aryl, an optionally substituted
-NR1-(CH2)n-(C=0)u(NRi)v(S02)w-Heteroaryl or an optionally substituted
-NR1-(CH2)n-(C=0)vNR1(S02)w-Heterocycle, an optionally substituted
-X -CrQ alkyl group; an optionally substituted
-X - Aryl group; an optionally substituted
R2'
-X - Heteroaryl group; an optionally substituted
R2'
-X - Heterocycle group; an optionally substituted;
R is an optionally substituted Cj-C6 alkyl, an optionally substituted
-(CH2)n-C(0)u(NR1)v(S02)w-Ci-C6 alkyl, an optionally substituted
-(CH2)n-C(0)u(NR1)v(S02)w-NR1NR2N, an optionally substituted
-(CH2)n-C(0)u(NRi)v(S02)w-NR1C(0)R1N, an optionally substituted
-(CH2)n-C(0)u(NRi)v(S02)w-C(0)NR1R2, an optionally substituted
-(CH2)n-C(0)u(NR1)v(S02)w-Aryl, an optionally substituted
-(CH2)n-C(0)u(NR1)v(S02)w-Heteroaryl, an optionally substituted
-(CH2)n-C(0)u(NR1)v(S02)w-Heterocycle, an optionally substituted
-NR1-(CH2)n-C(0)u(NR1)v(SO2)w-C1-C6 alkyl, an optionally substituted
-NR1-(CH2)n-C(0)u(NR1)v(S02)w- NR1NR2N, an optionally substituted
-NR1-(CH2)„-C(0)u(NRi)v(S02)w- NR!C(0)R1N, an optionally substituted
-NR1-(CH2)n-C(0)u(NRi)v(S02)w-Aryl, an optionally substituted
-NR1-(CH2)n-C(0)u(NR1)v(S02)w-Heteroaryl, an optionally substituted
-NR1-(CH2)„-C(0)u(NRi)v(S02)w-Heterocycle, an optionally substituted
-0-(CH2)n-(C=0)u(NR1)v(S02)w-Ci-C6 alkyl, an optionally substituted
-0-(CH2)n-(C=0)u(NRi)v(S02)w-NR1NR2N, an optionally substituted
-0-(CH2)n-(C=0)u(NR1)v(S02)w-NR1C(0)R1N, an optionally substituted
-0-(CH2)n-(C=0)u(NR1)v(S02)w-Aryl, an optionally substituted -0-(CH2)n-(C=0)u(NRi)v(S02)w-Heteroaryl or an optionally substituted
-0-(CH2)n- (C=0)u(NRi)v(S02)w-Heterocycle;
-(CH2)n-(V)n'-(CH2)n-(V)n'-Cj-C6 alkyl group, an optionally substituted
-(CH2)n-(V)n'-(CH2)n-(V)n'-Aryl group, an optionally substituted
-(CH2)n-(V)n'-(CH2)n-(V)n'-Heteroaryl group, an optionally substituted
-(CH2)n-(V)n'-(CH2)n-(V)n'-Heterocycle group, an optionally substituted
-(CH2)n-N(Rr)(C=0)m'-(V)n'-Ci-C6 alkyl group, an optionally substituted
-(CH2)n-N(Rr)(C=0)m'-(V)n'-Aryl group, an optionally substituted
-(CH2)n-N(R1')(C=0)m'-(V)n-Heteroaryl group, an optionally substituted
-(CH2)n-N(R1 ')(C=0)m'-(V)n'-Heterocycle group, an optionally substituted
-X -C!-C6 alkyl group; an optionally substituted
-X - Aryl group; an optionally substituted
-X - Heteroaryl group; an optionally substituted
-X - Heterocycle group; an optionally substituted;
Where Km and R2N are each independently H, C!-C6 alkyl which is optionally substituted with one or two hydroxyl groups and up to three halogen groups or an optionally substituted
-(CH2)n-Aryl, -(CH2)n-Heteroaryl or -(CH2)n-Heterocycle group;
V is O, S or NR!;
Ri is the same as above;
R! and Rr are each independently H or a C!-C3 alkyl group;
X" and X are each independently an optionally substituted -CH2)n-, -CH2)n-
CH(XV)=CH(XV)- (cis or trans), -CH2)n-CH≡CH- , -(CH2CH20)n- or a C3-C6 cycloalkyl group, where Xv is H, a halo or a C1-C3 alkyl group which is optionally substituted;
Each m is independently 0, 1 , 2, 3, 4, 5, 6;
Each m' is independently 0 or 1 ;
Each n is independently 0, 1 , 2, 3, 4, 5, 6;
Each n' is independently 0 or 1 ;
Each u is independently 0 or 1 ;
Each v is independently 0 or 1 ;
Each w is independently 0 or 1 ; and
ULM
wherein any one or more of R^ R^ R^ X and X' of is modified to be covalently
PTM
bonded to said group either directly or through said linker group, or a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
5. A compound according to any of claims 1-4 wherein
Figure imgf000315_0002
, when
PTM
present as a group, is each independently a group according to the chemical structure:
R1'
Figure imgf000315_0001
Wherein each of R1 ', R2 and RJ are the same as in claim 4 above and X is a C=0, C=S, -S(O) group or a S(0)2 group, and
wherein any one or more ofR1 , R and RJ are modified to bind a linker group which is
PTM
further covalently bonded to the group, or
a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
6. A compound according to claim 5 wherein X is C=0.
7. A compound according to any of claims 4-6 wherein R1 is a hydroxyl group or a group which may be metabolized to a hydroxyl or carboxylic group, such that the compound represents a prodrug form of an active compound.
8. A compound according to any of claims 4-7 wherein R1 is -(CH2)nOH, -(CH2)nSH, (CH2)n-0-(C1-C6)alkyl, -(CH2)nCOOH, -(CH20)nH, an optionally substituted -(CH2)nOC(0)- (C!-C6 alkyl), or an optionally substituted -(CH2)nC(0)-0-(C1-C6 alkyl), wherein n is 0 or 1
9. A compound according to any of claims 4-8 wherein R1 is or contains a carboxylic acid group, a hydroxyl group or an amine group, each of the hydroxyl group, carboxylic acid group or amine group being capable of being further chemically modified to provide a
PTM
covalent link to a linker group to which the group is bonded.
10. The compound according to any of claims 4-9 wherein R is an optionally substituted -NR'-T-Aryl, an optionally substituted -NR^T-Heteroaryl group or an optionally substituted -NR'-T-Heterocycle, where R1 is H or CH3, preferably H; and
T is an optionally substituted -(CH2)n- group, wherein each one of the methylene groups may be optionally substituted with one or two substituents, which may be optionally substituted; and n is 0, 1, 2 or 3.
11. The compound according to claim 10 wherein said Aryl group is an optionally substituted phenyl or naphthyl group, wherein said phenyl or naphthyl group is optionally
PTM
substituted with a linker group to which is attached a 1 ' group, a halogen, an amine, a monoalkyl- or dialkyl amine, OH, SH, COOH, CH3, CF3, OMe, OCF3, N02, CN group or an optionally substituted phenyl group, the phenyl group itself being optionally substituted with
PTM
a linker group attached to a 1 1 group and optionally at least one of F, CI, OH, SH,
COOH, CH3, CF3, OMe, OCF3, N02, or CN group, a naphthyl group, which may be optionally substituted, an optionally substituted heteroaryl or an optionally substituted heterocycle, each of which groups may be optionally substituted with a linker group to which
PTM
is attached a group.
12. The compound according to claim 10 wherein said Aryl group is a phenyl group which is optionally substituted with a heteroaryl group.
13. The compound according to claim 10 wherein said Heteroaryl is an optionally substituted isoxazole, an optionally substituted oxazole, an optionally substituted thiazole, an optionally substituted pyrrole, an optionally substituted imidazole, an optionally substituted diazole, an optionally substituted triazole, or an optionally substituted pyridine group, wherein said heteroaryl group is optionally substituted with a linker group to which is PTM
attached a ' ' group.
14. The compound according to claim 13 wherein said isoxazole is a methylsubstituted isoxazole, said oxazole is a methyl substituted oxazole, said thiazole is a methyl substituted thiazole, said pyrrole is a methylsubstituted pyrrole, said imidazole is a methylimidazole, a benzylimidazole, methoxybenzylimidazole, oximidazole or methyloximidazole, said diasole is a methyldiazole, said triazole is a methylsubstituted triazole, and said pyridine group is a halo-substituted pyridine, a methylsubstitutedpyridine group or an oxapyridine group where the pyridine group is linked to the phenyl group by an oxygen.
15. The compound according to claim 10 wherein said Aryl group is a phenyl group which is optionally substituted with a heterocycle group.
16. The compound according to claim 15 wherein said heterocycle group is an optionally substituted tetrahydrofuran, tetrahydrothiene, tetrahydroquinoline, piperidine, piperazine, oxane, thiane, pyrrolidine or morpholine.
17. The compound according to claim 16 wherein said heterocycle group is optionally
PTM
substituted with a linker group to which is attached a ' 1 group.
18. The compound according to claim 10 wherein said Heterocycle is an optionallyl substituted tetrahydrofuran, tetrahydrothiene, tetrahydroquinoline, piperidine, piperazine, oxane, thiane, pyrrollidine or morpholine.
19. The compound according to claim 11 wherein said Aryl group is a phenyl group which is optionally substituted with a halogen, an amine, monoalkylamine, dialkylamine, OH, SH, COOH, C¾, CF3, OMe, OCF3, N02, or CN group, an optionally substituted phenyl group, wherein said phenyl group is itself optionally substituted with at least one of F, CI, OH, SH, COOH, CH3, CF3, OMe, OCF3, N02, or CN group, a naphthyl group, which may be optionally substituted, or an optionally substituted heteroaryl or heterocycle group.
20. The compound according to claim 19 wherein said optionally substituted heteroaryl is an optionally substituted isoxazole, an optionally substituted oxazole, an optionally substituted thiazole, an optionally substituted pyrrole, an optionally substituted imidazole, an optionally substituted benzimidazole, an optionally substituted oximidazole an optionally substituted diazole group, including a methyldiazole group, an optionally substituted triazole group, including a methylsubstituted triazole group, an optionally substituted pyridine group, including a halo- (preferably, F) or methylsubstitutedpyridine group or an oxapyridine group, an optionally substituted furan, an optionally substituted benzofuran, an optionally substituted dihydrobenzofuran, an optionally substituted indole, an optionally substituted indolizine, an optionally substitutedazaindolizine, an optionally substituted quinoline, or an optionally substituted group according to the chemical structure:
Figure imgf000318_0001
Where S° is CHR , NR. , or O;
RHET is H, CN, N02, halo (preferably CI or F), optionally substituted Q-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups (e.g. CF3), optionally substituted 0(Ci-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted acetylenic group -C≡C-Ra where Ra is H or a C!-C6 alkyl group (preferably C C3 alkyl); IT* is H, CN, N02, halo (preferably F or CI), optionally substituted C]-C6 alkyl (preferably substituted with one or two hydroxyl groups or up to three halo groups), optionally
substituted 0-(C!-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups) or an optionally substituted -C(0)(C!-C6 alkyl) (preferably substituted with one or two hydroxyl groups or up to three halo groups);
RURE is H, a C]-C6 alkyl (preferably H or C1-C3 alkyl) or a-C(0)(C C6 alkyl) each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogen, preferably fluorine groups, or an optionally substituted phenyl group, an optionally
substituted heteroaryl, or an optionally substituted heterocycle, preferably for example piperidine, morpholine, pyrrolidine, tetrahydrofuran);
RPR0 is H, optionally substituted C!-C6 alkyl or an optionally substituted aryl group or an optionally substituted heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, benzofuran, indole, indolizine, azaindolizine; RPR01 and RPR02 are each independently H, an optionally subsituted Ci-C3 alkyl group or together form a keto group and
Each n is independently 0, 1, 2, 3, 4, 5, or 6, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
21. The compound according to claim 19 wherein said optionally substituted heterocycle is selected from the group consisting of pyrollidine, furan, tetrahydrofuran, tetrahydrothiene, piperidine, piperazine and morpholine.
22. The compound according to any of claims 1-21 wherein R3' is an optionally substituted -T-Aryl, an optionally substituted, -T-Heteroaryl, an optionally substituted
-T-Heterocycle, an optionally substituted -NR1 -T-Aryl, an optionally substituted
-NR1 -T-Heteroaryl or an optionally substituted -NR1 -T-Heterocycle; and
T is a -(CH2)n group, -(CH20)n- group, a -(OCH2)n- group, a -(CH2CH20)n- group, or a -(OCH2CH2)n- group, each of which groups is optionally substituted with one or two substituents; and n is 0, 1, 2 or 3.
23. The compound according to claim 22 wherein said Aryl group is an optionally
substituted phenyl or naphthyl group, wherein said phenyl or naphthyl group is optionally PTM
substituted with a linker group to which is attached a 1 ' group, or a halogen group, an amine, a monoalkyl- or dialkyl amine, OH, SH, COOH, CH3, CF3, OMe, OCF3, N02, CN, or a S(0)2 s group where Rs is a Cj-C6 alkyl group, a -(CH2)mNR1R2 group or an optionally substituted aryl, heteroaryl or heterocycle group, each of which may be substituted in ortho-, meta- or para- positions of the phenyl ring, or said Aryl group is optionally substituted, with an optionally substituted aryl group, an optionally substituted heteroaryl or an optionally substituted heterocycle, each of which groups may be optionally substituted with a linker
PTM
group to which is attached a group.
24. The compound according to claim 23 wherein said heteroaryl is an optionally substituted isoxazole, an optionally substituted oxazole, an optionally substituted thiazole, an optionally substituted isothiazole, an optionally substituted pyrrole, an optionally substituted imidazole, an optionally substituted oximidazole, an optionally substituted diazole, an optionally substituted triazole group, an optionally substituted pyridine group or an optionally substituted oxapyridine group, wherein said heteroaryl group is optionally substituted with a
PTM
linker group to which is attached a group.
25. The compound according to claim 24 wherein said optionally substituted isoxazole is a methylsubstituted isoxazole, said optionally substituted oxazole is a methylsubstituted oxazole, said optionally substituted thiazole is a methyl substituted thiazole, said optionally substituted isothiazole is a methyl substituted isothiazole, said optionally substituted pyrrole is a methylsubstituted pyrrole, said optionally substituted imidazole is a
a methylimidazole, a benzylimidazole or a methoxybenzylimidazole, said optionally substituted oximidazole is a methyloximidazole, said optionally substituted diazole is a methyldiazole, said optionally substituted triazole group is a methylsubstituted triazole group, said optionally substituted pyridine group is a halosubstituted or methylsubstitutedpyridine and said oxapyridine group is linked to the phenyl group by an oxygen.
26. The compound according to claim 23 wherein said heterocycle group is an optionally substituted tetrahydroquinoline, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, pyrrollidine, morpholine, oxane or thiane.
27. The compound according to claim 26 wherein said heterocycle group is optionally
PTM
substituted with a linker group to which is attached a ' ' group.
28. The compound according to claim 22 wherein said Heteroaryl group is an optionally substituted quinoline, an optionally substituted indole, an optionally sμbstituted isoxazole, an optionally substituted benzofuran, an optionally substituted thiophene or an optionally substituted pyridine.
29. The compound according to claim 28 wherein said isoxazole is a methylsubstituted isoxazole.
30. The compound according to claim 28 wherein said thiophene is a methylsubstituted thiophene.
31. The compound according to claim 28 wherein said pyridine is methylsubstituted.
32. The compound according to claim 22 wherein said Heterocycle is selected from the group consisting of tetrahydrofuran, tetrahydrothiophene, tetrahydroquinoline, piperidine, piperazine, pyrrolidine, morpholine, oxane or thiane, each of which groups is optionally
PTM
substituted with a linker group to which is attached a group.
33. The compound according to claim 22 wherein said heteroaryl group is an optionally substituted isoxazole, an optionally substituted oxazole, an optionally substituted thiazole, an optionally substituted pyrrole, an optionally substituted imidazole, an optionally substituted oximidazole, an optionally substituted diazole is a methyldiazole, an optionally substituted triazole group, an optionally substituted pyridine group or an optionallyl substituted oxapyridine group.
34. The compound according to claim 33 wherein said optionally substituted isoxazole is a methylsubstituted isoxazole, said optionally substituted oxazole is a methylsubstituted oxazole, said optionally substituted thiazole a methyl substituted thiazole, said optionally substituted pyrrole is a methylsubstituted pyrrole, said optionally substituted imidazole is a a methylimidazole, a benzylimidazole or a methoxybenzylimidazole, said optionally substituted oximidazole is a methyloximidazole, said optionally substituted diazole is a methyldiazole, said optionally substituted triazole group is a methylsubstituted triazole group, said optionally substituted pyridine group is a halosubstituted or methylsubstitutedpyridine and said oxapyridine group is linked to the phenyl group by an oxygen.
35. The compound according to claim 22 wherein said Heteroaryl group is an optionally substituted quinoline, an optionally substituted indole, an optionally substituted
benzimidazole, an optionally substituted benzodiazole, an optionally substituted
benzoxofuran, an optionally substituted imidazole, an optionally substituted isoxazole, an optionally substituted oxazole, an optionally substituted diazole, an optionally substituted benzofuran, an optionally substituted thiophene, an optionally substituted thiazole, an optionally substituted triazole, a triisopropylsilyl group, an optionally substituted -(CH2)m-0- C]-C6 alkyl group, an optionally substituted -(CH2)m-C(0)-0-C1-C6 alkyl group) or an optionally substituted 2-, 3, or 4-pyridine and m is 0, 1, 2, 3, 4, 5, or 6.
36. The compound according to claim 35 wherein said Heteroaryl group is a
methylsubstituted oxazole or a triazole which is optionally substituted with a methyl group, a triisopropylsilyl group, an optionally substituted -(CH2)m-0-Ci-C6 alkyl group or an optionally substituted -(CH2)m-C(0)-0-Ci-C6 alkyl group).
37. The compound according to claim 22 wherein said Heterocycle is selected from the group consisting of tetrahydroquinoline, tetrahydrofuran, tetrahydrothiene, piperidine, piperazine, pyrrollidine and morpholine, each of which groups may be optionally substituted.
38. A compound according to any of claims 1-4 wherein
Figure imgf000322_0001
, when
PTM
present as a group, is each independently a group according to the chemical structure:
Figure imgf000323_0001
Where R1 is OH or a group which can be metabolized in a patient or subject to OH;
R2' is an optionally substituted -NR^X1 2 -alkyl group, an optionally substituted -NRj-X1*2 -
Aryl group; an optionally substituted -NRr Xs2 -HET group, an optionally substituted -NR]-
X^'-Aryl-HET group or an optionally substituted -NR X^'-HET-Aryl group,
Ri is H or a C!-C3 alkyl group;
X 2' is an optionally substituted -CH2)n- , -CH2)n-CH(Xv)=CH(Xv)- (cis or trans),
-CH2)n-CH≡CH-, -(CH2CH2O)n- or a C3-C6 cycloalkyl group;
R3 is an optionally substituted -(CH2)n-(V)n'-(CH2)n-(V)n>-RS3 group, an optionally substituted -(CH2)n-N(Rr)(C=O)m-(V)n'-RS3' group, an optionally substituted -XR3'-alkyl group, an optionally substituted -XR3 -Aryl group; an optionally substituted -XR3 -HET group, an optionally substituted -XR3 -Aryl-HET group or an optionally substituted -XR3 -HET-Ajyl group,
RS3 is an optionally substituted Q-CJO alkyl group, an optionally substituted Aryl group or a HET group;
R is H or a Q-C3 alkyl group;
V is O, S or NRr;
XR3' is an optionally substituted -CH2)n- , -CH2)n-CH(Xv)=CH(Xv)- (cis or trans),
-CH2)n-CH≡CH-, -(CH2CH2O)n- or a C3-C6 cycloalkyl group;
Xv is H, a halo or a C1-C3 alkyl group which is optionally substituted with one or two hydroxyl groups or up to three halogen groups;
Alkyl is an optionally substituted Q-Cio alkyl group;
Aryl is an optionally substituted phenyl or naphthyl group; and
HET is an optionally substituted oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyroUidine, furan, dihydrofuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, benzofuran, indole, indolizine, azaindolizine, quinoline or a group according to the chemical structure:
Figure imgf000324_0001
Where Sc is CHRSS, NR , or O;
RHET is H, CN, N02, halo, optionally substituted Cj-C6 alkyl, optionally substituted 0(Ci-C6 alkyl) or an optionally substituted acetylenic group -C≡C-Ra where Ra is H or a C!-C6 alkyl group;
Rss is H, CN, N02, halo, optionally substituted d-C6 alkyl, optionally substituted 0-(d-C6 alkyl) or an optionally substituted -C(0)(Ci-C6 alkyl;
RURE is H, a d-C6 alkyl or a -C(0)(C!-C6 alkyl), each of which groups is optionally substituted with one or two hydroxyl groups or up to three halogens, or an optionally substituted heterocycle; and Yc is N or C-RYC, where RYC is H, OH, CN, N02, halo, optionally substituted d-C6 alkyl, optionally substituted 0(Ci-C6 alkyl) or an optionally substituted acetylenic group -C≡C-Ra where Ra is the same as above;
RPR0 is H, optionally substituted Ci-C6 alkyl or an optionally substituted aryl or an optionally substituted heteroaryl or heterocyclic group selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, diazole, oximidazole, pyrrole, pyrollidine, furan, dihydroiuran, tetrahydrofuran, thiene, dihydrothiene, tetrahydrothiene, pyridine, piperidine, piperazine, morpholine, quinoline, benzofuran, indole, indolizine, azaindolizine;
RPR01 and RPR02 are each independently H, an optionally subsituted Cj-C3 alkyl group or together form a keto group,
m' is 0 or 1 ;
Each n is independently 0, 1, 2, 3, 4, 5, or 6 and
Each n' is independently 0 or 1 ,
ULM
and wherein said group is covalently bonded to a linker group to which is attached
PTM
group, or a
pharmaceutically acceptable salt, stereoisomer, solvent or polymorph thereof.
39. A compound according to any of claims 1-4 wherein
Figure imgf000325_0002
when
PTM
present as a group, is each independently a group according to the chemical structure:
Figure imgf000325_0001
Where R1' is OH or a group which is metabolized in a patient or subject to OH; -NH-CH2-Aryl-HET;
RJ is a -CHR^'-NH-C O)-^ , 31P'11 group or a -CHR^ CR3' -R.j3rP2 g. roup
Where RLKJ is a d-C4 alkyl group;
R is C C3 alkyl nOCH3 group
where n is 1 or 2, o
Figure imgf000326_0001
CH3CH20- group is linked to phenyl in a meta or para position, or a morpholino group linked to the carbonyl at the 2- or 3-position;
R3P2 is a
Figure imgf000326_0002
group,
Where Aryl is phenyl;
HET is an optionally substituted thiazole or isothiazole;
RHHT is H or a halo group; and
ULM
wherein said group is covalently bonded to a linker group to which is attached a
PTM
group, or
a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
ULM
40. A compound according to claim 39 wherein said group is a group according to the chemical structure:
Figure imgf000326_0003
Figure imgf000327_0001
Figure imgf000327_0002
326
Figure imgf000328_0001
Figure imgf000328_0002
ULM
wherein said group is covalently bonded to a linker group to which is attached a
Figure imgf000328_0003
group, or
a pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
ULM
39. The compound according to any of claims 1-3 wherein said is
Figure imgf000329_0001
Where X is CI, F, Q-C3 alkyl or an optionalllyi substituted heterocycle;
j
R and R are each independently H, C1-C3 alkyl, or phenyl; and
ULM
Where said group is substituted with a linker group or a linker group to which is
PTM
optionally attached a group, or
a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof
ULM
40. The compound according to any of claims 1-3 wherein said group is
Figure imgf000329_0002
Where n is 0 or 1 ;
PTM
R is a linker or a linker attached to a group; and
X is H, F, CI, Q-C3 alkyl or heterocycle;
ULM
Wherein said group is substituted with a linker group or a linker group to which is
PTM
optionally attached a group, or
A pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof. ULM
41. The compound according to any of claims 1 -4 wherein said group is
Figure imgf000330_0001
Where n is 0 or 1 ;
PTM PTM
R is a linker or a linker attached to a group a linker or a linker attached to a
ULM
group linked to the 1 1 group through an amide, ester, ether or carbamate group;
R1 is C!-C3 alkyl optionally substituted with one or two hydroxyl groups or -C(0)NR3R4 where R3 and R4 are each independently H, C1-C3 alkyl, or phenyl; and
X is H, F, CI, Ci-C3 alkyl or optionally substituted heterocycle, or a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
ULM
The compound according to claim 1 or 2 wherein said group is:
Figure imgf000330_0002
Where n is 0 or 1;
PTM ULM
R is a linker or a linker attached to a group linked to the group through an amide, ester, ether, carbamate or heterocyclic group; and R is H, F, CI, C1-C3 alkyl optionally substituted with one or two hydroxyl groups, -O- C(0)NR3R4 or -C(0)NR3R4 wherein each of R3 and R4 is independently H, Q-C3 alkyl or phenyl, or
A pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
ULM
The compound according to any of claims 1-3 wherein said group is:
Figure imgf000331_0001
Where n is 0 or 1 :
PTM ULM
R is a linker or a linker attached to a group linked to the group through an amide, ester, ether, carbamate or heterocyclic group; and
Each X is independently is H, F, CI, C!-C3 alkyl optionally substituted with one or two hydroxyl groups, heterocyle, -0-C(0)NR3R4 or -C(0)NR3R4 wherein each of R3 and R4 is independently H, C1-C3 alkyl (preferably methyl), or phenyl, or
a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
ULM
The compound according to any of claims 1-3 wherein said group is:
Figure imgf000331_0002
Where n is 0 or 1 ; PTM ULM
R is a linker or a linker attached to a group linked to the group through an amide, ester, ether, carbamate or heterocyclic group;
R1 is C!-C3 alkyl group optionally substituted with one or two hydroxyl groups,
-0-C(0)NR3R4 or -C(0)NR3R4 wherein each of R3 and R4 is independently H, CrC3 alkyl or phenyl; and
X is independently is H, F, CI, Cj-C3 alkyl optionally substituted with one or two hydroxyl . groups or a heterocycle group, or
a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof.
ULM
The compound according to any of claims 1 -3 wherein said group is:
Figure imgf000332_0001
Where n is 0 or 1 ;
PTM ULM
R is a linker or a linker attached to a group linked to the group through an amide, ester, ether, carbamate or heterocyclic group;
R1 is H, Ci-C3 alkyl, which is optionally substituted with one or two hydroxyl groups, -0-C(0)NR3R4 or -C(0)NR3R4 wherein each of R3 and R4 is independently H, Q-C3 alkyl or phenyl; and
Each X is independently is H, F, CI, C1-C3 alkyl optionally substituted with one or two hydroxyl groups or a heterocycle, or
a pharmaceutically acceptable salt, enantiomer, diasteromer, solvate or polymorph thereof. 46. The compound according to any of claims 1-45 wherein said linker group L is a group:
Figure imgf000332_0002
ULM
Where Z is a group which links to X; and
PTM
X is a group linking Z to group ' ' .
47. The compound according to claim 46 wherein Z is absent (a bond), -(CH2)j-0, -(CH2)i-S,
Figure imgf000333_0001
group wherein Xj Yj forms an amide group, or a urethane group, ester or thioester group, or a
Figure imgf000333_0002
Each R is H, or a CrC3 alkyl, an alkanol group or a water soluble heterocyclic group;
Each Y is independently a bond, O, S or N-R;
and each i is independently 0 to 100.
48. The compound according to claim 47 wherein i is 1 to 10.
49. The compound according to claim 47 wherein i is 1 to 5.
50. The compound according to claim 47 wherein said water soluble heterocyclic group is morpholine, piperidine or piperazine.
51. The compound according to any of claims 46-50 wherein X is a
Figure imgf000333_0003
Where each D is independently a bond (absent),
O
— (CH2) -Y-C-Y (CH2) -.
'rri ; or
Figure imgf000334_0001
j is 1 to 100;
k is 1 to 100;
m' is 1 to 100;
n is i to 100;
X1 is 0, S orN-R;
R and Y are the same as in claim 32; and
CON is a bond or a connector group which connects Z to X, when present in the linker group.
52. The compound according to claim 51 wherein j is 1 to 10; k is 1 to 10, m; is 1 to 10 and n is i to 10.
CON
53. The compound according to claim 51 or 52 wherein is a bond (absent), a piperazinyl group or a
Figure imgf000334_0002
group,
Where X2 is O, S, NR4, S(0), S(0)2, -S(0)20, -OS(0)2, or OS(0)20;
X3 is O, S, CHR4, NR4; and
R4 is H or a Cj-C3 alkyl group, which is optionally substituted with onen or two hydroxyl groups. CO
54. The compound according to any of claims 51-53 wherein I 1
Figure imgf000335_0001
an amide group or a piperazinyl group.
ULM
A compound according to claim 1 wherein said group is a group according to
Affinity Table 2 or Figure 15 hereof which is modified to be covalently bonded to the
Figure imgf000335_0002
group through a linker group.
I IJLM
56. A compound according to claim 1 wherein said 1 group is a group according to the chemical structure:
Figure imgf000335_0003
Figure imgf000335_0004
Figure imgf000335_0005
Figure imgf000336_0001
335
Figure imgf000337_0001
Figure imgf000338_0001
337
Figure imgf000339_0001
338
Figure imgf000340_0001
339
Figure imgf000341_0001
Figure imgf000341_0002
340
Figure imgf000342_0001
Figure imgf000342_0002
Figure imgf000342_0003
341
Figure imgf000343_0001
342
Figure imgf000344_0001
Figure imgf000344_0002
Figure imgf000344_0003
Figure imgf000345_0001
Figure imgf000345_0002
344
Figure imgf000346_0001
PTM
which is modified to be covalently bonded to the group through a linker group, or Or a pharmaceutically acceptable salt thereof.
ULM
57. A compound according to claim 1 wherein said group is a group according to the chemical structure:
Figure imgf000347_0001
346
Figure imgf000348_0001
Figure imgf000348_0002
Figure imgf000349_0001
Figure imgf000349_0002
348
Figure imgf000350_0001
Figure imgf000350_0002
349
Figure imgf000351_0001
Figure imgf000351_0002
Figure imgf000351_0003
Figure imgf000352_0001
Figure imgf000352_0002
351
Figure imgf000353_0001
352
Figure imgf000354_0001
PTM
which is modified to be covalently bonded to the group through a linker group, or Or a pharmaceutically acceptable salt thereof.
58. A compound according to any one of the chemical structures set forth in figure 19 hereof:
wherein any one or more of R1PC, R2pc, R3PC, 4PC, R5PC, R6PC, 7PC, RSPC, ¾PC, RIOPC, Rupc , R12PC , Ri3PC and R14PC is a
Figure imgf000354_0002
group,
PTM
Where L is a linker group and is a protein targeting moiety, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thererof.
59. The compound according to claim 58 wherein no more than two of Ripe, R2P0 R3pc> PC,
R9PC5 RIOPC> Rape , I2PC , Rope and R14pc is a
Figure imgf000355_0001
group and the other of groups R1PC, R2pc, R3PC, RJPC, R5pc, Repc, 7PC, R8PC, R9PC RIOPC, Riipc , R12PC , ope and R1 PC are independently H or a CH3 group.
60. The compound according to claim 59 wherein only one of groups Ripe, R2pc, R3PC, 4PC,
R9PC5 RIOPC> Ri IPC , Ri2pc , Rope and R14pc is a
Figure imgf000355_0002
group and the other of groups R1PC, R2pc, R3PC, 4PC, RSPC, Repc,
R7pc, R8PG, R9PC, RIOPC, RIIPC , R12PC , I3PC and R14pc are independently H or a CH3 group.
61. The compound according to claim 60 wherein said other groups R^c, R2P R3PC» R4P0 R5pc, R6PC, R7PC5 R8PC R9PC5 RIOPC, RI IPC , Ri2pc , RI3PC and R1 PC are each H.
62. A compound according to claim 58 according to the chemical strucure:
Figure imgf000355_0003
P
Wherein R7PC and RIOPC are each independently a L- TM
group or H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
63. The compound according to claim 62 wherein either of R7pc or RIOPC is a
Figure imgf000355_0004
64. A compound according to claim 58 according to the chemical structure: Wherein
Figure imgf000356_0001
R PC is a L- PTM
group, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
65. A compound of claim 58 according to the chemical structure:
Figure imgf000356_0002
Wherein R7PC, Rnpc Rnpc, npc an R14pc are each ndependently a
group or H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
66. The compound according to claim 65 wherein one of R7PC, Rnpc, i2PC, RBPC andR1 Pc
Figure imgf000356_0003
group, and the other groups are H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof. compound according to claim 58 according to the chemical structure:
Figure imgf000357_0001
and RI4PC are each independently a
Figure imgf000357_0002
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
68. The compound according to claim 67 wherein any one of R4PC, R7PC, Ri lpc, Ri2PC, Ri3Pc
Figure imgf000357_0003
group and the other groups are H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
69. A compound according to claim 58 according to the chemical structure:
Figure imgf000357_0004
RI3PC andR14Pc are each independently a
Figure imgf000357_0005
r H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
70. The compound according to claim 70 wherein one of R3PC, R7pc, Riipc, Ri2Pc, Ri3Pc and
Figure imgf000358_0001
group and the other groups are H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
A compound of claim 58 according to the chemical structure:
Figure imgf000358_0002
group or H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
72. A compound according to claim 71 wherein one of R7PC and RIQPC is a
Figure imgf000358_0003
group and the other group is H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
A compound of claim 58 according to the chemical structure:
Figure imgf000358_0004
Wherein R7pc and Rjopc are each independently a
Figure imgf000358_0005
L- PTM
group or H and R PC is H or CH3, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
74. The compound according to claim 73 wherein one of R7pcandRiopc is a
Figure imgf000359_0001
group and the other group is H and Rgpc is H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
75. A compound according to claim 58 according to the chemical structure:
Figure imgf000359_0002
group or H and Rgpc is H or CH3, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
76. The compound according to claim 75 wherein one of R7pcand R10pc is a
Figure imgf000359_0003
group and the other of R7pc and R10PC is H and Rgpc is H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
77. A compound according to claim 58 according to the chemical structure:
Figure imgf000359_0004
Wherein R7pc andR10pc are each independently a L- PTM
group or H and Rgpc is H or CH3, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
78. A compound according to claim 77 wherein one of R7PC and Riopc is a
Figure imgf000360_0001
group and the other group is H and Rgpc is H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
79. A compound of claim 58 according to the chemical structure:
Figure imgf000360_0002
Wherein R7pc and RIOPC are each independently a L- PTM
group or H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
80. A compound according to claim 79 wherein one of R7pc and RIOPC is a
Figure imgf000360_0003
group and the other group is H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
A compound of claim 58 according to the chemical structure:
Figure imgf000360_0004
group or H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
82. The compound according to claim 81 wherein one of R7PC andR9pc is a
Figure imgf000361_0001
group and the other group is H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
83. A compound of claim 58 according to the chemical structure:
Wherei
Figure imgf000361_0002
n R7PC and RHPC are each independently a L- PTM
group or H and each of R12pc and R]3PC is H or CH3, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
84. The compound according to claim 83 wherein one of R7pc and R14PC is a
Figure imgf000361_0003
group and the other of R7Pc and R14PC group is H and each of R12PC and R13PC is H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
85. A compound of claim 58 according to the chemical structure:
Figure imgf000361_0004
Wherein R pc and R9pc are each independently a
Figure imgf000362_0001
group or H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
86. The compound according to claim 85 wherein one of R7pcandR9pc is a
Figure imgf000362_0002
group and the other group is H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
87. A compound of claim 58 according to the chemical structure:
Wherein R7pc andR9pc
Figure imgf000362_0003
are each independently a group or H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
88. The compound according to claim 87 wherein one of R7pc andR9pc is a
Figure imgf000362_0004
group and the other group is H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
89. A compound according to claim 58 according to the chemical structure:
Figure imgf000363_0001
Wherein R PC andRiopc are each independently a
Figure imgf000363_0002
L- PTM
group or H and R9pc is H or C¾, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
90. The compound according to claim 89 wherein one of R7pcandR10pc is a
Figure imgf000363_0003
group and the other group is H, and R9PC is H, or
A pharmaceutically acceptable salt, stereoisomer, solvate or polymorph thereof.
91. The compound according to any of claims 58 to 80 wherein said linker group is a polyethylene group containing about 2 to about 20 ethylene glycol units.
92. The compound according to claim 91 wherein said polyethylene glycol group contains between about 2 and 8 ethylene glycol units.
PTM
93. The compound according to any of claims 1-92 wherein said group is a C! to C12 alkylhalo group.
94. The compound according to claim 93 wherein said alkylhalo group is a C2 to C10 alkylhalo group wherein said halo group is CI or Br.
95. The compound according to claim 94 wherein said linker group is a polyethylene glycol group ranging in size from about 2 to about 8 ethylene glycol units. PTM
96. A compound according to any of claims 1-92 wherein said group is a moiety which binds to a target protein, wherein said target protein is selected from the group consisting of structural proteins, receptors, enzymes, cell surface proteins, proteins pertinent to the integrated function of a cell, including proteins involved in catalytic activity, aromatase activity, motor activity, helicase activity, metabolic processes (anabolism and catrabolism), antioxidant activity, proteolysis, biosynthesis, proteins with kinase activity, oxidoreductase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, ligase activity, enzyme regulator activity, signal transducer activity, structural molecule activity, binding activity (protein, lipid carbohydrate), receptor activity, cell motility, membrane fusion, cell communication, regulation of biological processes, development, cell
differentiation, response to stimulus, behavioral proteins, cell adhesion proteins, proteins involved in cell death, proteins involved in transport (including protein transporter activity, nuclear transport, ion transporter activity, channel transporter activity, carrier activity, permease activity, secretion activity, electron transporter activity, pathogenesis, chaperone regulator activity, nucleic acid binding activity, transcription regulator activity, extracellular organization and biogenesis activity and translation regulator activity.
PTM
A compound according to any of claims 1-92 wherein said group is a moiety which binds to a target protein, wherein said target protein is selected from the group consisting of B7.1 and B7, TI FRlm, TNFR2, NADPH oxidase, BclIBax and other partners in the apotosis pathway, C5a receptor, HMG-CoA reductase, PDE V phosphodiesterase type, PDE IV phosphodiesterase type 4, PDE I, PDEII, PDEIII, squalene cyclase inhibitor, CXCRl, CXCR2, nitric oxide (NO) synthase, cyclo-oxygenase 1, cyclo-oxygenase 2, 5HT receptors, dopamine receptors, G Proteins, i.e., Gq, histamine receptors, 5 -lipoxygenase, tryptase serine protease, thymidylate synthase, purine nucleoside phosphorylase, GAPDH trypanosomal, glycogen phosphorylase, Carbonic anhydrase, chemokine receptors, JAW STAT, RXR and similar, HIV 1 protease, HIV 1 integrase, influenza, neuramimidase, hepatitis B reverse transcriptase, sodium channel, multi drug resistance (MDR), protein P-glycoprotein (and MRP), tyrosine kinases, CD23, CD 124, tyrosine kinase p56 lck, CD4, CD5, IL-2 receptor, IL-1 receptor, TNF-alphaR, ICAM1, Cat+ channels, VCAM, VLA-4 integrin, selectins, CD40/CD40L, newokinins and receptors, inosine monophosphate dehydrogenase, p38 MAP Kinase, RaslRaflMEWERK pathway, interleukin-1 converting enzyme, caspase, HCV, NS3 protease, HCV NS3 RNA helicase, glycinamide ribonucleotide formyl transferase, rhinovirus 3C protease, herpes simplex virus- 1 (HSV-I), protease, cytomegalovirus (CMV) protease, poly (ADP-ribose) polymerase, cyclin dependent kinases, vascular endothelial growth factor, oxytocin receptor, microsomal transfer protein inhibitor, bile acid transport inhibitor, 5 alpha reductase inhibitors, angiotensin 11, glycine receptor, noradrenaline reuptake receptor, endothelin receptors, neuropeptide Y and receptor, adenosine receptors, adenosine kinase and AMP deaminase, purinergic receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2X1-7),
farnesyltransferases, geranylgeranyl transferase, TrkA a receptor for NGF, beta-amyloid, tyrosine kinase Flk-IIKDR, vitronectin receptor, integrin receptor, Her-21 neu, telomerase inhibition, cytosolic phospholipaseA2 and EGF receptor tyrosine kinase. Additional protein targets include, for example, ecdysone 20-monooxygenase, ion channel of the GABA gated chloride channel, acetylcholinesterase, voltage-sensitive sodium channel protein, calcium release channel, and chloride channels. Still further target proteins include Acetyl-CoA carboxylase, adenylosuccinate synthetase, protoporphyrinogen oxidase, and
enolpyruvylshikimate-phosphate synthase.
PTM
98. The compound according to any of claims 1-92 wherein said group is an Hsp90 inhibitor; a kinase inhibitor, a phosphatase inhibitor, an MDM2 inhibitor, a compound which targets human BET Bromodomain-containing proteins, an HDAC inhibitor, a human lysine methyltransferase inhibitor, a compound targeting RAF receptor, a compound targeting FKBP, an angiogenesis inhibitor, an immunosuppressive compound, a compound targeting an aryl hydrocarbon receptor, a compound targeting an androgen receptor, a compound targeting an estrogen receptor, a compound targeting a thyroid hormone receptor, a compound targeting HIV protease, a compound targeting HIV integrase, a compound targeting HCV protease or a compound targeting acyl protein thioesterase 1 and/or 2.
PTM
99. The compound according to any of claims 1-92 wherein said group is
N-[4-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-9H-FLUOREN-9-YL]-SUCCINAMIDE
Figure imgf000366_0001
Derivatized where a linker moiety L or a ULM group is attached via the terminal amide group;
p54
8-[(2,4-dimethylphenyl)sulfanyl]-3-pent-4-yn-1-yl-3H-purin-6-amine
Figure imgf000366_0002
Derivatized where a linker moiety may be attached via the terminal acetylene group;
(5 - [2,4-DIH YDROX Y-5 -( 1 -METH YLETH YL)PHEN YL] -N-ETH YL-4- [4-(MORPHOLIN- -YLMETHYL)PHENYL]ISOXAZOLE-3-CARBOXAMIDE) having the structure:
Figure imgf000366_0003
Derivatized where a linker moiety L -S- L- ULM group is attached via the amide group;
The Hsp90 inhibitor PU3 having the structure:
Figure imgf000367_0001
ULM
Derivatized where a linker moiety L or a group is attached via the butyl group;
The Derivatized Hsp90 inhibitors Geldanamycin ((4E,6Z,8S,95,10E,125,13i?,14S,16i?)-13- hydroxy-8, 14,19-trimethoxy-4, 10, 12, 16-tetramethyl-3 ,20,22-trioxo-2-azabicyclo [16.3.1],
17-alkylamino- 17-desmethoxy geldanamycin ( 17- AAG), or
17-(2-dimethylaminoethyl)amino-17-desmethoxy geldanamycin (17-DMAG)), where a linker may be attached via the amide group; the tyrosine kinase inhibitor Erlotinib (derivatized)
Figure imgf000367_0002
Where R as a linker moiety L or a L ULM group is attached via the ether group;
The kinase inhibitor Sunitanib (derivatized):
Figure imgf000368_0001
where R is a linker moiety L or a ULM group which is attached to the pyrrole moiety;
The kinase inhibitor Sorafenib (derivatized)
Figure imgf000368_0002
where R is a linker moiety L or a — ¾— L ULM group which is attached to the phenyl moiety;
The kinase inhibitor Desatinib (derivatized)
Figure imgf000368_0003
where R is a linker moiety L or a — ¾— L· ULM group which is attached to the pyrimidine;
The kinase inmhibitor Lapatinib (derivatized
Figure imgf000369_0001
Lapatinib
Where a linker moiety L or a L ULM group is attached via the terminal methyl of the sulfonyl methyl group;
Figure imgf000369_0002
3-(cyclopropylamino)-5 [3-(trifluoromethyl)phenyl]amino}pyrimido[4,5-c]quinoline-8-car-^ acid
Where a linker moiety L or a ULM group is attached via the amine (aniline), carboxylic acid or cyclopropyl group;
The kinase inhibitors Yl W and YIX (derivatized) having the structures:
Figure imgf000370_0001
YIX
1 -ethyl-3-(2-{[3-(1 -methylethyl)[1 ,2,4]triazolo[4,3-a]pyridin-6-yl]sulfanyl}benzyl)urea where a linker moiety L or a ULM group is attached via the propyl group;
Figure imgf000370_0002
1 -(3-tert-butyl-1 -phenyl-1 H-pyrazol-5-yl)-3-(2-{[3-(1 -methylethyl)[1 ,2,4]triazolo[4,3-a]pyridin-6-yl]sulfanyl}benzyl)urea
Derivatized where a linker moiety L or a ULM group is attached via the propyl group or the butyl group;
the kinase inhibitor 6TP and OTP (derivatized) having the structures
Figure imgf000370_0003
6TP
4-amino-2-[4-(tert-butylsulfamoyl)phenyl]-N-methylthieno[3,2-c]pyridine-7-carboxam Thienopyridine 19 where a linker moiety L or a -§- L- ULM group is attached via the terminal methyl group bound to amide moiety;
Figure imgf000371_0001
OTP
4-amino-N-methyl-2-[4-(mo holin-4-yl)pheyl]thieno[3,2-c]pyridine-7-carboxamide Thienopyridine 8
where a linker moiety L or a ULM group is attached via the terminal methyl group bound to the amide moiety;
The kinase inhibitor 07U (derivatized) having the structure:
Figure imgf000371_0002
07U
2-methyl-N~1 ~-[3-(pyridin-4-yl)-2,6-naphthyridin-1 -yl]propane-1 ,2-diamine
where a linker moiety L or a - L— ULM group is attached via the secondary amine or terminal/primary amino group;
The kinase inhibitor YCF (derivatized) having the structure:
Figure imgf000372_0001
where a linker moiety L or a — ¾— ULM group is attached via either of the terminal hydroxyl groups;
The kinase inhibitors XK9 and NXP (derivatized) having the structures:
Figure imgf000372_0002
XK9
N-{4-[(1 E)-N-(N-hydroxycarbamimidoyl)ethanehydrazonoyl]p enyl}-7-nitro-1 H-indole-2-carboxam
Figure imgf000372_0003
NXP
N-{4-[(1 E)-N-CARBAMIMIDOYLETHANEHYDRAZONOYL]PHENYL}-1 H-INDOLE-3-CARBOXAMIDE Derivatized where a linker moiety L or a group is attached via the terminal hydroxyl group (XK9) or the hydrazone group (NXP);
The kinase inhibitor Afatinib fN-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3- furanyl]oxy]-6-quinazolinyl]-4(dimethylamino)-2-butenamide), derivatized where a linker moiety L or a 1 group is attached via the aliphatic amine group;
The kinase inhibitor Fostamatinib ([6-({5-fluoro-2-[(3,4,5- trimethoxyphenyl)amino]pyrimidin-4-yl}amino)-2,2-dimethyl-3- oxo-2,3-dihydro-4H- pyrido[3,2-b]-l,4-oxazin-4-yl]methyl disodium phosphate hexahydrate), derivatized where a linker moiety L or a L group is attached via a methoxy group;
The kinase inhibitor Gefitinib (N-(3-chloro-4-fluoro-phenyl)-7-methoxy- 6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine), derivatized where a linker moiety L or a group is attached via a methoxy or ether group;
Figure imgf000373_0001
The kinase inhibitor Lenvatinib (4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7- methoxy-quinoline-6-carboxamide), derivatized where a linker moiety L or a
group 1S attached via the cyclopropyl group);
The kinase inhibitor Vandetanib (N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(l- methylpiperidin-4-yl)methoxy]quinazolin-4-amine), derivatized where a linker moiety L or a
—— group is attached via the methoxy or hydroxyl group); The kinase inhibitor Vemurafenib (propane- 1 -sulfonic acid {3-[5-(4-chlorophenyl)-lH- pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide), derivatized where a linker moiety L or a ULM group is attached via the sulfonyl propyl group);
The kinase inhibitor Gleevac (derivatized):
Figure imgf000374_0001
where R as a linker moiety L or a ULM group is is attached via the amide group or via the aniline amine group;
The kinase inhibitor Pazopanib (derivatized) (VEGFR3 inhibitor):
Figure imgf000374_0002
where R as a linker moiety L or a ? L I ^1^! group is is attached to the phenyl moiety or via the aniline amine group;
The kinase inhibitor AT- 9283 (derivatized) Aurora Kinase Inhibitor
Figure imgf000375_0001
where R is a linker moiety L or a L ULM group which is attached to the phenyl moiety;
The kinase inhibitor TAE684 (derivatized) ALK inhibitor
Figure imgf000375_0002
where R is a linker moiety L or a ? ^ ULM group which is attached to the phenyl moiety;
The kinase inhibitor Nilotanib (derivatized) Abl inhibitor:
Figure imgf000375_0003
where R is a linker moiety L or a ? ^ ULM group which is attached to the phenyl moiety or the aniline amine group; The kinase inhibitor NVP-BSK805 (derivatized) JAK2 inhibitor
Figure imgf000376_0001
group which is attached to the phenyl moiety or the diazole group;
The kinase inhibitor Crizotinib (derivatized) Alk inhibitor
Figure imgf000376_0002
where R is a linker moiety L or a »— L- ULM group which is attached to the phenyl moiety or the diazole group;
The kinase nhibitor JNJ (derivatized) FMS inhibitor
Figure imgf000377_0001
where R is a linker moiety L or a ? L 1 ULM| group which 1S attached to the phenyl moiety;
The kinase inhibitor Foretinib (derivatized) Met inhibitor
Figure imgf000377_0002
where R is a linker moiety L or a -Ι- L·- ULM group which is attached to the phenyl moiety or a hydroxyl or ether group on the quinoline moiety;
The allosteric protein tyrosine phosphatase inhibitor PTPIB (derivatized):
Figure imgf000377_0003
where a linker group L or a Ϊ- Lr- ULM group is attached at R; The inhibitor of SHP-2 domain of tyrosine phosphatase (derivatized):
Figure imgf000378_0001
where a linker group L or a ?— Lr- ULM group is attached at R;
The kinase inhibitor (derivatized) of BRAF (BRAF )/MEK:
Figure imgf000378_0002
Where a linker L or a L 1 ULM group is attached at R;
The inhibitor (derivatized) of tyrosine kinase ABL
Figure imgf000378_0003
Where R is a linker group L or a L ULM group;
The MDM2 Inhibitor nutlin-3, nutlin-2, nutlin-1 or Trans-4-Iodo-4'-Boranyl-Chalcone (derivatized), Trans-4-Iodo-4'-Boranyl-Chalcone, where a linker moiety L or a ULM group is attached via a hydroxy group;
A compound targeting human BET Bromodomain-containing protein Brd2, Brd3, Brd4
Figure imgf000379_0001
An HDAC inhibitor
Figure imgf000380_0001
where R is a linker group L -l- L- ULM group;
A human lysine methyltransferase inhibitor BIX-01294 or UNC0244(derivatized):
Figure imgf000380_0002
BIX-01294
where R is a linker group L or a ULM group;
Figure imgf000380_0003
UNC0224 where R is a linker group L or a ULM group;
Azacitidine (4-amino-l-P-D-ribofuranosyl-l,3,5-triazin-2(lH)-one) derivatized where a
Figure imgf000380_0004
linker group L or a group is attached via the hydroxy or amino groups; and Decitabine (4-amino-l-(2-deoxy-b-D-erythro-pentofuranosyl)-l, 3, 5-triazin-2(lH)-one) derivatized where a linker group L or a ? L 1 ULM
UL^iVi \ group is attached via either of the hydroxy groups or at the amino group).
An angiogenesis inhibitor selected from the group consisting of :
GA-1 (derivatized);
Estradiol (derivatized);
pihydroxytestosterone (derivatized) ;
Ovalicin (derivatized),
Fumagillin (derivatized);
An immunosuppressive compound selected from the group consisting of
AP21998 (derivatized);
Glucocorticoids, including hydrocortisone, prednisone, prednisolone, and
methylprednisolone), derivatized where a linker group L or a ULM group is bound, and beclometasone dipropionate, where a linker group L or a ULM group is bound;
Methotrexate, derivatized where a linker group L or a — L— -\ ULM group is bound to either of the terminal hydroxyls;
Ciclosporin, derivatized where a linker group L or a L ULM group is bound at any of the butyl groups;
Tacrolimus (FK-506) and rapamycin, derivatized where a linker group L or a
— I— L— ULM group is bound at one of the methoxy groups;
Actinomycin, derivatized where a linker group L or a ULM group is bound at one of the isopropyl groups; A compound targeting the aryl hydrocarbon receptor (AHR) selected from the group consisting of Apigenin, SRI and LGC006, derivatized to bind a linker group L or a
ULM group;
A compound targeting RAF receptor (kinase) according to the chemical structure:
Figure imgf000382_0001
A compound targeting FKBP according to the chemical structure:
Figure imgf000382_0002
"Where R designates a linker group L or a »— LT- ULM group;
A compound targeting androgen receptor (AR) according to the chemical structure:
Figure imgf000382_0003
Where R designates a linker group L or a ULM group; A SARM ligand of Androgen Receptor according to the chemical structure:
Figure imgf000383_0001
Where R designates a linker group L or a ULM group;
An Androgen Receptor Ligand DHT according to the chemical structure:
Figure imgf000383_0002
Where R designates a linker group L or a ULM group;
A compound targeting Estrogen Receptor (ER) according to the chemical structure:
Figure imgf000383_0003
Where R designates a linker group L or a L ULM group;
A compound targeting Thyroid Hormone Receptor (TR) according to the chemical structure:
Figure imgf000383_0004
Where R designates a linker group L or a L ULM group and MOMO indicates a methoxymethoxy group;
A compound targeting HIV Protease according to the chemical structure:
Figure imgf000384_0001
Where R designates a linker group L or a ?- L ULM group;
An Inhibitor of HIV Integrase according to the chemical structure:
Figure imgf000384_0002
derivatized where "R" designates a potential site for linker attachment,.
Figure imgf000385_0001
Where R designates a linker group L or a ?— Lr- ULM group;
A compound targeting HCV Protease according to the chemical structure:
Figure imgf000385_0002
Where R designates a linker group L or a ? L I ULMI group;
and
A compound targeting Acyl-protein Thioesterase-1 and -2 (APTl and APT2) according to the chemical structure:
Figure imgf000385_0003
Where R designates a linker group L or a -δ- L·- ULM group.
A compound according to any of claims 1-92 wherein said PTM
group is a
Figure imgf000386_0001
group, where w is 0 to 3.
101. The compound according to claim 100 where w is 1.
102. A compound according to the chemical structure:
Figure imgf000386_0002
Figure imgf000387_0001
Figure imgf000387_0002
or a pharmaceutically acceptable salt thereof.
103. A pharmaceutical composition comprising an effective amount of a compound according to any of claims 1-102 in combination with a pharmaceutically acceptable carrier, additive or excipient and optionally in further combination with an additional bioactive agent.
104. The composition according to claim 103 wherein said additional bioactive agent is an anticancer agent.
105. The composition according to claim 103 wherein said additional bioactive agent is an antiviral agent.
106. The composition according to claim 105 wherein said antiviral agent is an anti-HIV agent.
107. The composition according to claim 105 wherein said antiviral agent is an anti-HCV agent.
108. The composition according to claim 104 wherein said anticancer agent is selected from the group consisting of everolimus, trabectedin, abraxane, TLK 286, AV-299, DN-101, pazopanib, GSK690693, RTA 744, ON 0910.Na, AZD 6244 (ARRY-142886), AMN-107, TKI-258, GSK461364, AZD 1 152, enzastaurin, vandetanib, ARQ-197, MK-0457, MLN8054, PHA-739358, R-763, AT-9263, a FLT-3 inhibitor, a VEGFR inhibitor, an EGFR TK inhibitor, an aurora kinase inhibitor, a PIK-1 modulator, a Bcl-2 inhibitor, an HDAC inhbitor, a c-MET inhibitor, a P ARP inhibitor, a Cdk inhibitor, an EGFR TK inhibitor, an IGFR-TK inhibitor, an anti-HGF antibody, a PI3 kinase inhibitors, an AKT inhibitor, a JAK/STAT inhibitor, a checkpoint- 1 or 2 inhibitor, a focal adhesion kinase inhibitor, a Map kinase kinase (mek) inhibitor, a VEGF trap antibody, pemetrexed, erlotinib, dasatanib, nilotinib, decatanib, panitumumab, amrubicin, oregovomab, Lep-etu, nolatrexed, azd2171, batabulin, ofatumumab, zanolimumab, edotecarin, tetrandrine, rubitecan, tesmilifene, oblimersen, ticilimumab, ipilimumab, gossypol, Bio 111 , 131-I-TM-601 , ALT- 110, BIO 140, CC 8490, cilengitide, gimatecan, IL13-PE38QQR, ΓΝΟ 1001 , IPdRi KRX-0402, lucanthone, LY 317615, neuradiab, vitespan, Rta 744, Sdx 102, talampanel, atrasentan, Xr 311 , romidepsin, ADS- 100380, sunitinib, 5-fluorouracil, vorinostat, etoposide, gemcitabine, doxorubicin, liposomal doxorubicin, S'-deoxy-S-fluorouridine, vincristine, temozolomide, ZK-304709, seliciclib; PD0325901 , AZD-6244, capecitabine, L-Glutamic acid, N -[4-[2-(2-amino-4,7-dihydro-4- oxo-1 H - pyrrolo[2,3- d ]pyrimidin-5-yl)ethyl]benzoyl]-, disodium salt, heptahydrate, camptothecin, PEG-labeled irinotecan, tamoxifen, toremifene citrate, anastrazole, exemestane, letrozole, DES(diethylstilbestrol), estradiol, estrogen, conjugated estrogen, bevacizumab, IMC-1C11 , CHIR-258,); 3-[5-(methylsulfonylpiperadinemethyl)- indolylj-quinolone, vatalanib, AG-013736, AVE-0005, the acetate salt of [D- Ser(Bu t ) 6 ,Azgly 10 ] (pyro-Glu- His-Trp-Ser-Tyr-D-Ser(Bu t )-Leu-Arg-Pro- Azgly-NH 2 acetate [C59H84Ni8Oi4 -(C2H4O2)x where x = 1 to 2.4], goserelin acetate, leuprolide acetate, triptorelin pamoate,
medroxyprogesterone acetate, hydroxyprogesterone caproate, megestrol acetate, raloxifene, bicalutamide, flutamide, nilutamide, megestrol acetate, CP-724714; TAK-165, HKI-272, erlotinib, lapatanib, canertinib, ABX-EGF antibody, erbitux, EKB-569, PKI-166, GW- 572016, Ionafarnib, BMS-214662, tipifarnib; amifostine, NVP-LAQ824, suberoyl analide hydroxamic acid, valproic acid, trichostatin A, FK-228, SU11248, sorafenib, KR 951 , aminoglutethimide, arnsacrine, anagrelide, L-asparaginase, Bacillus Calmette-Guerin (BCG) vaccine, adriamycin, bleomycin, buserelin, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, diethylstilbestrol, epirubicin, fludarabine, fludrocortisone, fluoxymesterone, flutamide, gleevac, gemcitabine, hydroxyurea, idarubicin, ifosfamide, imatinib, leuprolide, levamisole, lomustine, mechlorethamine, melphalan, 6-mercaptopurine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, octreotide, oxaliplatin, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozocin, teniposide, testosterone, thalidomide, thioguanine, thiotepa, tretinoin, vindesine, 13-cis- retinoic acid, phenylalanine mustard, uracil mustard, estramustine, altretamine, floxuridine, 5-deooxyuridine, cytosine arabinoside, 6-mecaptopurine, deoxycoformycin, calcitriol, valrubicin, mithramycin, vinblastine, vinorelbine, topotecan, razoxin, marimastat, COL-3, neovastat, BMS-275291 , squalamine, endostatin, SU5416, SU6668, EMD121974, interleukin-12, IM862, angiostatin, vitaxin, droloxifene, idoxyfene, spironolactone, finasteride, cimitidine, trastuzumab, denileukin diftitox,gefitinib, bortezimib, paclitaxel, cremophor-free paclitaxel, docetaxel, epithilone B, BMS- 247550, BMS-310705, droloxifene, 4-hydroxytamoxifen, pipendoxifene, ERA- 923, arzoxifene, fulvestrant, acolbifene, lasofoxifene, idoxifene, TSE-424, HMR- 3339, ZK186619, topotecan, PTK787/ZK 222584, VX-745, PD 184352, rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, temsirolimus, AP- 23573, RAD001 , ABT-578, BC-210, LY294002, LY292223, LY292696, LY293684, LY293646, wortmannin, ZM336372, L-779,450, PEG-filgrastim, darbepoetin, erythropoietin, granulocyte colony-stimulating factor, zolendronate, prednisone, cetuximab, granulocyte macrophage colony-stimulating factor, histrelin, pegylated interferon alfa-2a, interferon alfa- 2a, pegylated interferon alfa-2b, interferon alfa-2b, azacitidine, PEG-L-asparaginase, lenalidomide, gemtuzumab, hydrocortisone, interleukin-11 , dexrazoxane, alemtuzumab, all- transretinoic acid, ketoconazole, interleukin-2, megestrol, immune globulin, nitrogen mustard, methylprednisolone, ibritgumomab tiuxetan, androgens, decitabine, hexamethylmelamine, bexarotene, tositumomab, arsenic trioxide, cortisone, editronate, mitotane, cyclosporine, liposomal daunorubicin, Edwina-asparaginase, strontium 89, casopitant, netupitant, an N -1 receptor antagonists, palonosetron, aprepitant, diphenhydramine, hydroxyzine,
metoclopramide, lorazepam, alprazolam, haloperidol, droperidol, dronabinol, dexamethasone, methylprednisolone, prochlorperazine, granisetron, ondansetron, dolasetron, tropisetron, pegfilgrastim, erythropoietin, epoetin alfa, darbepoetin alfa and mixtures thereof.
109. The composition according to claim 106 wherein said anti-HIV agent is a nucleoside reverse transcriptase inhibitors (NRTI), a non-nucloeoside reverse transcriptase inhibitor, protease inhibitors, a fusion inhibitor or a mixture thereof.
110. A method for regulating protein activity of a target protein in a patient in need comprising administering to said patient an amount of a compound according to any of claims 1-92 to said patient.
111. The method according to claim 110 wherein said target protein is selected from the group consisting of structural proteins, receptors, enzymes, cell surface proteins, proteins pertinent to the integrated function of a cell, including proteins involved in catalytic activity, aromatase activity, motor activity, helicase activity, metabolic processes (anabolism and catrabolism), antioxidant activity, proteolysis, biosynthesis, proteins with kinase activity, oxidoreductase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, ligase activity, enzyme regulator activity, signal transducer activity, structural molecule activity, binding activity (protein, lipid carbohydrate), receptor activity, cell motility, membrane fusion, cell communication, regulation of biological processes, development, cell differentiation, response to stimulus, behavioral proteins, cell adhesion proteins, proteins involved in cell death, proteins involved in transport (including protein transporter activity, nuclear transport, ion transporter activity, channel transporter activity, carrier activity, permease activity, secretion activity, electron transporter activity,
pathogenesis, chaperone regulator activity, nucleic acid binding activity, transcription regulator activity, extracellular organization and biogenesis activity and translation regulator activity.
112. The method according to claim 1 10 wherein said target protein is selected from the group consisting of B7.1 and B7, TINFRlm, TNFR2, NADPH oxidase, BclIBax and other partners in the apotosis pathway, C5a receptor, HMG-CoA reductase, PDE V
phosphodiesterase type, PDE IV phosphodiesterase type 4, PDE I, PDEII, PDEIII, squalene cyclase inhibitor, CXCR1, CXCR2, nitric oxide (NO) synthase, cyclo-oxygenase 1, cyclo- oxygenase 2, 5HT receptors, dopamine receptors, G Proteins, i.e., Gq, histamine receptors, 5- lipoxygenase, tryptase serine protease, thymidylate synthase, purine nucleoside
phosphorylase, GAPDH trypanosomal, glycogen phosphorylase, Carbonic anhydrase, chemokine receptors, JAW STAT, RXR and similar, HIV 1 protease, HIV 1 integrase, influenza, neuramimidase, hepatitis B reverse transcriptase, sodium channel, multi drug resistance (MDR), protein P-glycoprotein (and MRP), tyrosine kinases, CD23, CD 124, tyrosine kinase p56 lck, CD4, CD5, IL-2 receptor, IL-1 receptor, TNF-alphaR, ICAMl, Cat+ channels, VCAM, VLA-4 integrin, selectins, CD40/CD40L, newokinins and receptors, inosine monophosphate dehydrogenase, p38 MAP Kinase, RaslRaflMEWERK pathway, interleukin-1 converting enzyme, caspase, HCV, NS3 protease, HCV NS3 RNA helicase, glycinamide ribonucleotide formyl transferase, rhino virus 3C protease, herpes simplex virus- 1 (HSV-I), protease, cytomegalovirus (CMV) protease, poly (ADP-ribose) polymerase, cyclin dependent kinases, vascular endothelial growth factor, oxytocin receptor, microsomal transfer protein inhibitor, bile acid transport inhibitor, 5 alpha reductase inhibitors, angiotensin 11 , glycine receptor, noradrenaline reuptake receptor, endothelin receptors, neuropeptide Y and receptor, estrogen receptors, androgen receptors, adenosine receptors, adenosine kinase and AMP deaminase, purinergic receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2X1-7), farnesyltransferases, geranylgeranyl transferase, TrkA a receptor for NGF, beta- amyloid, tyrosine kinase Flk-IIKDR, vitronectin receptor, integrin receptor, Her-21 neu, telomerase inhibition, cytosolic phospholipaseA2 and EGF receptor tyrosine kinase.
Additional protein targets include, for example, ecdysone 20-monooxygenase, ion channel of the GABA gated chloride channel, acetylcholinesterase, voltage-sensitive sodium channel protein, calcium release channel, chloride channels, acetyl-CoA carboxylase,
adenylosuccinate synthetase, protoporphyrinogen oxidase, and enolpyruvylshikimate- phosphate synthase.
1 13. A method of treating a disease state or condition in a patient wherein dysregulated protein activity is responsible for said disease state or condition, said method comprising administering to said patient an effective amount of a compound according to any of claims 1-92 to said patient in order to regulate said protein activity in said patient.
114. The method according to claim 113 wherein said disease state or condition is asthma, multiple sclerosis, cancer, ciliopathies, cleft palate, diabetes, heart disease, hypertension, inflammatory bowel disease, mental retardation, mood disorder, obesity, refractive error, infertility, Angelman syndrome, Canavan disease, Coeliac disease, Charcot-Marie-Tooth disease, Cystic fibrosis, Duchenne muscular dystrophy, Haemochromatosis, Haemophilia, Klinefelter's syndrome, Neurofibromatosis, Phenylketonuria, Polycystic kidney disease, (PKD1) or 4 (PKD2) Prader-Willi syndrome, Sickle-cell disease, Tay-Sachs disease, Turner syndrome.
115. The method according to claim 113 wherein said disease state or condition is
Alzheimer's disease, Amyotrophic lateral sclerosis (Lou Gehrig's disease), Anorexia nervosa, Anxiety disorder, Atherosclerosis, Attention deficit hyperactivity disorder, Autism, Bipolar disorder, Chronic fatigue syndrome, Chronic obstructive pulmonary disease, Crohn's disease, Coronary heart disease, Dementia, Depression, Diabetes mellitus type 1 , Diabetes mellitus type 2, Epilepsy, Guillain-Barre syndrome, Irritable bowel syndrome, Lupus, Metabolic syndrome, Multiple sclerosis, Myocardial infarction, Obesity, Obsessive-compulsive disorder, Panic disorder, Parkinson's disease, Psoriasis, Rheumatoid arthritis, Sarcoidosis, Schizophrenia, Stroke, Thromboangiitis obliterans, Tourette syndrome, Vasculitis.
116. The method according to claim 113 wherein said disease state or condition is aceruloplasminemia, Achondrogenesis type II, achondroplasia, Acrocephaly, Gaucher disease type 2, acute intermittent porphyria, Canavan disease, Adenomatous Polyposis Coli, ALA dehydratase deficiency, adenylosuccinate lyase deficiency, Adrenogenital syndrome,
Adrenoleukodystrophy, ALA-D porphyria, ALA dehydratase deficiency, Alkaptonuria, Alexander disease, Alkaptonuric ochronosis, alpha 1 -antitrypsin deficiency, alpha- 1
proteinase inhibitor, emphysema, amyotrophic lateral sclerosis, Alstrom syndrome,
Alexander disease, Amelogenesis imperfecta, ALA dehydratase deficiency, Anderson-Fabry disease, androgen insensitivity syndrome, Anemia, Angiokeratoma Corporis Diffusum, Angiomatosis retinae (von Hippel-Lindau disease), Apert syndrome, Arachnodactyly
(Marfan syndrome), Stickler syndrome, Arthrochalasis multiplex congenital (Ehlers-Danlos syndrome#arthrochalasia type),ataxia telangiectasia, Rett syndrome, primary pulmonary hypertension, Sandhoff disease, neurofibromatosis type II, Beare- Stevenson cutis gyrata syndrome, Mediterranean fever, familial, Benjamin syndrome, beta-thalassemia
Bilateral Acoustic Neurofibromatosis (neurofibromatosis type II), factor V Leiden
thrombophilia, Bloch-Sulzberger syndrome (incontinentia pigmenti), Bloom syndrome, X- linked sideroblastic anemia, Bonnevie-Ullrich syndrome (Turner syndrome), Bourneville disease (tuberous sclerosis), prion disease, Birt-Hogg-Dube syndrome, Brittle bone disease (osteogenesis imperfecta), Broad Thumb-Hallux syndrome (Rubinstein-Taybi syndrome), Bronze Diabetes/Bronzed Cirrhosis (hemochromatosis), Bulbospinal muscular atrophy (Kennedy's disease), Burger-Grutz syndrome (lipoprotein lipase deficiency), CGD Chronic granulomatous disorder, Campomelic dysplasia, biotinidase deficiency, Cardiomyopathy (Noonan syndrome), Cri du chat, CAVD (congenital absence of the vas deferens), Caylor cardiofacial syndrome (CBAVD), CEP (congenital erythropoietic porphyria), cystic fibrosis, congenital hypothyroidism, Chondrodystrophy syndrome (achondroplasia),
otospondylomegaepiphyseal dysplasia, Lesch-Nyhan syndrome, galactosemia, Ehlers-Danlos syndrome, Thanatophoric dysplasia, Coffin-Lowry syndrome, Cockayne syndrome, (familial adenomatous polyposis), Congenital erythropoietic porphyria, Congenital heart disease, Methemoglobinemia/Congenital methaemoglobinaemia, achondroplasia, X-linked
sideroblastic anemia, Connective tissue disease, Conotruncal anomaly face syndrome, Cooley's Anemia (beta-thalassemia), Copper storage disease (Wilson's disease), Copper transport disease (Menkes disease), hereditary coproporphyria, Cowden syndrome,
Craniofacial dysarthrosis (Crouzon syndrome), Creutzfeldt- Jakob disease (prion disease), Cockayne syndrome, Cowden syndrome, Curschmann-Batten-Steinert syndrome (myotonic dystrophy), Beare-Stevenson cutis gyrata syndrome, primary hyperoxaluria,
spondyloepimetaphyseal dysplasia (Strudwick type), muscular dystrophy, Duchenne and Becker types (DBMD), Usher syndrome, Degenerative nerve diseases including de Grouchy syndrome and Dejerine- Sottas syndrome, developmental disabilities, distal spinal muscular atrophy, type V, androgen insensitivity syndrome, Diffuse Globoid Body Sclerosis (Krabbe disease), Di George's syndrome, Dihydrotestosterone receptor deficiency, androgen insensitivity syndrome, Down syndrome, Dwarfism, erythropoietic protoporphyria
Erythroid 5-aminolevulinate synthetase deficiency, Erythropoietic porphyria, erythropoietic protoporphyria, erythropoietic uroporphyria, Friedreich's ataxia,, familial paroxysmal polyserositis, porphyria cutanea tarda, familial pressure sensitive neuropathy,
primary pulmonary hypertension (PPH), Fibrocystic disease of the pancreas, fragile X syndrome, galactosemia, genetic brain disorders, Giant cell hepatitis (Neonatal hemochromatosis), Gronblad-Strandberg syndrome ( pseudoxanthoma elasticum), Gunther disease (congenital erythropoietic porphyria), haemochromatosis, Hallgren syndrome, sickle cell anemia, hemophilia, hepatoerythropoietic porphyria (HEP), Hippel-Lindau disease (von Hippel-Lindau disease), Huntington's disease, Hutchinson-Gilford progeria syndrome (progeria), Hyperandrogenism, Hypochondroplasia, Hypochromic anemia, Immune system disorders, including X-linked severe combined immunodeficiency, Insley-Astley syndrome, Jackson- Weiss syndrome, Joubert syndrome, Lesch-Nyhan syndrome, Jackson- Weiss syndrome, Kidney diseases, including hyperoxaluria, Klinefelter's syndrome, Kniest dysplasia, Lacunar dementia,Langer-Saldino achondrogenesis, ataxia telangiectasia, Lynch syndrome, Lysyl-hydroxylase deficiency, Machado- Joseph disease, Metabolic disorders, including Kniest dysplasia, Marfan syndrome, Movement disorders, Mowat- Wilson syndrome, cystic fibrosis, Muenke syndrome, Multiple neurofibromatosis, Nance-Insley syndrome, Nance-Sweeney chondrodysplasia, Niemann-Pick disease, Noack syndrome (Pfeiffer syndrome), Osier- Weber-Rendu disease, Peutz-Jeghers syndrome, Polycystic kidney disease, polyostotic fibrous dysplasia (McCune-Albright syndrome), Peutz-Jeghers syndrome, Prader-Labhart- Willi syndrome, hemochromatosis, primary hyperuricemia syndrome (Lesch- Nyhan syndrome), primary pulmonary hypertension, primary senile degenerative dementia, prion disease, progeria (Hutchinson Gilford Progeria Syndrome), progressive chorea, chronic hereditary (Huntington) (Huntington's disease), progressive muscular atrophy, spinal muscular atrophy, propionic acidemia, protoporphyria, proximal myotonic dystrophy, pulmonary arterial hypertension, PXE (pseudoxanthoma elasticum), Rb (retinoblastoma), Recklinghausen disease (neurofibromatosis type I), Recurrent polyserositis, Retinal disorders, Retinoblastoma, Rett syndrome, RFALS type 3, Ricker syndrome, Riley-Day syndrome, Roussy-Levy syndrome, severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), Li-Fraumeni syndrome, sarcoma, breast, leukemia, and adrenal gland (SBLA) syndrome, sclerosis tuberose (tuberous sclerosis), SDAT, SED congenital
(spondyloepiphyseal dysplasia congenita), SED Strudwick (spondyloepimetaphyseal dysplasia, Strudwick type), SEDc (spondyloepiphyseal dysplasia congenita)
SEMD, Strudwick type (spondyloepimetaphyseal dysplasia, Strudwick type), Shprintzen syndrome, Skin pigmentation disorders, Smith-Lemli-Opitz syndrome, South- African genetic porphyria (variegate porphyria), infantile-onset ascending hereditary spastic paralysis, Speech and communication disorders, sphingolipidosis, Tay-Sachs disease,
spinocerebellar ataxia, Stickler syndrome, stroke, androgen insensitivity syndrome,
tetrahydrobiopterin deficiency, beta-thalassemia, Thyroid disease Tomaculous neuropathy (hereditary neuropathy with liability to pressure palsies) Treacher Collins syndrome, Triplo X syndrome ( triple X syndrome), Trisomy 21
(Down syndrome), Trisomy X, VHL syndrome (von Hippel-Lindau disease), Vision impairment and blindness (Alstrom syndrome), Vrolik disease, Waardenburg syndrome, Warburg Sjo Fledelius Syndrome, Weissenbacher-Zweymiiller syndrome, Wolf-Hirschhorn syndrome, Wolff Periodic disease, Weissenbacher-Zweymiiller syndrome and
Xeroderma pigmentosum.
117. The method according to claim 113 wherein said disease state is cancer.
118. The method according to claim 117 wherein said cancer is squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, and renal cell carcinomas, cancer of the bladder, bowel, breast, cervix, colon, esophagus, head, kidney, liver, lung, neck, ovary, pancreas, prostate, and stomach; leukemias; benign and malignant lymphomas, particularly Burkitt's lymphoma and Non-Hodgkin's lymphoma; benign and malignant melanomas; myeloproliferative diseases; sarcomas, including Ewing's sarcoma,
hemangiosarcoma, Kaposi's sarcoma, liposarcoma, myosarcomas, peripheral
neuroepithelioma, synovial sarcoma, gliomas, astrocytomas, oligodendrogliomas,
ependymomas, gliobastomas, neuroblastomas, ganglioneuromas, gangliogliomas,
medulloblastomas, pineal cell tumors, meningiomas, meningeal sarcomas, neurofibromas, and Schwannomas; bowel cancer, breast cancer, prostate cancer, cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, esophageal cancer, pancreatic cancer, stomach cancer, liver cancer, colon cancer, melanoma; carcinosarcoma, Hodgkin's disease, Wilms' tumor or teratocarcinomas
119. The method according to claim 117 wherein said cancer is T-lineage Acute lymphoblastic Leukemia (T-ALL), T-lineage lymphoblastic Lymphoma (T-LL), Peripheral T-cell lymphoma, Adult T-cell Leukemia, Pre-B ALL, Pre-B Lymphomas, Large B-cell Lymphoma, Burkitts Lymphoma, B-cell ALL, Philadelphia chromosome positive ALL and Philadelphia chromosome positive CML
120. The method according to claim 113 wherein said disease state is an HIV infection.
121. The method according to claim 113 wherein said disease state is an HCV infection.
122. A compound library comprising compounds according to any of claims 1-92.
123. A method of screening a library of compounds according to claim 122 to identify a compound containing a targeting moiety which recognizes a target protein associated with a predetermined function of a cell comprising incubating a cell with said library of compounds; monitoring the predetermined function of the cell and identifying a compound or a number of compounds from said library that change the predetermined function of the cell.
124. The method according to claim 124 wherein a number of compounds which change the predetermined function of the cell are identified; said cell is incubated with a compound from said groups of compounds; the predetermined function of the cell is monitored; and a compound is identified that changes the predetermined function of the cell, wherein the identified compound contains a targeting moiety which recognizes said target protein associated with the predetermined function.
125. A method of degrading a target protein in a cell comprising exposing said cell to a compound according to any of claims 1-92 in an effective amount.
126. A method of degrading a target protein in a patient in need comprising administering to said patient an effective of a compound according to any of claims 1-92.
127. The method according to clalim 125 wherein said target protein is heat shock protein 90, a kinase, a phosphatase, MDM2, human BET Bromodomain-containing protein, HDAC, human lysine methyltransferase, a RAF receptor, FKBP, VEGF, an aryl hydrocarbon receptor, an androgen receptor, an estrogen receptor, thyroid hormone receptor, HIV protease, HIV integrase, HCV protease or acyl protein thioesterase 1 and/or 2.
128. The method according to claim 126 wherein said target protein is heat shock protein 90, a kinase, a phosphatase, MDM2, human BET Bromodomain-containing protein, HDAC, human lysine methyltransferase, a RAF receptor, FKBP, VEGF, an aryl hydrocarbon receptor, an androgen receptor, an estrogen receptor, thyroid hormone receptor, HIV protease, HIV integrase, HCV protease or acyl protein thioesterase 1 and/or 2.
129. Use of a compound according to any of claims 1-92 in a first medical application.
130. Use of a compound according to any of claims 1-92 for regulating protein activity of a target protein in a patient in need, comprising administering to said patient an amount of a compound according to any of claims 1-92 to said patient.
131. Use according to claim 130 wherein said target protein is selected from the group consisting of structural proteins, receptors, enzymes, cell surface proteins, proteins pertinent to the integrated function of a cell, including proteins involved in catalytic activity, aromatase activity, motor activity, helicase activity, metabolic processes (anabolism and catrabolism), antioxidant activity, proteolysis, biosynthesis, proteins with kinase activity, oxidoreductase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, ligase activity, enzyme regulator activity, signal transducer activity, structural molecule activity, binding activity (protein, lipid carbohydrate), receptor activity, cell motility, membrane fusion, cell communication, regulation of biological processes, development, cell
differentiation, response to stimulus, behavioral proteins, cell adhesion proteins, proteins involved in cell death, proteins involved in transport (including protein transporter activity, nuclear transport, ion transporter activity, channel transporter activity, carrier activity, permease activity, secretion activity, electron transporter activity, pathogenesis, chaperone regulator activity, nucleic acid binding activity, transcription regulator activity, extracellular organization and biogenesis activity and translation regulator activity.
132. Use according to claim 130 wherein said target protein is selected from the group consisting of B7.1 and B7, TINFRlm, TNFR2, NADPH oxidase, BclIBax and other partners in the apotosis pathway, C5a receptor, HMG-CoA reductase, PDE V phosphodiesterase type, PDE IV phosphodiesterase type 4, PDE I, PDEII, PDEIII, squalene cyclase inhibitor, CXCRl, CXCR2, nitric oxide (NO) synthase, cyclo-oxygenase 1, cyclo-oxygenase 2, 5HT receptors, dopamine receptors, G Proteins, i.e., Gq, histamine receptors, 5 -lipoxygenase, tryptase serine protease, thymidylate synthase, purine nucleoside phosphorylase, GAPDH trypanosomal, glycogen phosphorylase, Carbonic anhydrase, chemokine receptors, JAW STAT, RXR and similar, HIV 1 protease, HIV 1 integrase, influenza, neuramimidase, hepatitis B reverse transcriptase, sodium channel, multi drug resistance (MDR), protein P-glycoprotein (and MRP), tyrosine kinases, CD23, CD124, tyrosine kinase p56 lck, CD4, CD5, IL-2 receptor, IL-1 receptor, TNF-alphaR, ICAM1, Cat+ channels, VCAM, VLA-4 integrin, selectins, CD40/CD40L, newokinins and receptors, inosine monophosphate dehydrogenase, p38 MAP Kinase, RaslRaflMEWERK pathway, interleukin-1 converting enzyme, caspase, HCV, NS3 protease, HCV NS3 RNA helicase, glycinamide ribonucleotide formyl transferase, rhinovirus 3C protease, herpes simplex virus- 1 (HSV-I), protease, cytomegalovirus (CMV) protease, poly (ADP-ribose) polymerase, cyclin dependent kinases, vascular endothelial growth factor, oxytocin receptor, microsomal transfer protein inhibitor, bile acid transport inhibitor, 5 alpha reductase inhibitors, angiotensin 11 , glycine receptor, noradrenaline reuptake receptor, endothelin receptors, neuropeptide Y and receptor, estrogen receptors, androgen receptors, adenosine receptors, adenosine kinase and AMP deaminase, purinergic receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2X1-7), farnesyltransferases, geranylgeranyl transferase, TrkA a receptor for NGF, beta-amyloid, tyrosine kinase Flk-IIKDR, vitronectin receptor, integrin receptor, Her-21 neu, telomerase inhibition, cytosolic phospholipaseA2 and EGF receptor tyrosine kinase. Additional protein targets include, for example, ecdysone 20-monooxygenase, ion channel of the GABA gated chloride channel, acetylcholinesterase, voltage-sensitive sodium channel protein, calcium release channel, chloride channels, acetyl-CoA carboxylase, adenylosuccinate synthetase, protoporphyrinogen oxidase, and enolpyruvylshikimate- phosphate synthase.
133. Use of a compound according to any of claims 1-92 for treating a disease state or condition in a patient wherein dysregulated protein activity is responsible for said disease state or condition.
134. Use according to claim 133 wherein said disease state or condition is asthma, multiple sclerosis, cancer, ciliopathies, cleft palate, diabetes, heart disease, hypertension, inflammatory bowel disease, mental retardation, mood disorder, obesity, refractive error, infertility, Angelman syndrome, Canavan disease, Coeliac disease, Charcot-Marie-Tooth disease, Cystic fibrosis, Duchenne muscular dystrophy, Haemochromatosis, Haemophilia, Klinefelter's syndrome, Neurofibromatosis, Phenylketonuria, Polycystic kidney disease, (PKDl) or 4 (PKD2) Prader-Willi syndrome, Sickle-cell disease, Tay-Sachs disease, Turner syndrome.
135. Use according to claim 133 wherein said disease state or condition is Alzheimer's disease, Amyotrophic lateral sclerosis (Lou Gehrig's disease), Anorexia nervosa, Anxiety disorder, Atherosclerosis, Attention deficit hyperactivity disorder, Autism, Bipolar disorder, Chronic fatigue syndrome, Chronic obstructive pulmonary disease, Crohn's disease, Coronary heart disease, Dementia, Depression, Diabetes mellitus type 1, Diabetes mellitus type 2, Epilepsy, Guillain-Barre syndrome, Irritable bowel syndrome, Lupus, Metabolic syndrome, Multiple sclerosis, Myocardial infarction, Obesity, Obsessive-compulsive disorder, Panic disorder, Parkinson's disease, Psoriasis, Rheumatoid arthritis, Sarcoidosis, Schizophrenia, Stroke, Thromboangiitis obliterans, Tourette syndrome, Vasculitis.
136. Use according to claim 133 wherein said disease state or condition is
aceruloplasminemia, Achondrogenesis type II, achondroplasia, Acrocephaly, Gaucher disease type 2, acute intermittent porphyria, Canavan disease, Adenomatous Polyposis Coli, ALA dehydratase deficiency, adenylosuccinate lyase deficiency, Adrenogenital syndrome,
Adrenoleukodystrophy, ALA-D porphyria, ALA dehydratase deficiency, Alkaptonuria, Alexander disease, Alkaptonuric ochronosis, alpha 1 -antitrypsin deficiency, alpha- 1 proteinase inhibitor, emphysema, amyotrophic lateral sclerosis, Alstrom syndrome,
Alexander disease, Amelogenesis imperfecta, ALA dehydratase deficiency, Anderson-Fabry disease, androgen insensitivity syndrome, Anemia, Angiokeratoma Corporis Diffusum, Angiomatosis retinae (von Hippel-Lindau disease), Apert syndrome, Arachnodactyly
(Marfan syndrome), Stickler syndrome, Arthrochalasis multiplex congenital (Ehlers-Danlos syndrome#arthrochalasia type),ataxia telangiectasia, Rett syndrome, primary pulmonary hypertension, Sandhoff disease, neurofibromatosis type II, Beare- Stevenson cutis gyrata syndrome, Mediterranean fever, familial, Benjamin syndrome, beta-thalassemia
Bilateral Acoustic Neurofibromatosis (neurofibromatosis type II), factor V Leiden
thrombophilia, Bloch-Sulzberger syndrome (incontinentia pigmenti), Bloom syndrome, X- linked sideroblastic anemia, Bonnevie-Ullrich syndrome (Turner syndrome), Bourneville disease (tuberous sclerosis), prion disease, Birt-Hogg-Dube syndrome, Brittle bone disease (osteogenesis imperfecta), Broad Thumb-Hallux syndrome (Rubinstein-Taybi syndrome), Bronze Diabetes/Bronzed Cirrhosis (hemochromatosis), Bulbospinal muscular atrophy (Kennedy's disease), Burger-Grutz syndrome (lipoprotein lipase deficiency), CGD Chronic granulomatous disorder, Campomelic dysplasia, biotinidase deficiency, Cardiomyopathy (Noonan syndrome), Cri du chat, CAVD (congenital absence of the vas deferens), Caylor cardiofacial syndrome (CBAVD), CEP (congenital erythropoietic porphyria), cystic fibrosis, congenital hypothyroidism, Chondrodystrophy syndrome (achondroplasia),
otospondylomegaepiphyseal dysplasia, Lesch-Nyhan syndrome, galactosemia, Ehlers-Danlos syndrome, Thanatophoric dysplasia, Coffin-Lowry syndrome, Cockayne syndrome, (familial adenomatous polyposis), Congenital erythropoietic porphyria, Congenital heart disease, Methemoglobinemia/Congenital methaemoglobinaemia, achondroplasia, X-linked sideroblastic anemia, Connective tissue disease, Conotruncal anomaly face syndrome, Cooley's Anemia (beta-thalassemia), Copper storage disease (Wilson's disease), Copper transport disease (Menkes disease), hereditary coproporphyria, Cowden syndrome,
Craniofacial dysarthrosis (Crouzon syndrome), Creutzfeldt- Jakob disease (prion disease), Cockayne syndrome, Cowden syndrome, Curschmann-Batten-Steinert syndrome (myotonic dystrophy), Beare-Stevenson cutis gyrata syndrome, primary hyperoxaluria,
spondyloepimetaphyseal dysplasia (Strudwick type), muscular dystrophy, Duchenne and Becker types (DBMD), Usher syndrome, Degenerative nerve diseases including de Grouchy syndrome and Dejerine-Sottas syndrome, developmental disabilities, distal spinal muscular atrophy, type V, androgen insensitivity syndrome, Diffuse Globoid Body Sclerosis (Krabbe disease), Di George's syndrome, Dihydrotestosterone receptor deficiency, androgen insensitivity syndrome, Down syndrome, Dwarfism, erythropoietic protoporphyria
Erythroid 5-aminolevulinate synthetase deficiency, Erythropoietic porphyria, erythropoietic protoporphyria, erythropoietic uroporphyria, Friedreich's ataxia,, familial paroxysmal polyserositis, porphyria cutanea tarda, familial pressure sensitive neuropathy,
primary pulmonary hypertension (PPH), Fibrocystic disease of the pancreas, fragile X syndrome, galactosemia, genetic brain disorders, Giant cell hepatitis (Neonatal
hemochromatosis), Gronblad-Strandberg syndrome ( pseudoxanthoma elasticum), Gunther disease (congenital erythropoietic porphyria), haemochromatosis, Hallgren syndrome, sickle cell anemia, hemophilia, hepatoerythropoietic porphyria (HEP), Hippel-Lindau disease (von Hippel-Lindau disease), Huntington's disease, Hutchinson-Gilford progeria syndrome (progeria), Hyperandrogenism, Hypochondroplasia, Hypochromic anemia, Immune system disorders, including X-linked severe combined immunodeficiency, Insley-Astley syndrome, Jackson- Weiss syndrome, Joubert syndrome, Lesch-Nyhan syndrome, Jackson- Weiss syndrome, Kidney diseases, including hyperoxaluria, Klinefelter's syndrome, Kniest dysplasia, Lacunar dementia,Langer-Saldino achondrogenesis, ataxia telangiectasia, Lynch syndrome, Lysyl-hydroxylase deficiency, Machado- Joseph disease, Metabolic disorders, including Kniest dysplasia, Marfan syndrome, Movement disorders, Mowat- Wilson syndrome, cystic fibrosis, Muenke syndrome, Multiple neurofibromatosis, Nance-Insley syndrome, Nance-Sweeney chondrodysplasia, Niemann-Pick disease, Noack syndrome (Pfeiffer syndrome), Osier- Weber-Rendu disease, Peutz-Jeghers syndrome, Polycystic kidney disease, polyostotic fibrous dysplasia (McCune-Albright syndrome), Peutz-Jeghers syndrome, Prader-Labhart- Willi syndrome, hemochromatosis, primary hyperuricemia syndrome (Lesch- Nyhan syndrome), primary pulmonary hypertension, primary senile degenerative dementia, prion disease, progeria (Hutchinson Gilford Progeria Syndrome), progressive chorea, chronic hereditary (Huntington) (Huntington's disease), progressive muscular atrophy, spinal muscular atrophy, propionic acidemia, protoporphyria, proximal myotonic dystrophy, pulmonary arterial hypertension, PXE (pseudoxanthoma elasticum), Rb (retinoblastoma), Recklinghausen disease (neurofibromatosis type I), Recurrent polyserositis, Retinal disorders, Retinoblastoma, Rett syndrome, RFALS type 3, Ricker syndrome, Riley-Day syndrome, Roussy-Levy syndrome, severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), Li-Fraumeni syndrome, sarcoma, breast, leukemia, and adrenal gland (SBLA) syndrome, sclerosis tuberose (tuberous sclerosis), SDAT, SED congenital
(spondyloepiphyseal dysplasia congenita), SED Strudwick (spondyloepimetaphyseal dysplasia, Strudwick type), SEDc (spondyloepiphyseal dysplasia congenita)
SEMD, Strudwick type (spondyloepimetaphyseal dysplasia, Strudwick type), Shprintzen syndrome, Skin pigmentation disorders, Smith-Lemli-Opitz syndrome, South- African genetic porphyria (variegate porphyria), infantile-onset ascending hereditary spastic paralysis, Speech and communication disorders, sphingolipidosis, Tay-Sachs disease,
spinocerebellar ataxia, Stickler syndrome, stroke, androgen insensitivity syndrome,
tetrahydrobiopterin deficiency, beta-thalassemia, Thyroid disease
Tomaculous neuropathy (hereditary neuropathy with liability to pressure palsies)
Treacher Collins syndrome, Triplo X syndrome ( triple X syndrome), Trisomy 21
(Down syndrome), Trisomy X, VHL syndrome (von Hippel-Lindau disease), Vision
impairment and blindness (Alstrom syndrome), Vrolik disease, Waardenburg syndrome, Warburg Sjo Fledelius Syndrome, Weissenbacher-Zweyn uller syndrome, Wolf-Hirschhorn syndrome, Wolff Periodic disease, Weissenbacher-Zweymiiller syndrome and
Xeroderma pigmentosum.
137. Use according to claim 133 wherein said disease state is cancer.
138. Use according to claim 137 wherein said cancer is squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, and renal cell carcinomas, cancer of the bladder, bowel, breast, cervix, colon, esophagus, head, kidney, liver, lung, neck, ovary, pancreas, prostate, and stomach; leukemias; benign and malignant lymphomas, particularly Burkitt's lymphoma and Non-Hodgkin's lymphoma; benign and malignant melanomas; myeloproliferative diseases; sarcomas, including Ewing's sarcoma,
hemangiosarcoma, Kaposi's sarcoma, liposarcoma, myosarcomas, peripheral
neuroepithelioma, synovial sarcoma, gliomas, astrocytomas, oligodendrogliomas,
ependymomas, gliobastomas, neuroblastomas, ganglioneuromas, gangliogliomas,
medulloblastomas, pineal cell tumors, meningiomas, meningeal sarcomas, neurofibromas, and Schwannomas; bowel cancer, breast cancer, prostate cancer, cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma,
esophageal cancer, pancreatic cancer, stomach cancer, liver cancer, colon cancer, melanoma; carcinosarcoma, Hodgkin's disease, Wilms' tumor or teratocarcinomas
139. Use according to claim 137 wherein said cancer is T-lineage Acute lymphoblastic Leukemia (T-ALL), T-lineage lymphoblastic Lymphoma (T-LL), Peripheral T-cell lymphoma, Adult T-cell Leukemia, Pre-B ALL, Pre-B Lymphomas, Large B-cell Lymphoma, Burkitts Lymphoma, B-cell ALL, Philadelphia chromosome positive ALL and Philadelphia chromosome positive CML
140. Use according to claim 133 wherein said disease state is an HIV infection.
Use according to claim 133 wherein said disease state is an HCV infection.
142. Use of a compound according to any of claims 1-92 in a compound library.
143. Use of a compound according to any of claims 1-92 for degrading a target protein in a cell.
144. Use of a compound according to any of claims 1 -92 for degrading a target protein in a patient in need.
145. Use according to claim 143 or 144 144 wherein said target protein is heat shock protein 90, a kinase, a phosphatase, MDM2, human BET Bromodomain-containing protein, HDAC, human lysine methyltransferase, a RAF receptor, FKBP, VEGF, an aryl hydrocarbon receptor, an androgen receptor, an estrogen receptor, thyroid hormone receptor, HIV protease, HIV integrase, HCV protease or acyl protein thioesterase 1 and/or 2.
PCT/US2013/021136 2012-01-12 2013-01-11 Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase Ceased WO2013106643A2 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
AU2013207900A AU2013207900B2 (en) 2012-01-12 2013-01-11 Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase
KR1020207005900A KR102438072B1 (en) 2012-01-12 2013-01-11 Compounds and Methods for the Enhanced Degradation of Targeted Proteins and Other Polypeptides by an E3 Ubiquitin Ligase
MX2014008520A MX358660B (en) 2012-01-12 2013-01-11 Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase.
HK15109544.5A HK1208875A1 (en) 2012-01-12 2013-01-11 Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
EP19181352.6A EP3608317A1 (en) 2012-01-12 2013-01-11 Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
CA2861066A CA2861066C (en) 2012-01-12 2013-01-11 Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
KR1020227029492A KR102668696B1 (en) 2012-01-12 2013-01-11 Compounds and Methods for the Enhanced Degradation of Targeted Proteins and Other Polypeptides by an E3 Ubiquitin Ligase
MX2018010430A MX394449B (en) 2012-01-12 2013-01-11 COMPOUNDS AND METHODS FOR ENHANCED DEGRADATION OF TARGETED PROTEINS AND OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE.
JP2014552319A JP2015508414A (en) 2012-01-12 2013-01-11 Compounds and methods for enhanced degradation of target proteins and other polypeptides by E3 ubiquitin ligase
US14/371,956 US10730862B2 (en) 2012-01-12 2013-01-11 Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase
CN201380013806.8A CN104736569A (en) 2012-01-12 2013-01-11 Compounds and methods for enhancing degradation of target proteins and other polypeptides by E3 ubiquitin ligases
EP13736209.1A EP2802608A4 (en) 2012-01-12 2013-01-11 COMPOUNDS AND METHODS FOR THE REINFORCED REMOVAL OF TARGETED PROTEINS AND OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE
KR1020147022606A KR102204989B1 (en) 2012-01-12 2013-01-11 Compounds and Methods for the Enhanced Degradation of Targeted Proteins and Other Polypeptides by an E3 Ubiquitin Ligase
BR112014017095-9A BR112014017095A2 (en) 2012-01-12 2013-01-11 compound, pharmaceutical composition, method for regulating protein activity of a target protein, method for treating a disease state or condition, library of a compound, method for degrading a target protein, and use of a compound
CN202311258079.3A CN117736134A (en) 2012-01-12 2013-01-11 Compounds and methods for enhancing degradation of target proteins and other polypeptides by E3 ubiquitin ligases
RU2014133019A RU2666530C2 (en) 2012-01-12 2013-01-11 Compounds and methods for enhanced degradation of target proteins and other polypeptides by an e3 ubiquitin ligase
KR1020247016674A KR20240096553A (en) 2012-01-12 2013-01-11 Compounds and Methods for the Enhanced Degradation of Targeted Proteins and Other Polypeptides by an E3 Ubiquitin Ligase
AU2018201554A AU2018201554B2 (en) 2012-01-12 2018-03-05 Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
US16/224,088 US20190127359A1 (en) 2012-01-12 2018-12-18 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase
AU2020239664A AU2020239664B2 (en) 2012-01-12 2020-09-22 Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
AU2022205187A AU2022205187B2 (en) 2012-01-12 2022-07-12 Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
AU2024201732A AU2024201732A1 (en) 2012-01-12 2024-03-16 Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
US18/667,078 US20240317729A1 (en) 2012-01-12 2024-05-17 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261585769P 2012-01-12 2012-01-12
US61/585,769 2012-01-12

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/371,956 A-371-Of-International US10730862B2 (en) 2012-01-12 2013-01-11 Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase
US16/224,088 Continuation US20190127359A1 (en) 2012-01-12 2018-12-18 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase

Publications (2)

Publication Number Publication Date
WO2013106643A2 true WO2013106643A2 (en) 2013-07-18
WO2013106643A3 WO2013106643A3 (en) 2013-09-06

Family

ID=48782088

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/021136 Ceased WO2013106643A2 (en) 2012-01-12 2013-01-11 Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase

Country Status (12)

Country Link
US (3) US10730862B2 (en)
EP (2) EP3608317A1 (en)
JP (5) JP2015508414A (en)
KR (4) KR102438072B1 (en)
CN (2) CN117736134A (en)
AU (5) AU2013207900B2 (en)
BR (1) BR112014017095A2 (en)
CA (1) CA2861066C (en)
HK (1) HK1208875A1 (en)
MX (3) MX394449B (en)
RU (1) RU2666530C2 (en)
WO (1) WO2013106643A2 (en)

Cited By (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014108452A1 (en) * 2013-01-11 2014-07-17 Glaxosmithkline Intellectual Property Development Limited Proteolysis targeting chimeras (protacs) directed to the modulation of the estrogen receptor
WO2014187777A1 (en) * 2013-05-21 2014-11-27 Mediapharma S.R.L. Novel inhibitors of pvhl-elongin c binding
WO2015000868A1 (en) * 2013-07-03 2015-01-08 Glaxosmithkline Intellectual Property Development Limited Novel compounds
JP2015507636A (en) * 2012-01-06 2015-03-12 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド Heterocyclic compounds and methods of use thereof
US8987250B2 (en) 2012-04-20 2015-03-24 Gilead Sciences, Inc. Therapeutic compounds
US9006229B2 (en) 2011-04-21 2015-04-14 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use
US9102614B2 (en) 2010-07-02 2015-08-11 Gilead Sciences, Inc. Naphth-2-ylacetic acid derivatives to treat AIDS
CN105085620A (en) * 2015-06-25 2015-11-25 中山大学附属第一医院 Compound for targeted ubiquitination degradation of Smad3
WO2015184383A1 (en) * 2014-05-29 2015-12-03 St. Jude Children's Research Hospital Aryl-substituted imidazoles and methods of making and using same
WO2015160845A3 (en) * 2014-04-14 2015-12-10 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
EP2985285A1 (en) * 2014-08-11 2016-02-17 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9296758B2 (en) 2010-07-02 2016-03-29 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds
WO2016045115A1 (en) * 2014-09-28 2016-03-31 姜凡 Hiv-1 integrase inhibitor
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
WO2016105518A1 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2016172134A2 (en) 2015-04-22 2016-10-27 Glaxosmithkline Intellectual Property Development Limited Novel compounds
WO2016169989A1 (en) 2015-04-22 2016-10-27 Glaxosmithkline Intellectual Property Development Limited Iap e3 ligase directed proteolysis targeting chimeric molecules
WO2016204197A1 (en) * 2015-06-19 2016-12-22 学校法人東京理科大学 Protein degradation inducing tag and usage thereof
WO2017007612A1 (en) * 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017009650A1 (en) * 2015-07-14 2017-01-19 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
WO2017046036A1 (en) 2015-09-14 2017-03-23 Glaxosmithkline Intellectual Property Development Limited Compounds for the modulation of rip2 kinase activity
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
KR20170103977A (en) * 2015-01-20 2017-09-13 아비나스 인코포레이티드 Compounds and methods for targeted degradation of androgen receptors
WO2017182418A1 (en) 2016-04-20 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising ripk2 inhibitors
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
WO2017212329A1 (en) * 2016-06-10 2017-12-14 Otsuka Pharmaceutical Co., Ltd. Cliptac composition
WO2017211924A1 (en) * 2016-06-10 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Novel compounds
WO2017223415A1 (en) * 2016-06-23 2017-12-28 Dana-Farber Cancer Institute, Inc. Degradation of tripartite motif-containing protein 24 (trim24) by conjugation of trim24 inhibitors with e3 ligase ligand and methods of use
WO2017223452A1 (en) * 2016-06-23 2017-12-28 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use
KR20180011759A (en) * 2015-03-18 2018-02-02 아비나스 인코포레이티드 Compounds and methods for improved degradation of targeted proteins
GB2554071A (en) * 2016-09-14 2018-03-28 Univ Dundee Small molecules
JP2018509468A (en) * 2015-03-13 2018-04-05 ザ ユニバーシティ オブ ダンディーＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｄｕｎｄｅｅ Derivatives of 1-[(cyclopentyl or 2-pyrrolidinyl) carbonylaminomethyl] -4- (1,3-thiazol-5-yl) benzene useful for the treatment of proliferative, autoimmune or inflammatory diseases
US9938264B2 (en) 2015-11-02 2018-04-10 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
JP2018058787A (en) * 2016-10-04 2018-04-12 公益財団法人ヒューマンサイエンス振興財団 Heterocyclic compounds
US9988376B2 (en) 2013-07-03 2018-06-05 Glaxosmithkline Intellectual Property Development Limited Benzothiophene derivatives as estrogen receptor inhibitors
US20180177750A1 (en) * 2016-12-24 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
WO2018102067A3 (en) * 2016-11-01 2018-07-19 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
WO2018144649A1 (en) * 2017-01-31 2018-08-09 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2019043208A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag Dihydroquinolinones
WO2019043217A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag Dihydrobenzimidazolones
WO2019043214A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag Glutarimide
CN109475528A (en) * 2016-04-22 2019-03-15 达纳-法伯癌症研究所股份有限公司 Bifunctional molecules for EGFR degradation and methods of use
US10239888B2 (en) 2016-09-29 2019-03-26 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant E3 ubiquitin ligase
EP3319944A4 (en) * 2015-07-10 2019-04-24 Arvinas, Inc. Mdm2-based modulators of proteolysis and associated methods of use
KR20190044499A (en) 2017-10-20 2019-04-30 한국화학연구원 Compound for inducing the degradation of cereblon protein, preparation method thereof and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient
WO2019121562A1 (en) 2017-12-18 2019-06-27 F. Hoffmann-La Roche Ag Bifunctional inhibitors with egfr having a e3 ubiquitin ligase moiety
WO2019133531A1 (en) 2017-12-26 2019-07-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019149922A1 (en) 2018-02-05 2019-08-08 F. Hoffmann-La Roche Ag Compounds which cause degradation of egfr, for use against cancer
WO2019200217A1 (en) 2018-04-13 2019-10-17 Board Of Regents, The University Of Texas System Compounds and methods for selective proteolysis of glucocorticoid receptors
EP3556760A1 (en) 2018-04-19 2019-10-23 F. Hoffmann-La Roche AG Spiro compounds
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
US20190374657A1 (en) * 2017-02-08 2019-12-12 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation with heterobifunctional compounds
WO2019238886A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting usp14
WO2019238817A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting rpn11
WO2019238816A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting uchl5
WO2020023851A1 (en) * 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
WO2020027225A1 (en) 2018-07-31 2020-02-06 ファイメクス株式会社 Heterocyclic compound
US10584101B2 (en) 2016-10-11 2020-03-10 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2020061381A1 (en) * 2018-09-19 2020-03-26 La Jolla Institute For Immunology Ptprs and proteoglycans in rheumatoid arthritis
US10604506B2 (en) 2017-01-26 2020-03-31 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
WO2020086858A1 (en) 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
US10647698B2 (en) 2016-12-01 2020-05-12 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US10647702B2 (en) 2010-09-30 2020-05-12 St. Jude Children's Research Hospital Aryl-substituted imidazoles
WO2020113233A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN111233661A (en) * 2018-11-29 2020-06-05 暨南大学 Compounds targeting ubiquitination to degrade ERRα protein, pharmaceutical compositions and applications thereof
US10689345B2 (en) 2015-03-30 2020-06-23 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as USP30 inhibitors
US10723717B2 (en) 2016-12-23 2020-07-28 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US10723720B2 (en) 2017-09-13 2020-07-28 Amgen Inc. Bisamide sarcomere activating compounds and uses therof
US10730862B2 (en) 2012-01-12 2020-08-04 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase
WO2020162725A1 (en) * 2019-02-07 2020-08-13 한국화학연구원 Target protein eed degradation-inducing degraducer, preparation method thereof, and pharmaceutical composition for preventing or treating diseases related to eed, ezh2, or prc2, comprising same as active ingredient
US10758524B2 (en) 2014-07-22 2020-09-01 Bioventures, Llc Compositions and methods for selectively depleting senescent cells
WO2020181232A1 (en) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US10787443B2 (en) 2017-04-28 2020-09-29 Zamboni Chem Solutions Inc. RAF-degrading conjugate compounds
AU2016270442B2 (en) * 2015-06-04 2020-10-01 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
US20200306273A1 (en) * 2017-12-13 2020-10-01 Shanghaitech University Alk protein degradation agent and anti-tumor application thereof
WO2020206608A1 (en) * 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation
US10807977B2 (en) 2016-04-21 2020-10-20 Bioventures, Llc Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US10865202B2 (en) 2016-09-15 2020-12-15 Arvinas Operations, Inc. Indole derivatives as estrogen receptor degraders
WO2020264499A1 (en) 2019-06-28 2020-12-30 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021026349A1 (en) 2019-08-08 2021-02-11 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Combination therapy for treatment of cancer
EP3559002A4 (en) * 2016-12-23 2021-02-17 Arvinas Operations, Inc. EGFR PROTEOLYSIS CHIMERIC MOLECULES AND RELATED METHODS OF USES
US10933018B2 (en) 2015-10-30 2021-03-02 Timber Pharmaceuticals Llc Isotretinoin formulations and uses and methods thereof
US10946017B2 (en) 2015-06-05 2021-03-16 Arvinas Operations, Inc. Tank-binding kinase-1 PROTACs and associated methods of use
CN112707900A (en) * 2019-10-24 2021-04-27 上海科技大学 Protein degradation agent and application thereof in disease treatment
US11007269B2 (en) 2016-11-15 2021-05-18 Tokyo University Of Science Foundation P53 degradation inducing molecule and pharmaceutical composition
WO2021127561A1 (en) 2019-12-20 2021-06-24 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of egfr
US11046954B2 (en) 2015-08-06 2021-06-29 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses
US11052154B2 (en) 2016-11-15 2021-07-06 Tokyo University Of Science Foundation Ras protein degradation inducing molecule and pharmaceutical composition
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
WO2021178339A1 (en) * 2020-03-04 2021-09-10 Genentech, Inc. Heterobifunctional molecules as tead inhibitors
WO2021201036A1 (en) * 2020-03-31 2021-10-07 田辺三菱製薬株式会社 Hydroxypyrrolidine derivative and medicinal application thereof
WO2021217036A1 (en) * 2020-04-23 2021-10-28 Salem Aliasger K Gper proteolytic targeting chimeras
US11161841B2 (en) 2018-04-04 2021-11-02 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
WO2021229237A1 (en) 2020-05-14 2021-11-18 Ucl Business Ltd Cyclosporine analogues
US11220515B2 (en) 2018-01-26 2022-01-11 Yale University Imide-based modulators of proteolysis and associated methods of use
US11242344B2 (en) 2017-10-24 2022-02-08 Genentech, Inc. (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
US11261179B2 (en) 2017-04-14 2022-03-01 University Of Dundee Small molecules
US11291659B2 (en) 2017-10-05 2022-04-05 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
US11311609B2 (en) 2017-02-08 2022-04-26 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
US11331328B2 (en) 2014-05-05 2022-05-17 Bioventures, Llc Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents
WO2022103411A1 (en) * 2020-11-11 2022-05-19 Genentech, Inc. 1-(2-(4-cyclopropyl-1h-1,2,3-triazol-1-yl)acetyl)-4-hydroxy-n-(benzyl)pyrrolidin e-2-carboxamide derivatives as vhl inhibitors for the treatment of anemia and cancer
WO2022120355A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
RU2774863C2 (en) * 2015-01-20 2022-06-23 Арвинас, Инк. Compounds and methods for targeted degradation of androgen receptor
WO2022173032A1 (en) 2021-02-15 2022-08-18 アステラス製薬株式会社 Quinazoline compound for inducing degradation of g12d-mutation kras protein
US11427548B2 (en) 2015-01-20 2022-08-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11485750B1 (en) 2019-04-05 2022-11-01 Kymera Therapeutics, Inc. STAT degraders and uses thereof
EP4089103A1 (en) 2021-05-12 2022-11-16 Universität Duisburg-Essen Clpcp protease-binding cyclic heptapeptides
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11530229B2 (en) 2019-05-17 2022-12-20 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof
WO2023283130A1 (en) 2021-07-04 2023-01-12 Newave Pharmaceutical Inc. Isoquinoline derivatives as mutant egfr modulators and uses thereof
US11584748B2 (en) 2018-04-16 2023-02-21 C4 Therapeutics, Inc. Spirocyclic compounds
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11597768B2 (en) 2017-06-26 2023-03-07 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
WO2023034411A1 (en) 2021-09-01 2023-03-09 Oerth Bio Llc Compositions and methods for targeted degradation of proteins in a plant cell
US20230082997A1 (en) * 2014-04-14 2023-03-16 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
US11623932B2 (en) 2017-09-22 2023-04-11 Kymera Therapeutics, Inc. Protein degraders and uses thereof
CN115996907A (en) * 2020-06-01 2023-04-21 奈奥芬莱有限公司 Inhibitors of MLH1 and/or PMS2 for cancer therapy
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
WO2023094833A1 (en) * 2021-11-29 2023-06-01 Neophore Limited Indolines as protac compounds
US11666661B2 (en) 2018-03-23 2023-06-06 The Regents Of The University Of California Methods and compounds for targeted autophagy
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
US11685750B2 (en) 2020-06-03 2023-06-27 Kymera Therapeutics, Inc. Crystalline forms of IRAK degraders
US11701357B2 (en) 2016-08-19 2023-07-18 Beigene Switzerland Gmbh Treatment of B cell cancers using a combination comprising Btk inhibitors
US11707457B2 (en) 2019-12-17 2023-07-25 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11707452B2 (en) 2018-08-20 2023-07-25 Arvinas Operations, Inc. Modulators of alpha-synuclein proteolysis and associated methods of use
WO2023147328A1 (en) 2022-01-26 2023-08-03 Genentech, Inc. Antibody-conjugated chemical inducers of degradation with hydolysable maleimide linkers and methods thereof
WO2023171781A1 (en) 2022-03-11 2023-09-14 アステラス製薬株式会社 Heterocyclic compound for inducing degradation of g12d mutant kras protein
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
US11807641B2 (en) 2019-12-04 2023-11-07 Omeros Corporation MASP-2 inhibitors and methods of use
US11820781B2 (en) 2019-12-04 2023-11-21 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
US11826430B2 (en) 2019-05-14 2023-11-28 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2024006776A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and medical use thereof
WO2024006781A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and use thereof
US11866442B2 (en) 2018-10-15 2024-01-09 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
JP2024501537A (en) * 2020-12-30 2024-01-12 キャプター セラピューティクス エス．エー． Novel compounds that bind to cereblon and methods for their use
US20240024490A1 (en) * 2021-04-09 2024-01-25 The Broad Institute, Inc. Bifunctional molecules for selective modification of target substrates
WO2024019103A1 (en) 2022-07-21 2024-01-25 アステラス製薬株式会社 Heterocyclic compound that acts on g12d mutant kras protein
US11883393B2 (en) 2019-12-19 2024-01-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2024029613A1 (en) 2022-08-05 2024-02-08 アステラス製薬株式会社 Heterocyclic compound for inducing degradation of mutant kras protein
WO2024033537A1 (en) 2022-08-12 2024-02-15 Astellas Pharma Inc. Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity
WO2024034593A1 (en) 2022-08-09 2024-02-15 アステラス製薬株式会社 Heterocyclic compound for inducing degradation of g12v mutant kras protein
WO2024033538A1 (en) 2022-08-12 2024-02-15 Astellas Pharma Inc. Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity
US11904006B2 (en) 2019-12-11 2024-02-20 University Of Iowa Research Foundation Poly(diaminosulfide) particle-based vaccine
WO2024039210A1 (en) * 2022-08-17 2024-02-22 한국화학연구원 Compounds for inhibiting or decomposing cdk2 and/or cdk9, and medicinal uses thereof
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated
WO2024050016A1 (en) 2022-08-31 2024-03-07 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
US11932624B2 (en) 2020-03-19 2024-03-19 Kymera Therapeutics, Inc. MDM2 degraders and uses thereof
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US11951133B2 (en) 2019-04-09 2024-04-09 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof
WO2024075051A1 (en) 2022-10-07 2024-04-11 Pfizer Inc. Hsd17b13 inhibitors and/or degraders
WO2024075696A1 (en) 2022-10-03 2024-04-11 公立大学法人横浜市立大学 Imidazopyridine derivatives with bicyclic structure
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
US12006314B2 (en) 2021-05-03 2024-06-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2024127297A1 (en) 2022-12-16 2024-06-20 Pfizer Inc. 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof
US12016860B2 (en) 2021-04-08 2024-06-25 Nurix Therapeutics, Inc. Combination therapies with Cbl-b inhibitor compounds
US12030853B2 (en) 2019-12-04 2024-07-09 Omeros Corporation MASP-2 inhibitors and methods of use
US12043612B2 (en) 2020-05-09 2024-07-23 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same
WO2024157953A1 (en) 2023-01-24 2024-08-02 第一三共株式会社 Substituted benzene compound
US12065442B2 (en) 2018-08-22 2024-08-20 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
KR20240127965A (en) 2021-12-24 2024-08-23 아스텔라스세이야쿠 가부시키가이샤 Pharmaceutical composition comprising a quinazoline compound
US12084423B2 (en) 2018-05-18 2024-09-10 Bioventures, Llc Piperlongumine analogues and uses thereof
EP4428134A1 (en) 2023-03-10 2024-09-11 Dark Blue Therapeutics Ltd Protac degraders of mllt1 and/or mllt3
US20240299366A1 (en) * 2014-04-14 2024-09-12 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
US12091411B2 (en) 2022-01-31 2024-09-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof
US12110288B2 (en) 2019-12-04 2024-10-08 Omeros Corporation MASP-2 inhibitors and methods of use
US12118414B2 (en) 2018-01-22 2024-10-15 Bioventures, Llc BCL-2 proteins degraders for cancer treatment
US12129218B2 (en) * 2018-07-24 2024-10-29 Autotac Inc. AUTOTAC chimeric compound, and composition for preventing, ameliorating or treating diseases through targeted protein degradation comprising the same
US12150995B2 (en) 2020-12-30 2024-11-26 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof
US12162859B2 (en) 2020-09-14 2024-12-10 Arvinas Operations, Inc. Crystalline and amorphous forms of a compound for the targeted degradation of estrogen receptor
US12171768B2 (en) 2021-02-15 2024-12-24 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
WO2024261256A1 (en) 2023-06-22 2024-12-26 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION COMPRISING A pan-KRAS DEGRADER
WO2024261257A1 (en) 2023-06-22 2024-12-26 Astellas Pharma Inc. Pharmaceutical composition comprising a quinazoline compound
US12180193B2 (en) 2020-08-28 2024-12-31 Arvinas Operations, Inc. Accelerating fibrosarcoma protein degrading compounds and associated methods of use
US12187744B2 (en) 2021-10-29 2025-01-07 Kymera Therapeutics, Inc. IRAK4 degraders and synthesis thereof
US12195427B2 (en) 2018-05-29 2025-01-14 Omeros Corporation MASP-2 inhibitors and methods of use
US12208095B2 (en) 2019-08-26 2025-01-28 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
US12234230B2 (en) 2019-06-26 2025-02-25 Nurix Therapeutics, Inc. Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof
WO2025049555A1 (en) 2023-08-31 2025-03-06 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
WO2025056913A1 (en) 2023-09-15 2025-03-20 Oxford University Innovation Limited Compound and method
WO2025038987A3 (en) * 2023-08-17 2025-04-10 Katalytic Therapeutics, Inc. Pde4 protein degraders, pharmaceutical compositions, and therapeutic applications
WO2025120592A1 (en) 2023-12-07 2025-06-12 Pfizer Inc. Biphenyl and phenylpyridine compounds as inhibitors of kat2a and/or kat2b
US12351579B2 (en) 2019-01-29 2025-07-08 Foghorn Therapeutics Inc. Compounds and uses thereof
US12377106B2 (en) 2021-10-26 2025-08-05 Nurix Therapeutics, Inc. Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
EP4259144A4 (en) * 2020-12-09 2025-08-20 Kymera Therapeutics Inc SMARCA DECORATORS AND USES THEREOF
US12398121B2 (en) 2018-05-14 2025-08-26 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US12410171B2 (en) 2020-02-26 2025-09-09 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
US12448399B2 (en) 2023-01-26 2025-10-21 Arvinas Operations, Inc. Cereblon-based KRAS degrading PROTACs and uses related thereto
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2025248090A1 (en) 2024-05-31 2025-12-04 Tubulis Gmbh Novel brd4 binders
US12491251B2 (en) 2019-08-05 2025-12-09 Dana-Farber Cancer Institute, Inc. Degraders of cyclin-dependent kinase 7 (CDK7) and uses thereof
EP4663632A1 (en) 2024-06-13 2025-12-17 Sulis Therapeutics ApS Compounds useful for the modulation of the activity of sting
EP4663204A1 (en) 2024-06-13 2025-12-17 Sulis Therapeutics ApS Compounds useful for the modulation of the activity of sting

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016205334A1 (en) 2015-06-16 2016-12-22 Vascular Strategies Llc Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
RU2018105094A (en) * 2015-07-13 2019-08-14 Арвинас, Инк. ALANINE-BASED PROTEOLYSIS MODULATORS AND RELATED APPLICATION METHODS
GB201522768D0 (en) * 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
RU2752677C2 (en) * 2016-04-12 2021-07-29 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Vet protein decomposers
CN107305202B (en) * 2016-04-22 2020-04-17 北京睿创康泰医药研究院有限公司 HPLC method for analyzing impurities of levovatinib mesylate and preparation thereof and application of impurities as reference standard
AU2017254702B2 (en) * 2016-04-22 2020-12-24 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 9 (CDK9) by conjugation of CDK9 inhibitors with E3 ligase ligand and methods of use
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR THE DEGRADATION OF TARGET PROTEINS
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. CARBON-BONDED GLUTARIMIDE-TYPE DEGRONIMERS FOR THE DEGRADATION OF TARGET PROTEINS
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN105943526B (en) * 2016-05-18 2018-08-14 上海交通大学医学院附属上海儿童医学中心 Applications of the PD0325901 in maintaining arterial duct to open
KR101825065B1 (en) * 2016-05-24 2018-02-05 한국화학연구원 Pharmaceutical composition for inducing the degradation of ALK protein and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient
WO2018013559A1 (en) * 2016-07-12 2018-01-18 Accutar Biotechnology Inc. Novel compounds and uses thereof
CN106279120A (en) * 2016-07-15 2017-01-04 谢阳 A kind of N aryl-amino-carbonyl proline compounds and pharmaceutical composition thereof and application
CN106318920B (en) * 2016-09-14 2019-10-11 中国科学院天津工业生物技术研究所 Flavone-6-hydroxylase and its application in the synthesis of scutellarin
CA3034652A1 (en) 2016-09-26 2018-03-29 Dana-Farber Cancer Institute, Inc. Chromobox protein inhibitors and uses thereof
JP2019537585A (en) 2016-10-28 2019-12-26 アイカーン スクール オブ メディスン アット マウント シナイ Compositions and methods for treating EZH2-mediated cancer
CN106749060B (en) * 2016-11-11 2019-07-23 湖北龙翔药业科技股份有限公司 A kind of refining methd of ponazuril
US20190369111A1 (en) * 2016-11-15 2019-12-05 Tokyo University Of Science Foundation Molecular kinetics evaluation method and screening method
WO2018098275A1 (en) * 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
CA3045037A1 (en) * 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
WO2018103027A1 (en) 2016-12-08 2018-06-14 杭州领业医药科技有限公司 Crystal form of tipifarnib and preparation method and pharmaceutical composition thereof
CN106749513A (en) * 2017-01-23 2017-05-31 中国药科大学 Bifunctional molecule and its preparation and application based on the induction BET degradeds of VHL parts
AU2018261331C1 (en) * 2017-05-01 2022-08-04 Spg Therapeutics, Inc. Tripartite androgen receptor eliminators, methods and uses thereof
CN108976278B (en) * 2017-06-05 2021-04-06 海创药业股份有限公司 Chimeric molecule and preparation and application thereof
JP2020523319A (en) * 2017-06-07 2020-08-06 シルバーバック セラピューティックス インコーポレイテッド Antibody conjugates of immunomodulatory compounds and uses thereof
EP3634489A4 (en) * 2017-06-09 2021-03-10 Dana Farber Cancer Institute, Inc. Improved methods for generating small molecule degraders and dimerizers
CN118440096A (en) 2017-06-20 2024-08-06 C4医药公司 Degradation stator and degradation determinant for N/O-ligation of protein degradation
US10781435B2 (en) 2017-06-22 2020-09-22 Catalyst Biosciences, Inc. Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
CA3069544A1 (en) 2017-07-28 2019-01-31 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2019034332A1 (en) * 2017-08-18 2019-02-21 Cambridge Enterprise Limited Modular binding proteins
CN109422751B (en) * 2017-09-03 2022-04-22 上海美志医药科技有限公司 Compound with activity of degrading tyrosine protein kinase JAK3
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-hydroxypyrrolidin-2-yl)-hydroxamate compounds and methods of use thereof
US11110177B2 (en) 2017-11-10 2021-09-07 The Regents Of The University Of Michigan ASH1L degraders and methods of treatment therewith
CN111372585A (en) * 2017-11-16 2020-07-03 C4医药公司 Degradants and degrons for target protein degradation
JP2021014409A (en) * 2017-11-21 2021-02-12 京都薬品工業株式会社 Protein-binding drug
CA3091041A1 (en) * 2018-02-22 2019-08-29 Ichan School Of Medicine At Mount Sinai Protein arginine methyltransferase 5 (prmt5) degradation / disruption compounds and methods of use
AU2019231689A1 (en) 2018-03-06 2020-09-24 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
WO2019170150A1 (en) * 2018-03-09 2019-09-12 上海科技大学 Protein degradation targeting bcr-abl compound and antitumor application thereof
US11028088B2 (en) 2018-03-10 2021-06-08 Yale University Modulators of BTK proteolysis and methods of use
WO2019183523A1 (en) 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
KR20210018199A (en) 2018-03-26 2021-02-17 씨4 테라퓨틱스, 인코포레이티드 Cerevlon binder for decomposition of Ikaros
MX2020010368A (en) * 2018-04-01 2021-01-08 Arvinas Operations Inc Brm targeting compounds and associated methods of use.
EP3774772A1 (en) 2018-04-13 2021-02-17 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
TWI813666B (en) * 2018-04-20 2023-09-01 大陸商四川科倫博泰生物醫藥股份有限公司 A kind of multifunctional compound, its preparation method and its application in medicine
WO2019218904A1 (en) * 2018-05-18 2019-11-21 四川科伦博泰生物医药股份有限公司 Unnatural amino acid derivative, preparation method therefor and use thereof
JP2021527666A (en) * 2018-06-21 2021-10-14 アイカーン スクール オブ メディスン アット マウント シナイ WD40 Repeated Domain Protein 5 (WDR5) Degradation / Disruption Compounds and Methods of Use
WO2020010204A1 (en) * 2018-07-05 2020-01-09 Icahn School Of Medicine At Mount Sinai Protein tyrosine kinase 6 (ptk6) degradation / disruption compounds and methods of use
MX2021002559A (en) 2018-09-07 2021-07-21 Arvinas Operations Inc POLYCYCLIC COMPOUNDS AND METHODS FOR RAPIDLY ACCELERATED DIRECTED DEGRADATION OF FIBROSARCOMA POLYPEPTIDES.
WO2020056188A1 (en) * 2018-09-12 2020-03-19 Board Of Regents, The University Of Texas System Combination of parp inhibitor and brd4 inhibitor for the treatment of cancer
US20210356467A1 (en) * 2018-10-16 2021-11-18 Technology Innovation Momentum Fund (Israel) Limited Partnership Systems and method for screening small molecules of interest
CN111171113B (en) * 2018-11-09 2023-05-16 汪义朋 Small molecular compound for specifically degrading tau protein and application thereof
US12186400B2 (en) 2018-11-09 2025-01-07 Yipeng Wang Micromolecular compound specifically degrading tau protein, and application thereof
KR102864064B1 (en) 2018-12-19 2025-09-24 셀진 코포레이션 Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and therapeutic methods using the same
FI3897636T3 (en) 2018-12-19 2025-02-03 Celgene Corp Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
CN120698985A (en) 2018-12-20 2025-09-26 C4医药公司 Targeted protein degradation
US11547759B2 (en) 2019-01-30 2023-01-10 Montelino Therapeutics, Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
US11098025B2 (en) 2019-01-30 2021-08-24 Montelino Therapeutics, Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
WO2020163170A1 (en) * 2019-02-05 2020-08-13 The Board Of Regents Of The University Of Texas System Trapping-free parp inhibitors
WO2020168172A1 (en) * 2019-02-15 2020-08-20 Zamboni Chem Solutions Inc. Conjugate compounds for the degradation of raf
US20240108747A1 (en) 2019-03-21 2024-04-04 Lonza Sales Ag Extracellular vesicle conjugates and uses thereof
US12233356B2 (en) 2019-03-21 2025-02-25 Lonza Sales Ag Process for preparing extracellular vesicles
KR20210152515A (en) 2019-04-12 2021-12-15 씨4 테라퓨틱스, 인코포레이티드 Tricyclic disintegrants of Ikaros and Aiolos
AU2020263390A1 (en) * 2019-04-23 2021-10-07 Dana-Farber Cancer Institute, Inc. Degraders of cyclin-dependent kinase 12 (CDK12) and uses thereof
CN114423463B (en) 2019-05-06 2025-09-26 西奈山伊坎医学院 Heterobifunctional compounds as degraders of HPK1
CN110151767B (en) * 2019-05-08 2022-10-18 武汉威立得生物医药有限公司 Application of GNF-7 in preparation of medicine for treating influenza virus infection
CN111944012B (en) * 2019-05-17 2023-08-29 海创药业股份有限公司 Aromatic amine targeting AR and BET protein degradation chimeric compound and application thereof
CA3142713A1 (en) * 2019-06-03 2020-12-10 Regents Of The University Of Minnesota Compounds that degrade kinases and uses thereof
US11890346B2 (en) 2019-06-12 2024-02-06 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of c-MYC protein
MA56513A (en) * 2019-06-19 2022-04-27 Ribon Therapeutics Inc TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY
WO2021018018A1 (en) * 2019-07-26 2021-02-04 Beigene, Ltd. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inidbitors with e3 ligase ligand and methods of use
WO2021067606A1 (en) 2019-10-01 2021-04-08 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
AU2020368542B2 (en) 2019-10-17 2024-02-29 Arvinas Operations, Inc. Bifunctional molecules containing an E3 ubiquitine ligase binding moiety linked to a BCL6 targeting moiety
EP4048301B1 (en) 2019-10-23 2024-09-18 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Chimeric polypeptide for regulating immune cells
CN110713480B (en) * 2019-10-28 2021-02-26 浙江省医学科学院 AChE protein degradation product and preparation method and application thereof
CN110759902B (en) * 2019-11-01 2022-04-22 海南一龄医疗产业发展有限公司 SET8 lysine methyltransferase inhibitor and preparation method and application thereof
CN110684022B (en) * 2019-11-01 2022-07-08 海南一龄医疗产业发展有限公司 SET8 lysine methyltransferase inhibitor and intermediate, preparation method and application thereof
EP4054546A4 (en) * 2019-11-06 2023-10-18 Dana-Farber Cancer Institute, Inc. SELECTIVE HISTONE DEACETYLASE (HDAC) DEGRADATION PRODUCTS AND METHOD FOR THE USE THEREOF
CN112979747A (en) * 2019-12-16 2021-06-18 江苏恒瑞医药股份有限公司 Hydroxyproline derivative for preparing protein degradation targeting chimera
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
AU2021231898A1 (en) 2020-03-05 2022-10-27 C4 Therapeutics, Inc. Compounds for targeted degradation of BRD9
EP4121422A1 (en) 2020-03-21 2023-01-25 Arvinas Operations, Inc. Indazole based compounds and associated methods of use
JP2023518831A (en) 2020-03-21 2023-05-08 アルヴィナス・オペレーションズ・インコーポレイテッド Selective modulators of mutant LRRK2 proteolysis and related methods of use
KR20210122163A (en) * 2020-03-27 2021-10-08 (주) 업테라 Pyrazolo quinazoline derivative compounds inducing selective degradation of PLK1
WO2021207172A1 (en) 2020-04-06 2021-10-14 Arvinas Operations, Inc. Compounds and methods for targeted degradation of kras
WO2021219077A1 (en) * 2020-04-29 2021-11-04 泰比棣医药科技(石家庄)有限公司 Proteolysis targeting compound having tissue targeting capability and use thereof
CN111606969B (en) * 2020-05-13 2023-02-03 四川大学 PARP1 protein degradation agent and application thereof in tumor resistance
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
CN113321700B (en) * 2020-06-02 2022-07-01 泰比瑞医药科技(石家庄)有限公司 Bifunctional compound for degrading target protein and application thereof
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
KR20230111615A (en) 2020-10-21 2023-07-25 아비나스 오퍼레이션스, 인코포레이티드 Compounds and methods for targeted degradation of androgen receptor proteins
CN112174999A (en) * 2020-11-02 2021-01-05 兰州理工大学 A kind of titanium metal complex post-modification product with anticancer activity and its preparation method and application
EP4240733A1 (en) 2020-11-06 2023-09-13 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor and associated methods of use
CN116507617A (en) * 2020-11-11 2023-07-28 基因泰克公司 1- (2- (4-cyclopropyl-1H-1, 2, 3-triazol-1-yl) acetyl) -4-hydroxypyrrolidine-2-carboxamide derivatives as VHL inhibitors for the treatment of anaemia
CN116761797A (en) * 2020-11-30 2023-09-15 基因泰克公司 Pyrrolidine derivatives and methods of use
AU2022218128A1 (en) 2021-02-02 2023-08-17 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
WO2022187650A1 (en) * 2021-03-04 2022-09-09 The Scripps Research Institute Heterobifunctional compositions for targeted protein degradation and methods for their use
CN115043817A (en) * 2021-03-09 2022-09-13 苏州泽璟生物制药股份有限公司 SOS1 proteolysis regulator and preparation method and application thereof
WO2022192878A1 (en) * 2021-03-09 2022-09-15 Baylor College Of Medicine Cellular selectivity profiling against rna helicases and splicing regulators
BR112023018973A2 (en) 2021-03-19 2023-12-12 Arvinas Operations Inc INDAZOLE-BASED COMPOUNDS AND ASSOCIATED METHODS OF USE
EP4323352A1 (en) 2021-04-16 2024-02-21 Arvinas Operations, Inc. Modulators of bcl6 proteolysis and associated methods of use
CN115232108B (en) * 2021-04-23 2025-04-18 领泰生物医药(绍兴)有限公司 SOS1 degradation agent and preparation method and application thereof
CN113603676B (en) * 2021-04-28 2022-05-24 浙江工业大学 Targeted degradation of EGFR protein small molecule compound based on erlotinib and its preparation method and application
AU2022268925A1 (en) 2021-05-03 2023-11-16 Avilar Therapeutics, Inc. Potent asgpr-binding compounds for the degradation of immunoglobulins and other proteins
MX2023014059A (en) 2021-06-08 2024-03-12 C4 Therapeutics Inc THERAPEUTIC FOR THE DEGRADATION OF A MUTANT SERINE/THREONINE PROTEIN KINASE.
WO2022266258A1 (en) 2021-06-15 2022-12-22 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of irak-4
US11981672B2 (en) 2021-09-13 2024-05-14 Montelino Therapeutics Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
US20250059198A1 (en) 2021-11-24 2025-02-20 Arvinas Operations, Inc. Brm degrading compounds and associated methods of use
EP4436965A1 (en) 2021-11-24 2024-10-02 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
CN113979999B (en) * 2021-12-23 2022-05-20 北京鑫开元医药科技有限公司 Compound for targeted ubiquitination degradation of BCR-ABL kinase and preparation method, composition and application thereof
EP4466277A4 (en) * 2022-01-21 2025-12-10 Arvinas Operations Inc CONNECTIONS AND METHODS FOR TARGETED KRAS REDUCTION
CN116676273A (en) * 2022-02-22 2023-09-01 中国科学院深圳先进技术研究院 A kind of proteolytic targeting influenza virus and its preparation method and application
CN114560908B (en) * 2022-03-11 2024-10-25 国家纳米科学中心 Polypeptide PROTAC molecule and preparation method and application thereof
TW202404643A (en) 2022-04-20 2024-02-01 大陸商同宜醫藥（蘇州）有限公司 Compound and use thereof
WO2023220425A1 (en) * 2022-05-12 2023-11-16 Kymera Therapeutics, Inc. Bcl-xl/bcl-2 degraders and uses thereof
IL316803A (en) 2022-06-06 2025-01-01 C4 Therapeutics Inc Bicyclic-substituted glutarimide cereblon binders
WO2024020221A1 (en) 2022-07-21 2024-01-25 Arvinas Operations, Inc. Modulators of tyk2 proteolysis and associated methods of use
WO2024035780A1 (en) * 2022-08-09 2024-02-15 Board Of Regents Of The University Of Nebraska Akr1c3 targeted heterobifunctional small molecule proteolysis targeting chimeras
CN115028679B (en) * 2022-08-11 2022-11-15 深圳湾实验室 PROTAC compound with Cyclophilin A degradation activity and preparation method and application thereof
WO2024040080A1 (en) * 2022-08-19 2024-02-22 Erasca, Inc. Kras inhibitor conjugates
CN115475164B (en) * 2022-08-22 2024-06-04 西安交通大学 Protein degradation targeting chimeric capable of degrading PDGFR-beta, preparation method and application thereof
WO2024081913A1 (en) * 2022-10-14 2024-04-18 76Bio, Inc. Dual-specific bifunctional fusion proteins for ubiquitin-mediated degradation
IL321942A (en) 2023-01-09 2025-09-01 Arvinas Operations Inc Modulators of bcl6 proteolysis and associated methods of use
CN118852335A (en) * 2023-04-28 2024-10-29 中科中山药物创新研究院 Thiadiazolidinone derivatives and preparation methods and applications thereof
WO2024243441A1 (en) 2023-05-24 2024-11-28 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2024259758A1 (en) * 2023-06-21 2024-12-26 深圳湾实验室坪山生物医药研发转化中心 Distearoylphosphatidylethanolamine-polyethylene glycol derivative and liposome containing distearoylphosphatidylethanolamine-polyethylene glycol derivative
WO2025007000A1 (en) 2023-06-30 2025-01-02 Kumquat Biosciences Inc. Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
CN117024413B (en) * 2023-10-07 2024-01-09 天津匠新致成科技有限公司 3-aminopyrazine-2-formamide targeted proteolytic chimera, and preparation method, pharmaceutical composition and application thereof
WO2025096855A1 (en) 2023-11-02 2025-05-08 Kumquat Biosciences Inc. Degraders and uses thereof
CN117603225A (en) * 2023-11-30 2024-02-27 天津医科大学 A kind of protein degradation targeting chimera and preparation method thereof
CN117402178B (en) * 2023-12-15 2024-03-08 英矽智能科技(上海)有限公司 Pyrimidine compounds as JAK inhibitors and PHD inhibitors
WO2025137500A1 (en) 2023-12-21 2025-06-26 Dana-Farber Cancer Institute, Inc. Kinase inhibition and degradation
WO2025184594A1 (en) 2024-02-29 2025-09-04 Arvinas Operations, Inc. Modulators of bcl6 proteolysis and associated methods of use
WO2025213104A1 (en) 2024-04-05 2025-10-09 Arvinas Operations, Inc. Crystalline forms of a compound for the targeted degradation of bcl6
CN118515785B (en) * 2024-07-24 2024-11-08 上海青煜医药科技有限公司 Fusion protein, ubiquitination system containing same and application thereof

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ATE167180T1 (en) 1993-04-07 1998-06-15 Pfizer CYCLOALKYLHYDROXYUREASES AND THEIR USE AS LIPOXY-GENASE INHIBITORS
WO1997040065A2 (en) * 1996-04-24 1997-10-30 Peptide Therapeutics Limited Substrates and inhibitors of proteolytic enzymes
CA2204082A1 (en) * 1996-05-03 1997-11-03 Michael William John Urquhart Pharmaceutical compounds
US6218425B1 (en) * 1996-08-06 2001-04-17 Eli Lilly And Company 8-substituted B-nor-6-Thiaequilenin compounds having activity as selective estrogen receptor modulators
CA2218756A1 (en) * 1996-10-25 1998-04-25 Kristin Sue Marron Substituted benzo¢b!thiophene compounds having activity as selective estrogen receptor modulators
HRP970566A2 (en) 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser
JP4903922B2 (en) 1997-05-14 2012-03-28 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Complex compounds that degrade selected proteins
WO1999002175A1 (en) 1997-07-10 1999-01-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6262098B1 (en) * 1998-08-07 2001-07-17 Chiron Corporation Estrogen receptor modulators
AU1203000A (en) * 1998-10-09 2000-05-01 President And Fellows Of Harvard College Targeted proteolysis by recruitment to ubiquitin protein ligases
US6306663B1 (en) 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
AU769012B2 (en) * 1999-02-26 2004-01-15 Oklahoma Medical Research Foundation Novel component of von Hippel-Lindau tumor suppressor complex and SCF ubiquitin ligase
AU769652B2 (en) * 1999-05-05 2004-01-29 Cubist Pharmaceuticals, Inc. Novel prolines as antimicrobial agents
EP1225918A2 (en) 1999-10-19 2002-07-31 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6740495B1 (en) 2000-04-03 2004-05-25 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay
US6417394B2 (en) * 2000-04-05 2002-07-09 Bristol Myers Squibb Pharma Company Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
AU8821301A (en) * 2000-06-28 2002-01-08 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, design and use
AU2001285230C1 (en) * 2000-08-24 2008-03-13 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
PE20020354A1 (en) 2000-09-01 2002-06-12 Novartis Ag HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
WO2002020740A2 (en) 2000-09-08 2002-03-14 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
JP2005507363A (en) 2001-02-16 2005-03-17 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー Angiogenesis-inhibiting tripeptides, compositions and methods of their use
HN2002000136A (en) * 2001-06-11 2003-07-31 Basf Ag INHIBITORS OF THE PROTEASE OF HIV VIRUS, COMPOUNDS CONTAINING THEMSELVES, THEIR PHARMACEUTICAL USES AND THE MATERIALS FOR SYNTHESIS
CA2456187A1 (en) * 2001-08-03 2003-02-13 Qing Tang Pyrazole-derived kinase inhibitors and uses thereof
US20030133927A1 (en) 2001-10-10 2003-07-17 Defeo-Jones Deborah Conjugates useful in the treatment of prostate cancer
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
US7053046B2 (en) 2001-12-21 2006-05-30 Mcgrath Kevin Peptide activators of VEGF
US20060128632A1 (en) 2002-07-02 2006-06-15 Sharma Sushil K Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
US20030143590A1 (en) 2002-11-18 2003-07-31 Shyam Ramakrishnan Regulation of human dopamine-like g protein- coupled receptor
WO2005007621A2 (en) * 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
EP1656360B1 (en) * 2003-06-13 2007-08-15 Janssen Pharmaceutica N.V. Thiazoline derivatives as selective androgen receptor modulators (sarms)
WO2005111028A1 (en) * 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
MXPA06015169A (en) 2004-07-08 2007-08-21 Warner Lambert Co Androgen modulators.
DE102008020113A1 (en) 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituted dihydropyrazolones and their use
EA019420B1 (en) 2004-12-20 2014-03-31 Дженентех, Инк. Pyrrolidine inhibitors of iap (apoptosis inhibitors)
WO2006113942A2 (en) 2005-04-20 2006-10-26 Schering Corporation Method of inhibiting cathepsin activity
US7718846B2 (en) 2005-05-16 2010-05-18 Gideon Koren Animal models of long QT syndrome and uses thereof
KR20080052611A (en) * 2005-08-26 2008-06-11 메틸진 인크. Benzodiazepines and benzopiperazin derivatives of histone deacetylases
ATE484499T1 (en) 2005-08-30 2010-10-15 Boehringer Ingelheim Int GLUCOPYRANOSYL-SUBSTITUTED BENZYL DERIVATIVES, MEDICATIONS CONTAINING SUCH COMPOUNDS, THEIR USE AND PRODUCTION METHOD THEREOF
NZ570539A (en) * 2006-01-24 2011-07-29 Janssen Pharmaceutica Nv 2-substituted benzimidazoles as selective androgen receptor modulators (SARMS)
CA2643267A1 (en) * 2006-03-03 2007-09-20 Novartis Ag N-formyl hydroxylamine compounds
US7989487B2 (en) * 2006-07-06 2011-08-02 University Of Medicine And Dentistry Of New Jersey Estrogen receptor modulators and uses thereof
AU2007275415A1 (en) * 2006-07-20 2008-01-24 Ligand Pharmaceuticals Incorporated Proline urea CCR1 antagonists for the treatment of autoimmune diseases or inflammation
EP2089391B1 (en) 2006-11-03 2013-01-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
US8518891B2 (en) 2006-11-29 2013-08-27 Longqin Hu Chemotherapeutic conjugates and methods of use
US20080233850A1 (en) 2007-03-20 2008-09-25 3M Innovative Properties Company Abrasive article and method of making and using the same
AR066348A1 (en) 2007-04-30 2009-08-12 Genentech Inc IAP INHIBITORS
KR20100038108A (en) 2007-07-25 2010-04-12 브리스톨-마이어스 스큅 컴퍼니 Triazine kinase inhibitors
ES2413504T3 (en) * 2007-12-21 2013-07-16 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (SARM) and uses thereof
CN101910182B (en) 2007-12-28 2013-07-17 田边三菱制药株式会社 Antitumor agent
WO2010027564A2 (en) 2008-07-18 2010-03-11 Glaxosmithkline Llc Amido anti-viral compounds, compositions, and methods of use
CN101768155B (en) 2008-12-30 2012-09-05 天津药物研究院 Derivatives containing (aminomethyl-five-membered heterocyclo-4-carbonyl)-pyrrolidine-2-carboxylic acid, preparation method thereof and use thereof
US20120135089A1 (en) * 2009-03-17 2012-05-31 Stockwell Brent R E3 ligase inhibitors
US8614201B2 (en) 2009-06-05 2013-12-24 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of TRPA1
WO2011005510A2 (en) * 2009-06-22 2011-01-13 Cerapedics, Inc. Peptide conjugates and uses thereof
WO2011008260A2 (en) 2009-07-13 2011-01-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20110164191A1 (en) * 2010-01-04 2011-07-07 Microvision, Inc. Interactive Projection Method, Apparatus and System
CA2799403C (en) 2010-05-14 2020-01-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
HUE031073T2 (en) 2010-05-14 2017-06-28 Dana Farber Cancer Inst Inc Thienotriazolodiazepine compounds for treating neoplasia
WO2011160016A2 (en) * 2010-06-17 2011-12-22 The Trustees Of Columbia University In The City Of New York E3 binding pockets and identification and use of e3 ligase inhibitors
AU2011272860A1 (en) 2010-06-30 2013-02-07 Brandeis University Small-molecule-targeted protein degradation
EP2590656B1 (en) 2010-07-07 2017-11-15 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
PT2592933T (en) 2010-07-16 2017-05-23 Gaweco Anderson Mif inhibitors and their uses
CN103261169A (en) 2010-09-24 2013-08-21 密歇根大学董事会 Deubiquitinase inhibitors and methods for use of the same
AR084070A1 (en) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc BROMODOMINIUM INHIBITORS AND USES OF THE SAME
EP2649099A4 (en) 2010-12-07 2016-10-19 Univ Yale HYDROPHOBIC MARKING OF SMALL MOLECULES OF FUSION PROTEINS AND INDUCED DEGRADATION THEREOF
US20140243282A1 (en) 2010-12-31 2014-08-28 Satish Reddy Kallam Methods and compositions for designing novel conjugate therapeutics
WO2012142498A2 (en) 2011-04-13 2012-10-18 Innovimmune Biotherapeutics, Inc. Mif inhibitors and their uses
WO2013106646A2 (en) 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
KR102438072B1 (en) 2012-01-12 2022-08-31 예일 유니버시티 Compounds and Methods for the Enhanced Degradation of Targeted Proteins and Other Polypeptides by an E3 Ubiquitin Ligase
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
EP2846784A4 (en) 2012-05-11 2016-03-09 Univ Yale COMPOUNDS USEFUL FOR STIMULATING PROTEIN DEGRADATION AND METHODS USING THE SAME
EP2863923B1 (en) 2012-06-25 2019-05-08 Oncoethix GmbH Thienotriazolodiazepine compounds for the treatment of lymphomas
TWI569799B (en) 2012-09-21 2017-02-11 安羅格製藥股份有限公司 Method of inhibiting constitutively active phosphorylated flt3 kinase
GB201311910D0 (en) * 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel Compounds
NL2011274C2 (en) 2013-08-06 2015-02-09 Illumicare Ip B V 51 Groundbreaking platform technology for specific binding to necrotic cells.
HK1212345A1 (en) 2013-02-22 2016-06-10 Bayer Pharma Aktiengesellschaft 4-substituted pyrrolo- and pyrazolo-diazepines
US9492460B2 (en) 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
DK3071203T3 (en) 2013-11-18 2021-03-15 Forma Therapeutics Inc TETRAHYDROQUINOLINE COMPOSITIONS AS BET-BROMDOMAIN INHIBITORS
KR20250127179A (en) 2014-04-14 2025-08-26 아비나스 오퍼레이션스, 인코포레이티드 Imide-based modulators of proteolysis and associated methods of use
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
US20160022642A1 (en) 2014-07-25 2016-01-28 Yale University Compounds Useful for Promoting Protein Degradation and Methods Using Same
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
EP3201199A1 (en) 2014-10-02 2017-08-09 Glaxosmithkline Intellectual Property (No. 2) Limited Compound
EA033325B1 (en) 2014-10-27 2019-09-30 Тэнша Терапеутикс, Инк. Bromodomain inhibitors
US11352351B2 (en) 2015-01-20 2022-06-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
GB201504314D0 (en) 2015-03-13 2015-04-29 Univ Dundee Small molecules
HK1249058A1 (en) 2015-03-18 2018-10-26 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
CN108366992A (en) * 2015-11-02 2018-08-03 耶鲁大学 Proteolysis targets chimera compound and its methods for making and using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2802608A4 *

Cited By (361)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9296758B2 (en) 2010-07-02 2016-03-29 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds
US9102614B2 (en) 2010-07-02 2015-08-11 Gilead Sciences, Inc. Naphth-2-ylacetic acid derivatives to treat AIDS
US10647702B2 (en) 2010-09-30 2020-05-12 St. Jude Children's Research Hospital Aryl-substituted imidazoles
US9006229B2 (en) 2011-04-21 2015-04-14 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
JP2015507636A (en) * 2012-01-06 2015-03-12 スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド Heterocyclic compounds and methods of use thereof
US10730862B2 (en) 2012-01-12 2020-08-04 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase
US9096586B2 (en) 2012-04-20 2015-08-04 Gilead Sciences, Inc. Therapeutic compounds
US8987250B2 (en) 2012-04-20 2015-03-24 Gilead Sciences, Inc. Therapeutic compounds
WO2014108452A1 (en) * 2013-01-11 2014-07-17 Glaxosmithkline Intellectual Property Development Limited Proteolysis targeting chimeras (protacs) directed to the modulation of the estrogen receptor
WO2014187777A1 (en) * 2013-05-21 2014-11-27 Mediapharma S.R.L. Novel inhibitors of pvhl-elongin c binding
US9988376B2 (en) 2013-07-03 2018-06-05 Glaxosmithkline Intellectual Property Development Limited Benzothiophene derivatives as estrogen receptor inhibitors
US9993514B2 (en) 2013-07-03 2018-06-12 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2015000868A1 (en) * 2013-07-03 2015-01-08 Glaxosmithkline Intellectual Property Development Limited Novel compounds
US20230082997A1 (en) * 2014-04-14 2023-03-16 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
US20240299366A1 (en) * 2014-04-14 2024-09-12 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
RU2738833C2 (en) * 2014-04-14 2020-12-17 Арвинас, Оперэйшнз, Инк. Imide modulators of proteolysis and methods for using them
JP2021008507A (en) * 2014-04-14 2021-01-28 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Imid-based proteolysis modulators and related uses
JP7169327B2 (en) 2014-04-14 2022-11-10 アルビナス・オペレーションズ・インコーポレイテッド Imido-based proteolytic modulators and related methods of use
CN106458993B (en) * 2014-04-14 2025-08-29 阿尔维纳斯运营股份有限公司 Imide-based proteolysis modulators and related methods of use
AU2015247817B2 (en) * 2014-04-14 2019-10-31 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
CN106458993A (en) * 2014-04-14 2017-02-22 阿尔维纳斯股份有限公司 Imide-based proteolysis modulators and related methods of use
RU2738833C9 (en) * 2014-04-14 2022-02-28 Арвинас, Оперэйшнз, Инк. Imide modulators of proteolysis and methods for using them
JP2017513862A (en) * 2014-04-14 2017-06-01 アルビナス インコーポレイテッド Imide-based proteolytic modulators and related methods of use
AU2015247817C1 (en) * 2014-04-14 2022-02-10 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
US12239711B2 (en) * 2014-04-14 2025-03-04 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
EP3131588A4 (en) * 2014-04-14 2018-01-10 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
JP2022191517A (en) * 2014-04-14 2022-12-27 アルビナス・オペレーションズ・インコーポレイテッド Imido-based proteolytic modulators and related methods of use
AU2019240589B2 (en) * 2014-04-14 2021-10-21 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
AU2023285744B2 (en) * 2014-04-14 2025-11-20 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2015160845A3 (en) * 2014-04-14 2015-12-10 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US11331328B2 (en) 2014-05-05 2022-05-17 Bioventures, Llc Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents
WO2015184383A1 (en) * 2014-05-29 2015-12-03 St. Jude Children's Research Hospital Aryl-substituted imidazoles and methods of making and using same
US10758524B2 (en) 2014-07-22 2020-09-01 Bioventures, Llc Compositions and methods for selectively depleting senescent cells
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
EP2985285A1 (en) * 2014-08-11 2016-02-17 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
WO2016045115A1 (en) * 2014-09-28 2016-03-31 姜凡 Hiv-1 integrase inhibitor
US9770512B2 (en) 2014-12-23 2017-09-26 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2016105518A1 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
CN107257800B (en) * 2014-12-23 2020-06-30 达纳-法伯癌症研究所股份有限公司 Methods for inducing degradation of target proteins by bifunctional molecules
US9750816B2 (en) 2014-12-23 2017-09-05 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US11583586B2 (en) 2014-12-23 2023-02-21 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US10669253B2 (en) 2014-12-23 2020-06-02 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
CN107257800A (en) * 2014-12-23 2017-10-17 达纳-法伯癌症研究所股份有限公司 Method for inducing target protein degradation by bifunctional molecules
US10125114B2 (en) 2014-12-23 2018-11-13 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US11059801B2 (en) 2014-12-23 2021-07-13 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US9821068B2 (en) 2014-12-23 2017-11-21 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US10849980B2 (en) 2014-12-23 2020-12-01 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
RU2774863C2 (en) * 2015-01-20 2022-06-23 Арвинас, Инк. Compounds and methods for targeted degradation of androgen receptor
JP2018502925A (en) * 2015-01-20 2018-02-01 アルビナス インコーポレイテッド Compounds and methods for targeted androgen receptor degradation
KR20220151010A (en) * 2015-01-20 2022-11-11 아비나스 오퍼레이션스, 인코포레이티드 Compounds and Methods for the Targeted Degradation of the Androgen Receptor
KR20170103977A (en) * 2015-01-20 2017-09-13 아비나스 인코포레이티드 Compounds and methods for targeted degradation of androgen receptors
US11352351B2 (en) 2015-01-20 2022-06-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11427548B2 (en) 2015-01-20 2022-08-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
EP3268363B1 (en) * 2015-03-13 2022-05-04 The University of Dundee Derivatives of 1-[(cyclopentyl or 2-pyrrolidinyl)carbonylaminomethyl]-4-(1,3-thiazol-5-yl) benzene which are useful for the treatment of proliferative, autoimmune or inflammatory diseases
US11179373B2 (en) 2015-03-13 2021-11-23 University Of Dundee Derivatives of 1-[(cyclopentyl or 2-pyrrolidinyl)carbonylaminomethyl]-4-(l,3-thiazol-5-yl) benzene which are useful for the treatment of proliferative, autoimmune or inflammatory diseases
JP2018509468A (en) * 2015-03-13 2018-04-05 ザ ユニバーシティ オブ ダンディーＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｄｕｎｄｅｅ Derivatives of 1-[(cyclopentyl or 2-pyrrolidinyl) carbonylaminomethyl] -4- (1,3-thiazol-5-yl) benzene useful for the treatment of proliferative, autoimmune or inflammatory diseases
JP2018512449A (en) * 2015-03-18 2018-05-17 アルビナス インコーポレイテッド Compounds and methods for improved degradation of target proteins
JP2021073251A (en) * 2015-03-18 2021-05-13 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Compound and method for decomposing and improving target protein
JP2023109967A (en) * 2015-03-18 2023-08-08 アルビナス・オペレーションズ・インコーポレイテッド Compound and method for decomposing and improving target protein
JP7269731B2 (en) 2015-03-18 2023-05-09 アルビナス・オペレーションズ・インコーポレイテッド Compounds and methods for enhancing target protein degradation
EP4414369A2 (en) 2015-03-18 2024-08-14 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
KR102616762B1 (en) * 2015-03-18 2023-12-20 아비나스 오퍼레이션스, 인코포레이티드 Compounds and methods for enhanced degradation of targeted proteins
US10730870B2 (en) 2015-03-18 2020-08-04 Arvinas Operations, Inc. Compounds and methods for the enhanced degradation of targeted proteins
US11512083B2 (en) 2015-03-18 2022-11-29 Arvinas Operations, Inc. Compounds and methods for the enhanced degradation of targeted proteins
EP4414369A3 (en) * 2015-03-18 2024-10-16 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
KR20180011759A (en) * 2015-03-18 2018-02-02 아비나스 인코포레이티드 Compounds and methods for improved degradation of targeted proteins
US10689345B2 (en) 2015-03-30 2020-06-23 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as USP30 inhibitors
US11053198B2 (en) 2015-03-30 2021-07-06 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as USP30 inhibitors
US11390584B2 (en) 2015-03-30 2022-07-19 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as USP30 inhibitors
US11066365B2 (en) 2015-03-30 2021-07-20 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as USP30 inhibitors
WO2016172134A2 (en) 2015-04-22 2016-10-27 Glaxosmithkline Intellectual Property Development Limited Novel compounds
US10336744B2 (en) 2015-04-22 2019-07-02 Glaxosmithkline Intellectual Property Development Limited 1AP E3 ligase directed proteolysis targeting chimeric molecules
WO2016169989A1 (en) 2015-04-22 2016-10-27 Glaxosmithkline Intellectual Property Development Limited Iap e3 ligase directed proteolysis targeting chimeric molecules
AU2016270442B2 (en) * 2015-06-04 2020-10-01 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
AU2016270442C1 (en) * 2015-06-04 2022-06-02 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
US10946017B2 (en) 2015-06-05 2021-03-16 Arvinas Operations, Inc. Tank-binding kinase-1 PROTACs and associated methods of use
CN107922927A (en) * 2015-06-19 2018-04-17 学校法人东京理科大学 Breaks down proteins induction label and application thereof
WO2016204197A1 (en) * 2015-06-19 2016-12-22 学校法人東京理科大学 Protein degradation inducing tag and usage thereof
JPWO2016204197A1 (en) * 2015-06-19 2018-05-31 学校法人東京理科大学 Proteolytic induction tag and its use
US10976306B2 (en) 2015-06-19 2021-04-13 Tokyo University Of Science Foundation Protein degradation inducing tag and usage thereof
CN105085620B (en) * 2015-06-25 2018-05-08 中山大学附属第一医院 Compound for targeted ubiquitination degradation of Smad3
CN105085620A (en) * 2015-06-25 2015-11-25 中山大学附属第一医院 Compound for targeted ubiquitination degradation of Smad3
WO2017007612A1 (en) * 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US10464925B2 (en) 2015-07-07 2019-11-05 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
AU2016291578B2 (en) * 2015-07-10 2021-03-04 Arvinas Operations, Inc. MDM2-based modulators of proteolysis and associated methods of use
EP3319944A4 (en) * 2015-07-10 2019-04-24 Arvinas, Inc. Mdm2-based modulators of proteolysis and associated methods of use
AU2016291578C1 (en) * 2015-07-10 2021-07-15 Arvinas Operations, Inc. MDM2-based modulators of proteolysis and associated methods of use
WO2017009650A1 (en) * 2015-07-14 2017-01-19 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
US10669234B2 (en) 2015-07-14 2020-06-02 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
EP3800186A1 (en) * 2015-07-14 2021-04-07 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
US11293023B2 (en) * 2015-08-06 2022-04-05 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
US11046954B2 (en) 2015-08-06 2021-06-29 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses
US11554171B2 (en) 2015-08-19 2023-01-17 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US12171831B2 (en) 2015-08-19 2024-12-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain- containing proteins
WO2017046036A1 (en) 2015-09-14 2017-03-23 Glaxosmithkline Intellectual Property Development Limited Compounds for the modulation of rip2 kinase activity
US10933018B2 (en) 2015-10-30 2021-03-02 Timber Pharmaceuticals Llc Isotretinoin formulations and uses and methods thereof
US11471408B2 (en) 2015-10-30 2022-10-18 Timber Pharmaceuticals Llc Isotretinoin formulations and uses and methods thereof
US9938264B2 (en) 2015-11-02 2018-04-10 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
WO2017182418A1 (en) 2016-04-20 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising ripk2 inhibitors
US10807977B2 (en) 2016-04-21 2020-10-20 Bioventures, Llc Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof
US11319316B2 (en) 2016-04-21 2022-05-03 Bioventures, Llc Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof
CN109475528A (en) * 2016-04-22 2019-03-15 达纳-法伯癌症研究所股份有限公司 Bifunctional molecules for EGFR degradation and methods of use
CN109475528B (en) * 2016-04-22 2022-01-11 达纳-法伯癌症研究所股份有限公司 Bifunctional molecules for EGFR degradation and methods of use
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
WO2017212329A1 (en) * 2016-06-10 2017-12-14 Otsuka Pharmaceutical Co., Ltd. Cliptac composition
WO2017211924A1 (en) * 2016-06-10 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Novel compounds
US11786600B2 (en) 2016-06-10 2023-10-17 Otsuka Pharmaceutical Co., Ltd. Cliptac composition
WO2017223452A1 (en) * 2016-06-23 2017-12-28 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use
WO2017223415A1 (en) * 2016-06-23 2017-12-28 Dana-Farber Cancer Institute, Inc. Degradation of tripartite motif-containing protein 24 (trim24) by conjugation of trim24 inhibitors with e3 ligase ligand and methods of use
US10702504B2 (en) 2016-06-23 2020-07-07 Dana-Farber Cancer Institute, Inc. Degradation of tripartite motif-containing protein 24 (TRIM24) by conjugation of TRIM24 inhibitors with E3 ligase ligand and methods of use
US11285218B2 (en) 2016-06-23 2022-03-29 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use
US11701357B2 (en) 2016-08-19 2023-07-18 Beigene Switzerland Gmbh Treatment of B cell cancers using a combination comprising Btk inhibitors
US11234988B2 (en) 2016-09-14 2022-02-01 University Of Dundee Fluorohydroxyproline derivatives useful in the preparation of proteolysis targeted chimeras
GB2554071A (en) * 2016-09-14 2018-03-28 Univ Dundee Small molecules
US10865202B2 (en) 2016-09-15 2020-12-15 Arvinas Operations, Inc. Indole derivatives as estrogen receptor degraders
US11584743B2 (en) 2016-09-15 2023-02-21 Arvinas Operations, Inc. Indole derivatives as estrogen receptor degraders
US10239888B2 (en) 2016-09-29 2019-03-26 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant E3 ubiquitin ligase
JP2018058787A (en) * 2016-10-04 2018-04-12 公益財団法人ヒューマンサイエンス振興財団 Heterocyclic compounds
US11236051B2 (en) 2016-10-11 2022-02-01 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US20230331681A1 (en) * 2016-10-11 2023-10-19 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US12077509B2 (en) * 2016-10-11 2024-09-03 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11964945B2 (en) 2016-10-11 2024-04-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US10844021B2 (en) 2016-10-11 2020-11-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11952347B2 (en) 2016-10-11 2024-04-09 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US10584101B2 (en) 2016-10-11 2020-03-10 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11458123B2 (en) 2016-11-01 2022-10-04 Arvinas Operations, Inc. Tau-protein targeting PROTACs and associated methods of use
WO2018102067A3 (en) * 2016-11-01 2018-07-19 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
RU2805523C2 (en) * 2016-11-01 2023-10-18 Эрвинэс, Инк. Compounds targeting tau protein and related use thereof
US20230086457A1 (en) * 2016-11-01 2023-03-23 Arvinas Operations, Inc. Tau-protein targeting protacs and associated methods of use
US11007269B2 (en) 2016-11-15 2021-05-18 Tokyo University Of Science Foundation P53 degradation inducing molecule and pharmaceutical composition
US11052154B2 (en) 2016-11-15 2021-07-06 Tokyo University Of Science Foundation Ras protein degradation inducing molecule and pharmaceutical composition
US10647698B2 (en) 2016-12-01 2020-05-12 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US10899742B1 (en) 2016-12-01 2021-01-26 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US11104666B2 (en) 2016-12-01 2021-08-31 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US12172981B2 (en) 2016-12-01 2024-12-24 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US11597720B2 (en) 2016-12-01 2023-03-07 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US10994015B2 (en) 2016-12-23 2021-05-04 Arvinas Operations, Inc. EGFR proteolysis targeting chimeric molecules and associated methods of use
US11986531B2 (en) 2016-12-23 2024-05-21 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
EP3559002A4 (en) * 2016-12-23 2021-02-17 Arvinas Operations, Inc. EGFR PROTEOLYSIS CHIMERIC MOLECULES AND RELATED METHODS OF USES
US10723717B2 (en) 2016-12-23 2020-07-28 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
US20220378726A1 (en) * 2016-12-24 2022-12-01 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
US11857519B2 (en) 2016-12-24 2024-01-02 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
US20180177750A1 (en) * 2016-12-24 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
WO2018119357A1 (en) 2016-12-24 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
EP3558974A4 (en) * 2016-12-24 2021-03-10 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED ZESTY HOMOLOGATED POLYPEPTIDE 2 ACTIVATOR DEGRADATION
US12275716B2 (en) 2017-01-26 2025-04-15 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
US11384063B2 (en) 2017-01-26 2022-07-12 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
US10604506B2 (en) 2017-01-26 2020-03-31 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
US12441708B2 (en) 2017-01-31 2025-10-14 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2018144649A1 (en) * 2017-01-31 2018-08-09 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US20190374657A1 (en) * 2017-02-08 2019-12-12 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation with heterobifunctional compounds
US12023385B2 (en) * 2017-02-08 2024-07-02 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation with heterobifunctional compounds
US11311609B2 (en) 2017-02-08 2022-04-26 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
US11261179B2 (en) 2017-04-14 2022-03-01 University Of Dundee Small molecules
US10787443B2 (en) 2017-04-28 2020-09-29 Zamboni Chem Solutions Inc. RAF-degrading conjugate compounds
US11597768B2 (en) 2017-06-26 2023-03-07 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
WO2019043214A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag Glutarimide
US11787802B2 (en) 2017-09-04 2023-10-17 C4 Therapeutics, Inc. Dihydrobenzimidazolones for medical treatment
US12091397B2 (en) 2017-09-04 2024-09-17 C4 Therapeutics, Inc. Dihydroquinolinones for medical treatment
US11802131B2 (en) 2017-09-04 2023-10-31 C4 Therapeutics, Inc. Glutarimides for medical treatment
US11401256B2 (en) 2017-09-04 2022-08-02 C4 Therapeutics, Inc. Dihydroquinolinones for medical treatment
US12365681B2 (en) 2017-09-04 2025-07-22 C4 Therapeutics, Inc. Dihydrobenzimidazolones for medical treatment
US11254672B2 (en) 2017-09-04 2022-02-22 C4 Therapeutics, Inc. Dihydrobenzimidazolones for medical treatment
WO2019043217A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag Dihydrobenzimidazolones
WO2019043208A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag Dihydroquinolinones
US11254658B2 (en) 2017-09-13 2022-02-22 Amgen Inc. Bisamide sarcomere activating compounds and uses thereof
US10723720B2 (en) 2017-09-13 2020-07-28 Amgen Inc. Bisamide sarcomere activating compounds and uses therof
US11299479B1 (en) 2017-09-13 2022-04-12 Cytokinetics, Inc. Bisamide sarcomere activating compounds and uses thereof
US10899746B2 (en) 2017-09-13 2021-01-26 Amgen Inc. Bisamide sarcomere activating compounds and uses thereof
CN111601798B (en) * 2017-09-13 2023-08-11 美国安进公司 Bisamide sarcomere activating compounds and uses thereof
CN111601798A (en) * 2017-09-13 2020-08-28 美国安进公司 Bisamide Sarcomere Activating Compounds and Uses Thereof
US11780826B2 (en) 2017-09-13 2023-10-10 Amgen Inc. Bisamide sarcomere activating compounds and uses thereof
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11623932B2 (en) 2017-09-22 2023-04-11 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US10537560B2 (en) 2017-10-05 2020-01-21 Fulcrum Therapeutics. Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11291659B2 (en) 2017-10-05 2022-04-05 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11479770B2 (en) 2017-10-05 2022-10-25 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of DUX4
KR20190044499A (en) 2017-10-20 2019-04-30 한국화학연구원 Compound for inducing the degradation of cereblon protein, preparation method thereof and pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient
US11242344B2 (en) 2017-10-24 2022-02-08 Genentech, Inc. (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
US12036209B2 (en) 2017-11-17 2024-07-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
US20200306273A1 (en) * 2017-12-13 2020-10-01 Shanghaitech University Alk protein degradation agent and anti-tumor application thereof
US11771709B2 (en) * 2017-12-13 2023-10-03 Shanghaitech University ALK protein degradation agent and anti-tumor application thereof
WO2019121562A1 (en) 2017-12-18 2019-06-27 F. Hoffmann-La Roche Ag Bifunctional inhibitors with egfr having a e3 ubiquitin ligase moiety
US11318205B1 (en) 2017-12-26 2022-05-03 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2019133531A1 (en) 2017-12-26 2019-07-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US11723980B2 (en) 2017-12-26 2023-08-15 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
EP4613773A2 (en) 2017-12-26 2025-09-10 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US12168057B2 (en) 2017-12-26 2024-12-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US10874743B2 (en) 2017-12-26 2020-12-29 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US12006329B2 (en) 2018-01-12 2024-06-11 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11932635B2 (en) 2018-01-12 2024-03-19 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US12118414B2 (en) 2018-01-22 2024-10-15 Bioventures, Llc BCL-2 proteins degraders for cancer treatment
US11220515B2 (en) 2018-01-26 2022-01-11 Yale University Imide-based modulators of proteolysis and associated methods of use
US11834460B2 (en) 2018-01-26 2023-12-05 Yale University Imide-based modulators of proteolysis and associated methods of use
WO2019149922A1 (en) 2018-02-05 2019-08-08 F. Hoffmann-La Roche Ag Compounds which cause degradation of egfr, for use against cancer
US11666661B2 (en) 2018-03-23 2023-06-06 The Regents Of The University Of California Methods and compounds for targeted autophagy
US11161841B2 (en) 2018-04-04 2021-11-02 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
US11998606B2 (en) 2018-04-13 2024-06-04 Board Of Regents, The University Of Texas System Compounds and methods for selective proteolysis of glucocorticoid receptors
WO2019200217A1 (en) 2018-04-13 2019-10-17 Board Of Regents, The University Of Texas System Compounds and methods for selective proteolysis of glucocorticoid receptors
US11584748B2 (en) 2018-04-16 2023-02-21 C4 Therapeutics, Inc. Spirocyclic compounds
US12227504B2 (en) 2018-04-16 2025-02-18 C4 Therepeutics, Inc. Spirocyclic compounds
EP3556760A1 (en) 2018-04-19 2019-10-23 F. Hoffmann-La Roche AG Spiro compounds
US12398121B2 (en) 2018-05-14 2025-08-26 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US12084423B2 (en) 2018-05-18 2024-09-10 Bioventures, Llc Piperlongumine analogues and uses thereof
US12195427B2 (en) 2018-05-29 2025-01-14 Omeros Corporation MASP-2 inhibitors and methods of use
WO2019236483A1 (en) 2018-06-04 2019-12-12 C4 Therapeutics, Inc. Spirocyclic compounds
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
WO2019238817A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting rpn11
WO2019238886A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting usp14
WO2019238816A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting uchl5
US11925690B2 (en) 2018-06-13 2024-03-12 Amphista Therapeutics Limited Bifunctional molecules for targeting Rpn11
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11897882B2 (en) 2018-07-06 2024-02-13 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
US12129218B2 (en) * 2018-07-24 2024-10-29 Autotac Inc. AUTOTAC chimeric compound, and composition for preventing, ameliorating or treating diseases through targeted protein degradation comprising the same
WO2020023851A1 (en) * 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
US11639354B2 (en) 2018-07-31 2023-05-02 Fimecs, Inc. Heterocyclic compound
US12202829B2 (en) 2018-07-31 2025-01-21 Fimecs, Inc. Heterocyclic compound
WO2020027225A1 (en) 2018-07-31 2020-02-06 ファイメクス株式会社 Heterocyclic compound
US11707452B2 (en) 2018-08-20 2023-07-25 Arvinas Operations, Inc. Modulators of alpha-synuclein proteolysis and associated methods of use
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
US12065442B2 (en) 2018-08-22 2024-08-20 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
WO2020061381A1 (en) * 2018-09-19 2020-03-26 La Jolla Institute For Immunology Ptprs and proteoglycans in rheumatoid arthritis
US11866442B2 (en) 2018-10-15 2024-01-09 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
WO2020086858A1 (en) 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
IL282441B2 (en) * 2018-10-24 2025-07-01 Hoffmann La Roche Combined chemical influencing factors of decomposition and methods of use
US12440706B2 (en) * 2018-10-24 2025-10-14 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
IL282441B1 (en) * 2018-10-24 2025-03-01 Hoffmann La Roche Conjugated chemical inducers of degradation and methods of use
US20230067037A1 (en) * 2018-10-24 2023-03-02 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
CN113056287A (en) * 2018-10-24 2021-06-29 豪夫迈·罗氏有限公司 Conjugated chemical degradation inducers and methods of use
CN111233661A (en) * 2018-11-29 2020-06-05 暨南大学 Compounds targeting ubiquitination to degrade ERRα protein, pharmaceutical compositions and applications thereof
CN111233661B (en) * 2018-11-29 2023-03-31 暨南大学 Compound for targeted ubiquitination degradation of ERR alpha protein and medicinal composition and application thereof
US11352350B2 (en) 2018-11-30 2022-06-07 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12258341B2 (en) 2018-11-30 2025-03-25 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11807636B2 (en) 2018-11-30 2023-11-07 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11117889B1 (en) 2018-11-30 2021-09-14 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2020113233A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
US12351579B2 (en) 2019-01-29 2025-07-08 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020162725A1 (en) * 2019-02-07 2020-08-13 한국화학연구원 Target protein eed degradation-inducing degraducer, preparation method thereof, and pharmaceutical composition for preventing or treating diseases related to eed, ezh2, or prc2, comprising same as active ingredient
EP4470618A2 (en) 2019-03-06 2024-12-04 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
WO2020181232A1 (en) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
US11485750B1 (en) 2019-04-05 2022-11-01 Kymera Therapeutics, Inc. STAT degraders and uses thereof
US11746120B2 (en) 2019-04-05 2023-09-05 Kymera Therapeutics, Inc. Stat degraders and uses thereof
US12077555B2 (en) 2019-04-05 2024-09-03 Kymera Therapeutics, Inc. STAT degraders and uses thereof
WO2020206608A1 (en) * 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation
US12485144B2 (en) 2019-04-09 2025-12-02 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof
US11951133B2 (en) 2019-04-09 2024-04-09 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof
US11826430B2 (en) 2019-05-14 2023-11-28 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US12208141B2 (en) 2019-05-14 2025-01-28 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US12049471B2 (en) 2019-05-17 2024-07-30 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof
US11530229B2 (en) 2019-05-17 2022-12-20 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof
US12234230B2 (en) 2019-06-26 2025-02-25 Nurix Therapeutics, Inc. Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof
WO2020264499A1 (en) 2019-06-28 2020-12-30 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated
US12491251B2 (en) 2019-08-05 2025-12-09 Dana-Farber Cancer Institute, Inc. Degraders of cyclin-dependent kinase 7 (CDK7) and uses thereof
WO2021026349A1 (en) 2019-08-08 2021-02-11 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Combination therapy for treatment of cancer
US12208095B2 (en) 2019-08-26 2025-01-28 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
CN112707900A (en) * 2019-10-24 2021-04-27 上海科技大学 Protein degradation agent and application thereof in disease treatment
CN112707900B (en) * 2019-10-24 2022-06-10 上海科技大学 Protein degrading agents and their use in the treatment of disease
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US11807641B2 (en) 2019-12-04 2023-11-07 Omeros Corporation MASP-2 inhibitors and methods of use
US12486278B2 (en) 2019-12-04 2025-12-02 Omeros Corporation MASP-2 inhibitors and methods of use
US11820781B2 (en) 2019-12-04 2023-11-21 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
US12030853B2 (en) 2019-12-04 2024-07-09 Omeros Corporation MASP-2 inhibitors and methods of use
US12110288B2 (en) 2019-12-04 2024-10-08 Omeros Corporation MASP-2 inhibitors and methods of use
US11904006B2 (en) 2019-12-11 2024-02-20 University Of Iowa Research Foundation Poly(diaminosulfide) particle-based vaccine
US11707457B2 (en) 2019-12-17 2023-07-25 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11779578B2 (en) 2019-12-17 2023-10-10 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12427144B2 (en) 2019-12-19 2025-09-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11883393B2 (en) 2019-12-19 2024-01-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2021127561A1 (en) 2019-12-20 2021-06-24 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of egfr
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
US12410171B2 (en) 2020-02-26 2025-09-09 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
WO2021178339A1 (en) * 2020-03-04 2021-09-10 Genentech, Inc. Heterobifunctional molecules as tead inhibitors
US11932624B2 (en) 2020-03-19 2024-03-19 Kymera Therapeutics, Inc. MDM2 degraders and uses thereof
WO2021201036A1 (en) * 2020-03-31 2021-10-07 田辺三菱製薬株式会社 Hydroxypyrrolidine derivative and medicinal application thereof
JP2025026505A (en) * 2020-04-23 2025-02-21 ユニヴァーシティ オブ アイオワ リサーチ ファウンデーション GPER Proteolysis Targeting Chimera
WO2021217036A1 (en) * 2020-04-23 2021-10-28 Salem Aliasger K Gper proteolytic targeting chimeras
AU2021259858B2 (en) * 2020-04-23 2024-12-19 University Of Iowa Research Foundation GPER proteolytic targeting chimeras
US12043612B2 (en) 2020-05-09 2024-07-23 Arvinas Operations, Inc. Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same
WO2021229237A1 (en) 2020-05-14 2021-11-18 Ucl Business Ltd Cyclosporine analogues
CN115996907A (en) * 2020-06-01 2023-04-21 奈奥芬莱有限公司 Inhibitors of MLH1 and/or PMS2 for cancer therapy
US11685750B2 (en) 2020-06-03 2023-06-27 Kymera Therapeutics, Inc. Crystalline forms of IRAK degraders
US12180193B2 (en) 2020-08-28 2024-12-31 Arvinas Operations, Inc. Accelerating fibrosarcoma protein degrading compounds and associated methods of use
US12162859B2 (en) 2020-09-14 2024-12-10 Arvinas Operations, Inc. Crystalline and amorphous forms of a compound for the targeted degradation of estrogen receptor
CN116783183A (en) * 2020-11-11 2023-09-19 基因泰克公司 1- (2- (4-cyclopropyl-1H-1, 2, 3-triazol-1-yl) acetyl) -4-hydroxy-N- (benzyl) pyrrolidine-2-carboxamide derivatives as VHL inhibitors for the treatment of anemia and cancer
WO2022103411A1 (en) * 2020-11-11 2022-05-19 Genentech, Inc. 1-(2-(4-cyclopropyl-1h-1,2,3-triazol-1-yl)acetyl)-4-hydroxy-n-(benzyl)pyrrolidin e-2-carboxamide derivatives as vhl inhibitors for the treatment of anemia and cancer
WO2022120355A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
EP4259144A4 (en) * 2020-12-09 2025-08-20 Kymera Therapeutics Inc SMARCA DECORATORS AND USES THEREOF
US12150995B2 (en) 2020-12-30 2024-11-26 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
JP2024501537A (en) * 2020-12-30 2024-01-12 キャプター セラピューティクス エス．エー． Novel compounds that bind to cereblon and methods for their use
WO2022173032A1 (en) 2021-02-15 2022-08-18 アステラス製薬株式会社 Quinazoline compound for inducing degradation of g12d-mutation kras protein
KR20230145361A (en) 2021-02-15 2023-10-17 아스텔라스세이야쿠 가부시키가이샤 Quinazoline compound to induce degradation of G12D mutant KRAS protein
US12384794B2 (en) 2021-02-15 2025-08-12 Astellas Pharma Inc. Quinazoline compound for inducing degradation of G12D mutant KRAS protein
US12171768B2 (en) 2021-02-15 2024-12-24 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US12016860B2 (en) 2021-04-08 2024-06-25 Nurix Therapeutics, Inc. Combination therapies with Cbl-b inhibitor compounds
US20240024490A1 (en) * 2021-04-09 2024-01-25 The Broad Institute, Inc. Bifunctional molecules for selective modification of target substrates
US12006314B2 (en) 2021-05-03 2024-06-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof
EP4089103A1 (en) 2021-05-12 2022-11-16 Universität Duisburg-Essen Clpcp protease-binding cyclic heptapeptides
WO2023283130A1 (en) 2021-07-04 2023-01-12 Newave Pharmaceutical Inc. Isoquinoline derivatives as mutant egfr modulators and uses thereof
WO2023034411A1 (en) 2021-09-01 2023-03-09 Oerth Bio Llc Compositions and methods for targeted degradation of proteins in a plant cell
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
US12377106B2 (en) 2021-10-26 2025-08-05 Nurix Therapeutics, Inc. Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK
US12187744B2 (en) 2021-10-29 2025-01-07 Kymera Therapeutics, Inc. IRAK4 degraders and synthesis thereof
WO2023094833A1 (en) * 2021-11-29 2023-06-01 Neophore Limited Indolines as protac compounds
KR20240127965A (en) 2021-12-24 2024-08-23 아스텔라스세이야쿠 가부시키가이샤 Pharmaceutical composition comprising a quinazoline compound
WO2023147328A1 (en) 2022-01-26 2023-08-03 Genentech, Inc. Antibody-conjugated chemical inducers of degradation with hydolysable maleimide linkers and methods thereof
US12091411B2 (en) 2022-01-31 2024-09-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2023171781A1 (en) 2022-03-11 2023-09-14 アステラス製薬株式会社 Heterocyclic compound for inducing degradation of g12d mutant kras protein
KR20240162042A (en) 2022-03-11 2024-11-14 아스텔라스세이야쿠 가부시키가이샤 Heterocyclic compounds for inducing degradation of G12D mutant KRAS protein
WO2024006776A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and medical use thereof
WO2024006781A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and use thereof
WO2024019103A1 (en) 2022-07-21 2024-01-25 アステラス製薬株式会社 Heterocyclic compound that acts on g12d mutant kras protein
KR20250036820A (en) 2022-07-21 2025-03-14 아스텔라스세이야쿠 가부시키가이샤 Heterocyclic compounds acting on G12D mutant KRAS protein
WO2024029613A1 (en) 2022-08-05 2024-02-08 アステラス製薬株式会社 Heterocyclic compound for inducing degradation of mutant kras protein
KR20250044266A (en) 2022-08-05 2025-03-31 아스텔라스세이야쿠 가부시키가이샤 Heterocyclic compounds for inducing degradation of mutant KRAS protein
WO2024034593A1 (en) 2022-08-09 2024-02-15 アステラス製薬株式会社 Heterocyclic compound for inducing degradation of g12v mutant kras protein
WO2024033537A1 (en) 2022-08-12 2024-02-15 Astellas Pharma Inc. Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity
WO2024033538A1 (en) 2022-08-12 2024-02-15 Astellas Pharma Inc. Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity
WO2024039210A1 (en) * 2022-08-17 2024-02-22 한국화학연구원 Compounds for inhibiting or decomposing cdk2 and/or cdk9, and medicinal uses thereof
WO2024050016A1 (en) 2022-08-31 2024-03-07 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
US12156916B2 (en) 2022-09-07 2024-12-03 Arvinas Operations, Inc. Rapid accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2024075696A1 (en) 2022-10-03 2024-04-11 公立大学法人横浜市立大学 Imidazopyridine derivatives with bicyclic structure
WO2024075051A1 (en) 2022-10-07 2024-04-11 Pfizer Inc. Hsd17b13 inhibitors and/or degraders
WO2024127297A1 (en) 2022-12-16 2024-06-20 Pfizer Inc. 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof
WO2024157953A1 (en) 2023-01-24 2024-08-02 第一三共株式会社 Substituted benzene compound
EP4656635A1 (en) 2023-01-24 2025-12-03 Daiichi Sankyo Company, Limited Substituted benzene compound
US12448399B2 (en) 2023-01-26 2025-10-21 Arvinas Operations, Inc. Cereblon-based KRAS degrading PROTACs and uses related thereto
EP4428134A1 (en) 2023-03-10 2024-09-11 Dark Blue Therapeutics Ltd Protac degraders of mllt1 and/or mllt3
WO2024188906A1 (en) 2023-03-10 2024-09-19 Dark Blue Therapeutics Ltd Protac degraders of mllt1 and/or mllt3
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof
WO2024261256A1 (en) 2023-06-22 2024-12-26 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION COMPRISING A pan-KRAS DEGRADER
WO2024261257A1 (en) 2023-06-22 2024-12-26 Astellas Pharma Inc. Pharmaceutical composition comprising a quinazoline compound
WO2025038987A3 (en) * 2023-08-17 2025-04-10 Katalytic Therapeutics, Inc. Pde4 protein degraders, pharmaceutical compositions, and therapeutic applications
WO2025049555A1 (en) 2023-08-31 2025-03-06 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
WO2025056913A1 (en) 2023-09-15 2025-03-20 Oxford University Innovation Limited Compound and method
WO2025120592A1 (en) 2023-12-07 2025-06-12 Pfizer Inc. Biphenyl and phenylpyridine compounds as inhibitors of kat2a and/or kat2b
WO2025248090A1 (en) 2024-05-31 2025-12-04 Tubulis Gmbh Novel brd4 binders
EP4663632A1 (en) 2024-06-13 2025-12-17 Sulis Therapeutics ApS Compounds useful for the modulation of the activity of sting
EP4663204A1 (en) 2024-06-13 2025-12-17 Sulis Therapeutics ApS Compounds useful for the modulation of the activity of sting
US12496301B2 (en) 2024-12-06 2025-12-16 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy

Also Published As

Publication number Publication date
KR20200063135A (en) 2020-06-04
RU2018126714A3 (en) 2021-10-14
MX2022009478A (en) 2022-10-10
MX394449B (en) 2025-03-11
KR20240096553A (en) 2024-06-26
RU2018126714A (en) 2019-03-12
CN104736569A (en) 2015-06-24
AU2013207900B2 (en) 2017-12-07
JP2020063314A (en) 2020-04-23
CA2861066C (en) 2024-01-02
AU2022205187A1 (en) 2022-07-28
KR102438072B1 (en) 2022-08-31
AU2013207900A1 (en) 2014-07-24
AU2018201554A1 (en) 2018-03-29
AU2020239664A1 (en) 2020-10-15
CN117736134A (en) 2024-03-22
WO2013106643A3 (en) 2013-09-06
JP2021185202A (en) 2021-12-09
AU2020239664B2 (en) 2022-04-21
AU2013207900A8 (en) 2014-07-31
JP2015508414A (en) 2015-03-19
CA2861066A1 (en) 2013-07-18
BR112014017095A2 (en) 2017-06-13
KR20150010935A (en) 2015-01-29
HK1208875A1 (en) 2016-03-18
EP2802608A4 (en) 2015-08-05
MX2014008520A (en) 2015-08-14
AU2022205187B2 (en) 2024-04-04
JP2023171589A (en) 2023-12-01
AU2024201732A1 (en) 2024-04-11
US20140356322A1 (en) 2014-12-04
JP2019023206A (en) 2019-02-14
EP2802608A2 (en) 2014-11-19
US10730862B2 (en) 2020-08-04
EP3608317A1 (en) 2020-02-12
MX358660B (en) 2018-08-30
RU2666530C2 (en) 2018-09-11
RU2014133019A (en) 2016-02-27
KR102668696B1 (en) 2024-05-29
US20240317729A1 (en) 2024-09-26
KR20220124816A (en) 2022-09-14
AU2018201554B2 (en) 2020-06-25
KR102204989B1 (en) 2021-01-20
US20190127359A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
US20240317729A1 (en) Compounds &amp; Methods for the Enhanced Degradation of Targeted Proteins &amp; Other Polypeptides by an E3 Ubiquitin Ligase
AU2022271368B2 (en) Compounds and methods for the enhanced degradation of targeted proteins
HK40023141A (en) Compounds &amp; methods for the enhanced degradation of targeted proteins &amp; other polypeptides by an e3 ubiquitin ligase
RU2781452C2 (en) Compounds and methods for enhancing degradation of target proteins and other polypeptides, using e3 ubiquitin ligase
HK40107897A (en) Compounds and methods for the enhanced degradation of targeted proteins
RU2782063C2 (en) Compounds and methods for improved cleavage of target proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13736209

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2014552319

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2861066

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/008520

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2013207900

Country of ref document: AU

Date of ref document: 20130111

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013736209

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014133019

Country of ref document: RU

Kind code of ref document: A

Ref document number: 20147022606

Country of ref document: KR

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014017095

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014017095

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140710

ENP Entry into the national phase

Ref document number: 112014017095

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140710